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ABSTRACT 
Background Sub-Saharan Africa faces an epidemic of diabetes. The prevalence and 
incidence of sight threatening diabetic retinopathy in developed countries and 
associations between systemic factors, including glycaemic control, blood pressure 
and blood lipid levels, are well documented. In contrast the epidemiological 
literature from sub-Saharan Africa is sparse. In this resource-poor setting, 
population-specific variables such as a high burden of infectious disease and 
anaemia are likely to affect the spectrum of pathology encountered. I aimed to 
investigate the prevalence, incidence and progression of diabetic retinopathy in 
Southern Malawi, to investigate the risk factors for diabetic retinopathy severity 
and progression in this population and to characterise endothelial function in 
Southern Malawian subjects with diabetes. 
 
Methods I established the Malawi Diabetic Retinopathy Study, a 24 month 
prospective cohort study. Subjects were systematically sampled from two hospital-
based, primary care diabetes clinics. Visual acuity, glycaemic control, systolic blood 
pressure, HIV status, urine albumin–creatinine ratio, and haemoglobin and serum 
lipid levels were assessed.  Retinopathy was graded at an accredited reading centre 
using modified Wisconsin grading of four-field mydriatic photographs. Additionally, 
in order to investigate DR progression at five years, a cohort of subjects recruited to 
a cross-sectional study of diabetes complications in 2007 were traced and assessed. 
In a nested case-control study, serum markers of endothelial dysfunction and pulse 
amplitude tonometry were measured in a subset of subjects from the main cohort 
plus subjects without diabetes.  
 
Results 357 subjects were recruited to the 24 month cohort study. At baseline 
13.4% subjects were HIV-positive and 15.1% were anaemic. Baseline prevalence 
rates of any retinopathy, sight threatening diabetic retinopathy and proliferative 
retinopathy were 50.1% (95% CI 44.9–55.3), 29.4% (95% CI 24.7–34.1) and 7.3% 
(95% CI 4.6–10.0), respectively. Cumulative incidence at 2 years of sight threatening 
diabetic retinopathy for subjects with level 10 (no retinopathy), level 20 
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(background) and level 30 at baseline was 2.7% (95% CI 0.1-5.3), 27.3% (16.4-38.2) 
and 25.0% (0-67.4), respectively.  In a multivariate logistic analysis, 2 step 
progression of diabetic retinopathy at 2 years was associated with HbA1c (odds 
ratio 1.27, 95%CI 1.12-1.45), baseline grade of DR (1.39, 1.02-1.91) and HIV 
infection (OR 0.16, 0.03-0.78).  At 2 years, rates of progression to visual loss were: 
≥15 letters lost in 17 subjects (5.8%), moderate visual impairment (<60 letters) in 3 
subjects (1.0%), severe visual impairment (<50 letters) in 5 subjects (1.7%).  The five 
year incidence of sight threatening diabetic retinopathy in subjects recruited to the 
2007 cross sectional study, for those with level 10 and level 20 retinopathy at 
baseline, was 19.4% (11.3-27.4) and 81.3% (62.1-100), respectively.  In the case 
control study of endothelial function higher serum VEGF and E-selectin were 
associated with having diabetes in multivariate regression. Serum VCAM-1 was 
associated with death in multivariate regression. 
 
Conclusions I report the first cohort study of diabetic retinopathy from sub-Saharan 
Africa. I found a prevalence of sight threatening diabetic retinopathy, in subjects 
attending diabetes clinics, approximately 3 times that reported in recent European 
studies and a prevalence of proliferative retinopathy approximately 10 times higher.  
Progression to sight threatening diabetic retinopathy occurred approximately 3 
times more frequently than reported in Europe.  The negative association of HIV 
infection with retinopathy progression is a new finding.  I report the first evidence 
from sub-Saharan Africa of endothelial dysfunction in subjects with diabetes and of 
an association between levels of endothelial biomarkers and mortality in these 
subjects.  Results presented in this thesis highlight the urgent need for provision of 
services for retinopathy detection and management to avoid a large burden of 
vision loss. 
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analysis detailed in this thesis was performed by me.  I performed all laser 
treatment and follow-up clinics for research subjects during the course of the study.  
Clinical work was supervised by Dr Gerald Msukwa, Mr Nicholas Beare and 
Professor Simon Harding.  As part of the MDRS a cohort of subjects originally seen 
in 2007 was traced and re-examined.  In the original 2007 study clinical grading of 
DR was performed by Mr. Simon Glover.  Demographic and medical assessments 
were performed by the QECH diabetes clinic team as detailed in the original 
publications [1,2]. 
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Introduction to Thesis 
 
 
Diabetes has been recognised in Africa for over 100 years.  In 1901 Albert Cook, a 
medical missionary in Uganda, reported that “diabetes is rather uncommon and 
very fatal” [3].  However, it was not until the 1960s that the first reports on diabetic 
retinopathy (DR) appeared in the medical literature [4,5,6].  Present day Sub-
Saharan Africa (SSA) is in the midst of a health transition characterised by coexisting 
epidemic infectious disease and a rise in non-communicable disease (NCD), in 
societies facing high levels of perinatal and maternal disorders, child mortality and 
trauma.  The International Diabetes Federation has estimated that the number of 
adults with diabetes in Africa will increase from 12.1 million in 2010 to 23.9 million 
in 2030 [7] a presumed consequence of poor diet, sedentary lifestyles, obesity, and 
population growth and ageing (in part due to successes in combating communicable 
diseases).  Diabetes results in considerable morbidity, disability and early mortality.  
The epidemic rise in diabetes poses significant public health and socioeconomic 
challenges for the continent. 
  
Diabetes causes visual impairment through early onset cataract and DR, a 
progressive disease of the retinal microvasculature. Cataract and DR are the second 
and sixth leading causes of global visual impairment, respectively [8]. Both are 
included in the list of nine target diseases of the 'Vision 2020 Action Plan' a joint 
program of the WHO and the International Agency for the Prevention of Blindness.  
The prevalence and incidence of sight threatening diabetic retinopathy (STDR) in 
developed countries have been well documented [9,10,11].  Associations between 
systemic factors, including glycaemic control [12,13], blood pressure [14] and blood 
lipid levels [15] and the development and progression of retinopathy in these 
populations are well known.  In contrast there is a paucity of evidence on the 
epidemiology of DR in Africa.  In this resource-poor setting population-specific 
variables such as a high burden of infectious disease (including HIV and malaria), 
and anaemia are likely to affect the spectrum of pathology encountered.  
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Malawi (population 15.9 million) is one of the poorest countries in Southern Africa, 
with an annual per capita healthcare expenditure of US$77 [16].  The 2009 WHO 
Malawi National STEPwise Survey estimated a prevalence of diabetes of 5.6% in 
adults 25-64 years, with similar prevalence in rural and urban areas [17].  In 2007 a 
survey of diabetes complications was performed in patients attending the diabetes 
clinic at Queen Elizabeth Central Hospital (QECH), Blantyre [1].  This study reported 
a high prevalence of STDR and proliferative retinopathy (PDR) in subjects examined 
by slit lamp biomicroscopy: 19.6% and 5.7%, respectively [2]. 
 
In response to these important findings I set out to elucidate the determinants of 
severity and progression of DR in Southern Malawi.  This thesis, completed as part 
of a Wellcome Trust Clinical PhD Fellowship, outlines a program of both clinical and 
laboratory based research addressing the clinical determinants of DR severity and 
progression as well as the underlying cellular mechanisms.  The objectives of the 
thesis were the following: 
 
1. To investigate the prevalence, incidence and progression of DR in Southern 
Malawi  
2. To investigate the risk factors for DR severity and progression in this population 
3. To characterise endothelial function in Southern Malawian subjects with diabetes 
and to investigate relationships with severity of retinopathy 
 
This work provides valuable baseline epidemiological data for DR in Sub-Saharan 
Africa, delivers novel insights into the pathophysiology of this vascular disease and 
will guide future intervention studies in the region. 
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Chapter 1. Pathophysiology of Diabetic Retinopathy 
 
 
 
1.1 Aims of the chapter 
The first 4 chapters of this thesis comprise my literature review.  In chapters 1, 2 
and 3 I review the current literature concerning the pathophysiology of diabetic 
retinopathy (DR), grading of DR and determinants of severity and progression of 
retinopathy, respectively.  In Chapter 4 I report a systematic review of the 
epidemiology of diabetic retinopathy and maculopathy in Africa, summarise the 
findings of the literature review and present the hypothesis and aims of my thesis.  
In this first chapter I describe the normal anatomy and physiology of the retina and 
present an overview of the pathophysiological processes involved in DR.  Particular 
focus is given to the role of the vascular endothelium. 
 
1.2 Overview  
Diabetes has many manifestations in the eye.  The most significant causes of visual 
impairment are cataract and DR.  A variety of pathological processes are thought to 
contribute to the development of DR including dysfunction of the vascular 
endothelium, chronic low grade inflammation and changes in leukocyte cell biology.  
Progressive damage to the retinal microvasculature leads to the clinical 
manifestations of the disease which, in its early stages, is asymptomatic.  The 
pathophysiology of DR is a highly complex topic with an extensive literature.  The 
literature review presented in this chapter will examine in depth only those areas 
relevant to this thesis. 
 
DR can be broadly divided into clinical categories: background DR and pre-
proliferative DR (collectively described in North American literature as non-
proliferative DR (NPDR)) and proliferative (PDR).  NPDR is characterised by 
abnormal permeability and/or non-perfusion of capillaries leading to retinal 
ischaemia.  Diabetic maculopathy occurs when these processes affect the macula 
and are therefore a threat to visual functioning.  Clinically significant macular 
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oedema (CSMO) is a term from the Early Treatment of Diabetic Retinopathy Study 
(ETDRS) [19] and is an evidence based threshold for laser photocoagulation 
treatment.  PDR occurs when retinal ischaemia is sufficiently severe to lead to the 
formation of new vessels. Visual loss occurs in PDR when these vessels bleed, or 
tractional retinal detachment ensues from fibrovascular proliferation. Without 
treatment, 50% of patients with PDR will become blind within 5 years [18].  Laser 
photocoagulation has been shown to be effective at reducing the likelihood of 
visual impairment and blindness in patients with PDR [18] and macular edema [19] 
if timely treatment is performed. 
 
1.3 Retinal anatomy 
Like the rest of the central nervous system, the retina is embryologically derived 
from the neural tube.  The retina is the innermost of the three principle layers of 
the eye (the others being the corneo-scleral tract and the uveal tract) (Figure 1.1).  
The retina consists of 2 primary layers: an inner neurosensory retina and an outer 
retinal pigment epithelium.  The sub-retinal space is a potential space between 
these two layers.  The neurosensory retina is only attached firmly at the optic disc 
and anteriorly at the ora serrata.  While a number of definitions for the macula 
exist, that used by the Fundus Photograph Reading Center at the University of 
Wisconsin is a circular zone of retina with radius 3.8mm centred on the foveal 
centre (Figure 1.2).  This region is dominated by cone photoreceptors and 
histologically is seen to have more than a single layer of ganglion cell bodies.  The 
fovea is a 1.5mm diameter area at the centre of the macula, the centre of which is 
4.5mm temporal to the centre of the optic disc.  The centre of the fovea is a 
depression surrounded by thickened margins where cone photoreceptors are 
concentrated at maximum density.   
 
The retina is one of the most metabolically active tissues in the body.  In humans 
the retina has a dual blood supply: the inner two thirds are supplied by branches of 
the central retinal vessels, the outer one third is supplied by the choroidal 
circulation (both circulations are branches of the ophthalmic artery) [20].  An area 
at the centre of the fovea contains no retinal capillaries: the normal diameter of the 
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foveal avascular zone is less than 600μm.  Ischaemic maculopathy can be diagnosed 
when the avascular zone is over 1000μm in diameter; between 600 and 1000μm is 
intermediate between the two states. 
 
 
Figure 1.1 Cross section of the human eye demonstrating the 3 principle layers of 
the globe: (1) corneo-scleral tract (white), (2) uveal tract comprising choroid, cilary 
body and iris (pink), and (3) retina (red). Reprinted with permission [20]. 
 
 
Figure 1.2 Normal retinal anatomy of the human eye.  Position of the macula, fovea, 
optic nerve head and the vascular arcades marked.  (Courtesy of Liverpool Diabetic 
Eye Study). 
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1.4 Retinal physiology 
The retinal changes associated with diabetes have been described by Antonetti, 
Klein and Gardner [21] as dysfunction of the retinal neurovascular unit.  Neuronal 
cells, glia and pericytes and specialised vasculature make up this neurovascular unit 
(Figure 1.3).  Close physical and biochemical relationships between these cells 
contribute to important functions of the retina.  The blood-retinal barrier controls 
flow of fluids, metabolites and nutrients between the blood and the neural retina.  
The inner blood retinal barrier comprises non-fenestrated endothelial cells of the 
retinal capillaries and the tight junctions between these cells.  The outer blood 
retinal barrier is made up of retinal pigment epithelial cells and their intercellular 
tight junctions [20].  Interaction of glia and neurones are required for 
neurotransmitter release, energy balance and to maintain the proper ionic 
environment for neuronal signalling.   
 
In the ganglion cell layer the cell bodies of ganglion cells and astrocytes are in close 
proximity to retinal capillaries which provide their nutrients and oxygen.  A further 
capillary bed in the inner nuclear layer nourishes the amacrine and Muller cells.  
Retinal vessels do not receive an autonomic nerve supply.  Auto-regulation of 
retinal blood flow is mediated by pericytes and by levels of metabolites including 
lactate and carbon dioxide [22].  The outer retina receives oxygen and nutrients 
from the choroidal circulation.  Muller cells and photoreceptors are metabolically 
coupled to facilitate the production of electrochemical impulses following 
stimulation with light.  The retinal pigment epithelium provides support to the 
highly metabolically active photoreceptors. 
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Figure 1.3 The retinal neurovascular unit.  Vascular endothelial cells, pericytes, 
astrocytes and Muller cells in close proximity supporting the function of the 
ganglion cells and neural retina. 
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1.5 Pathophysiology of DR 
Here follows a brief overview of the pathophysiology of DR to provide background 
to the thesis. 
 
1.5.1 Histopathological lesions  
A number of anatomical lesions are well described in DR.  Pericytes are contractile 
cells which are important contributors to autoregulation of the microvasculature.  
Loss of these cells is an early and specific sign of DR.  Clinically pericyte loss and loss 
of vessel tone manifests as ‘venous beading’ and venous dilation.  Loss of 
intercellular contacts may promote endothelial cell proliferation and 
microaneurysm formation [23].  A number of changes in the capillary basement 
membrane are reported from electron microscopy in DR.  Thickening, deposition of 
fibrillar collagen and formation of vacuoles are associated with glycation of 
basement membrane collagen by enzymatic and non-enzymatic processes [24].  
These changes are thought to be critical in loss of inter-cellular signalling and 
therefore normal function of pericytes and endothelial cells. 
 
Microaneusyms (MA) are not specific to DR but are the earliest clinical sign of the 
disease (Figure 1.4).  MA are located in the inner retina and either acellular or 
hypercellular.  On ophthalmoscopy they appear as small, intraretinal red dots; on 
fluorescein angiography dots of hyperfluorescence show variable leakage in later 
images.  The mechanism of MA formation remains to be elucidated.  Pericyte loss 
may contribute by weakening the capillary wall and loss of anti-proliferative effect 
[23].  However, MAs occur in other diseases of the retinal microvasculature in which 
pericyte loss is not observed [25].   
 
Loss of the cellular elements of retinal capillaries is accompanied by endothelial 
dysfunction, leucocyte adhesion and changes in retinal blood flow [26].  ‘Capillary 
dropout’ describes the appearance on fluorescein angiography of non-perfused 
areas of the retinal capillary bed.  Again this finding is not specific to DR and the 
mechanisms of capillary cell death are poorly understood.  Breakdown of the blood 
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retinal barrier results in vision threatening macular oedema.  A key mechanism is 
loss of tight junctions between vascular endothelial cell processes [27].  An 
important mediator of blood retinal barrier breakdown, vascular endothelial growth 
factor (VEGF) alters endothelial cell tight junctions.  Components of the kallikrein–
kinin system including plasma kallikrein, factor XII, and kininogen are also involved 
in retinal vascular permeability through effects on bradykinin [23]. 
 
 
Figure 1.4 Trypsin digest preparation of human retina showing pathological changes 
of diabetic retinopathy.  Arrows indicate loss of retinal capillaries (thick solid arrow), 
capillary non-perfusion (thin solid arrow), and capillary microaneurysms (arrow 
outline). Reprinted with permission [21].  
 
1.5.2 Biochemical mechanisms  
Long term hyperglycaemia is the initial factor leading to the development of DR.  
The mechanisms by which hyperglycaemia leads to the development of DR are not 
fully understood.  A number of theories are proposed which are not mutually 
exclusive.   
 
The aldose reductase theory The aldose reductase (polyol or sorbitol) pathway is a 
series of intracellular reactions involving sorbitol dehydrogenase and aldose 
reductase.  The latter enzyme reduces aldose sugars into their respective sugar 
alcohols.  Glucose is reduced to sorbitol which is then oxidised into fructose by 
sorbitol dehydrogenase.  Hyperglycaemia leads to the activation of the aldose 
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reductase pathway.  The sorbitol dehydrogenase reaction is slower than the aldose 
reductase reaction.  The cell membrane is poorly permeable to sorbitol therefore 
high intracellular levels accumulate.  Osmotic stress may account for some of the 
pathological changes seen in DR.  The aldose reductase pathway utilises the 
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH).  Activation 
of this pathway in hyperglycaemia may reduce intracellular NADPH, alter 
intracellular redox balance and result in oxidative stress [28].  Interestingly, aldose 
reductase inhibitors have been effective in reducing signs of DR in animal models 
but not human trials [29]. 
 
Advanced glycation endproduct theory In the presence of hyperglycaemia proteins, 
lipids and nucleic acids may undergo modification by sugar derived products to 
form advanced glycation endproducts (AGEs).  Formation of AGEs may impair 
function of intra and extra cellular proteins and this has been proposed as a 
mechanism to explain vascular damage in diabetes [30].  AGEs bind to receptors 
including the immunoglobulin superfamily member ‘Receptor for AGE’ and the 
macrophage scavenger receptor.  Activation of intracellular kinases may lead to 
cellular dysfunction [31].  Inhibitors of the AGE pathway have been successful in 
preventing many effects of hyperglycaemia in animal studies [32] but human trials 
have been limited by toxicity of these agents.   
 
Reactive oxygen intermediates theory A further theory of the pathophysiological 
mechanisms in DR focusses on reactive oxygen intermediates.  There is evidence of 
oxidative stress in patients with diabetes: lower levels of the antioxidants vitamin C, 
vitamin E and glutathione [33] and raised levels of markers of oxidative stress 
including oxidised low density lipoprotein (LDL) cholesterol [34] are reported.  
Glucose is metabolised through glycolysis and oxidative phosphorylation in the 
mitochondria.  Free radicals are by-products of this reaction.  It is proposed that 
hyperglycaemia results in increased free radical production and consequent 
oxidative stress [23].  In animal models antioxidants have reduced development of 
the microvascular complications of diabetes [35] but trials in humans have not 
shown encouraging results. 
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Protein Kinase C theory Hyperglycaemia (as well as reactive oxygen species, AGEs 
and VEGF) results in pathological activation of protein kinase C (PKC).  The actions of 
this enzyme lead to increased vascular permeability, increased leucocyte adhesion 
to vascular endothelium, dysregulation of nitric oxide synthesis and alteration in 
retinal blood flow [36].  The PKC inhibitor ruboxistaurin is reported to prevent early 
vascular changes in retinopathy, neuropathy and nephropathy [37].  The 
prospective Protein Kinase C Diabetic Retinopathy Study did not show a difference 
in progression to sight threatening maculopathy or focal/grid laser at 30 months 
[38].  However, an open label extension showed a reduction in moderate visual loss 
(MVL) in those subjects with most exposure to ruboxistaurin [39].  Some 
commentators have suggested that use of a higher dose of ruboxistaurin in the 
initial trial may have resulted in a significant difference in favour of treatment. 
 
1.5.3 Inflammation in DR 
Systemic inflammation occurs in response to obesity and diabetes.  Circulating 
monocytes from subjects with diabetes, compared with controls, show greater 
production of superoxide and pro-inflammatory cytokines including interleukin-1, 
interleukin-6, and tumour necrosis factor-α (TNFα) [40].  Transforming growth 
factor-β1 (TGF-β1), a pleiotropic factor with predominantly immunosuppressive 
effects, is elevated in the serum of persons with diabetes [41].  Extensive evidence 
in humans and animal models supports the role in DR of persistent low-grade 
inflammation involving an influx of inflammatory effectors, both cytokines and 
leukocytes.   
 
Retinal inflammatory mediators including VEGF, interleukin-1β, TNFα, intercellular 
adhesion molecule-1 (ICAM-1) and angiotensin II are up regulated in diabetes [42].  
Activation of microgial cells occurs in early DR [43].  Activation of leucocytes and 
leucostasis has been demonstrated in animal models; the latter process dependent 
on ICAM-1 and its ligand CD18 [44].  Leucocyte activation and adhesion appears to 
play an important role in vascular endothelium dysfunction.  Exposure to chronic 
infections such as HIV or repeated episodes of acute infection (e.g. malaria) may 
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modify the systemic and local inflammatory response to hyperglycaemia.  The 
effects of infection on DR and the cellular mechanisms underlying these 
relationships are a theme in this thesis. 
 
1.5.4 Dysfunction of the vascular endothelium 
The endothelium plays a pivotal role in vascular health.  Adherence of leukocytes is 
associated with direct injury to and apoptosis of endothelial cells and with 
disruption of endothelial tight junctions [45].  Both diabetes and its complications 
are associated with altered serum levels of biomarkers of endothelial dysfunction.  
Markers of endothelial dysfunction including soluble intercellular adhesion 
molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and von 
Willebrand factor (vWf), are associated with macroangiopathy in subjects without 
diabetes and those with type 2 diabetes [46,47].  Serum levels of sICAM-1, sVCAM-1 
and CRP are reported to be elevated in subjects with DR [48, 49].  Elevated E-
selectin in patients with type 2 diabetes is associated with presence of DR [49] and 
progression of DR [50].  VEGF is a mitogen for endothelial cells, and its expression 
both in vivo and in vitro can be induced by hypoxia [51].  Serum VEGF is elevated in 
diabetic compared to control subjects [52,53,54].  A number of studies have 
demonstrated elevated VEGF in diabetic subjects with DR when compared to those 
without retinopathy [52,55].  The interaction of DR with other pathologies which 
induce dysfunction of the vascular endothelium is poorly understood.  HIV infection 
and many of the antiretroviral agents used to treat the condition are associated 
with changes in leukocyte cell biology, vascular endothelium dysfunction and 
vascular complications including retinopathy [56].   
 
1.5.5 Assessment of the vascular endothelium 
Serum biomarkers of endothelial dysfunction Assessment of vascular endothelial 
function is challenging due to its location.  Cytokines such as TNFα and interleukin-1 
are pleotropic proteins which regulate activity of leucocytes.  They participate in the 
cascade leading to greater expression of the leucocyte and vascular endothelial 
adhesion molecules including ICAM-1 and VCAM-1.  Serum levels of both cytokines 
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and adhesion molecules are elevated in diseases associated with vascular 
endothelial dysfunction such as diabetes (described above in Section 1.8).  
Endothelial microparticles (EMPs) are small vesicles that are released into the 
circulation from damaged or activated vascular endothelial cells [57].  EMPs 
released by apoptotic and activated cells exhibit different characteristics.  Serum 
levels correlate with clinical findings in coronary artery disease [58] and renal failure 
[59].  Serum biomarkers are accessible and measurement requires only simple 
enzyme-linked immunosorbent assay (ELISA) techniques.  However, serum levels 
reflect global endothelial dysfunction; specific areas of the vascular bed, which may 
exhibit particular functional characteristics, are not measured individually.  Serum 
markers do not directly measure specific functional properties of the vascular 
endothelium.  The establishment of the validity of particular biomarkers was 
beyond the scope of this thesis. 
 
Measurement of in vivo endothelial function The current reference standard for 
assessing endothelial function is coronary angiography with infusion of the 
endothelium-dependent vasodilator acetylcholine.  Vasodilation occurs due to 
receptor-mediated release of nitric oxide (NO) [60].  Clear disadvantages of this test 
are its highly invasive nature and the need for highly skilled interventional 
radiologists.  A much less invasive method is measurement of ‘flow mediated 
dilation’ (FMD) of the brachial artery.  The artery is occluded by external pressure 
with a sphygmomanometer cuff; release causes reactive hyperaemia and shear 
stress.  Artery diameter is measured before and after occlusion by high-resolution 
ultrasound.  The degree of dilation chiefly reflects endothelial function dependent 
on bioavailability of NO [61].  The principle disadvantage of this method is that it 
requires a highly skilled operator.  
 
A number of non-invasive, operator-independent tests have the capacity to 
measure endothelial function. Peripheral artery tonometry (PAT) measures digital 
pulsatile volume changes during reactive hyperaemia following upper arm blood 
flow occlusion.  The expected response is of a post occlusion increase of the PAT 
signal amplitude.  This response is at least 50% dependent on endothelial NO 
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activity [62].  The test has been validated against the FMD method [63] and has 
been used in the third-generation Framingham Heart Study cohort [64].  Decreased 
PAT response has been demonstrated in subjects with diabetes and others risk 
factors for vascular disease [65,66].  It is not currently possible to measure retinal 
vascular endothelial function in vivo.  Measurement of retinal blood flow is 
achievable but is influenced by numerous factors besides function of the 
endothelium [67]. 
 
 
1.6 Clinical manifestations of DR 
 
1.6.1 Natural course of DR 
DR is a microangiopathy chiefly affecting the pre-capillary arterioles, capillaries and 
post-capillary venules.  Five pathological processes underlie the natural course of 
DR: formation of capillary MA; increased vascular permeability; eventual vascular 
non-perfusion; proliferation of new blood vessels (which may bleed) and 
fibrovascular tissue; and contraction of fibrovascular tissue and the vitreous leading 
to tractional retinal detachment.  The disease can be classified into 3 stages on the 
basis of clinical features: (1) ‘background’ in which pathological changes are 
intraretinal; (2) ‘pre-proliferative’ the features of which precede proliferation of 
new vessels and fibrovascular tissue; and (3) proliferative in which the pathology 
extends onto or out-with the retina.  Diabetic maculopathy describes changes of DR 
beyond the background stage affecting the macula.   
 
1.6.2 Background diabetic retinopathy 
Microaneurysms Retinal capillary MAs are typically the earliest sign of DR which can 
be detected on clinical examination.  Histopathological characteristics of MAs are 
described above in Section 1.5.  Proposed mechanisms for MA formation include 
aborted vasoproliferation, weakness of the capillary wall secondary to pericyte loss, 
and increased intraluminal pressure [68].  MAs are located in the inner nuclear layer 
of the retina and range in diameter from 15 to 100 μm.  The walls of early MAs are 
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transparent; they appear as small red dots the same colour as retinal veins.  The 
natural history of MAs sees thickening of the wall with eventual luminal occlusion, a 
process which takes approximately 18 months but is influenced by treatment of 
diabetes [69].  As the wall thickens the colour of a MA changes from red to orange 
and finally to white.   
 
Haemorrhages Intraretinal haemorrhages appear as ‘dots’ and are located in the 
middle layers of the retina.  These haemorrhages arise from the venous end of 
capillaries.  Dot haemorrhages can be very difficult to distinguish from MAs on 
clinical examination.  Recent evidence from studies using optical coherence 
tomography (OCT) angiography suggests that there are other vascular abnormalities 
that may appear similar to MA including capillary loops and telangiectasia [72]. 
Haemorrhages from pre-capillary arterioles occur in the retinal nerve fibre layer and 
are described as ‘flame shaped’ (Figure 1.5).  Retinal nerve fibre layer haemorrhages 
also occur in the absence of diabetes and are associated with hypertension.  Other 
early features of DR include capillary dilation and venous dilation which may be 
present before MAs and occurs in up to 10% of subjects [68]. 
 
Figure 1.5 Colour fundus photograph demonstrating background diabetic 
retinopathy.  Arrows indicate flame shaped haemorrhage (superior temporal to 
optic disc), microaneurysm (temporal to optic disc) and blot haemorrhage 
(temporal to the fovea).  (Courtesy of Liverpool Diabetic Eye Study). 
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1.6.3 Preproliferative diabetic retinopathy  
Progression of DR is seen on fluorescein angiography as hypofluorescent areas of 
capillary non-perfusion.  Angiographic features are accompanied by the clinical 
features of preproliferative diabetic retinopathy (PPDR): deep round ‘blot’ 
haemorrhages, ‘cotton wool spots’, intra-retinal microvascular abnormalities 
(IRMA) and venous changes.  Presence of these feature correlates with risk of 
development of PDR [70] (this evidence is reviewed in Chapter 2 of this thesis). 
 
Blot haemorrhages In contrast to dot haemorrhages, blot haemorrhages represent 
deep retinal infarcts located in the outer plexiform layer of the retina.  They are 
found where clusters of capillaries occlude.   
 
Cotton wool spots (CWS) CWS are white lesions with indistinct margins located in 
the superficial retinal layers (Figure 1.6).  They comprise localised accumulations of 
axoplasmic debris with adjacent bundles of unmyelinated ganglion cell axons.  
Traditionally CWS were thought to represent focal infarcts from terminal arteriolar 
occlusion in the retinal nerve fibre layer.  However, an alternative hypothesis of 
CWS as boundary sentinels of inner retinal ischaemia has been suggested [71]. 
 
Figure 1.6 Colour fundus photograph demonstrating multiple white ‘cotton wool 
spots’ and large dark ‘blot’ haemorrhages along the vascular arcades.  (Courtesy of 
Liverpool Diabetic Eye Study). 
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Intraretinal microvascular abnormalities (IRMA) IRMA are vascular shunts joining 
retinal pre-capillary arterioles to venuoles.  On clinical examination they appear as 
intraretinal fine red lines which may have a tortuous configuration (Figure 1.7). 
Angiography demonstrates that these lesions are usually located adjacent to areas 
of capillary non-perfusion.  IRMA may be difficult to differentiate from new vessels.  
In contrast to neovascularisation they show no, or only mild, leakage on 
fluorescence angiography, do not cross major retinal vessels and are wholly 
intraretinal. 
 
Figure 1.7 Colour fundus photograph demonstrating intraretinal microvascular 
abnormalities (IRMA)(arrows).  The large calibre vein on the left of the photograph 
demonstrates ‘beading’ (Courtesy of Liverpool Diabetic Eye Study). 
 
Venous changes Where veins traverse areas of extensive capillary closure venous 
changes occur.  The most common change is venous beading.  Beading may occur 
due to loss of supporting tissue architecture or may represent foci of venous 
endothelial cell proliferation which failed to develop into neovacularisation.  
Infrequent abnormalities include venous loops and venous reduplication. 
 
1.6.4 Proliferative diabetic retinopathy 
PDR is the vascular response of the retina to extensive capillary closure.  Tissue 
ischaemia is thought to lead to production of angiogenic factors including hypoxia-
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inducible factor 1α (HIF1α), HIF2α and VEGF [68].  The clinical features of PDR are 
new vessels at the optic disc (NVD), new vessels elsewhere (NVE), pre-
retinal/vitreous haemorrhage and proliferation of fibrous tissue.    
 
New vessels at the disc (NVD) New vessels arise most commonly at the posterior 
portion of the fundus: usually within 45 degrees of the optic disc.  NVD are defined 
as neovascularisation arising on the disc or within 1 disc diameter of it (Figure 1.8).  
The normal disc has a network of fine capillaries on the surface: the pre-papillary 
capillary plexus. New vessels are distinguished from normal vessels by looping back 
to the disc, forming loops in which the top of the loop is wider than the base, 
presence of solid tips and variable vessel calibre.  If there is doubt NVD demonstrate 
profuse leakage on fluorescein angiography. 
 
 
Figure 1.8 Colour photograph showing new vessels at the disc (NVD)(Courtesy of 
Liverpool Diabetic Eye Study). 
 
New vessels elsewhere (NVE) New vessels arise from post-capillary venules and 
occur at the watershed between perfused and non-perfused retina.  Unlike normal 
retinal vessels they do not obey the law of fractals (Figure 1.9).    In the presence of 
more advanced ischaemia new vessels may form on the iris; neovascularisation 
within the anterior chamber angle forms a barrier to aqueous drainage and leads to 
neovascular glaucoma.  
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Figure 1.9 Colour photograph showing a large area of new vessels elsewhere (NVE). 
(Courtesy of Liverpool Diabetic Eye Study). 
 
Fibrous tissue New vessels undergo proliferation and regression in a dynamic cycle 
[68].  Initially non-fibrous they may develop fibrous tissue.  This tissue is at first 
translucent but becomes progressively opaque.  Dynamic interaction at the 
vitreoretinal interface results in an inflammatory response, increased scar 
formation and adhesions between the retina and vitreous, in a “wound healing” 
response.  New vessels and fibrous tissue are asymptomatic until vitreoretinal 
interaction leads to pre-retinal or vitreous haemorrhage or contraction of the 
vitreous precipitates tractional retinal detachment. 
 
1.6.5 Advanced diabetic retinopathy 
 
Pre-retinal and vitreous haemorrhage Proliferating vessels grow into the vitreous 
gel.  These new vessels are fragile; traction from the gel results in sub-hyaloid/pre-
retinal haemorrhage (Figure 1.10).  When blood breaks the posterior hyaloid 
surface it is described as vitreous haemorrhage.     
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Figure 1.10 Colour photograph showing a typical ‘boat shaped’ pre-retinal 
haemorrhage: blood is held behind the posterior hyaloid face and assumes this 
shape due to gravity.  Lesions of peripheral scatter laser are present. (Courtesy of 
Liverpool Diabetic Eye Study). 
 
Tractional retinal detachment Contraction of fibrovascular tissue and the adherent 
vitreous gel results in traction on the retina.  When tractional forces overcome 
adhesion between the retina and the underlying retinal pigment epithelium retinal 
detachment occurs.  This process progresses slowly unless retinal breaks occur 
leading to a combined tractional and rhegmatogenous (due to a retinal break) 
detachment (Figure 1.11). 
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Figure 1.11 Colour photograph showing extensive, elevated fibrovascular tissue on 
either side of the fovea.  Lines in the retinal tissue indicate traction across the fovea. 
The perifoveal, dark, ovoid lesion is a retinal hole (MDRS photographs). 
 
1.6.6 Diabetic maculopathy 
         
Macular oedema Thickening of the retina occurs via two mechanisms.  Abnormal 
capillary permeability (breakdown of the blood retinal barrier) leads to passage of 
fluid from the vascular compartment to surrounding retinal tissue.  Hypoxia leads to 
accumulation of intracellular fluid in retinal cells.  Leakage from clusters of MAs may 
appear as a discreet area of ‘focal’ oedema (Figure 1.12).  More widespread ‘diffuse’ 
oedema is thought to result from leakage from capillary segments as well as MAs.  
Retinal pigment epithelial dysfunction may also contribute [68].  Macular oedema 
disrupts the normal architecture of the retina and threatens vision.   
 
Exudates Retinal thickening can only be appreciated on stereoscopic viewing or 
OCT.  A surrogate marker of thickening is the presence of exudates.  These yellow, 
waxy and sharply demarcated lesions are composed predominantly of lipids and 
located in the outer plexiform layer.  When found in a circular or semi-circular 
configuration surrounding an area of thickening they are described as ‘circinate 
exudates’ (Figure 1.13). Lipid remains dispersed within the retina in the area of 
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oedema but is deposited at the edges as water and small molecules are reabsorbed 
by surrounding non-ischaemic tissue [68]. 
 
 
Figure 1.12 Left: Fluorescein angiogram images from a subject with diabetic 
macular oedema: leaking microaneurysms close to the centre of fovea (yellow 
arrow); foveal avascular zone (blue arrow). Right: Optical coherence tomography 
scan showing a cross section through the retina: intraretinal (black) fluid cysts 
indicate the presence of diabetic macular oedema. 
 
Figure 1.13 Colour photograph demonstrating a ‘circinate ring’ of exudates 
surrounding a cluster of microaneurysms.  In this example the exudates are not 
close to the central fovea; vision was Snellen 6/5. (Courtesy of Liverpool Diabetic 
Eye Study). 
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Ischaemia Capillary non-perfusion at the macula leads to ischaemia and dysfunction 
of the surrounding retinal tissue.  At present no specific treatments are available for 
ischaemic maculopathy.  However, medical management of diabetes and 
fractionated scatter laser treatment are thought to be beneficial.  Clinical clues to 
the diagnosis include poor vision (6/36 Snellen or worse), macular IRMA, blot 
haemorrhages and vessel ‘pruning’.  Definitive diagnosis is by fluorescein 
angiography.  Ischaemia may occur alone or in combination with leakage.  
 
1.7 Chapter summary 
The pathophysiology of DR is complex.  Dysfunction of the vascular endothelium is 
an important component and can be assessed by measurement of serum 
biomarkers and in vivo functional testing.  The clinical features of DR are well 
described but with the introduction of OCT and antiVEGF therapy are changing.  In 
Chapter 2 I will detail the various existing DR grading systems and review the 
evidence relating grades of retinopathy with risk of progression of retinopathy and 
risk of visual loss. 
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Chapter 2. Grading of Diabetic Retinopathy 
 
 
2.1 Aims of the chapter  
There are many methods of classifying diabetic retinopathy (DR).  In this chapter I 
describe the benefits and drawbacks of the existing systems and introduce the 
Liverpool Diabetic Eye Study (LDES) grading scheme. 
 
2.2 Overview  
In Chapter 1 of this thesis I detailed the clinical features of DR.  Classification is 
primarily based on the presence of these features (feature specific grading), 
examined either by ophthalmoscopy or using photography.  An ideal grading system 
would be sensitive, specific, reproducible by clinicians, technicians, graders and 
researchers, validated for prognosis in large cohort studies and quick to perform.  
Existing systems represent a compromise between these qualities.   
 
2.3 Historical grading systems 
 
The Hammersmith Hospital Grading System The forerunner of current feature 
specific grading systems based on comparison with standard photographs, this 
system was originally published in 1967 by Oakley and colleagues [73].  It was 
designed for assessment of patients undergoing pituitary ablation for DR.  Each of 
four features: microaneurysms, haemorrhages, exudates and fibrous proliferations, 
were graded on a five point scale against standard photographs.  In 1972 this 
system was modified by Kohner et al. [74] to include classification of new vessels 
and cotton wool spots (CWS).  This classification was not validated for prognosis of 
visual outcome. 
 
The Oxford Retinopathy Index This system for classifying early DR involves counting 
individual microaneurysms from colour fundus photographs at 25 fold 
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magnification.  It was originally published by Howard-Williams in 1986 [75].  Only a 
small area of the retina is examined.  This system has not been validated against 
other grading systems but is a sensitive indicator of DR progression [76]. 
 
2.4 Airlie House classification 
In 1968 a group of experts met at Airlie House, Virginia.  An important outcome of 
this symposium was the development of a standardised classification of DR.  The 
Airlie House system classified DR into background and proliferative.  Proliferative 
DR (PDR) was subdivided according to the presence of new vessels, fibrous 
proliferations and vitreous haemorrhage.  Each feature was graded according to 
location and extent [77].  This system was subsequently modified and used in the 
Diabetic Retinopathy Study (DRS) [78].  This randomised, controlled clinical trial 
commenced in 1971 and involved 1,758 subjects.   The DRS assessed the 
effectiveness of Xenon and Argon laser treatment for treating PDR.  At 2 years, 
photocoagulation significantly reduced the risk of severe visual loss (defined as 
visual acuity 5/200 or worse; approximately equivalent to Snellen 2/60) by 
approximately 50% compared to no treatment [79].  The benefit persisted 
throughout 5 years of follow-up [80].  The benefits of laser treatment were greatest 
in patients with features of DR termed ‘high risk characteristics’ by the DRS (Box 
2.1) [81].  The Airlie House classification system was useful for making comparisons 
between different treatment modalities.  However, it was insensitive to changes in 
early features of retinopathy.   
 
 
 
 
 
 
 
 
 
 
Box 2.1 High risk characteristics for severe visual loss defined by the 
Diabetic Retinopathy Study [81] 
1. New vessels at the disc greater than or equal to 1/3 disc area 
(standard photograph 10A) 
2. New vessels at the disc less than 1/3 disc area with pre-retinal or 
vitreous haemorrhage 
3. New vessels elsewhere greater than or equal to 1/2 disc area with 
pre-retinal or vitreous haemorrhage 
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2.5 Modified Airlie House classification 
Barbara Klein et al. described a classification system based on the prognostic 
significance of retinal features for visual loss.  In a study commenced in 1970 191 
non-obese subjects with diabetes of at least 5 years' duration and onset before 50 
years of age who were taking insulin were followed for 6 years.  Stereoscopic colour 
fundus photographs of seven 30 degree fields in each eye were taken at each of 3 
study visits [82].  In multivariate regression analysis individual clinical features were 
correlated with development of proliferative disease and visual loss.  The resulting 
‘Modified Airlie House Classification’ (or Wisconsin system) specified 6 levels of 
retinopathy for each eye; when both eyes are considered an 11-step grading 
scheme results.  An adaptation of this grading system was used in the Wisconsin 
Epidemiological Study of Diabetic Retinopathy (WESDR).  This large population-
based study aimed to describe the prevalence of complications associated with 
diabetes and to identify risk factors.  A cohort of 996 subjects with younger onset 
diabetes and 1,370 subjects with diagnosis of diabetes at age 30 or over was first 
examined between 1980 and 1982 [10,11]; 6 follow-up examinations took place in 
1984-86, 1990-92, 1995-96, 2000-01, 2006-07, and 2012-14 [83,84,85].   
 
The Modified Airlie House Classification was revised further for the Early Treatment 
of Diabetic Retinopathy Study (ETDRS) [86].  Again thirty degree colour photos of 7 
fields were graded.  Feature specific grading was performed against standard 
fundus photographs.  DR was classified into 13 levels ranging from level 10 (no DR) 
to 85 (severe vitreous haemorrhage or retinal detachment involving the macula).  
The ETDRS final retinopathy severity scale is shown in Table 2.1. Definitions of 
features used in the ETDRS are listed in Appendix 1.  This grading system remains 
the reference standard for classification of DR.  Due to complexity its use is almost 
entirely limited to research studies.   
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Table 2.1 Early Treatment of Diabetic Retinopathy Study (ETDRS) final retinopathy 
severity scale (for individual eyes).  Reproduced from [70]. 
Level Severity Definition* 
10 DR Absent Microaneurysms and other characteristics absent 
14 DR Questionable HE, SE, or IRMA definite; Microaneurysms absent 
15 DR Questionable Haemorrhage(s) definite;  Microaneurysms absent 
20 Microaneurysms only Microaneurysms definite, other characteristics 
absent 
35† Mild NPDR One or more of the following: 
 Venous Loops  ≥  D/1 
 SE, IRMA, or VB  =  Q 
 Retinal Haemorrhages present 
 HE  ≥  D/1 
 SE  ≥  D/1 
43 Moderate NPDR H/Ma  =  M/4-5  -  S/1  or  IRMA  =  D/1-3 (not both) 
47 Moderately Severe NPDR Both L43 characteristics and / or 1 (only) of the 
following: IRMA  =  D4-5;  H/Ma  =  S/2-3;  VB  =  D/1 
53 Severe NPDR One or more of the following: 
 ≥  2 of the 3 L47 characteristics; 
 H/Ma  ≥  S/4-5 
 IRMA  ≥  M/1 
 VB  ≥  D/2-3 
61 Mild PDR FPD or FPE present with NVD and NVE absent; or NVE 
= D 
65 Moderate PDR Either of the following: 
1. NVE  ≥  M/1 or NVD = D; and VH and PRH = A or Q 
2. VH or PRH  =  D and NVE  <  M/1 and NVD absent 
71 High Risk PDR Any of the following: 
(1) VH or PRH  ≥  M/1 
(2) NVE  ≥  M/1 and VH or PRH  ≥  D/1 
(3) NVD  =  2 and VH or PRH  ≥  D/1 
(4) NVD  ≥  M 
75 High Risk PDR NVD  ≥  M and VH or PRH  ≥  D/1 
81 Advanced PDR: Fundus 
partially obscured, center of 
Macular attached 
NVD  = Cannot Grade, or NVD  <  D  and NVE  =  
Cannot Grade in  ≥  1 field and absent in all others; 
and retinal detachment at center of macular  <  D 
85 Advanced PDR: Posterior 
Fundus obscured, or center 
of Macular detached 
VH  =  VS in field 1 and 2; or retinal detachment at 
center of macular  =  D 
90 Cannot Grade, even 
sufficiently for L81 or L85 
 
 
†NPDR levels 35 and above all require presence of microaneurysms 
* Severity categories for characteristics graded in multiple fields are of the form (maximum 
severity/extent), where maximum severity can be absent (A), questionable (Q), definitely present 
(D), moderate (M), severe (S), or very severe (VS), and extent is the number of fields at that severity 
level. 
DR = diabetic retinopathy; HE = hard exudates; SE = soft exudates (an old term for cotton wool 
spots); IRMA = intraretinal microvascular abnormalities; NPDR = non-proliferative DR; VB = venous 
beading; H/Ma = haemorrhages microaneusyms; PDR= proliferative DR; NVE = new vessels 
elsewhere (>1 disc diameter [DD] from disc); NVD = new vessels disc (within 1 DD of disc margin); 
FPD = fibrous proliferations disc; FPE = fibrous proliferations elsewhere; VH = vitreous haemorrhage; 
PRH = preretinal haemorrhage. 
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The ETDRS was a multicentre randomised controlled trial designed to assess the 
efficacy of laser therapy (scatter and macular photocoagulation) and aspirin therapy 
in reducing progression of DR to more advanced DR, the best time to initiate laser 
treatment and the natural history and risk factors for progression of DR.  It 
commenced in 1979.  3711 subjects were randomised to aspirin or placebo therapy.  
Additionally one eye in each patient was assigned to immediate laser: one of four 
combinations of focal and scatter treatment.  Aspirin use did not affect progression 
of DR to high risk characteristics in eyes assigned to deferral of photocoagulation 
[87].  The ETDRS defined the terms ‘severe non-proliferative diabetic retinopathy 
(NPDR)’ (level 53) and ‘very severe NPDR’ (Box 2.2).  The study showed a statistically 
significant reduction in severe visual loss in eyes receiving early scatter laser [88].  
Severe NPDR was associated with a high rate of progression to high risk 
characteristics: 15% at 1 year; 56% at 5 years [88].  Very severe NPDR was 
associated with higher rates of progression: 45% at 1 year; 71% at 5 years [88].  
Severe NPDR has subsequently become a widely accepted threshold for initiation of 
scatter laser treatment (‘the 4-2-1 rule’). 
 
 
 
 
 
 
 
 
 
2.6 Classification of diabetic maculopathy 
The ETDRS introduced the term clinically significant macular oedema (CSMO)(Box 
2.3) [86].  The study demonstrated that macular laser treatment reduced the risk of 
moderate visual loss (defined as loss of ≥15 letters on the ETDRS chart, equivalent 
Box 2.2 Severe non-proliferative diabetic retinopathy (NPDR) as defined in the 
Early Treatment of Diabetic Retinopathy Study (ETDRS) [86]  
• Severe NPDR, any one of the following: 
1. 4 quadrants of haemorrhages and microaneurysms (HMa) ≥ standard 
photograph 2A 
2. 2 quadrants of venous changes ≥ standard photograph 6A 
3. 1 quadrant of intraretinal microvascular abnormalities (IRMA) ≥ 
standard photograph 8A 
• Very Severe NPDR: any 2 of the above 
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to a doubling of the visual angle) by up to 50% in subjects with CSMO [15].  Macular 
laser reduced retinal thickening and was associated with an increase in moderate 
visual gain.  On the basis of results from the ETDRS, CSMO is the accepted threshold 
for macular laser treatment.  The ETDRS used clinical examination to grade CSMO in 
clinical sites but stereoscopic photographs can be used and formed the protocol for 
grading at the Wisconsin Reading Centre. 
 
Diabetic maculopathy has been classified using the terms focal, diffuse, ischaemic 
and mixed.  Unfortunately these terms are often used without clear definitions.  
Published definitions for focal and diffuse maculopathy are based on features 
observed on clinical examination, colour photographs, fluorescein angiography (FA) 
and optical coherence tomography (OCT), either alone or in combination 
[89,90,91,92].  Because of the large number of definitions and their inconsistent 
use, evaluation of published data on prevalence, prognosis and response to 
treatment of focal and diffuse maculopathy is challenging.  Evidence from the 
ETDRS, which defined these terms according to the source of fluorescein leakage, 
did not support the concept that classification into focal and diffuse maculopathy is 
predictive of outcome after laser treatment [89].  Further confusion arises because 
the term ‘focal’ is used to describe a technique of applying laser directly to 
microaneurysms when treating diabetic maculopathy [89].  Some authors have 
advocated that the use of these terms should be discouraged and replaced by a new 
vocabulary the features of which correlate with clinical outcomes [93].  
 
 
 
 
 
 
 
 
 
 
Box 2.3 Clinically significant macular oedema (CSMO) as defined in the 
Early Treatment of Diabetic Retinopathy Study (ETDRS) [86]  
1. Retinal oedema within 500μm of the centre of the fovea, or 
2. Hard exudates within 500μm of the centre of the fovea if 
associated with adjacent oedema, or 
3. Retinal oedema ≥ 1 disc diameter (1500μm) within 1 disc 
diameter of the centre of the fovea 
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2.7 Liverpool Diabetic Eye Study grading 
The LDES is a large cohort study of subjects in a newly established DR screening 
programme [9].  The LDES grading scheme is a simplified version of the ETDRS 
grading system described above [86].  Colour fundus photographs of 3 overlapping 
45 degree fields are graded. Retinopathy and maculopathy are classified separately.  
Modifications of the ETDRS system were made following discussions with the 
Wisconsin Fundus Photograph Reading Centre, Madison (Professor Simon Harding, 
personal communication).  It was thought that the ETDRS system was too detailed 
and complex for use in routine clinical care.  Therefore modifications were made to 
simplify the ETDRS system.  Alterations were also made to reflect data from the 
ETDRS on photographic risk factors for progression to PDR and CSMO [70].  Greater 
weighting was given to venous changes and intra-retinal microvascular 
abnormalities (IRMA).  Reduced weighting was given to CWS.  Additionally, 
presence of exudates outside the macula was excluded from the LDES system and 
no distinction was made between small haemorrhages and microaneurysms.   
 
The LDES grading scheme includes 10 levels for retinopathy and 6 for maculopathy 
(plus the option of ‘ungradeable’ for either category).  Level of retinopathy is 
determined for each eye and a grade assigned based on the worse eye.  Similarly, 
each eye is graded for maculopathy and the grade of the worse eye assigned to that 
subject.  The macula is defined as a circular zone centered on the fovea, whose 
radius is the distance from the centre of the fovea to the temporal margin of the 
optic disc.  In the LDES, retinal thickening is not determined directly for classification 
of maculopathy (this would require the use of clinical examination or stereoscopic 
photos).  A grading system based on the presence of exudates is used.  Levels of 
retinopathy and maculopathy in the LDES are shown in Table 2.2. 
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Table 2.2 Levels of retinopathy and maculopathy in the Liverpool Diabetic Eye Study 
[94] 
 
Level  Definition  
Retinopathy 
10 No retinopathy 
12 Questionable 
20       Haemorrhages or microaneurysms < ETDRS standard photograph 2A † 
30       Haemorrhages or microaneurysms > ETDRS standard photograph 2A,  
 and/or 1-6 cotton wool spots  
40       Haemorrhages/ microaneurysms  > ETDRS STD 2A and/or > 6 cotton wool spots;  
 and/or 1 quadrant venous changes; and/or IRMA < ETDRS STD 8A  
50       IRMA > ETDRS STD 8A  
 and/or 2 or more quadrants venous changes 
 and/or pre-retinal haemorrhage in absence of proliferation  
60       Fibrovascular proliferation and/or proliferative retinopathy  
70       Diabetic Retinopathy Study high risk characteristics 
71 Tractional retinal detachment 
72 No fundal view due to vitreous blood 
90       Ungradeable due to any other reason e.g. media opacity  
Maculopathy 
0       No maculopathy 
1       Questionable: < 50% certainty of presence of exudate 
2       Exudate >1 disc diameter (DD) from fixation  
3       Circinate ring of exudates within macula >1 disc area in size but not within 1 DD of fixation  
4       Exudates within 1 disc diameter of fixation  
 and/or presence of clinically significant macular oedema  
8 Exudates due to other diseases e.g. vein occlusion, choroidal neovascularisation 
90      Ungradeable 
† Definition of any diabetic retinopathy:  ≥ 1 haemorrhages of microaneusyms (HMa) in either eye.  
Flame shaped haemorrhages associated with hypertension are discounted. 
ETDRS STD = Early Treatment of Diabetic Retinopathy Study Standard Photograph 
IRMA = Intraretinal Microvascular Abnormalities 
 
 
 
2.8 Comparison of LDES grading with the WESDR and ETDRS systems 
Both the ETDRS and the WESDR used 7-field 30-degree colour stereoscopic 
photography [86].  In contrast the LDES used 3-field 45-degree non-stereoscopic 
photographs [9].  The former photographic protocol images a greater proportion of 
the retina but still covers only 17% of the total retinal area [86].  30-degree images 
provide greater magnification than 45-degree images.  Stereoscopic images allow 
the detection of retinal thickening and oedema.  However, 7-field stereoscopic 
photography is technically difficult, time consuming and expensive: important in the 
context of a screening program and a large epidemiological study [95]. 
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The LDES grading scheme is a simplified version of the ETDRS system [86].  The LDES 
scheme has been validated for progression to sight threatening diabetic retinopathy 
(STDR; defined below) for persons with type 1 [96] and type 2 diabetes [9].  
Mapping of LDES levels onto ETDRS grades provides additional (indirect) evidence 
for risk of progression.  The LDES moderate pre-proliferative retinopathy grade 
(level 40) is roughly equivalent to ETDRS level 43 with risk at 1 year of development 
of PDR and high risk PDR of 11.9% and 3.2%, respectively [70,97].  Unlike the ETDRS 
scheme the LDES scheme has not been validated in terms of the degree of risk of 
progression to visual loss or blindness; a limitation of this grading methodology.   
 
 
2.9 Classification of maculopathy in the LDES 
In clinical practice diagnosis of sight-threatening maculopathy depends upon 
examination by stereoscopic slit lamp biomicroscopy.  Research studies have 
utilised slit-lamp biomicroscopy, stereoscopic colour photographs and stereoscopic 
FA to detect the condition [98].  Screening for DR using non-stereoscopic 
photography relies on surrogate markers, chiefly exudates.  The LDES classifies 
maculopathy according to the pattern of exudates and their distance from the 
centre of the fovea (Table 3.2).  Evidence from the ETDRS shows that presence of an 
exudate within a disc diameter from the centre of the fovea has a sensitivity of 94% 
for detection of CSMO but a specificity of only 54% [99].  The LDES grading scheme 
can be criticised for an inability to directly detect retinal thickening and a 
dependence on surrogate markers which may result in an underestimate of the 
frequency of retinal thickening.   
 
2.10 Sight threatening diabetic retinopathy 
The definition of STDR is not universally agreed upon.  A number of definitions have 
been proposed [100,101,102,103].  In the LDES, STDR was defined as any of the 
following: moderate pre-proliferative retinopathy or worse (retinopathy level 40-
71+); macular exudates in a circinate pattern or within one disc diameter of the 
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foveal centre, or CSMO (maculopathy level 3-4).  Sight threatening retinopathy is a 
subset of STDR defined in the LDES as moderate pre-proliferative retinopathy or 
worse (level 40-71+).  Sight threatening maculopathy is a subset of STDR defined in 
the LDES as macular exudates in a circinate pattern or within one disc diameter of 
the foveal centre, or CSMO (level 3-4) [9]. 
 
2.11 Simplified grading schemes: the English National Screening 
Programme  
A National Screening Programme for diabetic eye disease has been developed in the 
UK.  A screening program requires a grading system which facilitates appropriately 
prioritised referrals to a treatment service but does not require the many 
classification levels necessary for detailed monitoring of DR in clinical practice or 
natural history research studies.  Structured discussions of an expert panel took 
place between 2000 and 2002 to review existing grading schemes and design a 
suitable classification.  The aims of the committee were to maximise detection of 
STDR (sensitivity) whilst minimising false positive referrals to the hospital eye 
service (specificity).  The principles employed in this simplified grading scheme 
were: separate grading of retinopathy and maculopathy; minimum number of 
steps; no lesion counting; compatibility with central monitoring; expandable for 
established more complex systems and for research; to allow precise quality 
assurance at all steps (in excess of the Exeter Standards for DR screening [104]).   
 
Table 2.3 details the English National Screening Programme (ENSP) grading scheme 
[105].  The ENSP originally defined STDR as: pre-proliferative retinopathy or worse 
(R2), sight-threatening maculopathy (M1) and/or presence of photocoagulation (P1) 
(more recently presence of photocoagulation has been removed from the ENSP 
definition of STDR). These levels equate to referable retinopathy or maculopathy.  
This is the same as the LDES definition for STDR except for the inclusion of presence 
of haemorrhages/microaneurysms (HMa) within 1 disc diameter of the centre of the 
fovea and a visual acuity of 6/12 or worse.  The National Screening Committee 
(NSC) decided that the significance of CWS was unclear.  Therefore CWS were 
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included in the grading protocol only as a marker to indicate that a grader should 
search for other signs of pre-proliferative DR.   
 
Table 2.3 Levels of retinopathy in the English National Screening Programme 
grading scheme.  Reproduced from [105]. 
 
Retinopathy  (R) 
 
Level 0  None 
Level 1   Background Microaneurysm(s), retinal haemorrhage(s)  
 any exudate 
Level 2 Pre-proliferative Venous beading,  
Venous loop or reduplication,  
Intraretinal microvascular abnormality (IRMA) 
Multiple deep, round or blot haemorrhages 
(CWS-careful search for above features) 
Level 3  Proliferative New vessels on disc (NVD) 
    New vessels elsewhere (NVE)   
Pre-retinal or vitreous haemorrhage 
Pre-retinal fibrosis  tractional retinal detachment  
 
Maculopathy (M) 
M1    Exudate within 1 disc diameter (DD) of the centre of  
the fovea  
    Circinate or group of exudates within the macula 
Retinal thickening within 1DD of the centre of the fovea  
(if stereo available) 
Any microaneurysm or haemorrhage within 1DD of the  
centre of the fovea only if associated with a best VA of  6/12  
(if no stereo) 
 
Photocoagulation (P)  Focal /grid to macula 
    Peripheral scatter 
 
Unclassifiable (U)  Ungradeable/unobtainable 
 
 
 
2.12 Comparison of the LDES and ENSP systems 
Both the LDES and ENSP systems require separate grading for retinopathy and 
maculopathy.  In both systems the principle outcome is presence or absence of 
STDR.  When used for screening purposes STDR equates to referable retinopathy or 
maculopathy.  The LDES is more detailed, has more levels and, unlike ENSP, relies 
on counting of DR lesions.  The definition of sight threatening maculopathy is very 
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similar in both systems except that ENSP includes presence of microaneurysms or 
haemorrhages within 1DD of the centre of the fovea if associated with a best VA of 
 6/12 as a referral criteria.  The significance of HMa within 1DD of the centre of the 
fovea in the absence of other lesions is unclear (Simon Harding, personal 
communication).  An unpublished study from 2005 (Paul Dodson, personal 
communication) indicated that 10% of persons with HMa within 1DD of the centre 
of the fovea (and no other lesions) progress to exudative maculopathy within 12 
months.  No subjects in this study had progressed to CSMO in this time period. 
 
Like the LDES the ENSP grading scheme has not been directly validated for risk of 
development of visual loss.  However, retinopathy level R2 maps to ETDRS level 43 
described in Section 2.8 above.  As described above, evidence from the ETDRS 
demonstrates that an exudate within a disc diameter from the centre of the fovea 
has a sensitivity of 94% for detection of CSMO [99].  Shortly after the introduction 
of the ENSP scale a very similar Scottish Diabetic Retinopathy Grading Scheme was 
produced [106].  Table 2.4 shows a comparison table of grading schemes used in 
screening programmes together with the international DR severity scale introduced 
in Section 2.12.   
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Table 2.4 Comparative table of grading classifications and suggested management 
of DR.  ETDRS = Early Treatment of Diabetic Retinopathy Study; LDES = Liverpool 
Diabetic Eye Study; ENSP= English National Screening Programme for Diabetic 
Retinopathy; SDRGS = Scottish Diabetic Retinopathy Grading System; ICDRSS = 
International Clinical Diabetic Retinopathy Disease Severity Scale.   Adapted from 
[98] 
 
ETDRS LDES ENSPDR SDRGS ICDRSS 
10 10 
Annual screen 
R0 No DR 
Annual rescreen 
1 No DR 
Annual rescreen 
No DR 
Annual screen 
20 20 
Annual screen 
R1 BDR  
Annual screen  
Inform physician 
2 Mild BDR 
Annual screen 
Mild NPDR 
Annual screen 
35 30  
Screen 6 
monthly 
3 Moderate BDR 
Early rescreen 
Moderate 
NPDR 
Refer 
43 40 
Refer 
R2  
Pre-proliferative DR 
Refer 
4 Severe BDR 
Refer 47 
53 50  
Refer  
Consider laser 
5 Very severe BDR Severe NPDR 
Consider laser 
61, 65 60  
Laser 
R3 PDR 
Fast-track refer 
6 PDR early PDR 
Urgent laser 
71, 75 70  
Urgent laser 
7 PDR – HRC PDR HRC 
Urgent laser 81, 85 8 Advanced 
DR = diabetic retinopathy; BDR = background diabetic retinopathy; NPDR = non-proliferative DR;  
PDR = proliferative DR; HRC = high-risk characteristics. 
 
 
2.13 Simplified grading schemes: an international clinical severity 
scale 
As described above the ETDRS system is regarded as the reference standard for 
grading DR.  This system has more levels than may be required in clinical care and 
the definitions of the levels are detailed, require comparison with standard 
photographs and are difficult to remember.  In order to provide a framework for 
improved communications between primary care physicians, endocrinologists, 
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ophthalmologists, and other eye care providers an international working group was 
convened by the American Academy of Ophthalmology (AAO) in 2002 to produce a 
simplified grading system for clinical use [107].  In order that the scheme was based 
on evidence of the natural history of DR and could be mapped to progression to 
visual loss, levels were based on the ETDRS system.  Risks of progression and vision 
loss can therefore be taken from the ETDRS and the WESDR.   
 
The resulting International Clinical Diabetic Retinopathy Severity Scales (ICDRSS) 
classification system has 5 levels for DR: 3 ‘low risk’ stages, a fourth stage of severe 
NPDR, and a fifth stage of proliferative DR (Table 2.5).  Level 2 corresponds to 
ETDRS level 20; level 3 to ETDRS level 35 through 47.  Level 4 corresponds to ETDRS 
level 53 (severe NPDR): the ‘4-2-1 rule’ a widely agreed threshold for scatter laser 
treatment.  Diabetic macular oedema (DMO) is graded as present or absent and 
then further classified according to distance from the centre of the macula.  This 2 
tiered system reflects the reality that many examiners may not have the training or 
equipment (stereoscopic examination techniques) required for reliable detection of 
retinal thickening.   
 
The ICDRSS classification system is primarily designed for use in the United States 
where standard practice is to refer to an Ophthalmologist at Level 3 retinopathy.  
This scheme is not suitable for health systems in which there is a need to detect 
sight threatening DR which is likely to require treatment.  An obvious criticism of 
the ICDRSS scale for maculopathy is that the distance of exudates in each category 
from the centre of the fovea is not explicitly stated.  This leads to a degree of 
subjectivity in grading.  The sensitivity and specificity of this system for detection of 
DR and DMO has not been validated against the reference standard ETDRS system 
in high-quality clinical studies.  The impact of the use of this system on medical 
treatment of those with diabetes (through greater communication between primary 
care physicians, endocrinologists and ophthalmologists), on the number of persons 
receiving appropriate timely treatment for DR and on the degree of visual loss 
prevented in a variety of settings has yet to be fully evaluated.  
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Table 2.5 The American Academy of Ophthalmology International Clinical Diabetic 
Retinopathy Severity Scales (ICDRSS) for retinopathy and maculopathy.  DMO = 
diabetic macular oedema. Reproduced from [107]. 
 
Retinopathy  
Level 1  No apparent retinopathy  No abnormalities 
Level 2   Mild non-proliferative  Microaneurysms only 
diabetic retinopathy  
Level 3  Mod non-proliferative  More than just microaneurysms but less than severe  
diabetic retinopathy  nonproliferative diabetic retinopathy    
Level 4  Severe non-proliferative  Any of the following:  
diabetic retinopathy  more than 20 intraretinal haemorrhages in each of 4 
quadrants;  
definite venous beading in 2+ quadrants;  
Prominent intraretinal microvascular abnormalities  
in 1+ quadrant(s) 
And no signs of proliferative retinopathy 
Level 5  Proliferative diabetic  One or more of the following: 
retinopathy  neovascularization, vitreous/preretinal haemorrhage 
 
Maculopathy  
DMO apparently absent    No apparent retinal thickening or hard exudates in 
posterior pole 
DMO apparently present    Some apparent retinal thickening or hard exudates in 
post. pole 
If diabetic macular oedema present:  
• Mild DMO: Some retinal thickening or hard exudates in posterior pole but distant from 
the centre of the macula 
• Moderate DMO: Retinal thickening or hard exudates approaching the centre of the 
macula but not involving the centre 
• SevereDMO: Retinal thickening or hard exudates involving the centre of the macula 
 
 
 
 
2.14 Definition of ‘any diabetic retinopathy’   
The definition of ‘any DR’ is important because a number of high quality studies 
have demonstrated retinal lesions meeting study specific criteria for DR in subjects 
defined as not having diabetes.  The Diabetes Prevention Program (DPP) [108] 
studied a cohort of 3819 subjects with elevated fasting glucose (5.3–6.9 mmol/l) 
and impaired glucose tolerance but with no history of diabetes and not meeting 
WHO criteria for the diagnosis of diabetes.  Fundus photography was performed in 
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a selected subgroup of subjects and photographs graded at the Fundus 
Photography Reading Centre at the University of Wisconsin.  After mean follow-up 
of 5.6 years, retinopathy consistent with DR (defined as presence of any 
microaneurysms) was detected in 12.6% of subjects who developed diabetes during 
the study and 7.9% of subjects who remained without diabetes [108].  This study 
demonstrates that retinopathy may start in the state now considered ‘pre-diabetes’ 
and that DR, as currently defined, may be less specific to diabetes than previously 
thought.  To further complicate the picture resolution of type 2 diabetes is reported 
(for example following bariatric surgery [109]).  This scenario may be associated 
with presence of retinopathy but not diabetes. 
 
The Blue Mountains Eye Study of 2335 subjects without diabetes, as evaluated by 
the absence of a history of diabetes and normal fasting plasma glucose, 
demonstrated a 9.7% 5-year cumulative incidence of developing retinal 
microaneurysms, haemorrhages, CWS or exudates [110].  In this study retinal 
changes were not associated with high blood pressure or fasting plasma glucose.  
Retinopathy has also been reported in subjects with normal glucose tolerance.  A 
cross sectional study of Pima Indians (a population with an extremely high 
prevalence of diabetes) demonstrated retinal lesions consistent with DR (using the 
same criteria as the DPP) in 12% of subjects with impaired glucose tolerance and 3% 
with normal glucose tolerance [111].  It is clear that retinal vascular lesions are not 
uncommon regardless of glycaemic status.  The LDES grading scheme draws no 
distinction between dot haemorrhages and microaneurysms increasing the 
possibility that retinal lesions detected and defined as DR may not be specific to 
diabetes. 
 
2.15 The role of optical coherence tomography and fluorescein 
angiography 
The use of imaging technology has aided understanding of retinal vascular diseases 
including DR.  However, the majority of grading schemes have relied on clinical 
characteristics observed on colour fundus photographs and/or clinical examination.  
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The ETDRS included use of stereoscopic FA to assess characteristics including 
capillary loss, capillary dilatation, arteriolar abnormalities, abnormalities of the 
retinal pigment epithelium, cystoid changes and leakage.  A classification system 
based on comparison with standard photographs was produced [112]. 
Fluorescein leakage (particularly diffuse leakage), capillary loss and dilatation at 
baseline were associated with severity of DR assessed on colour fundus 
photographs and with likelihood of progression to PDR during follow-up [113].  FA 
was also used to guide laser treatment of macular oedema [89]. 
 
OCT is an imaging technique which uses low coherence interferometry to capture 
micrometer-resolution images of biological tissue.  OCT has revolutionised 
understanding of macular pathology including DMO and the vitreo-macular 
interface.  Several studies have produced grading schemes based principally on 
morphological characteristics of DMO on OCT [114, 115].  Bolz et al [116] recently 
published a more comprehensive grading scheme based on both OCT and FA 
findings.  The protocol contained four areas of interest: subretinal fluid; area of 
oedema; vitreo-retinal interface abnormalities; and source of leakage.  The authors 
suggested that their grading scheme may facilitate improved choice of appropriate 
therapies for DMO e.g. choice between macular grid laser and anti-VEGF therapies.  
However, the treatment strategies appropriate for the different categories of DMO 
in this grading scheme are not well defined.  Validation studies are required in 
relation to visual function and disease prognosis.  FA and OCT imaging are not 
widely available in Sub-Saharan Africa.  Grading schemes based on these imaging 
techniques are not yet applicable in this region. 
 
2.16 Automated grading of DR 
Grading DR by clinical examination or by manual inspection of fundus images 
requires trained professionals and is time consuming.  It is therefore expensive and 
a major limitation on the cost effectiveness of DR screening programmes.  
Automated systems have been developed to detect and grade DR from fundus 
photographs.  The process of analysing retinal images requires identification of 
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basic anatomical structures, recognition of pathological features, and extraction and 
classification of lesions.  A number of computer algorithms have been developed for 
automated segmentation of anatomical features (optic disc, blood vessels and the 
fovea) and abnormal lesions (microaneurysms and exudates) [117,118]. 
 
The ‘Retmarker’ automated grading system has been tested according to its ability 
to accurately assign fundus photographs to ‘disease’ or ‘no disease’ categories.  This 
system has been tested on fundus photographs from a screening service and 
compared to manual grading for a dataset which included 33,535 patient episodes.  
The software achieved between 95.0 and 98.1% and between 97.6% and 100% 
sensitivity for disease/no disease in subjects with referable retinopathy and PDR, 
respectively [119,120,121].  It was estimated that use of this system would result in 
a workload reduction for manual graders of between 38 and 46%.  The authors 
concluded that use of this automated system could safely reduce the workload of 
manual graders with large potential cost savings.  A prospective observational study 
is currently being conducted to quantify screening performance, diagnostic 
accuracy and cost-effectiveness of automated primary grading of fundus images in 
the ENSP with results expected in 2015 (Mr Adnan Tufail, Moorfields Eye Hospital, 
personal communication).  It is likely that automated grading will play an increasing 
role in DR research studies and screening programmes with significant cost 
implications. 
 
2.17 Chapter summary  
There are many grading schemes for DR.  The reference standard is the ETDRS scale: 
levels are validated for progression of retinopathy and visual loss as described in the 
WESDR and the ETDRS.  Other grading schemes including the LDES scale map to 
ETDRS levels providing an evidence base for referral and treatment thresholds.  
Detailed and validated grading schemes for DR facilitate studies of the determinants 
of severity and progression of DR.  In Chapter 3 I review the existing evidence on 
this topic. 
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Chapter 3. Determinants of Severity and Progression of 
Diabetic Retinopathy  
 
 
3.1 Aims of chapter  
In this chapter I review and appraise the existing evidence on the determinants of 
severity and progression of diabetic retinopathy (DR).  
 
3.2 Introduction 
The macro- and micro-vascular complications of diabetes were once thought to be 
an inevitable consequence of the disease.  Major epidemiological studies since the 
1970s have informed understanding of the pathophysiology of diabetes and DR and 
are key to understanding primary prevention of retinopathy.  The vast majority of 
these studies were performed in Europe and North America.  In the absence of 
good epidemiological evidence from sub-Saharan Africa (SSA), results are 
generalised to this region.  The evidence presented below is a starting point for 
investigation of determinants of severity and progression of DR in Southern Malawi. 
 
3.3 Outcome measures in studies of epidemiology and treatment  
Comparison between individual studies of DR is impeded by use of a number of 
different classification systems and a variety of different methods to assess the 
retina.  Classification of DR is described in Chapter 2 of this thesis.  The reference 
standard for assessment uses modifications of the Airlie House classification [86] 
based on grading of seven stereoscopic, 30 degree photographs.  Each eye receives 
a score and the grades for both eyes are combined on a stepped scale (usually 
according to grade in the worst eye).  Maculopathy is graded separately.  
Progression is usually defined in clinical trials and epidemiological studies as a 2 or 3 
step increase in DR grade from baseline (eg. 2 step = either 2 step progression in 
one eye or 1 step progression in both eyes).  Other surrogate markers of 
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progression include occurrence of vitreous haemorrhage, need for scatter laser 
photocoagulation and need for vitreoretinal surgery.  
 
Visual acuity (VA) is the preferred primary outcome for studies assessing treatments 
of DR.  The main disadvantage of this approach is that other pathologies (e.g. 
cataract) and additional interventions (e.g. cataract surgery) may adversely or 
beneficially affect vision independent of effect on DR.  The reference standard for 
measurement of VA is the Early Treatment Diabetic Retinopathy Study (ETDRS) 
chart read at 4m.  Advantages over the conventional Snellen chart include reduced 
effect of crowding as each line has 5 letters.  Loss of 15 letters (3 lines) is equivalent 
to doubling of the visual angle and was termed in the  ETDRS studies as ‘moderate 
visual loss’ (MVL). 
 
3.4 Overview of determinants of severity and progression  
Traditionally, determinants of DR severity and progression have been classified into 
modifiable and non-modifiable risk factors.  Epidemiological studies as well as 
intervention studies have informed our understanding of modifiable factors.  
Glycaemic control and blood pressure are the variables which have been most 
thoroughly studied.  More recently, intervention studies have addressed the role of 
lipids in DR.  There is little data on the contribution of anaemia and infections 
including HIV.  Large, high-quality cohort and cross sectional studies have reported 
the effects of non-modifiable risk factors.  The effect of duration of diabetes since 
diagnosis is well studied; a number of authors have estimated the mean duration of 
diabetes prior to diagnosis in groups of subjects with type 2 disease based on 
progression of DR data.  The role of ethnicity in DR prevalence and progression is 
unclear.  Genetic studies will offer further insights into the pathophysiology of DR 
and open the possibility of individually targeted therapies based on genotype. 
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3.5 Modifiable risk factors 
 
3.5.1 Measurement of glycaemic control 
Glycaemic control is an important determinant of DR severity and progression as 
described in Section 3.5.2 below.  Measures of glycaemic control in diabetes include 
fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c).  HbA1c is a form of 
haemoglobin produced in a non-enzymatic glycation pathway by exposure of 
haemoglobin to plasma glucose.  Measurement involves 2 processes.  The first 
separates the fractions of haemoglobin by either affinity chromatography (AC), ion 
exchange chromatography (IEC) or capillary electrophoresis (CE).  The second 
measures the concentration of HbA1c based on a specific chemical reaction to the 
glycated N-terminal of the haemoglobin beta-chain.  Tests are either 
immunochemical or enzymatic.  Total haemoglobin concentration is also measured 
allowing the proportion of glycated haemoglobin to be determined.  Although 
different analytes are measured by these assays, testing is standardised by the 
reference measurement procedure of the International Federation of Clinical 
Chemistry (IFCC). 
 
Both FPG and HbA1c measurements show a relationship to risk of retinopathy 
[122].  Measurement of HbA1c is the standard method for monitoring glycaemic 
control in Europe and North America.  More recently, recognising that testing is 
now highly standardised, the American Diabetes Association have approved its use 
for diagnosis of diabetes [123].  The advantages of HbA1c over FPG include 
convenience (no fasting required), fewer day-to-day fluctuations during episodes of 
illness or stress, and evidence to suggest greater pre-analytical stability [123].  
Disadvantages of HbA1c include greater cost and the fact that testing requires strict 
quality management.  Accredited laboratories must demonstrate internal control 
procedures and participate in an external quality assessment programme.  
Measurement of HbA1c is affected by haemoglobin variants (including Hb S & C 
prevalent in black Africans), anaemia (more prevalent in the developing world) and 
HIV infection (highly prevalent in many countries in sub-Saharan Africa).  For these 
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reasons FPG, not HbA1c, is the standard for measurement of glycaemic control in 
most countries in sub-Saharan Africa.  To my knowledge HbA1c has not been 
validated in populations in East Africa. 
 
3.5.2 Glycaemic control 
Two pivotal randomised controlled trials (RCTs) demonstrated the importance of 
good glycaemic control in reducing the incidence and progression of retinopathy in 
diabetes: the Diabetes Complications and Control Trial (DCCT) in type 1 diabetes 
and the United Kingdom Prospective Diabetes Study (UKPDS) in type 2 diabetes.   
 
DCCT   
The DCCT was conducted in 29 centres in the United States and Canada between 
1983 and 1989.  1441 subjects with type 1 diabetes of greater than 1 and less than 
15 years duration (726 with no retinopathy and 715 with background DR at 
baseline) were randomised to either intensive or conventional glycaemic control 
(mean HbA1c achieved 7.2% and 9.1%, respectively).  Mean duration of follow-up 
was 6.5 years [12,124,125,126]. 
 
For subjects with no DR at baseline the incidence of retinopathy (defined as a 
change of three steps on the ETDRS scale that was sustained over a six month 
period) was 76% (95% CI 62-85) lower in the intensive therapy arm than the 
conventional arm [12].  For subjects with background retinopathy at baseline 
intensive therapy reduced the risk of retinopathy progression by 3 steps (or more) 
by 54% (95% CI 39-66).  Intensive therapy reduced the risk of severe non-
proliferative DR or proliferative retinopathy (PDR) by 47% and that of treatment 
with laser photocoagulation by 56% [12].  Figure 3.1 shows cumulative incidence of 
DR progression in subjects with and without retinopathy at baseline.  The authors 
concluded that intensive control was most effective when started before 
retinopathy was detectable. 
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Figure 3.1 Cumulative incidence of sustained 3 step progression of retinopathy in 
subjects with type 1 diabetes receiving intensive or conventional therapy. A: 
subjects with no retinopathy at baseline. B: subjects with background DR at 
baseline.  Numbers of subjects in each therapy group who were evaluated at years 
3,5,7 and 9 are shown below the graphs.  Taken from the DCCT [12]. 
 
In the DCCT, intensive therapy reduced the incidence of microalbuminuria by 39%, 
albuminuria by 54% and neuropathy on clinical examination by 60% [12].  The 
absolute risks of nephropathy and retinopathy were proportional to the mean 
HbA1c level over the follow-up period preceding each event.  Mortality did not 
differ significantly between the intensive and conventional therapy arms.  However, 
the incidence of severe hypoglycaemia was 3 times higher in the intensive arm.  A 
person not involved in the trial was killed in a road traffic accident after being hit by 
a motorbike ridden by a subject in the intensive arm who had an episode of 
hypoglycaemia.  More weight gain was observed in the intensive therapy arm.  
 
Follow-up of the DCCT cohort continued annually as part of the Epidemiology of 
Diabetes Interventions and Complications (EDIC) study [127,128].  During this study 
glycaemic control no longer differed substantially between the original 2 treatment 
arms of the trial: at one year the difference was 0.4% (HbA1c 8.3% in the former 
conventional therapy arm and 7.9% in the former intensive arm, p<.001) and by 5 
years the difference was non-significant.  In analyses using the DCCT final 
retinopathy grade as a new baseline, at 4 years of EDIC further progression of DR 
was between 66 to 77% less (depending on the measure used) in the former 
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intensive arm than the former conventional arm [127].  This phenomenon has been 
termed ‘metabolic memory’.  Cumulative incidence of 3 step progression was still 
significantly less at 7 years [127] and 10 years [128].  Significantly fewer former 
intensive subjects than former conventional subjects required laser treatment 
during EDIC [128].  The EDIC study demonstrated a reduction in cardiovascular 
disease in the former intensive group which had not been apparent in the DCCT 
[129]. 
 
The overall results of the DCCT/EDIC were interpreted by the authors to show that 
the benefits of intensive glycaemic control take some years to manifest but 
subsequently persist beyond the period of intervention.  The authors hypothesised 
that the predictive association of risk of DR with preceding mean HbA1c was a 
causal relationship and that total glycaemic exposure determines the degree of 
retinopathy observed at any one time.  A HbA1c target level of 7.0% or less was 
suggested [127] although the authors acknowledged the risks of increased 
hypoglycaemic events and excess weight gain with intensive therapy regimes 
[130,131].   
 
The DCCT did not define the optimum methods to achieve good glycaemic control 
while minimising adverse events; subsequent studies would explore the benefits 
and risks of treatment regimens aimed at reducing mean HbA1c further.  While the 
DCCT/EDIC analyses were adjusted for a number of baseline physiological 
parameters there was no adjustment for use of medications other than 
hypoglycaemic agents (e.g. aspirin and angiotensin-converting enzyme inhibitors) 
which is a potential confounder.  The DCCT/EDIC studies commenced over 30 years 
ago and results are increasingly difficult to apply to current practice.  Many aspects 
of diabetes care have changed markedly over this time.  In particular management 
of blood pressure was generally much worse than at present.  These caveats 
notwithstanding concepts such as metabolic memory are still highly relevant.    
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UKPDS  
The UKPDS was conducted between 1977 and 1997.  3867 subjects with newly 
diagnosed type 2 diabetes (median age 54 years; IQR 48-60 years) who, after 3 
months diet treatment had a fasting plasma glucose concentration of 6.1-15.0 
mmol/L, were randomly assigned to intensive glycaemic control with a 
sulphonylurea or insulin, or conventional therapy with diet [132,133,134,135]. 
Mean HbA1c levels achieved were 7.0% (6.2–8.2) and 7.9% (6.9–8.8), respectively.  
Median follow-up was 10.0 years (IQR 7.7–12.4).  Subjects in the intensive 
treatment arm had a significant 25% risk reduction in microvascular endpoints.  
Most of this reduction was due to fewer subjects requiring retinal laser treatment.    
The UKPDS investigated surrogate endpoints, including 2 step progression of DR, at 
visits at 3 year intervals.  Subjects in the intensive treatment arm demonstrated a 
34% reduction in incidence of DR and 17% lower rate of 2 step progression (a 
difference which was significant even when subjects who received retinal laser were 
excluded).  Each 1% reduction in HbA1c gave a 31% reduced risk of incidence or 2 
step progression of DR.  
 
Relatively few subjects in the UKPDS developed late complications of DR such as 
vitreous haemorrhage or blindness.  This may be because the follow-up period was 
not long enough.  A more likely explanation is that subjects were examined 
regularly and received laser photocoagulation as necessary.  Despite this the 
intensive arm showed a 16% reduction in legal blindness.  With regard to 
macrovascular endpoints the UKPDS showed evidence of a 16% risk reduction for 
myocardial infarction, which included non-fatal and fatal myocardial infarction and 
sudden death.  This difference was not statistically significant by conventional 
criteria: p=0·052.  It is possible that this difference may have been greater given a 
longer duration of follow-up.  Interpretation of this outcome is complicated by the 
multifactorial nature of cardiovascular disease.  Diabetes-related mortality and all-
cause mortality did not differ between the intensive and conventional groups.  
However, the study was not sufficiently powered to exclude a beneficial effect on 
mortality. 
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The number needed to treat to prevent one subject developing any of the single 
trial endpoints (either micro or macrovascular) over 10 years was 19.6 subjects 
(95% CI 10–500).  The ‘complication free interval’ (defined as the time at which 50% 
of subjects had at least one diabetes related trial endpoint) was 14.0 years in the 
intensive arm and 12.7 years in the conventional arm (p=0.029).  As in the DCCT the 
proportion of subjects experiencing hypoglycaemic episodes was significantly higher 
in the intensive arm.  In subjects treated with insulin each year, 3% had a major 
episode and 40% a minor or major hypoglycaemic episode.  Subjects in the intensive 
arm also demonstrated significantly increased weight: mean 3.1 kg (99% CI –0.9 to 
7.0, p<0·0001) at 10 years. 
 
Importantly the UKPDS showed that clinical benefit could be gained at lower HbA1c 
values than DCCT.  The UKPDS compared a difference in HbA1c between intensive 
and conventional arms of 0.9% (7.0 vs 7.9%) over 10 years.  This is smaller than the 
difference compared in the DCCT: 1.9% (7.2 vs 9.1%).  The DCCT studied younger 
subjects with type 1 diabetes and used slightly different (mainly surrogate) outcome 
measures.  With this caveat, comparison of DCCT and UKPDS results suggests that 
the benefits of HbA1c reduction on risk of progression of microvascular disease are 
proportional: 21% for retinopathy in UKPDS and 63% in the DCCT, and, for 
albuminuria, 34% and 54% respectively. 
 
ACCORD and ADVANCE  
The DCCT and UKPDS demonstrated unequivocal reductions in ocular morbidity 
with improved glycaemic control.  However, the potential benefits of tighter control 
remain controversial.  The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR 
Controlled Evaluation (ADVANCE) were large RCTs of glycaemic control to levels 
lower than the DCCT and UKPDS.  In the ACCORD study 10,251 subjects with type 2 
diabetes who were at high risk for cardiovascular disease were randomised to 
either intensive or standard glycaemic control (target <6.0% or 7.0 to 7.9%; at one 
year achieved mean HbA1c were 6.4% and 7.5%, respectively).  Of these 
participants 5518 with dyslipidiaemia were randomised to either intensive or 
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standard therapy: 160 mg daily of fenofibrate plus simvastatin or placebo plus 
simvastatin.  The remaining 4733 subjects were randomised to either intensive or 
standard therapy for systolic blood-pressure control: target <120 or <140 mm Hg 
[136,137].  A sub-group of 2856 subjects was evaluated at 4 years for the effects of 
these interventions on the progression of DR by 3 (or more) steps on the ETDRS 
scale or development of DR necessitating laser photocoagulation or vitrectomy. 
 
At 4 years follow-up, progression of DR was seen in 7.3% of the intensive group and 
10.4% of the standard group (adjusted odds ratio 0.67; 95% CI 0.51 - 0.87; p=0.003).  
In the ACCORD Eye study there was a non-significant trend towards reduced MVL 
(23.8% vs 26.3%; hazard ratio 0.88; 95% CI 0.77-1.01; p=0.06).  However, in the 
entire ACCORD population there was a significant reduction in MVL in the intensive 
group (19.1% vs 20.7% with standard therapy; hazard ratio, 0.91; 95% CI, 0.83 to 
1.00; P = 0.047)[138].  The authors concluded that intensive glycaemic control 
reduced the rate of progression of DR and reduced visual loss (even in a population 
receiving regular eye examination and with access to treatment for DR).  
Unfortunately the ACCORD trial showed a significantly increased risk of having a 
hypoglycaemic event that necessitated assistance in the intensive arm.  Most 
worryingly the intensive regime was associated with an increase in all-cause 
mortality after mean 3.5 years follow-up.  This led to the premature cessation of the 
glycaemic trial.  The study may therefore have underestimated the reported effect 
of glycaemic treatment on DR.  More importantly though ACCORD demonstrates 
real risks associated with intensive treatment strategies.  The ACCORD population 
were older than those of the DCCT and UKPDS and pre-selected to be at high risk of 
cardiovascular disease.  Results from the trial regarding risks should be generalised 
to all patients with type 2 diabetes with caution. 
 
The ADVANCE study randomly assigned 11,140 patients with type 2 diabetes to 
either intensive (gliclazide plus other drugs) or standard control.  After median 
follow-up 5 years mean HbA1c achieved was 6.5% and 7.3%, respectively [139].  A 
subgroup of 1241 subjects in the ADVANCE Retinal Measurements (AdRem) study 
underwent retinal photography and ETDRS grading of DR [140].  In the main study 
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intensive control reduced the incidence of major microvascular events (hazard ratio 
0.86; 95% CI, 0.77 to 0.97; p=0.01) and of combined major macrovascular and 
microvascular events (hazard ratio 0.90; 95% CI 0.82-0.98; p=0.01).  These results 
were mainly due to a reduction in incidence of nephropathy.   
 
In the main study there was no significant difference between the 2 arms in the 
number of subjects undergoing retinal photocoagulation.  However, the absolute 
numbers requiring laser treatment were low thus limiting the power of the study to 
detect a difference.  In the AdRem sub-study there was no significant reduction in 
development or progression of DR or maculopathy.  There were no significant 
differences between the intensive and standard arms with regard to major 
macrovascular events, death from cardiovascular cause or death from any cause.  
Intensive control was associated with an increased risk of severe hypoglycaemia 
(hazard ratio 1.86; 95% CI 1.42-2.40; p<0.001) and an increased risk of 
hospitalisation.   
 
Steno 2  
Trials assessing multifactorial interventions have informed understanding of the 
effects of glycaemic control on DR.  The Danish Steno 2 study randomised 160 
subjects with type 2 diabetes and persistent microalbuminuria to an intervention 
comprising tight glucose control, the use of renin–angiotensin system blockers, 
aspirin, and lipid-lowering agents and behavioural modification or standard care.  
The mean treatment period was 7.8 years and subsequent follow-up continued for 
a mean of 5.5 years.  The intensive group showed reduced risk of retinal 
photocoagulation (relative risk 0.45; 95% CI 0.23-0.86; p=0.02), all-cause mortality 
(hazard ratio 0.54; 95% CI 0.32-0.89; p = 0.02), death from cardiovascular causes 
(hazard ratio, 0.43; 95% CI 0.19-0.94; p=0.04) and of cardiovascular events (hazard 
ratio, 0.41; 95% CI 0.25-0.67; p<0.001) [141]. Few major side effects were reported.  
This study showed large relative and absolute improvements in microvascular and 
macrovascular outcomes.  It was not designed to identify the relative contributions 
of the individual elements in the intervention package.  The Steno 2 study is one of 
the most important studies on which modern diabetes management is based.  Box 
52 
 
3.1 lists the targets for modifiable risk factors and behavioural changes that were 
set in the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therapeutic issues in glycaemic control 
A goal of HbA1c <7% is suitable for the majority of persons with diabetes [142].  
Certain patients may benefit from lower HbA1c targets (≤ 6.5%) but the beneficial 
effects for DR progression are limited.  For some patients, including those with 
cardiovascular disease or a record of severe hypoglycaemia, the risks in terms of 
mortality of a HbA1c target <7% may outweigh the benefits.  A phenomenon 
observed in both the DCCT and UKPDS was rapid DR progression in a minority of 
subjects (13% in DCCT) within the first 18 months of the initiation of intensive 
therapy [143].  A similar observation was made in patients achieving excellent 
glycaemic control following combined renal and pancreas transplants [144].  
Patients with poor glycaemic control, with diabetes of long duration and moderate 
Box 3.1 Targets for modifiable risk factors and lifestyle changes set 
by the Steno 2 study [141] 
• Glycosylated haemoglobin (HbA1c) < 6.5% 
• Blood pressure < 130/80 mmHg 
• Total cholesterol < 175 mg/dl 
• Triglycerides < 150 mg/dl  
• Angiotensin-converting enzyme (ACE) inhibitor (regardless of blood 
pressure): equivalent to captopril 50mg twice daily 
• Aspirin 150 mg daily to patients with a history of cardiovascular 
disease 
• Reduction in intake of dietary fat: total daily intake of fat less than 
30% of total daily energy intake, and intake of saturated fatty acids 
of less than 10% of total daily energy intake 
• Regular exercise: at least 30 min three to five times a week 
• Smoking cessation  
• A dietary supplement consisting of vitamins C (250 mg daily) and E 
(100 mg daily), folic acid and chromium picolinate 
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or severe non-proliferative DR require careful monitoring by an ophthalmologist for 
at least 12 months before and following initiation of intensive therapy.   
 
Thiazolidinediones (glitazones) are hypoglycaemic agents used in type 2 diabetes.   
There is evidence of a beneficial effect of these agents on DR progression beyond 
their hypoglycaemic effects [145].  However, some studies have identified an 
increased risk of maculopathy with glitazone use [146]. A large prospective study of 
170,000 subjects using the Diabetes Case Identification Database at Kaiser 
Permanente, Southern California, 9.9% of whom were taking glitazones, identified a 
2.6-fold increased risk of developing diabetic maculopathy (95% CI 2.4–3.0) [147].  
Other studies [145] including ACCORD [148] have not identified an increased risk of 
DMO.  Current practice is to avoid glitazones in patients who develop maculopathy, 
particularly when peripheral oedema is also present.  
 
 
3.5.3 Blood pressure 
UKPDS  
The UKPDS was the first study to demonstrate unequivocally that tight blood 
pressure control reduces both the macrovascular and microvascular complications 
of diabetes.  1148 subjects with type 2 diabetes and hypertension were randomised 
to either tight BP control with the angiotensin converting enzyme inhibitor (ACEI) 
captopril or the beta blocker atenolol as the main treatment (target <150/85 
mmHg) or less tight control (target <180/105mmHg) [14].  After 8.4 years median 
follow-up the mean BP achieved in the 2 arms was 144/82mmHg and 154/87mmHg, 
respectively (a difference of 10mmHg systolic BP and 5mmHg diastolic BP).  The 
tight control group demonstrated a reduction in risk of all diabetes related 
endpoints (24%; 95% CI 8%-38%; p=0.0046), deaths related to diabetes (32%; 6%-
51%; p=0.019), and strokes (44%; 11-65%; p=0.013). There was a nonsignificant 
reduction in all-cause mortality. 
 
The UKPDS showed a 37% reduction in risk of microvascular endpoints (95% CI 11%-
56%; p=0.0092) mainly due to reduced risk of retinal laser treatment (Figure 3.2). At 
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9 years follow-up the tight control group demonstrated a 34% reduction in the rate 
of 2 step DR progression (99% CI 11-50%; p = 0.0004) and a 47% reduced risk of 
MVL (7-70%; p = 0.004).  Reduction in MVL was primarily due to reduced incidence 
of maculopathy [149].  The authors of the UKPDS suggested that, as maculopathy 
generally responds less well to laser photocoagulation than PDR, reduced incidence 
of maculopathy was a particularly important clinical endpoint.  While treatment of 
maculopathy has improved since the 1990s with the advent of intravitreal anti-VEGF 
agents this remains a valid claim. 
 
 
 
 
Figure 3.2 KaplanMeier plots 
of proportions of patients 
with tight or normal BP 
control who developed 
microvascular end points 
(mostly retinal 
photocoagulation), fatal or 
nonfatal myocardial infarction 
or sudden death, and fatal or 
nonfatal strokes in the 
UKPDS.  Reproduced from 
[14]. 
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Studies investigating more aggressive BP control  
Results from the UKPDS, along with those from observational studies in type 1 
diabetes [150,151], led to the introduction of guidelines for target blood pressure 
<130/80mmHg for persons with diabetes [152,153]. Subsequent studies 
investigated more aggressive BP control and lower thresholds for initiation of 
antihypertensive therapy.  The ACCORD trial did not demonstrate a significant 
effect of intensive (targeting a sBP <120 mm Hg) versus standard (targeting a sBP 
<140 mm Hg) blood-pressure control on the progression of DR at 4 years (10.4% vs. 
8.8%, P = 0.29)[136].  Similarly the ADVANCE study did not show a significant 
beneficial effect of intensive blood pressure control on progression of DR [140].  In 
this study a fixed combination of perindopril and indapamide or placebo were 
added to current antihypertensive therapy.  The difference in sBP between the 
treatment groups was only 5.6 mm Hg, which may account for the lack of benefit 
seen.  Interestingly, when all subjects in the trial were analysed together, maximum 
sBP and visit-to-visit variability in sBP were independent risk factors for both 
macrovascular and microvascular complications [151]. In the AdRem sub-study 
described above, in which 1241 subjects underwent photographic grading of DR, no 
benefit of more intensive BP control was shown in terms of DR incidence or 
progression.  However, there was a significant reduction in incidence of 
maculopathy (OR 0.50, CI 0.29–0.88; p=0.016) in the intensive group [140].  
 
In common with the above studies the Appropriate Blood Pressure Control in 
Diabetes (ABCD) randomised trial, showed no beneficial effect of intensive 
compared to moderate BP control [154].  Therefore trials since the UKPDS have 
failed to demonstrate a benefit in terms of DR incidence and progression with 
target blood pressures below those of the UKPDS.  A possible explanation for these 
findings is the shorter follow-up of these more recent studies.  An alternative or 
additional explanation is that the findings may demonstrate a ‘floor effect’ for the 
benefits of BP control.  It is important to note that the evidence differs according to 
the starting level of blood pressure; it is more difficult for more recent trials to 
detect an effect.  
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Therapeutic issues in blood pressure control   
Unresolved questions include whether particular anti-hypertensives confer benefit 
over others for persons with diabetes, whether particular agents provide 
advantages over and above their blood pressure lowering effects, and whether anti-
hypertensive agents are beneficial for normotensive subjects with diabetes.  
Components of the renin-angiotensin system are over expressed in the retina in 
diabetes [155].  A number of studies have investigated the effects of targeting this 
system with ACEIs or angiotensin 2 type 1 receptor (ATR-1) blockers.  In addition to 
their effects on microvascular disease there is evidence of neuroprotection from 
these agents in DR in animal models [156].  The ‘Steno 2’ trial tested a multifactorial 
intervention including renin-angiotensin system blockers.  As described above, 
subjects who received this intervention showed reduced risks of retinal 
photocoagulation as well as all-cause mortality, death from cardiovascular disease 
and progression to end-stage renal disease [141].  However, the trial design was not 
factorial and the effects of the individual elements of the intervention cannot be 
examined separately. 
 
The EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus 
(EUCLID) reported that in normotensive subjects (blood pressure ≤140/90 mmHg), 
the ACE inhibitor lisinopril did not reduce the incidence of DR but decreased 2 step 
progression on the ETDRS scale and progression to PDR [157].  However, the 
placebo group in this trial demonstrated significantly higher HbA1c than the 
treatment group.  When the results were adjusted for glycaemic control the 
difference in 2 step progression was no longer significant.  Other limitations of this 
trial include its short follow-up (2 years) and the fact that it was underpowered to 
detect differences in DR which was not a primary outcome.  In the Renin 
Angiotensin System Study (RASS) subjects with type 1 diabetes and normal blood 
pressure were randomised to enalapril (an ACE inhibitor) or losartan (an AT1-R 
blocker) or placebo.  After 5 years, 2-step progression was significantly reduced in 
both the enalapril and losartan groups independent of changes in blood pressure or 
glycaemic control [158]. 
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The Diabetic Retinopathy Candesartan Trials (DIRECT) programme was designed to 
address the question of whether the ATR-1 blocker candesartan could reduce 
incidence and progression of DR in subjects with type 1 and 2 diabetes [159,160].  
Three randomised trials were conducted: a primary prevention study involving 
1,241 subjects with type 1 diabetes and no DR (DIRECT prevent 1), a secondary 
prevention study of 1,905 subjects with type 1 diabetes and DR (DIRECT protect 1), 
and a secondary prevention study of 1,905 subjects with type 2 diabetes and DR 
(DIRECT protect 2).    Subjects with type 1 diabetes were included if they were 
normoalbuminuric and normotensive (defined as BP ≤130/85mmHg).  Subjects with 
type 2 diabetes were included if they were normo-albuminuric and normotensive 
without anti-hypertensives or had BP ≤ 160/90 on treatment.  All subjects were 
randomised to candesartan 16-32mg day or placebo. Median follow-up was 4.7 
years. 
 
DIRECT-Prevent 1 showed a non-significant reduction (18% relative risk reduction; 
p=0.051) in incidence of DR.  In a post hoc analysis, in which the primary end point 
was changed from 2 step to 3 step ETDRS progression, demonstrated a significant 
difference between treatment and placebo groups (35% RR reduction; p=0.003).  
DIRECT protect 1 did not show a difference between progression of DR between the 
treatment or placebo arms.   In contrast, in type 2 subjects, DIRECT protect 2 
reported a non-significant reduction in the progression of diabetic retinopathy (13% 
relative risk; p=0.20) and a significant 34% increase in diabetic retinopathy 
regression (P=0.009).  Although DIRECT achieved none of its primary endpoints and 
there is no proof the beneficial effects observed were specific to blockage of the 
renin angiotensin system, this study suggests an overall beneficial effect of 
candesartan in DR.   
 
The ADVANCE trial (described above) did not show a significant beneficial effect of 
intensive blood pressure control using a fixed combination of perindopril and 
indapamide on progression of DR [140].  When compared to DIRECT these results 
could suggest that candesartan but not ACE inhibitors might have beneficial effects 
in DR.  However, ADVANCE showed a lower overall rate of DR progression limiting 
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power to detect moderate effects of the intervention.  Therefore, while blood 
pressure control is a critical modifiable risk factor for the vascular complications of 
diabetes, questions remain over optimum management strategies. 
 
3.5.4 Lipids 
The first evidence of the role of lipids in the development of DR came in the 
Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) [161].  
Subsequently the ETDRS supported the link between lipid levels and development 
of maculopathy [162].  In the DCCT, increasing grade of DR was associated with 
raised triglycerides and negatively correlated with HDL cholesterol [163].  These 
findings, along with data to suggest that serum VEGF is raised in patients with 
hyperlipidaemia and reduced by lipid lowering agents [164,165], led to 
interventional trials of statins and fibrates in DR.  In the Collaborative Atorvastatin 
Diabetes Study (CARDS) 2,838 subjects with type 2 diabetes were randomised to 
atorvastatin or placebo [166]. After median follow-up of 3.9 years a non-significant 
trend to reduced risk of laser photocoagulation was noted in the atorvastatin arm 
(OR 0.79; p= 0.14).  There was no difference in progression of DR between the two 
groups.  Progression of DR was not a primary endpoint in the CARDS and the trial 
was stopped 2 years earlier than planned because the pre-specified endpoint for 
efficacy in preventing acute coronary events and strokes had been met.  However, 
this and other data suggests that the role of statins in DR is at best limited [167]. 
 
Fibrates are agonists for peroxisome proliferator-activated receptor-α (PPARα) 
activation.  Their pleotropic actions include reduction in triglyceride levels, 
reduction in total and LDL cholesterol and increase in HDL cholesterol.  PPARα 
agonists are also reported to inhibit VEGF production and may have 
neuroprotective properties [168,169].  The Fenofibrate Intervention and Event 
Lowering in Diabetes (FIELD) study was a multinational RCT involving 9795 patients 
with type 2 diabetes aged 50-75 years and not taking statins [15].  Participants were 
randomised to fenofibrate 200mg daily or placebo.  The need for laser photo-
coagulation was a pre-specified tertiary endpoint.  In a sub-study 1012 subjects had 
retinal photography and grading of DR by ETDRS criteria.   
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Fenofibrate treatment was associated with reduced need for laser treatment (5·2% 
vs 3·6%, p=0·0003) in the whole study population.  In the DR grading sub-study the 
number of events was small.  The primary endpoint of the sub-study (2 step ETDRS 
progression) showed no difference between the two groups.  However, fenofibrate 
was associated with reduced risk of 2 step progression in subjects who already had 
retinopathy (p=0.004).  Subjects in the placebo arm had a higher rate of 
commencing statin therapy which may have masked a greater treatment benefit in 
this study.  A further weakness of the study was the lack of predefined criteria for 
laser treatment.  Interestingly the beneficial effects of fenofibrate observed in the 
FIELD study were independent of lipid levels, blood glucose control and blood 
pressure.  Therefore the mechanism of action of fenofibrate in DR merits further 
study. 
 
The ACCORD trial (described above) gave further evidence that fenofibrate could 
slow the progression of DR [136].  While intensive treatment of blood pressure in 
this trial did not show a significant reduction in DR progression, treatment of 
dyslipidaemia with 160mg fenofibrate plus simvastatin was effective compared to 
placebo plus simvastatin.  Progression of DR by 3 or more ETDRS steps (or 
development of DR necessitating laser or vitrectomy) was reduced in the 
fenofibrate arm (6.5 vs 10.2%; adjusted OR: 0.60, 95% CI: 0.42–0.87; p = 0.006).  The 
effect size was similar to that of intensive versus standard glycaemic control (7.3 vs 
10.4%; adjusted OR: 0.67, 95% CI: 0.51–0.87; p = 0.003).  In contrast to the FIELD 
study there was a difference in triglyceride levels at 1 year between the fenofibrate 
group (120 mg/dL) and the placebo group (147 mg/dL).  This implies that the 
mechanism of effect may, in part, have been due to alterations in lipid levels.  In 
summary, dyslipidaemia appears to play a role in the pathophysiology of diabetic 
retinopathy and maculopathy.  However, the picture is complex and effective 
management strategies require further investigation. 
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3.5.5 HIV 
Sub-Saharan Africa faces a growing problem of chronic non-communicable disease 
whilst concurrently experiencing continuing high rates of infectious disease.  The 
interaction of infections such as HIV, TB and malaria with diabetes and its 
complications will be increasingly important as the prevalence of the disease grows.  
Persons with HIV are at increased risk of insulin resistance due to the pro-
inflammatory effects of the virus, direct effects of antiretroviral therapy (ART) and 
indirectly through effects of ART on metabolism including body fat distribution.  HIV 
lipodystrophy is a complex syndrome seen in people living with HIV for long 
duration most of whom are taking ART [170].  ART for HIV (specifically nucleoside 
reverse transcriptase inhibitors and protease inhibitors) has been associated with 
an increased risk of developing the metabolic syndrome [171]. 
 
Evidence of the effect of HIV on prevalence and incidence of microvascular 
complications of diabetes is extremely limited.  Nephropathy is common in both 
diabetes and HIV. HIV associated nephropathy (HIVAN) is a complication of the 
infection which presents as proteinuria.  American studies report that the condition 
principally affects subjects of African heritage [172,173].  Gupta et al reported that 
both diabetes and hypertension were associated with proteinuria in a large cohort 
of HIV positive subjects [174].  In 2007 a cross-sectional study of the complications 
of diabetes was performed at the diabetes clinic at Queen Elizabeth Central Hospital 
(QECH), Blantyre (described in detail in Chapter 4) [1].  In this study albuminuria was 
independently associated with duration of diabetes and HIV infection but not 
glycaemic control, blood pressure or age.  Whether HIV and diabetes have a 
synergistic effect in the kidney and the mechanism of such an interaction is not 
known. 
 
Distal predominantly sensory symmetrical polyneuropathy (DSSP) is a peripheral 
neuropathy attributable to the HIV infection itself or secondary effects of certain 
ART agents [175].  Diabetes has been associated with this condition [176,177].  
However, differentiating peripheral neuropathies due to diabetes and HIV is likely 
to be difficult.  The 2007 QECH study found no difference in prevalence of sensory 
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neuropathy between those subjects with and without HIV [1].  Very little is known 
about the interaction between HIV infection and DR.  One case report suggested 
regression of DR following initiation of ART [178].  As part of the 2007 study at the 
QECH diabetes clinic our group reported retinal findings from 281 persons with 
diabetes.  Prevalence of HIV in these subjects with diabetes was 13%; no association 
of STDR with HIV infection was found [2]. 
 
HIV has a number of manifestations in the posterior segment of the eye.  HIV is 
associated with an increased risk of chorioretinal infection including viral retinitis 
(e.g. cytomegalovirus (CMV)), syphilitic retinitis and toxoplasma retinochoroiditis.  
Ocular and central nervous system non-Hodgkin’s lymphoma occur more commonly 
in HIV.  Approximately 75% of HIV infected persons develop microvascular 
abnormalities of the conjunctiva or retina.  Retinal vessel tortuosity, cotton wool 
spots, telangiectasia, intra-retinal haemorrhages and venous and arterial occlusions 
are described.  Proposed pathological mechanisms include HIV-induced thrombotic 
tendency, immune phenomena or as a direct result of HIV infection of vascular 
tissue [179]. 
 
3.5.6 Tuberculosis and malaria  
 A recent meta-analysis reported a 3-fold incident risk of tuberculosis in persons 
with diabetes [180].  The relative risk appears to be highest at younger ages [181].  
It has been suggested that TB may increase the risk of diabetes and some TB 
treatments such as isoniazid have hyperglycaemic effects [182].  It is reported that 
concomitant disease is associated with worse outcomes for both diabetes and TB 
[182].  To my knowledge no high quality study has investigated the effects of TB on 
prevalence or progression of DR.  Similarly little is known about the effects of 
malarial infection on the complications of diabetes.  Repeated vascular endothelial 
activation in episodes of acute infection could predispose to endothelial 
perturbation and microvascular pathology.  While diagnosis of acute infection is 
straight forward, quantifying the burden of malaria over a prolonged 
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epidemiological study is challenging.  Therefore this is an extremely difficult topic to 
investigate. 
 
3.5.7 Anaemia  
Iron-deficiency and malaria-attributable anaemia are significant health problems in 
the developing world [183].  In Malawi the prevalence of anaemia in adult males 
and non-pregnant females is reported to be 32% and 71%, respectively [184].  The 
Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic 
Study (SN-DREAMS) was a large Indian, population-based, cross-sectional study.  
1414 subjects with diabetes were assessed for diabetes and systemic parameters.  
In a post hoc analysis of a subgroup of subjects with ‘suboptimal’ glycaemic or BP 
control (HbA1c ≥ 7%; BP >130/80 mm Hg) factors associated with DR were presence 
of anaemia, younger age, male gender and microalbuminuria.  A number of low-
quality, cross sectional studies from Indian [185], Korea [186], China [187] and Iran 
[188] have also reported an association between low haemoglobin and DR. 
 
3.5.8 Smoking 
Smoking is an important determinant of the macrovascular complications of 
diabetes and is independently associated with progression of nephropathy in 
subjects with type 2 diabetes [189].  The WESDR found no significant relationship 
with incidence or progression of DR.  However, smoking was associated with all-
cause mortality [190]. In the UKPDS smoking was independently associated with 
reduced incidence of retinopathy and with reduced risk of DR progression [13].  A 
pharmacological effect of one of the components of tobacco smoke could explain 
this relationship.  However, this would not justify the promotion of smoking in 
patients with diabetes because the deleterious effects of tobacco on cardiovascular 
and pulmonary health would far outweigh reduction in retinopathy risk in terms of 
overall morbidity.   
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3.6 Non-modifiable risk factors 
 
3.6.1 Duration of diabetes 
The Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) 
demonstrated that duration of diabetes is the most important non-modifiable 
determinant of development and progression of DR [83,84,190].  A potential 
confounder to the relationship of systemic parameters to DR is the period of 
undiagnosed disease in type 2 diabetes.  A number of studies have estimated the 
delay between onset and diagnosis of type 2 diabetes using data on prevalence of 
DR.  Using two distinct populations in Western Australia and Wisconsin, Harris et al 
reported a point estimate of the onset of detectable retinopathy of 4.2 to 6.5 years 
prior to diagnosis of diabetes [191].  The authors used very limited data based on a 
small number of subjects from the Whitehall cohort study [192] to estimate that the 
onset of diabetes itself could be approximately 5 years more (i.e. between 9 to 12 
years in total).   
 
In Scotland, Ellis et al graded retinopathy in 291 subjects with type 1 diabetes and 
295 persons with type 2 diabetes and acquired data on duration of diabetes from a 
regional database [193].  Onset of detectable retinopathy was estimated to occur 
5.7 years (95% CI 4.6 to 7.0) before diagnosis of diabetes.  Using data on time to 
onset of STDR in type 1 diabetes this study estimated a 95% CI of length of 
preclinical diabetes to be between 3.0 and 9.4 years.  Both the above studies used 
linear models which may be overly simplistic and both included stages of 
retinopathy not specific to diabetes.  More recently Porta et al derived an estimate 
of 6.05 years between onset and diagnosis of type 2 diabetes using quadratic and 
linear models.  These authors calculated appearance of ‘moderate DR’ 2.66 years 
before diagnosis of diabetes in patients with onset of diabetes ≥30 years of age.  
Moderate retinopathy was estimated to appear 3.29 years after diagnosis of 
diabetes in subjects with onset of diabetes <30 years.  These figures were added 
together to give an estimate of duration of diabetes before onset. 
 
64 
 
3.6.2 Type of diabetes 
Diabetes can be classified into two groups: type 1 (previously known as ‘juvenile 
onset’) is associated with destruction of the pancreatic islet beta cells leading to 
failure of insulin production; type 2 (previously described as ‘adult onset’ or ‘non-
insulin dependent’) diabetes is characterized by both insulin deficiency and insulin 
resistance.  Epidemiological data on type 1 diabetes in Africa is sparse.  Traditionally 
the proportion of type 1 diabetes was thought to be low although this could reflect 
high mortality [194].   Disease characteristics appear to differ from European 
populations.  Peak age of onset is later in African communities, typically 22-29 years 
[194]. Other phenotypes of diabetes are recognised in patients of African origin.  
'Atypical African diabetes' was first described in the 1960s. The most often reported 
atypical form is characterised by an initial clinical presentation of apparent type 1 
diabetes with severe hyperglycaemia and ketosis, and subsequent long-term 
remission with or without relapses or a clinical course compatible with type 2 
diabetes [195].  Malnutrition-related diabetes mellitus (previously known as 
‘tropical diabetes’) is characterised by early-onset non-ketotic diabetes in 
underweight patients, with very high subsequent insulin requirements. Unlike true 
type 1 diabetes beta cell autoimmunity is not apparent [195].   
 
Globally, the prevalence of DR differs between type 1 and type 2 diabetes.  In a 
recent systematic review the age standardised prevalence in type 1  and type 2 
diabetes of DR was 77.3% (95% CI , 76.3 – 78.3) and 25.2% (24.96– 25.36), 
respectively [196].  Figures for PDR, DMO and STDR were 32.4% (31.8–33.0) vs 3.0% 
(2.9 – 3.0), 14.3% (13.9–14.6) vs 5.6% (5.5–5.7) and 38.5% (37.8–39.2) vs 6.9% (6.8 – 
7.0), respectively.  These figures are not adjusted for other disease risk factors 
including duration of diabetes, glycaemic control and blood pressure which differ 
between type 1 and 2 diabetes.  Studies reporting prevalence of DR are subject to 
classification issues: large studies and those in resource poor settings do not have 
access to the investigations necessary to reliably differentiate type 1 and 2 diabetes 
in all subjects. 
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3.6.3 Age  
Features of sight threatening diabetic retinopathy (STDR) are generally not seen 
before puberty [197]. The reasons for this are unclear; levels of growth hormone, 
insulin-like growth factor and sex hormones such as testosterone and lower blood 
pressure have been suggested as potential explanations [198]. Most large 
epidemiological studies have found only very small effects of age on DR incidence 
and progression.  There may be a tendency to reduced incidence of proliferative 
retinopathy in very old age.  For example in the WESDR no subjects over 80 years 
developed PDR [197]. However, the numbers of subjects of this age in major studies 
are small.   
 
3.6.4 Ethnicity 
Clear differences in prevalence of diabetes between different ethnic groups have 
been reported.  For example Pacific Islanders and Native Americans including the 
‘Pima Indians’ have particularly high rates [199].  However, the literature on DR and 
ethnicity is much less clear.   The Veterans Affairs Diabetes Trial (VADT) reported 
that the prevalence of DR equal to or greater than moderate NPDR differed 
significantly between Hispanics (36%), African Americans (29%) and non-Hispanic 
whites (22%) [200]. Differences were not accounted for by differences in age, 
duration of diagnosed diabetes, HbA1c or blood pressure.  A UK study reported that 
patients of South Asian ethnicity demonstrated greater prevalence of DR and DMO 
than Caucasians [201].  However, these subjects also had worse blood pressure, 
HbA1c and total cholesterol as well as younger age at diagnosis.  Socioeconomic 
status is an important, unmeasured potential confounder in the above studies.  
Interestingly, published rates of macrovascular complications in Africa are relatively 
low [194].  For example, prevalence of coronary heart disease in individuals with 
type 2 diabetes in sub-Saharan Africa is estimated at 5% [194].  Approximately half 
that in some European states [202]. The reasons for this remain unclear and the 
literature is by no means comprehensive.   
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3.6.5 Genetic factors  
The genetics of DR is a large and rapidly evolving area beyond the scope of this 
thesis.  An excellent recent review is available from Cho and Sobrin [203].  In brief, 
multiple genes are thought to influence DR phenotype.  Twin and familial studies 
have demonstrated familial clustering [204].  Estimates of heritability for DR are as 
high as 27% and for PDR as high as 52% [205]. Linkage analyses, candidate gene 
association studies and genome-wide association studies (GWAS) have not yet 
identified reproducible loci for DR risk although associations with chromosomes 1, 3 
and 12 have been reported [206].  The most studied individual genes are those 
encoding vascular endothelial growth factor, the receptor for advanced glycation 
end products and aldose reductase.  GWAS methodology has been used successfully 
to study other complex polygenic diseases. Combination of large datasets from 
different ethnicities will be important in future to detect variants with sufficient 
effect sizes. 
 
3.7 Chapter summary 
In this chapter I have reviewed the major studies which have informed 
understanding of the determinants of severity and progression of DR.  An excellent 
body of work exists concerning systemic risk factors such as glycaemic control, BP 
and lipids.  The vast majority of studies were performed in Europe and North 
America.  At present results are extrapolated to populations in Africa; primary 
evidence has yet to be accrued.  Little is known about the effect on DR of a number 
of risk factors important to populations in Sub-Saharan Africa.  These ‘population 
specific risk factors’ include HIV infection and anaemia.  As the number of persons 
living with diabetes in Africa grows, understanding interactions between these 
diseases is becoming increasingly important for health service providers.  
Understanding epidemiological relationships is the first step to study of the 
pathophysiological interactions between disease states.  In Chapter 4 of this thesis I 
will describe a systematic review of the available literature on the epidemiology of 
diabetic retinopathy and maculopathy in Africa.  Having identified gaps in the 
67 
 
knowledge base of DR in Sub-Saharan Africa, the Malawi Diabetic Retinopathy Study 
will address some of these. 
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Chapter 4. Epidemiology of Diabetic Retinopathy and 
Maculopathy in Africa: a Systematic Review 
 
 
4.1 Aims of chapter 
This is the last section of my literature review.  In this chapter I summarise findings 
from studies reporting the prevalence and incidence of diabetic retinopathy (DR) 
and diabetic maculopathy in African countries in light of the rising prevalence of 
diabetes mellitus.  In the final part of the chapter I bring together findings from the 
literature review and present the hypothesis and aims of my thesis. 
 
4.2 Introduction 
The International Diabetes Federation (IDF) has estimated that the number of 
adults with diabetes in Africa will increase by 98%, from 12.1 million in 2010 to 23.9 
million in 2030 [207] a presumed consequence of poor diet, sedentary lifestyles, 
obesity, population growth and ageing (in part due to successes in combating 
communicable diseases) [199].  31 of the 48 least economically developed 
countries, as defined by the UN, are situated in Africa [208].  The epidemic rise in 
diabetes therefore poses significant public health and socioeconomic challenges for 
the continent.   
 
As described in Chapter 1, diabetes causes visual impairment through cataract and 
DR, a progressive disease of the retinal microvasculature.  DR can be graded on the 
basis of the clinical features as detailed in Chapter 2.  The grades of retinopathy 
correlate with likelihood of development of proliferative DR and can be 
standardised by standard retinal photographs as used in the Early treatment of 
Diabetic Retinopathy Study (ETDRS) [19].  DR is the sixth leading cause of global 
blindness [8], and is one of nine target disease areas of the 'Vision 2020 action plan' 
a joint program of the WHO and the International Agency for the Prevention of 
Blindness.  It is the leading cause of blindness in the working age population in the 
USA and in many European countries (and was until recently in the UK) [209].  With 
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increasing prevalence of diabetes in Africa, it is likely that DR will become an 
important cause of blindness.   On this continent genetic factors, limited access to 
healthcare, and high rates of malnutrition, infectious disease, HIV and anaemia are 
likely to affect the spectrum of pathology encountered.  
 
An overall assessment of current levels of DR in Africa has not been performed 
previously.  In order to estimate the current and future burden of disease, to 
provide data to enable the assessment of changes that may result from service 
development, and to inform future research a systematic review of the 
epidemiological literature was required.  The aim of this systematic review was 
therefore to summarise findings from reliable research studies of estimates of the 
prevalence and incidence of diabetic retinopathy and maculopathy in African 
countries.  I completed this review under the supervision of Professor Paul Garner 
at Liverpool School of Tropical Medicine (LSTM); the results have been published 
[210]. 
 
 
4.3 Methods  
 
4.3.1 Data sources and search strategy 
I performed a systematic narrative review of published literature according to the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement [211].  Relevant studies published between 1948 and February 2011 
were identified by searching, using a pre-defined strategy, the following electronic 
databases: Medline (Pubmed), Embase (OVID) and Embase Classic, Science Citation 
index and Conference Proceedings Citation index (ISI Web of Science).  The 
following were also searched: the African regional database 'African Index Medicus', 
the grey literature database 'OpenSIGLE', the WHO International Clinical Trials 
Registry and the meta-Register of Controlled Trials (mRCT).   I developed 
customised searches with the help of Vittoria Lutje, a Cochrane Collaboration 
trained trials co-ordinator at the Cochrane Infectious Diseases group, LSTM.  Search 
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histories are reproduced in Appendix 2.  No language, publication status, time limits 
or language restrictions were applied to electronic searches.  Search results were 
merged using reference management software (Endnote, Thomson Reuters) and 
duplicate records removed. The reference lists of articles identified, including 
existing reviews, were hand-searched.   
 
4.3.2 Selection criteria 
The following were included: studies reporting prevalence or incidence or 
progression of DR or diabetic maculopathy; cross sectional or cohort study design; 
studies of subjects with diabetes mellitus resident in African countries.  Exclusion 
criteria were: studies with fewer than 50 subjects; studies of populations of African 
origin residing outside the continent; reports not published in English; case series 
and conference abstracts.  To improve the current relevance of the review those 
reports published before 1990 were excluded. 
The method used to apply selection criteria was as follows.  I examined titles and 
abstracts and removed obviously irrelevant reports.  I retrieved full text copies of 
the potentially relevant reports.  Multiple reports of the same study were linked 
together.  Full-text reports were examined independently by me and a colleague 
(Ian MacCormick, specialist trainee in ophthalmology and clinical PhD student at the 
Malawi-Liverpool-Wellcome clinical research programme) for compliance with 
eligibility criteria.  Disagreements were resolved by discussion. 
 
4.3.3 Data extraction and assessment of risk of bias 
Major outcome variables were extracted independently by Ian MacCormick and me 
into a spreadsheet (Excel, Microsoft) with a standardised approach.  The main 
outcome variables extracted were the prevalence of DR, proliferative diabetic 
retinopathy (PDR) and diabetic maculopathy and the incidence of DR, PDR and 
diabetic maculopathy.  Prevalence of grades of retinopathy were recorded by 
patient according to the worse eye and, unless stated, are presented as such below.  
Studies were stratified by the source of the population sample (with community 
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studies more likely to give a more accurate population based assessment of 
prevalence); and risk of bias was assessed by seeking evidence of incomplete 
outcome data (missing data, subjects excluded from report, subjects lost to follow 
up in cohort studies).
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4.4 Results  
 
4.4.1 Literature search  
The literature search yielded 380 citations of which 142 were reviewed in full text; 
71 met the inclusion criteria and reported on a total of 62 studies (Figure 4.1) 
[2,212-281]. The literature search report is shown in Table 4.1.   
 
Table 4.1 Literature search report for articles reporting prevalence, incidence or 
progression of DR or diabetic maculopathy in African countries.  Four further 
articles were identified through hand searching and personal communication. 
Source Date range searched Retrieved (before 
duplicate removal)  
ELECTRONIC DATABASES 
Medline (Pubmed) 1948 – 6/2/2011 204 
Embase (OVID) + Embase classic 1947 – 6/2/2011 333 
Science citation index + Conference 
proceedings citation index (ISI web of science) 
1900 – 7/2/2011 199 
Total number of records in Endnote database after deleting duplicates 370 
OTHER DATABASES 
African Index Medicus database Searched 8/2/2011 5 
OpenSigle Searched 8/2/2011 0 
ONGOING TRIALS REGISTERS 
WHO international clinical trials registry 
current controlled trials: meta register of 
controlled trials (mRCT) 
Searched 8/2/2011 1 
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Figure 4.1 Identification process for eligible studies.  Format reproduced from the 
PRISMA statement [6]. 
 
 
 
 
 
 
 
 
 
 
 
 
           
   
 
 
 
    
   
Id
en
ti
fi
ca
ti
o
n
 4 additional records 
identified through 
hand searching 
380 records after 
duplicates 
removed 
Sc
re
en
in
g 
 238 records 
excluded 
380 abstracts screened 
El
ig
ib
ili
ty
 
 
71 full text articles 
excluded: 
11 review articles 
25 did not report 
DR prevalence  
3   not English 
language 
32 Published 
before 1990 
 
 
 
142 full text articles 
assessed for eligibility 
In
cl
u
d
ed
 
62 studies included in the 
review (from 71 articles) 
 
742 records identified 
through database 
searching 
74 
 
4.4.2 Characteristics of included studies  
Characteristics of the included studies are summarised in Table 4.2.   
 
Design: Only 3 community based studies were identified [212-214]. In Mauritius 
1998 researchers followed up the population based study performed in 1992 [212] 
with a survey of the same cohort 6 years later [215].  An additional cohort study 
followed persons with type 1 diabetes identified from a hospital clinic [216-218].  All 
other studies were clinic-based surveys or case control studies; the majority were 
undertaken in diabetes clinics (hospital or primary care) or hospital ophthalmology 
clinics.   
 
Distribution: The 62 studies were performed in 21 countries.  Geographical 
distribution of studies was uneven and, within geographical regions, certain 
countries were over-represented.  All of 19 studies undertaken in Western Africa 
took place in Nigeria except 1 which covered Nigeria and Ghana [219] and 1 from 
Mali [220].  Within East Africa 2 studies were conducted in the Seychelles [221,222] 
and 2 in Mauritius [212,215], relatively wealthy, ethnically diverse, small island 
nations.  There was no clear correlation between the average standard of living in a 
country, as measured by per capita gross domestic product (GDP), and reported 
prevalence of DR (Figure 4.2) or PDR (Figure 4.3).  Only five studies specifically 
reported data from rural populations [212-214,223,224].   
 
Subject selection:  Clinic-based studies were highly heterogeneous in patient 
selection in relation to age range, gender, ethnicity, duration and type of diabetes 
and co-morbidity.  Of those studies conducted in diabetes clinics, 18 included all 
patients with diabetes attending the clinic while 14 confined their study to a 
subgroup, for example subjects with type 2 diabetes [225], children 5-18 years 
[226], or persons with duration of diabetes >5 years [227].  Of the 9 studies 
conducted in ophthalmology clinics 4 studied patients with a particular diagnosis 
(neovascular glaucoma [228], retinal disease [229,230], blind patients [231]), 1 
studied persons attending specific diabetes eye clinics [222] and 4 studied a cross 
section of all eye patients [232-235].  In those studies that differentiated type 1 and 
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2 diabetes (30 studies) most used study specific definitions making inter-study 
comparisons problematic. 
 
Assessment of retinopathy: Methods of assessment and classification of 
retinopathy varied widely.  Only 9 studies used retinal photography [212,215,236-
242] and 6 of these were conducted in South Africa [236-238,240-242].  30 studies 
classified retinopathy simply as present or absent; 32 used a recognised grading 
system.  Most used an adaptation of the ETDRS grading system [19].  However, the 
application and its reporting varied widely.  In no study was an external validation of 
the practitioner's grading reported. 
 
Evidence of bias:  There was evidence of incomplete outcome data in a number of 
studies.  In the majority of clinic based studies the number of subjects approached 
to participate was not reported making selection bias difficult to assess.  Many 
studies reported prevalence of a number of diabetic complications.  In some studies 
a low proportion of subjects were examined for retinopathy.  For example, in 
Harzallah et al [243] only 19% of 593 subjects underwent retinal examination.  
Many studies excluded subjects with significant cornea or media opacities [244,245] 
or with ungradeable photographs [236]. 
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Table 4.2 Characteristics of 62 studies reporting prevalence of diabetic retinopathy  
and maculopathy in Africa.   
Geographical region defined according to UN scheme of geographical regions [282]. * Initial 
population based survey performed in Mauritius in 1992[212] followed up with a survey of the same 
cohort 6 years later [215]. † Includes 2 studies from the Seychelles and 1 from Mauritius. ‡ Hospital 
or primary care diabetes clinic. 
Characteristic Geographical region 
North 
Africa 
Western 
Africa 
Southern 
Africa 
Middle 
Africa 
Eastern 
Africa† 
Total  
Study design 
Community-based 
cross-sectional 
1 1   1* 3 
Cohort   1  1* 2 
Diabetic clinic 
survey‡  
4 5 10 2 11 32 
Hospital eye clinic 
survey 
 5  1 3 9 
Other hospital-
based survey 
2 5 2  2 11 
Case control 2 3    5 
Year published 
1990-1999 5 3 4 2 5 19 
2000-2011 4 16 9 1 13 43 
Type of diabetes 
Type 1 alone 1  2  1 4 
Type 2 alone 4 8 1  2 15 
Type 1 & 2 
(separately) 
1 2 3  5 11 
Mixed 3 9 7 3 10 32 
Practitioner grading retinopathy 
Ophthalmologist 1 12 7 3 11 34 
Physician 4 3 2  2 11 
Trained grader 1    2 3 
Not specified 3 4 4  3 14 
Instrument 
Slit lamp bio-
microscopy 
2 7 3 2 9 23 
Retinal photo  1  6 1 2 10 
Direct ophth'scope 1 5 4  1 11 
Not specif’d/other 5 7   6 18 
Other study characteristics 
Recognised 
grading system  
4 5 10 2 11 32 
Associations of DR 
reported 
6 8 8 2 9 32 
Vision reported 1 7 3 1 7 19 
Total number of 
studies 
9 19 13 3 18  
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Figure 4.2 Prevalence of DR in people with diabetes according to national per capita 
gross domestic product (GDP). Red markers: population-based studies. Blue 
markers: cohort and clinic-based studies. For cohort studies, prevalence in baseline 
survey shown. GDP per capita figures: IMF 2011 [283]. Abbreviations: USD United 
States Dollars.  
 
 
Figure 4.3 Prevalence of PDR in persons with diabetes according to national per 
capita gross domestic product (GDP).  Red markers: population-based studies. Blue 
markers: cohort and clinic-based studies. For cohort studies, prevalence in baseline 
survey shown.  
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4.4.3 Community based studies  
I identified 3 community-based studies (Table 4.3).  In Egypt 1991-4, researchers 
examined the prevalence of diabetes and the relationship between HbA1c and 
retinopathy [213,239,246,247].  Articles by Herman [239] and Penman [246] report 
different prevalence of DR as graded from retinal photography: 35.4 % in 376 
subjects in the former and 31.6% in 335 subjects in the latter.  No explanation for 
this difference between the two reports is offered suggesting missing data in one or 
both analyses.  Herman et al [239] demonstrated in multivariate analysis that DR 
was associated with longer duration of diabetes (per 10 years) (OR = 1.37, 95 % CI 
1.09, 1.73) and higher HbA1c (per unit) (OR = 1.15, 95 % CI 1.03, 1.27). 
 
Researchers in Mauritius 1992 [212] investigated prevalence of and risk factors for 
DR in Asian, Indian, Chinese and Creole Mauritians.  This high quality study 
demonstrated a high prevalence of DR in all major ethnic groups in Mauritius.   The 
prevalence of DR and PDR were particularly high in known diabetes: 44.3% and 
2.3%, respectively.  Muslim Indians had the lowest prevalence of DR: 10.8% and 
34.0% for new and known diabetes, respectively); significantly lower than Creoles 
(18.8% and 53.8%, respectively).  The following were independently associated with 
retinopathy: duration of diabetes, fasting plasma glucose, systolic blood pressure, 
albuminuria and decreasing body mass index.   
 
4.4.4 Cohort studies  
Table 4.4 summarises cohort studies of DR conducted in Africa.   In Mauritius 1998 
researchers followed up the population based study performed in 1992 [212] with a 
survey of diabetes complications [215].  Of subjects with diabetes in the initial 
survey 40.5% were re-examined.  The 6 year incidence of DR and PDR in subjects 
with diabetes but no DR in the first survey was 23.8% (95% confidence interval 18.3-
29.3) and 0.4% (0-1.2), respectively. The incidence of PDR was much higher in 
subjects with mild non-proliferative diabetic retinopathy (NPDR) (5.2%) and 
moderate NPDR (29.4%) in the first survey.  Duration of diabetes and fasting blood 
glucose were independently associated with incidence of retinopathy.  In South 
Africa 1982-2002 Gill and co-workers identified a cohort of patients with diabetes 
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diagnosed before age 30 years requiring insulin therapy [216].  In those subjects 
seen at 10 years prevalence of DR had increased from 6% to 52% and PDR from 0 to 
3% [217].  In subjects seen at 20 years prevalence of DR had increased from 12% to 
59% [218].  Incidence of retinopathy was not reported in these studies.   
 
No other prospective cohort studies were identified.  However, studies reflecting 
cumulative incidence of DR are available. In South Africa, Distiller at al [237] 
reported on 1520 type 1 and 8026 type 2 patients who had maintained membership 
for ≥ 5 years of a community-based, privately funded diabetes management 
program. In type 1 subjects prevalence of any retinopathy at baseline and at 5 years 
was 22.3% and 28%, respectively and in type 2 subjects 20.5% and 26.6%, 
respectively.  In retrospective studies of persons with diabetes of long duration 
Lester [248] showed a prevalence of DR of 45.5% in 121 Ethiopian patients with 
duration of diabetes > 20 years while Distiller [238] reported presence of DR in 
14.8% of 148 South African Caucasian subjects with type 1 diabetes of >18 years 
duration. 
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Table 4.3 Community based cross-sectional studies reporting prevalence of DR in Africa 
Study Methods Subjects and sub-groups n Outcome 
Any DR % 
(95% CI) 
PDR 
(%) 
Mac. 
(%) 
Studies reporting prevalence of diabetes and DR in the general population 
Egypt,  
1991-4 
[213, 239, 
246, 247] 
Stratified random sampling of persons ≥20 years in urban and rural 
areas near Cairo. 4620 adults underwent random glucose testing. 
Those at high risk of diabetes and a sample of those at low risk 
(total 1451) had fasting glucose test. Diabetes diagnosed by WHO 
criteria [online supplementary reference 101]. RP graded according 
to Airlie House Classification and BIO exam by ophthalmologist. 
Those ungradeable on photography and BIO excluded from analysis 
of RP and BIO, respectively.  
Subjects with diabetes 
(RP)* 
335 31.6 0.9 4.5‡ 
Subjects with diabetes 
(BIO)* 
404 20.3 0 1.2‡ 
Known diabetes (RP) § 287 41.5 (35.8-47.2)   
Newly diag diabetes (RP)§ 89 15.7 (8.2-23.3)   
Impaired GT (RP)§ 103 1.9 (0-4.6)   
Mauritius 
1992  
[212] 
6553 persons in 14 geographically defined clusters underwent GTT.  
In 11 clusters all adults aged 25-74 were invited to attend; in 3 
clusters age stratified sampling of adults 35-64 performed.  Those 
with diabetes and 25% of those with impaired GTT (WHO 
criteria(115)) had 3-field, 45° stereoscopic RP of the right eye.  
Grading by certified assessor according to modified Airlie House 
criteria. Those with ungradeable photographs excluded. 
All subjects with diabetes 746 30.2 (26.9-33.5) 1.3  
Known diabetes 388 44.3 (39.4-49.2) 2.3  
Newly diagnos’d diabetes 358 14.8 (11.1-18.5) 0.3  
Impaired GT 165 9.1   (4.7-13.5) 0  
Indian race with diabetes 186 22.8 (18.7-28.9) 1.1  
Creole race with diabetes 160 35.7 (28.1-43.3) 1.3  
Study of cause of visual impairment in the general population  
Nigeria, 
2005-
2007 
[214] 
National multistage, stratified cluster sampling of  persons ≥40 year 
to determine cause of VI. 13591 VA tested; 3129 had uncorrected 
VA <6/12 in better eye examined by ophthalmologist. Primary 
cause of VI recorded.   
Subjects with VA <6/12 
better eye 
3129 0.29   
The Prevalence of DR in Egypt 1991-4 was reported in four publications:  * denotes data from Penman 1998 [246], § denotes data from Herman 1998 [239].  ‡ Maculopathy 
in Penman 1998 [246] defined as any exudates present in macular region.  Abbreviations: RP retinal photography; BIO binocular indirect ophthalmoscopy; DO direct 
ophthalmoscopy; GTT Glucose tolerance test;  VA visual acuity; VI Visual impairment.
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Table 4.4 Cohort studies reporting prevalence and incidence of DR in Africa.  
Study Methods Subjects and sub-groups n Outcome 
Any DR % 
(95%CI) 
PDR 
% 
Progres
sion (%) 
1. Mauritius 1992-1998 
Initial 
population 
based 
study 1992 
[212] 
Population based study of prevalence of diabetes and 
DR: methodology outlined in Table 1 
All subjects with diabetes 746 30.2 (26.9-33.5) 1.3  
Known diabetes 388 44.3 (39.4-49.2) 2.3  
Newly diagnosed diabetes 358 14.8 (11.1-18.5) 0.3  
Second 
survey 
1998 [215] 
Of those assessed for complications in 1992, 528 
attended the follow-up survey.  Grading of retinopathy 
as in first assessment. 
Subjects with diabetes  302 33.8 3.0 25.2 
Diabetes with no DR at baseline  227 23.8* 0.4† 23.8 
Diabetes, mild NPDR at baseline 58  5.2† 27.7 
Diabetes, mod. NPDR at baseline 17  29.4
† 
35.3 
2. South Africa 1982-2002 
Baseline 
assessment 
1982 [216] 
88 black South Africans with diabetes requiring insulin 
therapy diagnosed <30yrs attending the diabetes clinic 
at Baragwanath Hospital, Soweto screened for diabetic 
complications. 66 examined by a physician using DO. 
Subjects with diabetes requiring 
insulin therapy diagnosed <30yrs 
66 12.1 0  
Sub-group seen at 10yrs 33 6 0  
Sub-group seen at 20 yrs 17 12     
10 yr 
follow-up 
1992 [217] 
Of the original cohort 24 were lost to follow-up, 10 had 
died.  Of 54 still attending clinic 36 were examined.  In 3 
patients cataracts prevented fundal view. 
Subjects with diabetes requiring 
insulin therapy diagnosed <30yrs 
33 52 3  
20 yr  
2002 [218] 
Of the original cohort 21 died, 39 lost to follow-up, 28 
still attending clinic, of which 17 were assessed. 
Subjects with diabetes requiring 
insulin therapy diagnosed <30yrs 
17 59   
* Incidence of DR at 6 years  † Incidence of PDR at 6 years.  PDR Proliferative diabetic retinopathy; NPDR Non-proliferative diabetic retinopthy.
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4.4.5 Hospital-based and primary care-based surveys  
Tables 4.5, 4.6 and 4.7 summarise hospital based and primary care based surveys 
reporting prevalence of DR using a recognised grading system. The most recent 
large study from Northern Africa was conducted in Cairo during 2007-2008 in 
endocrinology clinics in 2 major teaching hospitals [244].  Prevalence of PDR (2.3%) 
and clinically significant macular oedema (CSMO) (11.5%) reported in this study 
were high.  Of four studies from Western Africa [249-252] none reported the 
prevalence of maculopathy (Table 4.5).  Only three studies were identified from 
Middle Africa [227,253,254].   Longo-Mbenza et al [253] studied 3010 persons with 
diabetes attending diabetes primary care facilities using retinal photography; 
prevalence of DR was 31.6%.   
 
Hospital based surveys from Eastern Africa cover 9 countries showing a general 
trend of increasing prevalence of DR from earlier to more recent studies (Table 4.6). 
Diabetes clinic based surveys from Southern Africa in general report higher 
prevalence of DR and PDR than comparable clinics in other regions of Africa (Table 
4.7).  PDR prevalence greater than 4% was recorded in 3 studies of unselected 
diabetes clinic attendees from South Africa [224,241,255].  Data on prevalence of 
diabetic maculopathy was limited from all regions. However, 8 studies suggest high 
prevalence [2,222,224,230,241,244,255,256,].  Of note, 3 South African, primary 
care-based studies were identified. Levitt [255], Mash [241] and Read [256] 
reported high prevalence of PDR and maculopathy (Table 4.7), comparable to 
hospital based surveys in the same country and higher than hospital based surveys 
elsewhere in Africa. 
 
Two studies from South Africa compared prevalence of DR in different ethnic 
groups [240,256].  The authors acknowledge the effect of environmental factors on 
different racial communities even in the post-apartheid era.  Kalk et al [240] studied 
507 'poor or indigent' persons attending a free hospital diabetes clinic.  Prevalence 
of DR was similar in persons of African (37%), European (41%) or Indian (37%) 
heritage.  However, 'severe DR' (study specific classification) was significantly more 
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frequent in Africans (52%) and Indians (41%) compared to Europeans (26%). Read et 
al [256] found no relationship between ethnicity and DR prevalence. 
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Table 4.5 Hospital based surveys of persons with diabetes reporting prevalence of 
DR using a recognised grading system in Northern, Western and Middle Africa.  
Study Country Methods n Any 
DR 
(%) 
PDR 
(%) 
CSM
O 
(%) 
Nothern Africa 
Elbagir 
1995 
[257] 
Sudan Persons with diabetes requiring 
insulin (duration >1 yr) aged 15-
75yrs attending medical OPD 
examined with DO by a 
physician 
91 43 10* NR 
Macky 
2011 
[244] 
Egypt Pts >18yrs age attending a 
diabetes clinic examined with SL 
by Ophthalmologist. Excluded 
47 pts due to media opacities 
132
5 
20.5 2.3 11.5 
Western Africa 
Ikem 
2001 
[252] 
Nigeria Consecutive subjects with type 
2 diabetes seen at medical OPD.  
Examined by physician; 
instrument not stated.  
132 41.1 1.0 NR 
Alebiosu  
2003 
[249] 
Nigeria Hospitalised subjects with type 
2 diabetes and nephropathy. 
Examined with DO by physician.   
191 47.1 12.6 NR 
Omolas
e 2010 
[250] 
Nigeria Persons with diabetes attending 
medical OPD.  Examined with 
DO by Ophthalmologist. 
100 15.0 2.0 NR 
Onakpo
ya 2010 
[251]  
Nigeria Type 2 patients attending a 3° 
centre diabetes clinic; invited 
for screening by 
Ophthalmologist with DO. 3.6% 
NFV. 
80 21.6 1.2 NR 
Middle Africa 
Sobngwi 
1999 
[254] 
Came-
roon 
Adults attending diabetes clinic. 
Excluded pts with renal disease.  
SL exam by Ophthalmologist. 
64 37.5 1.6 NR 
* 'Severe retinopathy' by WHO multinational study criteria [284]. Abbreviations: Pts Patients; IO 
Indirect ophthalmoscope; DO Direct ophthalmoscope; SL Slit lamp biomicroscopy; RP Retinal 
photography; OPD Out-patient department; NFV No fundal view; DRC Democratic republic of Congo; 
NR Not reported. 
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Table 4.6 Hospital based surveys of persons with diabetes reporting prevalence of 
DR using a recognised grading system in Eastern Africa   
 
Study Country Methods n Any 
DR 
(%) 
PD
R 
(%) 
Any 
maculo
pathy 
(%) 
Sulivan 
1990 
[221] 
Seychelle
s 
Persons with diabetes requiring 
insulin therapy attending 
diabetic clinic examined by a 
physician. Instrument NR. 
108 15.7 2.8 NR 
Lester 
1992 § 
Ethiopia Type 1 diabetes seen 1976-90. 
Exam by physician. Instrument 
NR. 
431 9.5 2.6 1.2 
Lester 
1993 § 
Ethiopia Type 2 diabetes seen 1976-91. 
Exam by physician. Instrument 
NR. 
503 41.1 6.9 4.0 
Taylor 
1997 
[222] 
Seychelle
s 
Type 2 diabetes: 184 attending 
an eye clinic, 199 invited for 
screening. Ophthalmologist SL 
exam 
383 28 4 19 
Seyoum 
2001 
[258] 
Ethiopia Persons attending a diabetes 
clinic. DO exam by 
Ophthalmologist. 3 subjects 
excluded as NFV. 
302 37.8 1.7 NR 
Teshom
e 2004 
[230] 
Ethiopia Consecutive patients seen at a 
retinal clinic (not all had 
diabetes). SL exam by 
Ophthalmologist. 
139
0 
28.7 9.9 11.1‡ 
Mumba 
2007 
[259] 
Tanzania Pts >18yrs attending diabetes 
clinic. No previous fundus exam. 
SL exam by Ophthalmologist  
86 20.9 1.2 NR 
Mwale 
2007 
[245] 
Kenya Type 2 diabetes clinic pts. SL 
exam by Ophthalmologist. 
Excluded cornea or media 
opacity. 
96 22.6 0 NR 
Gill 
2008 
[223] 
Ethiopia Consecutive pts attending 
hospital diabetes clinic  in a 
remote region.  SL exam by 
Ophthalmologist. 
105 21 1.9 NR 
Glover 
2011  
[2] 
Malawi Consecutive adults attending a 
hospital diabetes clinic. SL exam 
by Ophthalmologist. 
281 32.0 5.7 15.0* 
* Sight threatening maculopathy according to Liverpool Diabetic Eye Study adaptation of the Early 
Treatment Diabetic Retinopathy Study (ETDRS) grading [285]. ‡ Clinically significant macular oedema.  
§ Multiple publications [248,260,261] with overlapping populations have emanated from  the 
diabetes clinic at Yekatit 12 Hospital, Addis Ababa, Ethiopia. For the purposes of this review these 
papers are viewed as one study.  Data presented from Lester 1992 [260] and Lester 1993 [261].  
Abbreviations as Table 4.   
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Table 4.7 Hospital-based and primary care-based surveys of persons with diabetes 
reporting prevalence of DR using a recognised grading system in Southern Africa 
Study Country Methods n Any 
DR 
(%) 
PDR 
(%) 
CSMO 
(%) 
Mollentz 
1990 
[242] 
South 
Africa 
Black subjects with diabetes 
>5yrs duration attending 
diabetes clinic. RP graded by 
Ophthalmologist. 
86 29.7
‡ 
1.2‡ NR 
Levitt 
1997  
[255] 
South 
Africa 
Black Africans attending 
diabetes primary care service. 
Examined by a physician with 
DO 
243 55.4 4.3 31.1† 
Rotchford 
2002  
[244] 
South 
Africa 
Adults attending a nurse-led 
primary care diabetes service in 
rural KwaZulu-Natal. Examined 
with SL by an Ophthalmologist. 
253 40.3 5.6 10.3 
Huddle 
2005 
[262] 
South 
Africa 
Pregnant women with diabetes 
attending a clinic: type 1, type 2 
and gestational diabetes. DO 
exam; practitioner grading 
retinopathy NR. 
733 7.6 0.1 NR 
Carmiche
al 2005* 
[236] 
South 
Africa 
Persons attending an urban 
diabetes clinic: 588 black, 739 
white, 180 indian. RP graded by 
Ophthalmologist. Ungradeable 
photographs excluded. 
151
7 
26.5 NR NR 
Mengesh
a 2006 
[263] 
Botswan
a 
Persons with diabetes attending 
government health facilities. SL 
exam by Ophthalmologist. 
401 9.2 3.0 NR 
Mash 
2007 
[241] 
South 
Africa 
Persons attending primary care 
diabetes service: 44% 'black'; 
56% 'coloured'. RP graded by 
Ophthalmologist. 17.5% 
photographs ungradeable. 
400 62.4 6.1 15.2† 
Read 
2007 
[256] 
South 
Africa 
Type 2 pts attending a primary 
care diabetes clinic (124 'Black'; 
119 'Coloured'; 5 'White'; 1 
'Asian'). DO exam by 
Ophthalmologist. 
248 32.3 2.4 8.5 
*Three reports [236,240,264] described grades of DR in overlapping populations.  Figure for 
any DR taken from the largest report [236] (n=1517).  † Any maculopathy.  ‡Percentage of 
eyes (not patients) with specified grade of DR.  Abbreviations as Table 4.   
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4.4.6 Studies reporting visual acuity  
Nineteen studies reported visual acuity (VA) in subjects with diabetes; parameters 
reported varied widely between studies.  Only the Nigerian national blindness and 
visual impairment survey [214] tested logMAR acuity.  The population-based 
Mauritius diabetes complication study [212] reported best correct visual acuity 
(BCVA) <6/12 in 7.1% of subjects with diabetes at baseline. There was no difference 
in this figure for subjects with and without retinopathy.  The Diabetes in Egypt 
project [246] reported VA in 427 subjects with diabetes.  Of these 31 (7.3 %) were 
blind (defined as BCVA in the better eye less than 6/60); 239 (56 %) had a BCVA 
between 6/12 and 6/60.  It is likely that media opacities accounted for a proportion 
of this visual impairment: 123 eyes had cataract; 11 had corneal opacity; 17 had 
both.   
 
The Nigerian national blindness and visual impairment survey was conducted 
between 2005 and 2007 [214].  DR was identified as the primary cause of visual 
impairment in 0.29% of 3129 subjects with uncorrected VA worse than 6/12 and in 
0.5% of those with acuity less than 3/60.  This study is likely to underestimate the 
visual impact of DR as examiners were instructed to preferentially record treatable, 
then preventable causes of visual impairment i.e. cataract would be recorded in 
preference to DR if both were affecting visual acuity to similar degrees.  
 
4.5 Discussion  
 
4.5.1 Overall commentary  
This systematic narrative review describes 62 studies reporting the prevalence and 
incidence of DR and maculopathy in Africa before February 2011.  The 
methodological approach used standard inclusion, appraisal and data extraction 
techniques.  Few high-quality, population-based studies were identified; the 
majority of studies were surveys of hospital clinic attendees.  Identified studies 
were highly heterogeneous in terms of subject selection and method of assessment 
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and classification of retinopathy.  Despite these inconsistencies between studies, 
the review identified rates of DR prevalence in many areas of Africa comparable 
with high-income countries.  Prevalence of PDR and maculopathy was high in recent 
studies particularly those from Southern and Eastern Africa.  Common themes were 
identified in the associations of DR and impact on vision. 
 
4.5.2 Methodology of included studies  
The review identified 3 high quality, population-based, cross-sectional studies of DR 
epidemiology [212,213,214].  Only two cohort studies were identified.  Large 
epidemiological studies are expensive; the population-based studies were 
conducted in states with relatively greater resources: Nigeria, Mauritius and Egypt.  
The lack of studies from Middle Africa is likely to reflect lack of resources, poor 
health infrastructure, and deficiency of trained medical professionals.  The relatively 
small number of studies identified from Northern Africa is partially explained by the 
tendency of francophone countries to publish in French.   
 
The literature is dominated by studies of urban populations reflecting the 
distribution of major health facilities.  Urbanisation is seen as an important factor 
driving the diabetes epidemic [286]; studies including only urban populations may 
over-estimate overall prevalence of DR.  A caveat is that in resource poor settings 
patients travel long distances to health facilities and rural patients may therefore be 
included.  The majority of studies identified were hospital clinic-based surveys; 
selection bias is a major issue and the findings should be generalised to other 
settings with caution.  Another bias is that clinics are seen by many as a point to 
collect medication; persons with diet-controlled diabetes may be under-
represented.  The classification of diabetes in Africa is problematic particularly 
where investigations are limited.  Disease characteristics differ from Caucasian 
populations. For example, peak age of onset of type 1 diabetes is later in African 
communities, typically 22-29 years [194].  Other phenotypes of diabetes are 
recognized in people of African origin including 'atypical African diabetes' and 
'malnutrition-related diabetes' [195].  
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Adaptations of the ETDRS grading system have become the accepted reference 
standard for classifying retinopathy in research settings.  Despite this, its use in 
everyday clinical practice is difficult due to a large number of levels requiring 
correlations with standard photographs and grading rules which must be 
remembered.  General ophthalmologists and physicians in resource poor settings 
may not be able to use this system to a reproducible level.  Stereoscopic 
photography with validated grading is the reference standard for assessing 
retinopathy.  Digital photography allows transfer of images to distant reading 
centres as performed in the Diabetes in Egypt project [213,239,246,247].  This will 
be one direction of future research. 
 
4.5.3 Prevalence and incidence of DR and diabetic maculopathy  
Community-based studies identified in this review reported prevalence rates of DR 
and PDR comparable with American and European diabetic populations.  The 
Diabetes in Egypt project [213,239,246,247] reported a prevalence of DR and PDR in 
subjects with diabetes of 31.6% and 0.9%, respectively.  The Mauritius diabetes 
complication study [212] reported 30.2% DR and 1.3% PDR; the prevalence of PDR 
in subjects with known diabetes was 2.3%.  In comparison, a 2005-2008 cross-
sectional sample of US adults with diabetes aged 40 years and older estimated 
prevalence of DR and PDR as 28.5% and 1.5%, respectively [287].  Recent population 
based studies in Europe have reported similar rates [102,288-291].  Younis et al 
[288] studied 8062 persons with diabetes entering an English primary care-based 
screening program.  The prevalence of any retinopathy and PDR in type 1 diabetes 
was 45.7% and 3.7%, respectively, and in type 2 diabetes 25.3% and 0.5%, 
respectively.   
 
The lack of community-based studies from Sub-Saharan Africa is important.  Very 
high prevalence of DR, PDR and maculopathy has been reported in notable high-
quality, clinic-based surveys in the last decade: in Eastern Africa by Glover et al [2] 
(32.0% DR, 5.7% PDR, 15% sight threatening maculopathy), and in South Africa by 
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Mash [36] (62.4% DR, 6.1% PDR, 15.2% any maculopathy) and Rotchford [224] (DR 
40.3%, PDR 5.6%, 10.3% CSMO).  These figures are likely to reflect factors including 
ethnicity, poor access to medical services, late diagnosis, and co-pathology including 
infection (importantly HIV and malaria), hypertension, malnutrition, and anemia.  
We found no clear relationship between per capita GDP and prevalence of DR or 
PDR.  However, the increased infrastructure to detect disease in states with greater 
resources is an important confounding factor. 
 
The influence of ethnicity on DR prevalence in populations of African origin has yet 
to be determined.  In the USA, Zhang et al [287] reported prevalence of both DR 
and vision threatening retinopathy (defined as ETDRS severe non proliferative 
diabetic retinopathy, PDR, or CSMO) to be higher in non-Hispanic black subjects 
(38.8% and 9.3%, respectively) compared to non-Hispanic whites (26.4% and 3.2%, 
respectively).  Previous studies have shown similar results [292,293].  However, 
differences were attributable to risk factors for retinopathy [293].  Therefore no 
ethnic propensity to retinopathy has been identified [294].   
 
Neither of the two cohort studies identified by this review reported 2 or 3 step 
progression on the ETDRS scale as used in recent European studies [136].  The 
Mauritius diabetes complication study [215] reported 6-year incidence of DR 
(23.8%).  Six-year progression to PDR was reported from no DR (0.4%), mild NPDR 
(5.2%) and moderate NPDR (29.4%).  The United Kingdom Prospective Diabetes 
Study (UKPDS) reported similar 6-year incidence of DR: 22% [13].  However, the 
UKPDS population were studied from a later time point: clinical diagnosis of 
diabetes.  In the Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) 
4-year progression of DR and progression to PDR was observed in 41.2% and 10.5% 
of type I subjects, 34% and 7.4% of insulin-treated type II subjects and 24.9% and 
2.3% of non-insulin treated subjects, respectively [295].   
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4.5.4 Impact of diabetic retinopathy on vision  
Estimates of the proportion of African persons with diabetes who are visually 
impaired are high even compared to older European and American studies.  7.3 % 
of subjects in the Diabetes in Egypt project [246] had BCVA in the better eye less 
than 6/60.  In contrast, of the WESDR population 3.6% of subjects aged less than 30 
years at diagnosis, and 1.6% of subjects aged greater than or equal to 30 years at 
diagnosis were legally blind according to US standards [10,11].  The WHO estimates 
that in the United States and Canada 17% of blindness is attributable to DR [296].  
While data is sparse, the proportion of visual impairment and blindness due to DR in 
Africa is appears to be considerably less. However the prevalence of visual 
impairment and blindness is significantly higher in Africa [296] reflecting high 
prevalence of pathologies including uncorrected refractive error, cataract, corneal 
opacities and glaucoma.   
 
4.6 Conclusions of systematic review 
The findings of this review have important implications for both research and 
clinical practice and can be summarised thus:  
• There is a paucity of high quality epidemiological data on DR in Africa 
• Existing estimates of prevalence of any DR, proliferative DR and maculopathy are 
comparable to recent European and American studies 
• Large, community-based cross-sectional and cohort studies are needed to 
investigate rates and determinants of DR prevalence, incidence and progression 
in Africa   
• Consensus is needed on the most appropriate methods of identification and 
classification of retinopathy for research and clinical practice 
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4.7 Summary of the literature review; aims and objectives of thesis  
 
4.7.1 Findings of the literature review: Chapters 1, 2, 3 and 4 
The pathophysiology of DR is complex.  Dysfunction of the vascular endothelium is 
an important component and can be assessed by measurement of serum 
biomarkers and in vivo functional testing.  The clinical features of DR are well 
described.  There are many grading schemes for DR.  The reference standard is the 
ETDRS scale: levels are validated for progression of retinopathy and visual loss as 
described in the WESDR and the ETDRS.  Other grading schemes including the LDES 
scale map to ETDRS levels providing an evidence base for treatment thresholds and 
facilitating studies of the determinants of severity and progression of DR.   
 
An solid body of work exists concerning systemic risk factors such as glycaemic 
control, BP and lipids.  The vast majority of studies were performed in Europe and 
North America.  At present results are extrapolated to populations in Africa; primary 
evidence has yet to be accrued.  Little is known about the effect on DR of a number 
of risk factors important to populations in Sub-Saharan Africa.  These ‘population 
specific risk factors’ include HIV infection and anaemia.  There is a paucity of high 
quality epidemiological data on DR in Africa.  Large, community-based cross-
sectional and cohort studies are needed to investigate rates and determinants of DR 
prevalence, incidence and progression in Africa.   
 
4.7.2 Previous work on diabetes complications at Queen Elizabeth 
Central Hospital 
In 2007 a cross-sectional study of the complications of diabetes was performed at 
Queen Elizabeth Central Hospital (QECH), Blantyre [1].  620 consecutive patients 
attending the diabetes clinic were assessed.  Subjects completed a questionnaire 
and were examined for BP, BMI and visual acuity and underwent a neurovascular 
assessment of the feet.  Fasting plasma glucose (FPG), HbA1c and HIV tests were 
performed.  A subgroup of subjects had urine albuminuria and serum creatinine 
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measured.  In this study control of glycaemia and hypertension were poor: mean 
FPG 182.7 mg/dl (SD 92, range 11.6--580); mean HbA1c 9.4% (SD 2.5, range 5--
19.6); 52% of subjects had sBP ≥ 140 mmHg.  13.7% of subjects were HIV positive.  
Microvascular complication rates were high.  Prevalence of nephropathy (defined as 
≥1+ albuminuria on dipstick testing) was 34.7%.  HIV positive subjects were more 
likely to have albuminuria (48.0% v 33.3% p<0.05).  Objective evidence of 
neuropathy was present in 33.1%.   
 
A subgroup of 281 subjects from the cohort were examined by one ophthalmologist 
from our group [2].  Sampling was ad hoc: subjects were examined when the 
ophthalmologist was present.  Retinopathy was assessed by clinical ocular 
examination at the slit lamp and graded according to the LDES scale.  Prevalence of 
any DR, STDR and PDR in type 1 diabetes was 28.1% (95% CI 12.5 to 43.7%), 18.8% 
(5.2 to 32.2%) and 12.5% (1.0 to 24.0%), respectively.  In type 2 diabetes prevalence 
of any DR, STDR and PDR was 32.5% (26.7 to 38.3%), 19.7% (14.7 to 24.6%) and 
4.8% (2.2 to7.5%), respectively.  In multivariate analysis STDR was associated with 
albuminuria (OR 2.6; p=0.02), neuropathy (OR 3.4; p=0.005) and insulin use (OR 5.3; 
p=0.0004), but not with HIV status.  Strengths of this study included its relatively 
large sample size, use of a detailed grading system for DR and collection of data on 
HIV status.  Principle limitations of the work were that this was a single centre, 
clinic-based study, the lack of systemic sampling and absence of external validation 
of retinopathy grading. 
 
4.7.3 Hypothesis 
In the knowledge of the important data from QECH described above, I planned to 
investigate further the epidemiology of DR in Southern Malawi.  Studies presented 
in this thesis are based on the hypothesis that, in the Malawian population, DR is 
more common and progresses more quickly than that seen in developed countries.  
I hypothesised that factors particular to this population alter the spectrum of 
disease to that observed in the West, and that these factors include anaemia, co-
infection with HIV and poorly controlled blood sugar and blood pressure.  I 
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suggested that the effects of these factors are mediated at the level of the 
endothelium; endothelial perturbation results in exhaustion of the mechanisms for 
endothelial self-repair leading to the development of maculopathy and ischaemic 
retinopathy.   
 
4.7.4 Research questions addressed in this thesis 
This thesis will address the following questions: 
1. What is the prevalence, incidence and progression of grades of DR in 
patients attending diabetes clinics in Southern Malawi? 
2. What are the determinants of severity and progression of DR in Southern 
Malawi? 
3. Is there evidence of endothelial perturbation in patients attending diabetes 
clinics in Southern Malawi and is degree of endothelial dysfunction related 
to severity and progression of DR? 
 
The Malawi Diabetic Retinopathy Study (MDRS) was designed to address the 
questions listed above.   The design of this programme of research and the results 
from it are described in subsequent chapters.   
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Chapter 5. Malawi Diabetic Retinopathy Study: Aims, Design 
and Methodology 
 
 
5.1 Aims of the chapter  
In this chapter I describe the background, aims and methods of the Malawi Diabetic 
Retinopathy Study (MDRS), the study that I established to undertake the clinical 
work in my research fellowship and reported in this thesis. 
 
5.2 Introduction 
In Chapters 1 to 3 of this thesis I reviewed the pathophysiology of diabetic 
retinopathy (DR), grading schemes for DR and the existing evidence on the 
determinants of severity and progression of DR.  I explained that in resource-poor 
Sub-Saharan Africa, population-specific variables, such as irregular drug supply, 
poor patient education and a high burden of infective disease and anaemia, are 
likely to affect the spectrum of pathology encountered.  My systematic review of 
the epidemiology of DR in Africa (Chapter 4) highlighted the paucity of high quality 
epidemiological data about DR in Sub-Saharan Africa.   
 
5.3 Background to the MDRS 
To my knowledge, no cohort studies have investigated determinants of severity and 
progression of DR in Sub-Saharan Africa.  The 2009 WHO Malawi national STEPwise 
survey estimated a prevalence of diabetes of 5.6% in adults 25-64 years, with 
similar prevalence in rural and urban areas [17].  In 2007 a pilot, cross sectional 
study was performed using clinical ocular examination to assess grades of DR in 
patients attending the diabetes clinic at Queen Elizabeth Central Hospital (QECH), 
Blantyre [2].  This study reported a high prevalence of sight threatening diabetic 
retinopathy (STDR) and proliferative retinopathy (PDR): 19.6% and 5.7%, 
respectively.   
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In response to these important findings I set out to elucidate the prevalence, 
incidence and progression of DR and visual impairment amongst adults attending 
diabetes clinics in Southern Malawi.   This thesis describes the findings from the 
MDRS: a formal observational programme of research using a systematically 
sampled cohort, standardised clinical photography, independent grading at an 
accredited reading centre as well as data collected on covariates specific to this 
population.  Data was collected on markers of endothelial function as part of a 
nested case control study.   
 
5.4 Aims and objectives of the MDRS  
The aim of the MDRS was to investigate the determinants of severity and 
progression of DR in Southern Malawi.  The main hypothesis underlying this 
research is that, in the Malawian diabetic population, DR is more common, more 
aggressive and different in character than that seen in developed countries.  It is 
likely that factors particular to this population alter the spectrum of disease to that 
observed in the West, and that these factors include anaemia, co-infection with HIV 
and poorly controlled blood pressure.  I hypothesise that the effects of these factors 
are mediated at the level of the endothelium: endothelial perturbation and 
increased cell death results in exhaustion of the mechanisms for endothelial self-
repair leading to the development of ischaemic retinopathy.  This thesis outlines a 
program of both clinical and laboratory based research addressing the clinical 
determinants of DR severity and progression as well as the underlying cellular 
mechanisms.  
 
The objectives of the MDRS were the following: 
1. To investigate the prevalence, incidence and progression of DR in Southern 
Malawi  
2. To investigate the risk factors for DR severity and progression in this population 
3. To characterise endothelial function in Southern Malawian subjects with diabetes 
and to investigate relationships with severity of retinopathy 
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5.5 Design of the MDRS 
The MDRS was a programme of research comprising 3 core components: 
1. Prospective cohort study of people with diabetes  
Section 5.9 (Methods) and Chapters 6, 7 and 8 (Results)   
Prevalence, incidence and progression of DR were studied over a period of 24 
months.  Associations between grades of retinopathy and clinical and 
laboratory risk factors were investigated.  
2. Study of DR progression at 5 years   
Section 5.10 (Methods) and Chapter 9 (Results)  
In 2007 a cross sectional study was performed of 281 patients attending the 
QECH diabetic clinic.  This cohort was traced and re-examined at 5 years. 
3. Case-control study of endothelial function in Malawian subjects with diabetes 
Section 5.11 (Methods) and Chapter 10 (Results)   
A subset of subjects from the cohort study (1) was investigated.  Endothelial 
function was studied in 4 groups: subjects with diabetes and STDR, subjects 
with diabetes and DR but not STDR, subjects with diabetes but without DR and 
subjects without diabetes.   
 
5.6 Setting  
QECH in Blantyre is the only teaching hospital in Malawi. It provides primary and 
secondary care to the population of greater Blantyre (approximately 1.0 million, 
50% adult), an urban and semi-urban population, and tertiary care to the Southern 
region of the country (approximately 6.0 million).  In Southern Malawi primary care 
for diabetes is non-existent at health centre level.  Therefore primary care for 
diabetes is delivered at district hospitals.  Neither Blantyre nor Zomba have a 
district hospital so the central hospitals have to provide this service. 
 
The diabetes clinic at QECH provides predominantly primary diabetes care to 
approximately 2,000 patients.  The clinic represents the most specialised care in the 
public sector available to persons with diabetes in Malawi.  Zomba Central Hospital 
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(ZCH) is approximately 60 miles from Blantyre.  It provides primary and secondary 
care to the urban, semi-urban and rural population of Zomba district (approximately 
500,000 people).  In 2011 the newly established diabetes clinic served 
approximately 250 patients.  Many of this population were newly diagnosed with 
diabetes and had received no previous eye screening or treatment.  2010 saw the 
opening of the Lions Eye Hospital attached to ZCH.   
 
An important component of health care in Malawi is the ‘health passport’.  This 
booklet is carried by all patients in Malawi and contains details of medical 
interventions received from a variety of facilities and specialties.  For most out-
patient care this document is used in place of conventional hospital records.  In the 
MDRS the health passport was used to acquire details of past medical history, to 
make referrals to other specialties including medicine, surgery and physiotherapy, 
to document brief details of diagnosis and treatments performed and to record 
dates of follow-up clinics. 
 
5.7 Data management  
The MDRS utilised a custom-made ‘REDCap’ database hosted at the Malawi 
Liverpool Wellcome Trust (MLW) Clinical Research Programme.  REDCap (Research 
Electronic Data Capture, Vanderbilt University, Tennessee, USA) is a secure, web-
based application designed to support data capture for research studies.  The 
system provides audit trails for tracking data manipulation.  Each study subject was 
allocated a unique identifier.  Data on subject demographics, physical examination 
including visual acuity (VA) and point of care tests were manually recorded by the 
MDRS study team onto specially designed, paper-based data collection forms.  I 
recorded clinical DR grading onto paper-based forms originally designed for the 
Liverpool Diabetic Eye Study (LDES) [94].   
 
Data from the paper forms was entered onto the study database by Chrissy Pindani 
(study Research Nurse).  Once the data was entered a series of steps were taken to 
check for transcription errors.  Data entry for each data form was checked by me 
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with 100% quality assurance on critical variables.  Once the dataset for a particular 
analysis was complete I performed manual (visual) and automated (STATA) checking 
of critical variables.  Outliers thus identified (defined as a value that is more than 3 
standard deviations from the mean) were then checked manually against original 
data forms.  A number of minor errors were found and corrected before analysis.  
 
Laboratory results were received in a web based format via the Prelink Laboratory 
Information Management System (Prelink LIMS, Johannesburg, SA).  I entered these 
results into the study database.  In a similar fashion I entered into the database 
results from ELISA assays and peripheral artery tonometry testing.  The database 
was stored on centrally managed servers that were protected against data loss.  
Data was extracted from the database for analysis into either Microsoft Excel 
(Microsoft, Seattle, Washington USA) or STATA version 12 (StataCorp, Texas, USA). 
 
 
5.8 Ethical approval 
The MDRS received ethical approval from Liverpool School of Tropical Medicine 
Research Ethics Committee (protocol number: 11.88) and the College of Medicine 
Research Ethics Committee (COMREC) in Malawi (protocol number: P.08/11/1115).  
There were several subsequent amendments to address minor study modifications. 
See Appendices 3A-C and 4A-D for details of the consent forms and patient 
information sheets in English (Chichewa translations were also used but are not 
included in this thesis). Written informed consent was obtained from all subjects.  
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MDRS CORE COMPONENTS 
 
5.9 Prospective cohort study of persons with diabetes 
 
5.9.1 Subjects   
Systematic random sampling was used to select subjects from the general diabetes 
clinics at QECH and ZCH (the only public sector diabetes clinics in Blantyre and 
Zomba) between December 2011 and May 2012.  Patients attend these clinics for 
medical management of diabetes; no eye care is provided.  The first subject was 
selected from the first 6 patients in the diabetes clinic line using marbles in a bag 
numbered 1 to 6.  Then every 6th individual was approached until ten subjects were 
selected (the maximum number which could be assessed in a morning).  Inclusion 
criterion was a diagnosis of diabetes according to American Diabetes Association 
(ADA) criteria [123] (Box 5.1).   
 
Glycosylated haemoglobin (HbA1c) testing is not available in the public sector in 
Malawi.  Therefore, in practice, inclusion criterion was diagnosis of diabetes 
according to ADA criteria numbers 2, 3 or 4.  Exclusion criteria were age less than 18 
years, first visit to the diabetes clinic, and diagnosis of gestational diabetes 
according to ADA criteria [123].  As described above, the diabetes clinics at QECH 
and ZCH provide predominantly primary diabetes care (primary care for diabetes 
does not exist at health centre level and there are no district hospitals in Blantyre 
and Zomba).  Central hospitals are tertiary centres which receive referral cases.  In 
order to effectively exclude referral cases from the MDRS cohort, patients living 
more than 60km from the clinic in question were excluded. 
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5.9.2 Classification of type 1 and type 2 diabetes  
Type 1 diabetes was diagnosed when subjects had commenced insulin therapy 
within 2 weeks of diagnosis and 2 of the following 4 features were present: age ≤ 19 
years at diagnosis; BMI ≤ 25kg/m2; ketones 2+ on urinalysis; symptoms ≤ 4 weeks 
duration.  Type 2 diabetes was diagnosed in subjects stabilised on oral medications 
or diet from diagnosis (fasting blood sugar (FBS) ≤130mg/dL on two occasions 
within 3 months).  For subjects not fulfilling the above criteria, diagnosis of type 1 or 
type 2 diabetes was decided by two clinicians (PB and TA) with reference to clinical 
notes.  Subjects with type 2 diabetes were sub-classified based on treatment: 
insulin requiring with or without oral hypoglycaemic agents, oral hypoglycaemic 
agents alone or dietary measures alone. 
 
Criteria for the diagnosis of diabetes have been extensively debated [123,297].  
Differentiating type 1 and type 2 diabetes can be difficult even with extensive 
laboratory investigations (including serum C-peptide and islet cell autoantibodies) 
Box 5.1 American Diabetes Association criteria for diagnosis of diabetes [123] 
1. HbA1C ≥ 6.5%.  The test should be performed in a laboratory using a method that is 
National Glycohaemoglobin Standardisation Program (NGSP) certified and standardised to 
the Diabetes Control and Complications Trial (DCCT) assay*. 
2. Fasting plasma glucose ≥ 126 mg/dl (7.0mmol/l).  Fasting is defined as no caloric intake 
for at least 8 h*. 
3. 2-hour plasma glucose ≥ 200 mg/dl (11.1mmol/l) on oral glucose tolerance testing. The 
test should be performed as described by the World Health Organisation, using a glucose 
load containing the equivalent of 75g anhydrous glucose dissolved in water*. 
4. In a patient with classic symptoms of hyperglycaemia or hyperglycaemic crisis, a 
random plasma glucose ≥ 200mg/dl (11.1mmol/l). 
*In the absence of unequivocal hyperglycaemia, criteria 1-3 should be confirmed by 
repeat testing. 
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which were not available to this study [123,298].  There are issues with classification 
of diabetes which are specific to Africa.  The mean age of onset of type 1 diabetes is 
reported to be higher than other regions [195].  Other phenotypes of diabetes are 
recognised including ‘ketosis prone atypical diabetes’ and ‘malnutrition-related 
diabetes’ [195,299] (Box 5.2).  While our criteria are study specific they are similar 
to definitions used in large population based studies of DR [293,300-305] while 
taking into account the regional context. 
 
 
 
 
 
 
 
 
 
 
 
 
5.9.3 Clinical assessment  
A standardised case record form was completed by the study team by questioning 
subjects and by reference to the ‘health passport’ carried routinely by patients in 
Malawi.  Information was obtained about demographic details, date of diagnosis of 
diabetes, as well as anti-diabetic, anti-hypertensive, and anti-retroviral (ART) 
medications.  Assessment of past medical history included presence or absence of 
stroke, ischaemic heart disease, neuropathy, foot ulcers, amputation, erectile 
dysfunction, previous diagnosis of tuberculosis, previous diagnosis of syphilis, 
diagnosis of malaria within the past year, and previous eye examination.  Smoking 
was defined as current, former or never.   
 
Box 5.2 Summary features of ‘ketosis prone atypical’ and 
‘malnutritional-related’ diabetes [after reference 195]  
Ketosis prone atypical   Malnutrition-related 
Ketotic presentation    Insidious onset 
Children or young adults   Young adults 
3:1 male excess    2:1 Male excess 
Islet autoimmunity rare   Occasional ‘type 1’ HLA pattern 
Often strong family history   Past or present malnutrition 
Remission possible    Steatorrhoea in some areas 
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Physical examination was undertaken by a trained nurse or trained research 
assistants who were part of the study team.  Blood pressure was measured using 
the United Kingdom Prospective Diabetes Study (UKPDS) protocol [14] (HEM-907 
XL, Omron, Lake Forest, IL).  Subjects were classified as hypertensive according to 
the WHO definition [17]: subject either taking antihypertensive medication, or 
systolic blood pressure (sBP) ≥140mmHg, or diastolic blood pressure (dBP) ≥ 
90mmHg.  Weight (Seca 875, Birmingham, UK) and height were recorded.  VA 
(uncorrected and using pinhole) was measured as the number of letters read on a 
standard Early Treatment of Diabetic Retinopathy Study (ETDRS) chart (Sussex 
Vision, UK) using a standard protocol (testing at 4 metres initially and then at 1 
metre if <20 letters are read at 4 metres).  For illiterate subjects a 4m logarithm of 
the minimum angle of resolution (logMAR) ‘Tumbling E’ chart was used (Sussex 
Vision, UK).  For each subject with VA in the better eye <80 letters I recorded what 
was, according to my clinical judgement, the primary cause of visual impairment.  
Causes of visual impairment were classified as DR, cataract, DR and cataract, age-
related macular degeneration, glaucoma and ‘other’. 
 
HIV status was defined as ‘unknown’, ‘known HIV positive not taking ART’, ‘known 
HIV positive taking ART’, or ‘known HIV negative’ (documented negative HIV test 
within 1 month).  All subjects in the first 2 categories were offered HIV point of care 
testing according to Malawian national protocol [306] (Determine Rapid Test, 
Abbott, Hoofddorp, the Netherlands; Uni-Gold Recombigen, Trinity Biotech, Bray, 
Ireland; Bioline, SD, Korea).  Those subjects diagnosed with HIV were referred to the 
dedicated HIV clinic at QECH from which ART is available.  Haemoglobin was 
measured with a point of care test (Hb301, HemoCue, Angelholm, Sweden).  
Thresholds for anaemia were set according to WHO guidelines: 13.0g/dL for men; 
12.0g/dL for women [307].  
 
Blood samples were assayed for putative biochemical risk factors: fasting glucose, 
triglycerides, low density lipoprotein (LDL) cholesterol, high density lipoprotein 
(HDL) cholesterol, serum creatinine, and urine albumin-creatinine ratio (ACR) 
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(colorimetric assays performed at Malawi Liverpool Wellcome laboratories, 
Blantyre, Malawi using the Synchron CX5, Beckman Coulter, CA).  Glycosylated 
haemoglobin (HbA1c) was measured using Boronate affinity chromatography 
performed at Norfolk and Norwich University Hospitals Laboratories, UK.  A detailed 
description of HbA1c measurement in the MDRS is given below in Section 5.12.  
Hypercholesterolaemia was defined according to the WHO as ≥ 5.0 mmol/L [17].  
Photographs of the MDRS study team assessing subjects are shown in Figure 5.1. 
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Figure 5.1 Photographs of the MDRS study team assessing study subjects. 
Photograph A: Sister Chrissy Pindani taking a venous blood sample.  Photograph B:  
Research Assistant Moffat Chidzuwa measuring visual acuity using a 4m logMAR 
‘Tumbling E’ chart. 
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5.9.4 Assessment of retinopathy  
Digital fundus photography of four 45° standard fields [94] with a stereo macular 
image was performed through dilated pupils (guttae tropicamide 1% and 
phenylephrine 2.5%) using CR6 fundus cameras (Canon, Reigate, UK).  Photographic 
fields used in the MDRS are shown in Figure 5.2.  MDRS standards for field position 
and quality are shown in Figure 5.3.  Dual grading of photographic images was 
performed by accredited graders at the Liverpool Ophthalmic Reading Centre (an 
accepted reference standard for grading of retinopathy).  In the event of 
disagreement between graders arbitration was performed by a senior 
ophthalmologist accredited in grading.  Graders followed protocols established in 
Liverpool.  Briefly, images were graded on graphic quality monitors against 
photographic standards defined for the ETDRS on standardised data forms in 
sessions lasting a maximum of 2 hours before a break, to ensure adequate quality. 
 
In addition to fundus photographs, all subjects were examined by me (PB) using 
slit-lamp biomicroscopy.  Cataract was graded according to the Lens Opacities 
Classification System (LOCS) III [308] and considered clinically significant when 
graded at ≥3 in any category (nuclear opalescence, nuclear colour, cortical or 
posterior subcapsular). A photograph of the MDRS study team performing retinal 
photography is shown in Figure 5.4. 
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Figure 5.2. Photographic fields used in the MDRS.  Digital fundus photography of 
four 45° standard fields with a stereoscopic macula image were performed.  
Illustrations show the right eye.  Circle indicates the optic disc; cross indicates the 
centre of the fovea.  Field 1: Disc centred image.  Field 2. Macular centred stereo image 
(2 images: a and b). Field 3:  Superior temporal image. Positioned with the disc in the 5 
o'clock or 7 o'clock positions for upper temporal quadrant in the right and left eyes, 
respectively.  All of the disc should be visible with the disc margin abutting the edge of the 
image.  Field 4:  Inferior temporal image.  Disc in the 1 o'clock or 11 o'clock positions for the 
lower temporal quadrant in right and left eyes, respectively.  
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Figure 5.3. Standards for photograph field position and image quality used in the 
MDRS  
 
A. Disc and macular centred images 
Definitions for disc and macular centred images are taken from the English National 
Screening Programme [309].  A combined assessment of field position and image quality 
was made as follows.   
Good 
Macular image  
 
 
 
Disc image 
Centre of fovea ≤1DD from centre of 
image 
AND  
Vessels clearly visible within 1DD of centre 
of fovea 
AND  
Vessels visible across >90% of image 
Centre of disc ≤1DD from centre of image 
AND  
Fine vessels clearly visible on surface of 
disc 
AND 
 Vessels visible across >90% of image 
 
 
 
 
Adequate (Fair) 
Macular image  Disc image 
Centre of fovea >2DD from edge of image 
AND  
Vessels visible within 1DD of centre of 
fovea 
Complete optic disc >2DD from edge of 
image 
AND  
Fine vessels visible on surface of disc 
In some unusual cases (particularly in patients with a large disc), an image may fall within 
both good and adequate categories above.  In such cases, the image was classified as good. 
 
Inadequate (ungradeable; poor) 
Failure to meet the definition of adequate above. 
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B. Upper temporal and lower temporal image quality 
The following definitions are specific to the MDRS. 
Good   
Complete disc visible AND  
Disc at 1.30 or 4.30 or 7.30 or 10.30 for right or left, inferotemporal or supereotemproal 
images, respectively AND  
Fine vessels clearly visible on surface of disc AND  
Vessels visible across >90% of image 
Adequate   
Some portion of optic disc visible AND  
Disc within 1 DD of correct position AND 
Fine vessels visible on surface of disc AND 
Vessels visible across 50% of image 
Inadequate   
Failure to meet the definition of adequate above 
 
Definitions of disc, fovea, 1DD for purposes of field position 
Definitions taken from the English National Screening Program [309].  The image shown 
below is a perfectly aligned macular view of the right eye.  The fovea lies at the centre of 
the image and is marked by a ‘+’ symbol. 
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Figure 5.4 Photograph of Ophthalmic Clinical Officer Owen Mkangadzula 
performing retinal photography  
 
 
5.9.5 Grading of retinopathy 
Retinopathy and maculopathy were classified by feature specific grading using 
definitions established in the Liverpool Diabetic Eye Study (LDES) [94].  The LDES 
protocol was produced in 1991 and involves a simplification of the Wisconsin 
grading system.  This in turn was based on the modified Airlie House classification 
used in the ETDRS [86] and is based on standard photographs. LDES definitions can 
therefore be mapped to ETDRS disease steps.  Definitions of clinical features used in 
the ETDRS are shown in Appendix 1. In the LDES changes were made to definitions 
of retinopathy grades on discussion between the LDES team and the Wisconsin 
Reading Centre team (SP Harding personal communication) with reduced weighting 
of cotton wool spots, increased weighting of venous signs and intra-retinal 
microvascular anomalies (IRMA), exclusion of exudates outside the macula and no 
distinction made between small haemorrhages and microaneurysms [94] (Table 
5.1).   
 
Each of eight clinical features of retinopathy is graded by greatest degree in any 
field and an overall retinopathy score assigned.  Grading of maculopathy is based on 
the presence of exudates and/or oedema in the macular region.  Macular oedema is 
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assessed according to the ETDRS criteria for clinically significant macular oedema 
(CSMO) which is a stage of exudative maculopathy directly threatening or involving 
the fovea [86] (Box 5.3).  In the LDES and in the MDRS, STDR was defined as any of 
the following: moderate pre-proliferative retinopathy or worse (level 40-71+); 
macular exudates in a circinate pattern or within one disc diameter of the foveal 
centre, or CSMO (level 3-4: sight threatening maculopathy); or other diabetes 
related retinal vascular disease: central or branch retinal artery occlusion, central or 
branch retinal vein occlusion.   
 
For the purposes of analysis, for each feature of DR photographic grading took 
precedence over clinical examination.  If any feature was classified as ‘ungradeable’ 
on photographic grading the biomicroscopy grade for that feature was used.  Only if 
a feature was deemed ‘ungradeable’ on both photographic and clinical grading was 
‘cannot grade (CG)’ recorded as the final grade for this feature.  If a single feature 
was graded CG (most likely with IRMA) the following algorithm applied: 
 
1. If a feature higher on the LDES scale was present then this took precedence and 
a grade was assigned 
2. If no higher feature was present then the retinopathy grade for that eye was 
assigned based on the features which could be graded ('minimum grade') 
 
 
 
 
 
  
Box 5.3. Definition of clinically significant macular oedema (CSMO) as 
used in the Early Treatment of Diabetic Retinopathy Study (ETDRS) [86] 
1. Retinal thickening within 500µm of the foveal centre 
2. Exudates within 500µm of the foveal centre which are associated with adjacent 
retinal thickening 
3. Retinal thickening at least 1 disc area in size any part of which is located within 1 
disc area of the foveal centre 
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Table 5.1 Levels of retinopathy and maculopathy in the Liverpool Diabetic Eye 
Study [94] 
Level  Definition  
Retinopathy 
11 No retinopathy 
12 Questionable 
20       Haemorrhages or microaneurysms < ETDRS standard photograph 2A † 
30       Haemorrhages or microaneurysms ≥ ETDRS standard photograph 2A,  
 and/or 1-6 cotton wool spots  
40       Haemorrhages/ microaneurysms  ≥ ETDRS STD 2A and/or ≥ 6 CWS;  
 and/or 1 quadrant venous changes; and/or IRMA < ETDRS STD 8A  
50       IRMA ≥ ETDRS STD 8A  
 and/or 2 or more quadrants venous changes 
 and/or pre-retinal haemorrhage in absence of proliferation  
60       Fibrovascular proliferation and/or proliferative retinopathy  
70       Diabetic Retinopathy Study high risk characteristics 
71 Tractional retinal detachment 
72 No fundal view due to vitreous blood 
90       Ungradeable due to any other reason e.g. media opacity  
Maculopathy 
0       No maculopathy 
1       Questionable: < 50% certainty of presence of exudate 
2       Exudate >1 disc diameter (DD) from fixation  
3       Circinate ring of exudates within macula >1 disc area in size but not within 1 DD of 
fixation  
4       Exudates within 1 disc diameter of fixation  
 and/or presence of clinically significant macular oedema  
8 Exudates due to other diseases e.g. vein occlusion, choroidal neovascularisation 
90      Ungradeable 
† Definition of any diabetic retinopathy:  ≥ 1 haemorrhages of microaneusyms (HMa) in either eye.  
Flame shaped haemorrhages associated with hypertension are discounted. 
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5.9.6 Study schedule  
Subject recruitment (Visit 1) took place at the diabetes clinics at QECH and ZCH 
between December 2011 and May 2012.  12 month follow-up (Visit 2) occurred 
between December 2012 and May 2013.  24 month follow-up (Visit 3) took place 
between December 2013 and May 2014.  Table 5.4 gives a summary of data 
collected at each study visit.  Subjects were recalled for follow-up visits by 
telephone.  Subjects without telephones or whose telephone number changed 
between study visits were traced by the MDRS study team.   
 
Tracing was systematic.  The team attended the diabetes clinic at QECH and ZCH 
weekly between December 2012 and May 2013 and again between December 2013 
and May 2014 to approach patients in the clinic waiting room.  Subjects not found 
at the diabetes clinic were visited at home to offer an appointment (Figure 5.5).  If 
the subject had relocated attempts were made to contact them via their church or 
place of worship.  Finally the president and vice president of the patients’ 
organisation, the Diabetes Association of Malawi were contacted in order to 
personally identify subject whereabouts. 
 
Figure 5.5 Research Nurse Chrissy Pindani visiting a study subject at home to offer 
an appointment.  
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Table 5.4 Study schedule for the MDRS cohort study: data collected at each 
patient visit  
Data collection method Data collected / test 
performed 
Visit number 
1 2 3 
Case record form  Demographic details  X X X 
Past medical history X X X 
Physical examination BP, height and weight X X X 
Visual acuity X X X 
Point of care tests Hb; HIV VCT  X X X 
Laboratory biochemical 
tests 
HbA1c; urine ACR X X X 
TG, LDL and HDL X   
Ophthalmology Retinal photograph X X X 
Clinical grading of DR X X X 
BP = blood pressure; Hb = haemoglobin; HIV VCT = human immunodeficiency virus voluntary testing 
and counselling; LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein 
cholesterol; TG = triglycerides; HbA1c = glycosylated haemoglobin; ACR = albumin creatinine ratio.  
 
5.9.7 Study outcomes 
The primary outcome of the cohort study was progression of DR by 2 or more steps 
on the LDES severity scale.  ‘2 step progression’ equates to either 1 step progression 
in one eye and 1 step progression in the other eye or 2 step progression in one eye. 
 
Secondary outcome variables at baseline were:  
1. Prevalence of all grades of retinopathy  
2. Prevalence of STDR  
3. Associations of systemic variables with STDR  
4. Prevalence of moderate and severe visual loss as defined by WHO [310]  
 
Secondary outcome variables at 12 and 24 month follow-up were:  
1. Incidence of retinopathy  
2. Progression of DR by ≥3 steps on the LDES Severity Scale 
3. Progression to STDR 
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4. Progression to sight threatening maculopathy 
5. Development of DR necessitating scatter laser 
6. Development of maculopathy necessitating macular laser 
7. Composite end point of either progression of DR by 2 or more steps on the LDES 
scale or development of DR necessitating scatter laser 
8. Associations of systemic variables with progression of retinopathy by ≥2 steps, 
development of DR necessitating scatter laser, and the composite end point of 
either progression of DR by 2 or more steps on the LDES scale or development of DR 
necessitating scatter laser 
9. Loss of 5 letters on the ETDRS visual acuity scale  
10. Loss of 15 letters on the ETDRS visual acuity scale 
11. Progression to moderate and severe visual loss as defined by WHO [310] 
 
Development of DR necessitating scatter laser is defined as ‘listed for scatter laser 
after the first study visit and up to and including the final study visit’ (i.e. this 
endpoint cannot be achieved twice).  Development of DR requiring laser treatment 
does not include those listed for scatter at baseline.  Similarly development of 
maculopathy necessitating macular laser is defined as ‘listed for macular laser after 
first study visit and up to and including the final visit. 
 
5.9.8 Sample size calculation: longitudinal data 
This study was powered for the primary endpoint (2 years): progression of 
retinopathy by 2 or more steps on the LDES scale.  On the basis of previous studies 
[83,84,190] I anticipated 20% progression over the 2 year study period.  I intended 
to use multiple logistic regression analysis (mixed effects) to analyse the effect on 
progression of retinopathy of six variables: sBP, HbA1c, Hb, HIV, urine ACR, and LDL 
cholesterol.  In logistic regression analysis, as a rule of thumb, the number of the 
least common of the two possible outcomes (in this case progression of DR by 2 or 
more steps) divided by the number of predictor variables should be at least 10.   
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Three hundred subjects would give 60 (20%) with progression and therefore with 6 
variables the rule described above holds.  Allowing for loss to follow-up and 
mortality of 20% gives 360 sample size.  My sample size calculation was based on 
logistic regression analysis of data from two time points: start and end of the trial.  
The MDRS cohort underwent 3 assessments: baseline, 1 year and 2 years allowing 
greater power of analysis.  The correlation between data from the same subject at 
several time points was taken into account using mixed-effects terms in the logistic 
model. 
 
5.9.9 Sample size calculation: cross sectional data  
I performed the following sample size calculation to ensure that the sample of 300 
subjects estimated above, based on the logistic regression analysis, would also be 
sufficient to identify a significant difference in the proportion of subjects with STDR 
at baseline according to a single clinical variable.  The example of HIV is used here 
as, based on our group’s recent cross sectional study [2], the percentage of HIV 
positive patients is expected to be 15% (i.e. small numbers relative to other 
variables). 
 
I used the chi-squared (χ2) test with unequal sample sizes for the study to be 
powered with 90% power to detect 25% difference in prevalence of STDR between 
subjects with and without HIV at the 5% level of significance.  The expected 
prevalence of STDR in a cohort based on our recent cross sectional study [2] was 
20%.  Therefore, a prevalence of STDR of 45% for the population of patients with 
HIV was considered to show a clinically significant change.  Since the expected 
prevalence of HIV in the cohort was 15%, the ratio in sample sizes between the two 
groups was estimated to be 3/17, and the sample size needed (nQuery Advisor) was 
n1=43 subjects with HIV and n2=238 subjects without HIV, giving a total sample size 
of 280 subjects. 
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5.9.10 Statistical analysis  
I performed all of the statistical analysis personally.  Support from one of my 
supervisors Dr Marta Garcia-Finana from the Department of Biostatistics, University 
of Liverpool was used to verify the data analysis.  An a priori analysis plan was 
followed.  Grades of DR were calculated by patient according to the worse or only 
gradeable eye.  Retinopathy and maculopathy were graded separately by worse eye 
i.e. the worse grade for retinopathy and the worse grade for maculopathy could be 
taken from different eyes.  Visual acuity data were investigated by patient according 
to the better eye.   
 
For normally distributed continuous data, mean and standard deviation (SD) were 
calculated.  For continuous data which was not normally distributed median and 
interquartile ranges were calculated.  Frequencies were quoted for categorical data.  
95% confidence intervals (CIs) were calculated for proportions.  When comparing 2 
groups (numerical data) with independent measurements the unpaired t-test was 
used when data was normally distributed and the Wilcoxon rank sum test when 
data was not normally distributed.  For categorical data Fisher’s exact test was used 
when comparing 2 categories and 2 groups of independent measurements.  The chi-
squared (χ2) test for trend was used to analyse trends across >2 groups.  All tests 
were two-sided and data were considered significant when p<0.05.     
 
When assessing cumulative and annual incidence at 24 month follow-up (visit 3), 
study subjects with baseline retinopathy data and at least one subsequent visit 
were analysed.  Cumulative and annual incidence rates of grades of DR and STDR 
were calculated for one year intervals using the life table method.  The life-table 
method allows for censored data taking into account varying intervals of follow-up 
after the first study visit.  Subjects who had not developed DR, STDR or other 
outcome threshold contribute to person-years of follow up until their last study 
visit.  Separate life table calculations were performed for each baseline grades of 
retinopathy progressing to each different endpoint (e.g. any retinopathy, level 20 
DR, level 30 DR, STDR, etc.).  The number of patients at each time interval and the 
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number reaching endpoint at each time interval are included in the life tables.  All 
calculations were performed using STATA version 12 (StataCorp, Texas, USA).  
Details of specific analyses are given in the relevant results chapters. 
 
5.9.11 Treatment of retinopathy 
Subjects with STDR who met thresholds for either scatter (peripheral retinal 
photocoagulation) or macular argon laser treatment, were treated by me in a linked 
dedicated laser clinic.  Threshold for scatter laser treatment was the ETDRS ‘4-2-1’ 
rule (4 quadrants of haemorrhages and microaneurysms (HMa) ≥ ETDRS standard 
2A, and/or 2 quadrants of venous beading ≥ standard 6A, and/or 1 quadrant of 
IRMA ≥ standard 8A).  Standard treatment was approximately 3000 burns placed 
approximately one burn width apart outside the arcades and 2 disc diameters from 
the centre of the fovea, keeping 500µm from the nasal margin of the disc.  Scatter 
treatment was applied in 2 sessions if no maculopathy was present or 3 sessions if 
maculopathy was present (fractionated treatment).   
 
Threshold for macular laser was CSMO as defined in Box 5.3 and visual acuity less 
than 80 ETDRS letters (equivalent to 6/9 Snellen).  Macular laser was also 
performed for ‘sight threatening exudates’ defined as thick or streak exudates close 
to the foveal centre but not meeting the definition of CSMO.  Macular laser was 
performed according to the modified grid technique [311]: ‘direct treatment’ of 
microaneurysms in areas of retinal thickening (avoiding microaneurysms within 500 
microns from the centre of the fovea), and ‘grid treatment’ (barely visible burns 2 
burn widths apart) applied to areas of thickening and not treated during the direct 
microaneurysm treatment. Treatment and response to treatment was recorded as 
part of the MDRS.  Subjects with other treatable ophthalmic or systemic pathology 
were either treated by me or referred to the appropriate service at QECH or ZCH.  
Figure 5.6 shows a photograph of a patient being counselled for laser treatment. 
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Figure 5.6 Photograph of the author and Research Assistant Moffat Chidzuwa (out 
of shot right) counselling a patient with reference to their retinal photographs  
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5.10 Study of DR progression at 5 years  
 
5.10.1 Background to the study of DR progression at 5 years 
A cross sectional study of complications of diabetes was conducted at the QECH 
diabetes clinic in 2007 [1].  Of 620 subjects included in the study 281 were 
examined for retinopathy by an ophthalmologist.  The results of this sub-study have 
been published [2] and are referred to in Chapter 4 of this thesis.  In 2007 laser 
treatment was not available in the public sector in Blantyre.  A frequency doubled 
neodymium-doped yttrium aluminium garnet (Nd:YAG) laser (Purepoint Alcon 
Texas) was donated to Lions First Sight Eye Unit in Blantyre in 2010, by the World 
Diabetes Foundation. However, few patients were treated in 2010 or 2011.  Recall 
of the 2007 subjects would be a valuable opportunity to assess progression of 
retinopathy and visual loss over 5 years in a population not exposed to laser 
treatment.  
 
In this part of the MDRS I aimed to trace as many of the 2007 subjects as possible, 
document grades of DR and thereby assess progression of retinopathy over 5 years, 
report associations of progression and document visual loss and causes of visual 
loss in an untreated cohort. The results of this study are presented in Chapter 9 of 
this thesis.  
 
5.10.2 Setting: changes at the QECH diabetes clinic between 2007 and 
2012 
In the period 2007 to 2012 the clinic underwent a number of changes.  The number 
of registered patients increased from approximately 800 to 2000.  A vibrant nurse-
led patient education programme supported by the World Diabetes Foundation 
commenced in 2008.  Its aims are to improve compliance with diet and medications 
and educating patients on the complications of diabetes.  An electronic records 
system (Diabetes and Hypertension System, Baobab Health Trust, Malawi) was 
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installed in early 2010.  This runs in parallel to the ‘health passport’ system 
described above.   
 
In 2007, medications regularly available free of charge were glibenclamide and 
insulin (lente and soluble). Metformin was available from private pharmacies but 
rarely from the hospital pharmacy.  By 2011 metformin was more frequently 
available free of charge.  However, supplies of all drugs remained intermittent.  
Tests available at the clinic were the same in 2007 as 2012.  Glycaemic control was 
measured by fasting blood sugar (FBS) on the day of clinic and blood pressure, 
height and weight was measured by nursing staff.  Measurement of lipids, 
glycosylated haemoglobin and urine test sticks for microalbuminuria were not 
available routinely.  
 
5.10.3 Subjects 
Consecutive subjects attending for routine out-patient review between March and 
June 2007 were invited to participate in the original cross sectional study of 
complications of diabetes, reported elsewhere [1].  Of 620 subjects included in the 
study 281 were examined for retinopathy by an Ophthalmologist [2].  Sampling was 
ad hoc: subjects had slit lamp examination if the Ophthalmologist was present at 
the particular clinic at which they were recruited.   
 
5.10.4 Tracing of subjects from the 2007 cohort 
The 2007 study was not planned as a cohort study.  Patient names and date of birth 
were recorded and a sticker placed in their health passport.  No contact details 
were recorded.  The population of Blantyre is extremely fluid.  Migration levels 
between rural and urban environments and between towns are known to be high.  
It is common for people who become disabled (for example as a result of a stroke) 
to relocate to be cared for by family members.  Under normal circumstances no 
attempt is made to contact subjects who fail to attend a clinic appointment.  
Although no formal study has assessed mortality rate in the QECH diabetes clinic 
population, it is believed to be high.  Many persons die at home and there is no 
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system for registering deaths.  Subject tracing was therefore expected to be 
extremely difficult. 
 
A systematic approach to tracing of subjects was developed.  All subjects recruited 
to the MDRS main cohort were asked about participation in the 2007 study and 
their health passports checked for the study sticker.  The QECH diabetes clinic 
electronic patient record system was searched by patient name by the MDRS study 
team.  Identified subjects were then contacted by phone.  The MDRS study team 
attended the diabetes clinic weekly between May and November 2012 to approach 
patients in the clinic waiting room.  Finally the President and Vice-president of the 
patient’s organisation the Diabetes Association of Malawi reviewed the list of 
subjects from 2007 in order to personally identify subject whereabouts.  Written 
informed consent was obtained from all subjects prior to enrolment. 
 
 5.10.5 Confirmation of subject death 
Confirmation of subject death was attempted in a systematic manner.  The relatives 
of subjects reported to be deceased were visited at home by the study Research 
Nurse between May and November 2012.  The nurse was trained to record, on a 
standard form, brief written narratives from families or other reliable informants.  If 
available the death certificate and the health passport were reviewed and cause of 
death and/or brief details of last illness recorded.  A subject was recorded as dead if 
confirmed by a relative or ‘Traditional Authority’ (village leader in rural districts), or 
if a death certificate or marked grave was seen by the study nurse.   I assigned a 
probable cause of death after reading the form.  
 
5.10.6 Clinical assessment 
In the 2007 study a self-reported questionnaire was completed with the assistance 
of a research assistant and with reference to the subject’s ‘health passport’.  Data 
was collected on demographic details, diet, past medical history and medications.  
Diabetes with young age at onset and early use of insulin was deemed to be type 1 
with all others as type 2.  Subjects with type 2 diabetes were sub-classified based on 
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treatment: insulin-requiring with or without oral hypoglycaemic agents, oral 
hypoglycaemic agents alone or dietary measures alone.  For the purposes of the 
analysis below the 2007 allocation of diabetes type was retained i.e. subjects were 
not reclassified in 2012.   
 
In 2007 a physical examination by a trained clinician included blood pressure, 
height, weight and neurovascular assessment (abridged four point monofilament 
examination with a 10g monofilament [312]).  Visual acuity (corrected with pin-
hole) was measured using a Snellen chart (not, as in 2012, using an ETDRS chart).  
FBS, HbA1c and HIV status were tested.  A subgroup of subjects were also tested for 
microalbuminuria and serum creatinine.  In 2012 all subjects were assessed in the 
same manner as subjects of the main MDRS cohort (described above in Sections 
5.9.3 to 5.9.6).   
 
5.10.7 Assessment of retinopathy 
In both 2007 and 2012, retinopathy and maculopathy were classified by feature 
specific grading using definitions established in the LDES [94].  In 2007 slit lamp 
biomicroscopic retinopathy grading with 90 and 60 dioptre lenses was performed 
by one experienced Ophthalmologist (Mr Simon Glover) [2]. Pupils were dilated 
with 1% tropicamide +/- 10% phenylephrine.  There was no external validation 
procedure.  In 2012 all subjects were assessed in the same manner as the main 
MDRS cohort (described above in Sections 5.9.4 and 5.9.5).  The 2012 grading 
procedure was more robust: dual grading with arbitration of digital fundus 
photography of four 45° standard fields [94] performed by accredited graders at a 
recognised reading centre.  Subjects with STDR who met thresholds for laser 
treatment were treated by me as described in Section 5.9.11. 
 
5.10.8 Statistical analysis 
The 2007 study was not planned as a cohort study.  Therefore no power calculation 
was performed.  General statistical methods are described above in Section 5.9.10.  
Details of specific analyses are given in results chapters. 
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5.11 Case-control study of endothelial function in Malawian subjects 
with diabetes  
 
5.11.1 Background to the study of endothelial function   
Endothelial dysfunction is implicated in the pathophysiology of DR.  Adherence of 
leukocytes is associated with direct injury to and apoptosis of endothelial cells and 
with disruption of endothelial tight junctions [45].  This nested case-control study 
aimed to characterise endothelial function in Malawian subjects with diabetes and 
investigate relationships with severity of retinopathy. 
 
5.11.2 Subjects  
A subset of subjects from the main cohort study (Section 5.9) were investigated plus 
control subjects (without diabetes).  I planned to study endothelial function in 4 
groups each consisting of 40 subjects:  
1. subjects with diabetes and STDR at baseline  
2. subjects with diabetes and DR but without STDR  
3. subjects with diabetes but without DR  
4. control subjects without diabetes  
All subjects recruited to the main cohort study were offered the chance to 
participate in the case control study until each of the above groups reached their 
recruitment goal (40 subjects in each).   
 
5.11.3 Control subjects  
Systematic random sampling was used to recruit control subjects (without diabetes) 
from spouses of patients attending the QECH diabetes clinic between May and June 
2012.  A list of registered patients was obtained from the clinic.  The first subject 
was selected from the first 6 patients on the list using marbles in a bag numbered 1 
to 6.  This patient was telephoned and asked if their spouse wished to participate in 
the study.  Then every 6th individual was approached until the quota was fulfilled.  
Inclusion criterion was being a spouse of a patient attending the QECH diabetes 
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clinic.  Exclusion criteria were age < 18 years and a diagnosis of diabetes according 
to ADA criteria [123] (Box 5.1).  Therefore control subjects with fasting blood 
glucose ≥ 7.0mmol/l or HbA1c ≥ 6.5% were excluded from the study. 
 
Control subjects underwent all the assessments of the main cohort study: 
demographic and medical history case record form (Section 5.9.3), physical 
examination including visual acuity (Section 5.9.3), point of care and biochemical 
tests (Section 5.9.3), and retinal photography and grading (Section 5.9.4 and 5.9.5).  
Additionally a venous blood sample was taken in order to test plasma levels of 
endothelial biomarkers and a peripheral artery tonometry measurement was made. 
 
5.11.4 Serum markers of endothelial dysfunction 
I measured plasma levels of 4 parameters of endothelial function: vascular 
endothelial growth factor (VEGF), soluble vascular cell adhesion molecule (sVCAM-
1), E-selectin and soluble inter-cellular adhesion molecule-1 (sICAM-1).  In addition 
levels of C-reactive protein (CRP) were measured by MLW laboratories.  These 
parameters reflect inflammation (CRP, sICAM-1), endothelial dysfunction (E-selectin 
and sVCAM-1) and angiogenesis (VEGF), respectively.   
 
Levels of VEGF, sVCAM-1, sICAM-1 and E-selectin were quantified using enzyme-
linked immunosorbent assay (ELISA) kits (R&D systems, Minneapolis, USA).  These 
assays employ a quantitative sandwich enzyme technique.  Plasma samples were 
prepared by MLW technicians: whole blood samples were collected in ethylene-
diamine-tetra-acetic acid (EDTA) tubes and centrifuged for 15 minutes at 1000g 
within 2 hours of collection.  Plasma was then aliquoted and stored at -20 degrees 
until ELISAs were performed.  A standard of each of the molecules being measured 
(e.g. VEGF) was provided by the manufacturer of the ELISA kits.  This standard was 
reconstituted with 1.0mL of calibrator diluent solution provided by the 
manufacturer.  This stock solution was used to make a dilution series of the 
molecule in question.  The dilution series served as a positive control and to 
126 
 
 
produce a standard curve from which to derive the concentration of each molecule 
in the plasma samples.  Calibrator diluent solution served as a negative control. 
 
Each standard, negative control and sample was processed in duplicate.  VEGF ELISA 
is described below. ELISAs for other molecules differed only in the specific solutions 
used; all were supplied by the manufacturer of the test kits. 100μl of assay diluent 
was added to each well of a microplate provided in the ELISA kit. 100μl of standard, 
negative control or plasma sample was added per well.  The microplate was then 
covered with an adhesive strip supplied in the kit and incubated for 2 hours at room 
temperature.  Each well was then aspirated and washed 3 times with 400μl of 
manufacturer supplied wash buffer using an autowasher (ELx50 microplate strip 
washer, Biotek, Vermont, US).   
 
200μl of VEGF conjugate was added to each well.  Samples were covered and 
incubated at room temperature for 2 hours.  Aspiration/wash was repeated as 
described above.  200μl of substrate solution was added to each well and incubated 
at room temperature for 25 mintes protected from light.  50μl of 2M sulphuric acid 
was added to each well.  The optical density of each well was determined with 30 
minutes using an absorbance microplate reader set to 450nm (ELx808, BioTek, 
Vermont, US).  The concentration of each biomarker was calculated from the optical 
density using a standard curve.  Readings from duplicate wells were averaged and 
the zero standard optical density (control) subtracted.  A standard curve was 
created by plotting mean absorbance for each standard against concentration.  The 
line of best fit was determined by regression analysis.  The concentration of VEGF in 
each sample was determined using the regression formula. 
 
5.11.5 Pulse amplitude tonometry  
Digital pulse amplitude tonometry (PAT) was measured using the ‘EndoPAT-2000’ 
(Itamar, Israel).  This device is a non-invasive method of evaluating endothelial 
function.  A fingertip probe measures pulse wave amplitude at baseline, during 
brachial artery occlusion (by a blood pressure cuff inflated to suprasystolic 
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pressures for 5 minutes) and during reactive hyperaemia following cuff release.  A 
second probe is placed on the contralateral finger to serve as a control.  Prior to 
testing subjects were allowed to rest whilst seated for 15 minutes.  Clothing which 
might restrict blood flow to the arms as well as jewellery and watches were 
removed.  As per the manufacturer’s instructions the room temperature was 
maintained at 21-24°C using an air conditioning unit.  A blood pressure reading was 
taken from the control arm prior to testing.  Subjects were positioned in a reclining 
position (45 degrees) for testing with the arms supported.   
 
Probes were placed on the subject’s index fingers.  If the index finger was 
unsuitable the middle finger was used.  Digital pulse wave amplitude was recorded 
for a resting baseline period of five minutes.  A blood pressure cuff applied to the 
study arm was then inflated to 200 mmHg, or 50 mmHg above systolic blood 
pressure, whichever was greater.  After five minutes arterial occlusion the cuff was 
rapidly deflated.  Pulse wave amplitude was then recorded for five minutes.  Post 
occlusion-pre occlusion ratio (reactive hyperaemia-PAT (rhPAT) index), Framingham 
reactive hyperaemia (FRHI), and augmentation index (a measure of arterial 
stiffness) were calculated automatically by an inbuilt computer algorithm.  The 
EndoPAT software normalises the rhPAT index to the control arm to correct for 
changes in systemic vascular tone. 
 
5.11.6 Statistical analysis 
A basic a priori analysis plan was followed. However, the analysis was, by its nature, 
exploratory.  In cross sectional analysis endothelial function was compared across 4 
groups (described above in Section 5.11.2).  Multiple linear regression models were 
used to compare subjects with and without diabetes, subjects with and without 
diabetic retinopathy and subjects with and without STDR with reference to five 
serum markers: CRP, ICAM-1, E-selectin, VCAM-1 and VEGF, in addition to rhPAT 
index, FRHI and augmentation index.  I constructed a logistic regression model 
(backwards stepwise with probability of removal of 0.2) to determine the odds ratio 
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(OR) and 95% CIs for the presence of diabetes in association with an initial 8 
variables: age, sex, CRP, VEGF, ICAM-1, VCAM-1, E-selectin, and rhPAT index. 
 
In longiditudinal analysis, endothelial function was compared between subjects 
with diabetes whose retinopathy progressed by 2 steps on the LDES scale and 
subjects whose retinopathy did not progress at 24 months.  Baseline endothelial 
function was also compared between subjects who had died and those who 
survived at 24 months.  Multiple logistic regression analysis (mixed effects) was 
used to analyse the effect on progression of retinopathy (and in a separate analysis 
on death) of an initial 8 variables: age, sex, CRP, VEGF, ICAM-1, VCAM-1, E-selectin, 
and rhPAT index.  Further details of analyses performed in the endothelial sub-study 
are given in Chapter 10, Section 10.3.2. 
 
 
5.11.7 Sample size calculations 
The case control of endothelial function was powered for 2 endpoints at baseline: 
serum level of VEGF and rhPAT index.  Using the unpaired t-test 40 subjects in each 
group would be required to detect a difference of 100pg/ml in VEGF level.  On the 
basis of previous studies I estimated that the standard deviation for VEGF level for 
subjects with diabetes but no retinopathy would be 100pg/ml [48].  A similar SD 
was assumed across groups.  The power considered was 80% and the significance 
level 0.0167 (which is 0.05/3 to adjust for 3 comparisons using Bonferroni 
correction).  Using the unpaired t-test 40 subjects per group would also be required 
to detect a difference of 0.3 units in rhPAT index (assuming SD of 0.4) with power 
80% and significance level 0.0167 (3 comparisons).   
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5.12 Measurement of glycosylated haemoglobin (HbA1c) in the MDRS  
 
5.12.1 Issues encountered in HbA1c measurement 
A number of issues were encountered in the measurement of HbA1c.  A description 
of these difficulties, subsequent analysis and the action taken is given below.  The 
original plan was to test all HbA1c samples at the MLW laboratories.  MLW uses a 
turbidimetric immunoinhibition (colorimetric) assay.  Delays to commencement of 
HbA1c testing at MLW meant that baseline samples from the main cohort were 
stored for approximately 1 year at -80 degrees prior to testing.  A large number of 
very low and very high results were noted when testing commenced in November 
2012.  Therefore whole blood samples were sent to Norwich and Norfolk University 
Hospital, UK for boronate affinity chromatography testing: a method reported to be 
affected to a lesser degree by prolonged storage [313].   
 
Samples were sent to Norwich from the following: all subjects in the MDRS main 
cohort at visit one (baseline visit); all subjects from the study of DR progression at 5 
years; all subjects without diabetes (control subjects) from the case control study of 
endothelial function; and a 20% sample of subjects in the MDRS main cohort at visit 
2 (12 months).  Comparisons between samples tested at MLW laboratories and 
those tested at Norwich for subjects in the MDRS main cohort at visit one are 
shown in Table 5.5 and Figures 5.7, 5.8, 5.9 and 5.10.  Table 5.6 shows a comparison 
between HbA1c measurements from MLW and Norwich laboratories from each of 
the 4 groups of subjects listed above.  
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Table 5.5 Comparison between HbA1c results from MLW and Norwich laboratories 
for subjects in the MDRS main cohort at visit 1 (baseline visit).  STDR = sight 
threatening diabetic retinopathy. 
Parameter MLW Norwich 
Number of observations 302 351 
Mean HbA1c 9.262252 7.81994 
SD 4.352496 2.51909 
Univariate logistic 
regression STDR 
OR 1.04;  
95% CI 0.98 – 1.10; 
p=0.159 
OR 1.14;  
95% CI 1.04 – 1.25; 
p=0.004 
 
Figure 5.7 Scatter plot of fasting blood sugar (FBS) versus glycosylated haemoglobin 
(HbA1c) measured at MLW laboratories for subjects in the MDRS main cohort at 
visit 1 (baseline visit).  Correlation: 0.3075. 
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Figure 5.8 Scatter plot of fasting blood sugar (FBS) versus glycosylated haemoglobin 
(HbA1c) measured at Norwich and Norfolk University Hospital laboratories for 
subjects in the MDRS main cohort at visit 1 (baseline visit).  Correlation: 0.6398. 
 
 
Figure 5.9 Scatter plot of HbA1c results from MLW and Norwich and Norfolk 
University Hospital laboratories for subjects in the MDRS main cohort at visit 1 
(baseline visit). Correlation: 0.521. 
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Figure 5.10 Bland Altman plot (differences between pairs of measurements plotted 
against mean of each pair) of HbA1c results from MLW and Norwich laboratories for 
subjects in the MDRS main cohort at visit 1 (baseline visit). Mean difference (MLW 
greater mean):  1.46 (95% CI 1.03-1.88). Range: 3.30-18.70. Pitman's Test of 
difference in variance: r = 0.568, n = 301, p = 0.0001  
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Table 5.6 Comparison of HbA1c measurements from MLW and Norwich laboratories categorised by subject group.  STDR=sight threatening 
diabetic retinopathy.  FBS=fasting blood sugar. 
 
Parameter 
Subject group 
Main cohort visit 1 Five year cohort Control subjects Main cohort visit 2 
MLW Norwich MLW Norwich MLW Norwich MLW Norwich 
Dates samples 
taken 
Dec 2011-May 2012 May-Sept 2012 May-July 2012 Dec 2012 – Apr 2013 
Pre-test duration 
of storage (mths) 
12 14 6 9 9 9 3 4 
Number of 
observations 
302 351 103 131 33 42 280 71 
Mean 9.26 7.81 10.01 8.29 5.53 4.92 9.15 8.11 
SD 4.35 2.52 4.08 2.32 1.20 0.68 2.94 2.62 
Univariate 
regression STDR 
OR (95% CI) 
1.04 
 (0.98 – 1.10) 
1.14 
(1.04–
1.25) 
1.06 
(0.97-
1.17) 
1.16 
(0.99–
1.35) 
NA NA 1.15 
(1.06-
1.26) 
1.18  
(0.97 –
1.43) 
Correlation FBS 0.308 0.640 0.40 0.64 0.603 0.812 0.499 0.732 
Correlation MLW 
vs Norwich 
0.52 0.64 0.59 0.88 
Bland-Altman 
mean difference 
1.46 1.76 0.59 1.62 
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5.12.2 Summary of comparisons between laboratories and action 
taken 
HbA1c measurements from MLW laboratories showed higher means and greater 
standard deviation (SD) than those from Norwich.  Estimates of SD from samples 
tested at Norwich remained relatively constant between the different groups of 
subjects while estimates of SD from MLW were greater for earlier samples.  
Differences in means and SD within subjects groups were smaller in later samples 
which may be explained by reduced storage times prior to testing.  HbA1c 
measurements from MLW showed a weaker correlation with fasting blood sugar 
and a less strong association with STDR.  The strength of association (correlation) 
between MLW and Norwich was reasonable and better for later (main cohort visit 
2) samples.  From the Bland Altman plots it is clear that MLW measurements 
tended to be higher than those from Norwich. There was a tendency for more large 
positive differences than large negative ones (positive skew) and a tendency for 
greater positive differences with greater HbA1c. 
 
In conclusion, HbA1c measurements from Norwich appeared to be a better marker 
of glycaemic control and correlate better with retinopathy.  However, mean values 
from Norwich were lower than expected and lower than seen in the 2007 survey of 
diabetes complications at QECH [1] (mean HbA1c 9.4).  There is no obvious seasonal 
effect: main cohort study visits 1 and 2 occurred during the wet (malaria) season 
while most of the five year cohort were seen in the dry season.  I took the decision 
to use the measurements from the Norwich laboratory and all samples from visit 3 
were therefore tested in Norwich.  Possible explanations for the unexpectedly low 
HbA1c measurements from the MDRS cohort are considered in Chapter 11 of this 
thesis (Discussion).  
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Chapter 6. Malawi Diabetic Retinopathy Study: Cross 
Sectional Data  
 
 
 
6.1 Aims of the chapter 
This chapter details the baseline demographic characteristics, systemic variables, 
prevalence of retinopathy grades and visual acuity data from the Malawi Diabetic 
Retinopathy Study (MDRS) cohort. 
 
6.2 Introduction  
The number of adults with diabetes in Africa is predicted to increase from 12.1 
million in 2010 to 23.9 million in 2030 [207].  The prevalence and incidence of sight 
threatening diabetic retinopathy (STDR) in developed countries are well 
documented.  Associations between systemic factors, including glycaemic control, 
[12,13,97,314] blood pressure [14,157,314,315,316] and blood lipid levels, [15] and 
the development and progression of retinopathy in these populations are well 
known.  I conducted with colleagues a systematic review of the literature on the 
epidemiology of diabetic retinopathy (DR) in Africa which is presented in Chapter 4 
[210].  This review identified only 2 cohort studies which investigated determinants 
of severity and progression: a population based study from Mauritius [212,215] and 
a relatively small study of people with type 1 diabetes in South Africa [216,217,218].  
Neither study was performed in eastern Africa and neither investigated the effect of 
population specific variables such as HIV infection and anaemia. 
   
A cross sectional survey of 281 persons attending the diabetes clinic at Queen 
Elizabeth Central Hospital (QECH), Blantyre indicated a prevalence of proliferative 
retinopathy (PDR) and STDR approximately ten times and six times that seen in 
Western Europe, respectively [2].  Because of these important findings I set out to 
estimate the prevalence of grades of DR and visual impairment due to DR in a 
formal observational study using a systematically sampled cohort, standardised 
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clinical photography, independent grading by graders in an accredited reading 
centre and collecting data on covariates specific to the population.  The MDRS is a 
prospective, observational, cohort study of persons attending 2 hospital diabetes 
clinics over 24 months.  The study aims to describe the prevalence, incidence and 
progression of DR in Southern Malawi and to investigate the determinants of DR 
severity and progression in this population.  In this chapter I report baseline data 
from this cohort.  
 
6.3 Methods 
Study setting, sampling of subjects, clinical assessment and assessment of 
retinopathy are fully described in Chapter 5 Methods.  In brief, subjects were 
systematically sampled from 2 hospital-based diabetes clinics providing 
predominantly primary care for diabetes.  Visual acuity, glycaemic control, blood 
pressure, HIV status, urine albumin-creatinine ratio (ACR), haemoglobin and serum 
lipids were assessed.  Retinopathy was graded at an accredited reading centre using 
modified Wisconsin grading of 4-field mydriatic photographs. 
 
6.3.1 Statistical analysis 
An a priori analysis plan was followed.  Grades of DR were calculated by patient 
according to the worse or only gradeable eye.  Visual acuity data were investigated 
by patient according to the better eye. 95% confidence intervals (CIs) were 
calculated for proportions.  I constructed a logistic regression model (backwards 
stepwise with probability of removal of 0.2) to determine the odds ratio (OR) and 
95% CIs for the presence of STDR in association with an initial 11 variables: duration 
of diabetes, age, sex, sBP, glycosylated haemoglobin (HbA1c), urine ACR, 
haemoglobin level, HIV status, LDL cholesterol, HDL cholesterol and triglycerides.  
These variables were chosen either because they have been associated with 
development and progression of DR in other populations (duration, age, sex, sBP, 
HbA1c, urine ACR, and lipids) or because they are population specific variables, 
have plausible links to development of DR and whose effect on DR has not been 
investigated in high quality studies (HIV and anaemia).  Adjusted ORs and 95% CIs 
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were calculated for presence of STDR.  All tests were two-sided and considered 
statistically significant when p<0.05. All calculations were performed using STATA 
version 12 (StataCorp, Texas, USA). 
 
 
6.4 Results 
 
6.4.1 Recruitment 
417 patients were approached to participate in the study (Figure 6.1 and 6.2).  24 
were excluded: 6 did not meet criteria for diagnosis of diabetes; 1 had gestational 
diabetes; 17 were either under 18 years of age, visiting the clinic for the first time or 
resident >60km from the clinic.  There was an increase in patients with newly 
diagnosed or suspected diabetes attending the clinic in May 2012.  Therefore there 
was an increase in excluded subjects during this month.  36 declined: 1 had to 
attend work; 1 was recruited but left before assessment; 34 gave no reason for 
declining.  357 subjects were included (255 from QECH; 102 from Zomba Central 
Hospital (ZCH)).  Data collection was thorough.  The number of subjects with 
missing data for each variable was as follows: demographic details, HIV and 
retinopathy grading 0; visual acuity and blood pressure 1 (0.3%); Urine ACR 3 
(0.8%), body mass index (BMI) 4 (1.1%); Hb, lipids and serum creatinine 5 (1.4%); 
HbA1c 6 (1.7%); fasting blood sugar 7 (2.0%). 
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Figure 6.1. Flow diagram for enrolment of subjects to the MDRS 
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Figure 6.2 Numbers of subjects who were recruited to, excluded from or declined 
recruitment to the MDRS by month in 2011/12. 
 
 
6.4.2 Participants  
Participant characteristics are listed in Table 6.1.  Of those with type 2 diabetes, 231 
(71.7%) were prescribed oral agents alone, 12 (3.4%) were diet controlled and 79 
(24.5%) were prescribed insulin.  48 (13.4%) subjects were HIV positive: 34 taking 
anti-retroviral therapy (ART); 4 known HIV+ but not taking ART (all WHO stage 1); 
and 10 new diagnoses (5 subjects WHO stage 1; 2 stage 2; 2 stage 3; and 1 stage 4).  
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24 (17.1%) men and 30 women (13.8%) were anaemic as defined above.  Of the 
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31 had either sBP ≥140mmHg or dBP ≥ 90mmHg (i.e. were newly diagnosed with 
probable hypertension).  55.3% of subjects had a BMI > 25 kg/m2; Table 6.2 shows 
study subjects classified according to BMI. 
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having TB or syphilis, respectively.  6 subjects (1.7%) were current smokers.  46 
(12.9%) of subjects could recall having a dilated eye examination in the past. 
 
Table 6.1 Participant characteristics: demographic, clinical and biochemical 
measurements of subjects in the MDRS study (n=357) 
Characteristic Entire cohort Type 1 diabetes Type 2 diabetes 
n 357 35 (9.8%) 322 (90.2%) 
Female sex 216 (60.5%) 8 (22.8%) 208 (64.6%) 
Age (yrs; median, IQR) 54.1 (43.8-61.1) 28.3 (23.1-33.3) 55.2 (47.9-62.2) 
BMI >25 kg/m2 198 (55.3%) 7 (20.0%) 191 (59.3%) 
Duration (yrs;med,IQR) 4.1 (1.9-8.1) 4.1 (1.4-8.2) 4.1 (2.0-8.1) 
Hypertensive (see text) 234 (65.5%) 3 (8.6%) 231 (71.7%) 
sBP (mmHg; median, IQR) 135 (120-156) 116 (109-127) 138 (124–160) 
HbA1c (IFCC, mmol/mol) 
(mean; SD) 
61.9 (27.5) 81.6 (27.8) 59.8 (26.6) 
HbA1c (NGSP%; mean; SD) 7.8 (2.5) 9.6 (2.5) 7.6 (2.4) 
Haemoglobin (g/dl,mean;SD) 13.9 (1.9) 14.6 (1.8) 13.9 (1.9) 
Anaemia (see text) 54 (15.1%) 5 (14.3%) 49 (15.2%) 
HIV positive 48 (13.4%) 4 (11.4%) 44 (13.7%) 
Total chol. >5.0mmol/L 115 (32.2%) 4 (11.4%) 111 (34.5%) 
LDL cholesterol (mmol/L; 
mean, SD; range) 
2.43; 0.95; 0.3-
6.0 
1.74; 0.70; 0.6-
3.1 
2.51; 0.94; 0.3-
6.0 
Raised urine ACR (Male >2.5 
mg/mmol; Female >3.5) 
115 (32.2%) 
(51 male; 64 
female) 
10 (28.6%) 
(7 male; 3 
female) 
105 (32.6%) 
(44 male; 61 
female) 
 
  
141 
 
Table 6.2 Subjects in the MDRS study classified according to category of BMI 
(kg/m2)  
Category Range of BMI (kg/m2) Number of subjects (%) 
Severely underweight < 16.0 3 (0.8) 
Underweight 16.0 ≥ x < 18.5 10 (2.8) 
Normal 18.5 ≥ x < 25 141 (39.5) 
Overweight 25 ≥ x < 30 126 (35.3) 
Obese class 1 30 ≥ x < 35 46 (12.9) 
Obese class 2 35 ≥ x < 40 18 (5.0) 
Obese class 3 ≥ 40 9 (2.5) 
No data  4 (1.1) 
 
 
6.4.3 Comparison of photographic and clinical DR grading  
Biomicroscopy grading was compared with the reference standard of photographic 
grading.  For all grades of retinopathy Cohen’s Kappa was 0.6723 (95% CI 0.606-
0.738) and weighted Kappa 0.820 (Table 6.3).  For grades of maculopathy Cohen’s 
Kappa was 0.843 (95% CI 0.781-0.905) and weighted Kappa 0.888 (Table 6.4).  These 
levels of concordance between photographic and clinical grading are within 
published acceptable limits for DR grading [317]. 
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Table 6.3 Comparison for all grades of retinopathy between clinical grading and the 
reference standard of photographic grading (expected frequencies in parentheses) 
(n=320). Percentage agreement: 78.8%. 
 Photographic grade Total 
10 20 30 40 50 60+ 
Clinical 
grade 
10 149 (86.6) 19     168 
20 16 59 (21.6) 3    78 
30  10 11 (1.6)    21 
40  1 7 17 (2.0)  1 26 
50   3 5 5 (0.2)  13 
60+    2 1 11 (0.5) 14 
Total  165 89 24 24 6 12 320 
 
 
Table 6.4 Comparison for grades of maculopathy between clinical grading and the 
reference standard of photographic grading (expected frequencies in parentheses) 
(n=320).  Percentage agreement: 93.75%. 
 Photographic grade Total 
0 1 2 3 4 8 90 
Clini
cal 
grad
e 
0 233 (177.0)    6   239 
1  0 (0)      0 
2 3  3 (0.15) 2 4   12 
3    0 (0.01) 1   1 
4 1  1 1 63 (15.3)   66 
8      1 (0.003)  1 
90  1     0 1 
Total  237 1 4 3 74 1 0 320 
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6.4.4 Prevalence of grades of retinopathy 
Prevalence of grades of retinopathy are shown in Table 6.5.  Prevalence of 
retinopathy according to type 1 or type 2 diabetes is shown in Table 6.6. Figure 6.3 
shows prevalence of any retinopathy, STDR and PDR categorized by time since 
diagnosis of diabetes. 87 (24.4%) subjects had cataract (19 unilateral; 68 bilateral).  
16 subjects (4.5%) were pseudophakic (5 unilateral; 11 bilateral).  There were few 
subjects with diet controlled diabetes.  The Liverpool Diabetic Eye Study (LDES) 
collected data on subjects with diabetes at point of initiation of a screening 
programme between 1991 and 1999 [288].  For comparison prevalence of 
retinopathy grades in persons with type 2 diabetes prescribed oral medications 
and/or insulin (i.e. excluding diet controlled type 2) from our study and the LDES 
[288] are shown in Table 6.7.   
 
Table 6.5 Prevalence (95% CI) of retinopathy grades according to worse eye in 
subjects in the MDRS study (n=357). STDR: Sight threatening diabetic retinopathy. 
Grade n % (95% CI) 
No retinopathy (level 10) 177 49.6  (44.4 - 54.8) 
Any retinopathy (level 20-71+) 179 50.1  (44.9 - 55.3) 
Level 20 retinopathy 
 
94 26.3  (21.8 – 30.9) 
Level 30 retinopathy 25 7.0  (4.4 – 9.7) 
Level 40 retinopathy 26 7.3  (4.6 – 10.0) 
Level 50 retinopathy 8 2.2  (0.7 – 3.8) 
Proliferative or worse 
(≥ level 60 retinopathy) 
26 7.3  (4.6 – 10.0) 
Ungradeable 1 0.3  (0 - 0.8) 
Sight threatening maculopathy 93 26.1  (21.5 – 30.6) 
STDR 105 29.4  (24.7 - 34.1) 
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Table 6.6 Prevalence with 95% CI of retinopathy grades according to worse eye in 
persons with type 1 (n=35) and type 2 diabetes (n=322). 
 Type 1 diabetes Type 2 diabetes 
Grade n % (95% CI) n % (95% CI) 
No retinopathy  
(level 10) 
20 57.1 (40.8 – 73.5) 157 48.8 (43.3 – 54.2) 
Any retinopathy  
(level 20-71+) 
15 42.9 (26.5 – 59.3) 164 50.9 (45.5 – 56.4) 
Level 20 
 
10 28.6 (13.6 - 43.5) 84 26.1 (21.3 – 30.9) 
Level 30 1 2.9 (0 – 8.4) 24 7.5 (4.6 – 10.3) 
Level 40 1 2.9 (0 – 8.4) 25 7.8 (4.8 – 10.7) 
Level 50 0 0 8 2.5 (0.8 – 4.2) 
Proliferative or worse 
(≥ level 60) 
3 8.6 (0 – 17.9) 23 7.1 (4.3 – 10.0) 
Ungradeable 0 0 1 0.3 (0 – 0.9) 
Sight threatening 
maculopathy 
6 17.1 (4.7 – 29.6) 87 27.0 (22.2 – 31.9) 
STDR 9 25.7 (11.2 – 40.2) 96 29.8 (24.8 – 34.8) 
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Figure 6.3.  Prevalence (% with 95% CI) of any retinopathy, sight-threatening 
diabetic retinopathy (STDR) and proliferative diabetic retinopathy (PDR) categorised 
by time since diagnosis of diabetes in subjects in the MDRS study (n=357) 
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Table 6.7 Prevalence with 95% CI of retinopathy grades according to worse eye in 
people with type 2 diabetes prescribed oral medications and/or insulin (i.e. 
excluding diet controlled type 2 diabetes).  Comparison of subjects this study 
(n=310) and the Liverpool Diabetic Eye Study (LDES) (n= 4102). 
 MDRS 
2011-2012 
LDES 
1991-1999 
Grade n %  (95% CI) n % (95% CI) 
No retinopathy (level 
10) 
149 48.1 (42.5 – 53.6) 2646 64.5 (63.0-66.0) 
Any retinopathy 
(level 20-71+) 
160 51.6 (46.1 – 57.2) 1456 35.5 (34.0-37.0) 
Level 20 retinopathy 81 26.1 (21.2 – 31.0) 943 23.0 (21.7 – 24.3) 
Level 30 retinopathy 24 7.7 (4.8 – 10.7) 240 5.9 (5.1 - 6.6) 
Level 40 retinopathy 24 7.7 (4.8 – 10.7) 163 4.0 (3.4 - 4.6) 
Level 50 retinopathy 8 2.6 (0.8 – 4.4) 82 2.0 (1.6 - 2.4) 
Proliferative or worse 
(≥level 60) 
23 7.4 (4.5 – 10.3) 28 0.7 (0.4 - 0.9) 
Ungradeable 1 0.3 (0 – 1.0) NA NA 
Sight threatening 
maculopathy 
86 27.7 (22.8 – 32.7) 320 7.8 (7.0 – 8.6) 
STDR 94 30.3 (25.2 – 35.4) 348 8.5 (7.6 – 9.3) 
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6.4.5 Associations of retinopathy  
Duration of diabetes, HbA1c, sBP, haemoglobin and LDL cholesterol were risk 
factors for STDR in multivariate analysis (Table 6.8).   Descriptive analysis showed 
that urine ACR did not demonstrate a linear association with probability of STDR; a 
natural log transformation was more suitable for the model.  There was no 
difference in prevalence of any retinopathy, sight threatening retinopathy and 
proliferative retinopathy between subjects from Blantyre and Zomba (data not 
shown). 
Table 6.8 Risk factors for association of presence of sight-threatening diabetic 
retinopathy (STDR) at baseline in subjects in the MDRS study (n=357). 
 
 
 OR 95% CI p value 
Univariate logistic regression 
Duration of diabetes (years) 1.13 1.08 – 1.18 0.001* 
HbA1c (NGSP %) 1.14 1.04 – 1.25 0.004* 
sBP (mmHg) 1.02 1.01 – 1.03 0.001* 
log[Urine ACR] (mg/mmol) 1.42 1.22 – 1.65 0.001* 
Haemoglobin (g/dl) 0.83 0.73 - 0.94 0.003* 
HIV positive 0.43 0.19 – 0.95 0.037* 
LDL cholesterol (mmol/L) 1.41 1.10 – 1.80 0.006* 
HDL cholesterol (mmol/L) 1.90 0.97 – 3.73 0.060 
Triglycerides (mmol/L) 0.99 0.82 – 1.21 0.933 
Sex (male) 0.61 0.38 – 0.99 0.045* 
Age (years) 1.01 0.99 - 1.03 0.142 
Multivariate logistic regression 
Duration of diabetes (years) 1.11 1.05 -  1.17 0.001* 
sBP (mmHg) 1.03 1.01 -  1.04 0.001* 
HbA1c (NGSP %) 1.31 1.13 -  1.50 0.001* 
Haemoglobin (g/dl) 0.80 0.68 -  0.95 0.011* 
LDL cholesterol (mmol/L) 1.63 1.18 -  2.25 0.003* 
log[Urine ACR] (mg/mmol) 1.19 0.98 -  1.44 0.073 
Age (years) 0.97 0.95 -  1.00 0.053 
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6.4.6 Treatment 
One subject had undergone a course of laser photocoagulation prior to study 
enrolment.  63 subjects were listed for a course of laser treatment at their first 
study visit.   Threshold for scatter laser treatment was the ‘4-2-1 rule’ (4 quadrants 
of haemorrhages/microaneurysms (HMa) ≥ Early Treatment of Diabetic Retinopathy 
Study (ETDRS) standard photograph 2A, or 2 quadrants of venous beading  ≥ 6A, or 
1 quadrant of intra-retinal microvascular abnormalities (IRMA) ≥8A). Threshold for 
macular laser treatment was clinically significant macular oedema (CSMO) or 
exudates which were tracking towards the centre of the fovea and were therefore 
‘sight threatening’ in the opinion of the examining clinician (PB).  Table 6.9 shows 
the number of subjects who were listed for, started and completed a course of laser 
treatment. 
 
Table 6.9 Laser treatment of subjects in the MDRS cohort (n=63).  Numbers of study 
subjects listed for laser treatment, started treatment and completed a course of 
treatment within one year categorised by type of treatment.  
 
Treatment (unilateral 
or bilateral) 
Number of subjects 
listed for treatment 
Started 
treatment 
Completed course  
Scatter and macular 
laser 
39 36 29 
Scatter alone 11 11 11 
Macular laser alone 13 12 12 
 
 
6.4.7 Vision 
Visual acuity measurements for study subjects are shown in table 6.10.  According 
to WHO definitions [310] 343 subjects (96.1 %; 95% CI 94.1 - 98.1) had ‘normal 
vision’ (equal to or better than 60 letters), 8 subjects (2.2 %; 95% CI 0.7 - 3.8) had 
‘moderate visual impairment’ (50 to 59 letters), and 5 subjects (1.4 %; 95% CI 0.2-
2.6) were ‘severely visually impaired or blind’ (<50 letters).  The most common 
primary causes of visual impairment, in the opinion of the examining 
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ophthalmologist (PB), for subjects with corrected visual acuity worse than 80 letters 
(equivalent to 6/12 Snellen or worse) (n=97) were DR (33.0%), cataract (28.9%), and 
both DR and cataract (15.5%) (Table 6.11).  Therefore in 48.5% of cases DR was the 
sole or equal contributing cause of visual loss.  Figure 6.4 shows visual acuities in 
the study population classified according to age.  In univariate analysis vision < 70 
letters was significantly associated with increasing age (years; OR 1.04; 95% CI 1.01 - 
1.08; p=0.01), duration of diabetes (years; OR 1.06; 95% CI 1.01 – 1.12; p=0.03) and 
STDR (OR 2.59; 95%CI 1.16 – 5.79; p=0.02) 
 
Table 6.10 Prevalence with 95% CI of corrected ETDRS visual acuities according to 
better eye in subjects in the MDRS study (n=357). Approximate Snellen acuities in 
parentheses. 
Visual acuity n % 95% CI 
≥ 90  (6/5) 88 24.6 20.1 - 29.1 
80 - 89 (6/7.5) 171 47.9 42.7 - 53.1 
70 -79 (6/12) 71 19.9 15.8 - 24.0 
60 - 69 (6/18) 13 3.6 1.7 – 5.6 
50 - 59 (6/30) 8 2.2 0.7 - 3.7 
40 - 49 (6/75) 3 0.8 0 - 1.7 
Hand movements 1 0.3 0 – 0.8 
Light perception 1 0.3 0 - 0.8 
No light perception 0 0  
No data 1 0.3 0 – 0.8 
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Table 6.11 Primary causes of visual impairment in the opinion of the examining 
clinician (PB) for subjects with corrected visual acuity equivalent to 6/12 Snellen or 
worse.  Subjects classified according to level of visual impairment (n=97). 
 Level of visual impairment 
 6/12 6/18 Moderate visual 
impairment 
Severely visually 
impaired or blind 
n 71 13 8 5 
DR 24 (34%) 2 (15%) 5 1 
DR and 
cataract 
9 (13%) 4 (31%) 1 1 
Cataract 20 (28%) 6 (46%) 1 1 
AMD 3 (4%)    
Glaucoma 2 (3%)    
Other 13* (18%) 1§ (8%) 1≠ 2ƚ 
Details of other causes of visual impairment:  
* 1 Posterior capsule opacification (PCO); 2 Epiretinal membrane; 1 optic atrophy; 1 complicated 
cataract surgery; 1 dry eye; 1 macular hole; 1 unidentified maculopathy; 5 no cause identified. 
§ PCO 
≠ Optic atrophy secondary to sphenoid meningioma 
Ƚ 1 inherited retinopathy; 1 posterior uveitis (likely syphilitic)  
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Figure 6.4 Visual acuity in the better eye in subjects in the MDRS study grouped 
according to age (n=357).  Corrected visual acuity classified as ≥80 letters, 70-79 
letters, 60-69 letters and <60 letters 
 
 
 
 
6.5 Discussion 
 
6.5.1 Principal findings 
This chapter details the baseline prevalence of diabetic retinopathy and visual 
impairment as well as associations of STDR in the MDRS cohort.  Subjects were 
sampled from a mixed urban and rural population attending for routine primary and 
secondary diabetes care.  Retinopathy was found in 50%; this was sight threatening 
in 30% with immediately sight-threatening proliferative disease in 7.3%.  In 
multivariate analysis, duration of diabetes, worse glycaemic control, higher systolic 
blood pressure, lower haemoglobin level and elevated LDL cholesterol were 
significantly associated with presence of STDR.  In this selected population the 
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60 letters (worse than 6/18) was 7.3% and 3.6%, respectively.  In 48.5% of subjects 
with visual loss DR was the sole or equal contributing cause. 
 
6.5.2 Comparison with African studies 
This study found a higher prevalence of any DR, STDR and PDR than reported in the 
2007 pilot study from Malawi (any DR 32.0%; STDR 19.6%; PDR 5.7%)[2], which 
formed part of a larger cross sectional survey of diabetes complications [1]. In that 
study 281/620 were examined for DR.  Higher estimates in my study are likely to 
reflect differences in subject sampling (systematic vs ad hoc), grading of DR 
(accredited grading of standard photographs vs clinical grading), differences 
between centres (this study also included persons from Zomba, a more rural 
setting), and changes in disease prevalence over time. 
 
Two published population based studies from Africa have reported prevalence of 
DR in persons with diabetes, neither from sub-Saharan Africa (SSA).  In these studies 
from Egypt [239] and Mauritius [212] the prevalence range for any DR was 30.2 to 
31.6%, PDR 0.9 to 1.3%, and any maculopathy 1.2 to 4.5%.  A recent population 
based survey (n=4414) from Nakuru, Kenya identified, in 277 persons with diabetes, 
a prevalence of ‘any DR’ and ‘severe non-proliferative DR or proliferative DR’ of 
35.9% (95% CI: 29.7-42.6) and 13.9% (10.0-18.8), respectively [A. Bastawrous 
personal communication, Data submitted for publication]. 
 
Clinic-based studies from SSA report a wide range of prevalences but vary widely in 
quality and methods.  Very high prevalence of DR, PDR and maculopathy has been 
reported in clinic-based surveys from South Africa in the last decade by Mash et al. 
[241] (62.4% any DR, 6.1% PDR, 15.2% any maculopathy) and Rotchford et al. [224] 
(40.3% any DR, 5.6% PDR, 10.3% clinically significant macular oedema).  These 
estimates are comparable to the MDRS reflecting similarities between these 
populations in socioeconomic status, access to health care, diet and levels of 
infective and non-communicable co-morbidity. 
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6.5.3 Comparison with studies outside Africa  
Population based studies from low and middle income countries have reported 
lower rates.  The Chennai Urban Rural Epidemiology Study (CURES) reported a 
prevalence of retinopathy of 17.6% in 1736 subjects with type 2 diabetes [318].  In 
the Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics 
Study in urban Indian subjects older than 40 years with diabetes the prevalence of 
any retinopathy, proliferative retinopathy and CSMO was 18%, 1.6% and 1.4%, 
respectively [319].  In Europe the population based Liverpool Diabetic Eye Study 
(LDES) [288] reported findings from 8062 subjects with diabetes (10.3% type 1) 
entering a primary care-based screening programme.  The prevalence of any 
retinopathy, STDR and PDR was 27.4%, 7.0% and 0.8%, respectively.  Other 
European population-based studies have reported similar prevalence to the LDES 
[102,285,289-291,301].  The number of subjects with diet controlled diabetes in the 
MDRS was low.  However, even after removing diet controlled subjects from both 
cohorts, in subjects with type 2 diabetes the prevalence of STDR and PDR in this 
study compared to the LDES was approximately 3 times and 10 times higher, 
respectively.  The high prevalence of retinopathy in our study compared with recent 
Asian and Western studies is likely due to late diagnosis of diabetes, poor access to 
health services, and inadequate drug supply as well as comorbidity.   
 
In common with our study the risk of development and progression of retinopathy 
in European and North American populations has been shown to be related to 
duration of diabetes [10,11,314], high HbA1c [12,13,97,314], high blood pressure 
[14,157,314-316], microalbuminuria  [320] and serum lipid levels [15].  Associations 
between retinopathy and age [10] and gender [10] have been demonstrated but 
were not apparent in our cohort.  Prevalence of proteinuria and hyper-
cholesterolemia in this study are similar to previous cross sectional work from the 
Blantyre diabetes clinic [1,321] detailed in Chapter 4, Section 4.7.2.  The median 
time since diagnosis of diabetes in our cohort is relatively short at 4 years.  Although 
very likely to be an underestimate of disease duration, this makes the high 
prevalence of STDR even more striking.  The mean HbA1c in our cohort (7.8%) is 
surprisingly low.  The 2007 Blantyre study of diabetic complications reported a 
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mean of 9.4%. [1]    Since 2007 several care improvement initiatives have been 
implemented in the diabetes clinics at QECH and ZCH [322].  In addition compared 
with the current cohort the 2007 subjects included a higher proportion of type 1 
subjects (18%), who seem to have worse control, a higher proportion of type 2 
subjects taking insulin (29%) and a longer mean duration of diabetes (7.0 yrs). 
 
6.5.4 Associations of STDR 
This study has demonstrated an association between lower haemoglobin level and 
presence of STDR.  Cross sectional (but not cohort) studies have demonstrated an 
association between presence of DR and anaemia in India [323-325] and China 
[187].  To my knowledge this relationship has not been shown previously in an 
African population.  We hypothesise that the mechanism underlying this 
relationship is impaired oxygen delivery and therefore increased oxygen stress at a 
microvascular level.  The aetiology of anaemia in SSA is multifactorial and includes 
deficiencies of micronutrients (e.g. iron, B12, folate); haemoglobinopathies; 
infections and chronic diseases (e.g., malaria, HIV, tuberculosis)[183].  
Micronutrient deficiencies are potential therapeutic targets.  Whether treatment of 
anaemia reduces diabetic microvascular complications is not known.  A potential 
confounder of the association between haemoglobin and retinopathy is 
socioeconomic status.  Socioeconomic data was not collected in this study. 
 
Both HIV infection and anti-retroviral therapies are associated with a vasculopathy 
which manifests as increased cardiovascular and cerebrovascular risk [326,327]. 
There is also evidence of a higher prevalence of diabetic microvascular 
complications in persons with HIV [1].  This study showed no significant relationship 
in multivariate analysis between presence of STDR and HIV status.  In univariate 
analysis a protective effect of HIV is suggested.  We believe that early diagnosis of 
diabetes in this subgroup is an important confounder:  patients attending medical 
facilities for ART treatment are more likely to be tested for diabetes than the 
general population.  The effect of HIV status on DR progression will be shown by the 
MDRS cohort study. 
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6.5.5 Vision 
Few studies have investigated VA in people with diabetes in SSA.  Prevalence of 
visual impairment in this study (1.4% of subjects with VA 6/60 or worse in the better 
eye) is comparable with published European and American data.  In the Wisconsin 
Epidemiological Study of DR (WESDR) a VA of 6/60 (US equivalent 20/200) or worse 
in the better eye occurred in 3.6% of type 1 subjects and 1.6% of type 2 subjects 
[328].  In Iceland, Kristinsson et al. [290] reported VA of 6/60 or worse in the better 
eye in 1.0% of type 1 subjects and 1.6% of type 2 subjects.  The similar levels of 
visual impairment are surprising given the higher prevalence of STDR in our cohort.  
A potential bias is that subjects who become visually impaired may cease to attend 
clinics.  Visual impairment may significantly increase chance of mortality in a society 
where loss of vision entails loss of economic productivity.  Supporting this possible 
explanation are our results showing a high proportion of people attending clinics 
with STDR which is not yet symptomatic.  This disease is potentially treatable to 
prevent visual loss; the case for intervention is then extremely strong.  In this study 
63 subjects were listed for a course of laser treatment while only 1 patient had 
received laser treatment prior to the study.  This equates to a laser coverage of 
1.6% at the time of the study. 
 
6.5.6 Limitations of this work 
These findings are likely to be representative of small cities/large towns in SSA but 
should be generalized to other settings with some caution.  While some patients 
travel long distances to attend clinics, rural subjects are likely to be 
underrepresented and form a selected sub-group of the rural diabetes population.  
A significant proportion of patients spend some time in the city and some (e.g. at 
planting and harvesting time) at their village; differentiating rural and urban 
populations is difficult.  It is possible that our data underestimate retinopathy.  
Patients who do not attend clinics may be less likely to be diagnosed with diabetes 
or to comply with therapy.  Conversely those with established complications may be 
more likely to attend clinics and participate in research studies.  Despite these 
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limitations, I believe that the size of this study and the degree of confidence around 
my findings render them useful. 
 
 
6.6 Chapter summary 
The results presented in this chapter provide an estimate of current prevalence of 
DR and visual impairment in a mixed urban and rural population attending diabetes 
clinics in Southern Malawi.  I have demonstrated a novel association of STDR: 
haemoglobin level, a population specific target for intervention.  I have reported the 
number of subjects requiring laser treatment.  The prevalence of diabetes in Africa 
is increasing rapidly and there is an urgent need for service provision.  This study 
provides data which is vital for the design of prevention and early detection 
programmes in the region which I will address further in this thesis.  These findings 
represent a baseline against which the efficacy and cost-effectiveness of such 
interventions can be judged.  
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Chapter 7. 12 month Follow-up of the Malawi Diabetic 
Retinopathy Study Cohort 
 
 
7.1 Aims of the chapter 
This chapter details the demographic characteristics, clinical and biochemical 
parameters, progression of retinopathy grades and visual acuity data for the Malawi 
Diabetic Retinopathy Study (MDRS) cohort at 12 month follow-up. 
 
7.2 Introduction 
The MDRS is a prospective, observational, cohort study of persons attending 2 
hospital diabetes clinics over 24 months. The study aims to describe the prevalence, 
incidence and progression of diabetic retinopathy (DR) in Southern Malawi and to 
investigate the determinants of DR severity and progression in this population. The 
MDRS uses a systematically sampled cohort, standardised clinical photography, 
independent grading by graders in an accredited reading centre and collects data on 
covariates specific to the population.  In this chapter I report a planned interim 
analysis from this cohort 12 months after the baseline assessment.  As this is an 
interim analysis and in order to avoid repetition, a detailed discussion of the 
findings is covered in Chapter 8. 
 
7.3 Methods 
 
7.3.1 Setting, subjects and clinical assessment 
Study setting, sampling of subjects, clinical assessment and assessment of 
retinopathy are described in Chapter 5 methods.  Subjects were systematically 
sampled from 2 hospital based, primary care diabetes clinics.  At 12 months, visual 
acuity, glycaemic control (HbA1c), blood pressure, HIV status, urine albumin 
creatinine ratio (ACR) and haemoglobin were assessed.  Retinopathy was graded at 
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an accredited reading centre using modified Wisconsin grading of 4-field mydriatic 
photographs. 
 
7.3.2 Subject tracing 
Tracing of subjects was systematic.  All subjects recruited to MDRS main cohort 
were asked to give telephone numbers and an address.  Telephone was the first line 
method of contact.  If a subject could not be contacted by telephone they received 
a home visit from the MDRS study team.  Additionally the MDRS study team 
attended the diabetes clinic weekly between December 2012 and May 2013 to 
approach patients in the clinic waiting room.  Finally the president and vice 
president of the patient’s organisation the Diabetes Association of Malawi reviewed 
the list of subjects in order to personally identify their whereabouts. 
 
7.3.3 Confirmation of subject death 
Confirmation of subject death was performed in a systematic manner.  The relatives 
of subjects reported to be deceased were visited at home by the study research 
nurse (Chrissy Pindani) between December 2012 and May 2013.  The nurse was 
trained to record, on a standard form, brief written narratives from families or 
other reliable informants.  If available, the death certificate and the health passport 
were reviewed and cause of death and/or brief details of last illness recorded.  A 
subject was recorded as dead if confirmed by a relative or ‘Traditional Authority’ 
(village leader in rural districts), or if a death certificate or marked grave was seen 
by the study nurse.   I assigned a probable cause of death after reading the form.  
 
7.3.4 Statistical analysis 
An a priori analysis plan was followed. The MDRS was powered for progression of 
DR at 24 months.  However, an interim analysis was scheduled at 12 months.  As 
described in Chapter 5 Methods, grades of DR were calculated by patient according 
to the worse or only gradeable eye.  Visual acuity (VA) data were investigated by 
patient according to the better eye.  95% confidence intervals (CIs) were calculated 
for proportions.  I constructed a logistic regression model (backwards stepwise with 
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probability of removal of 0.2) to determine the odds ratio (OR) and 95% CIs for 2 
step progression on the Liverpool Diabetic Eye Study (LDES) scale in association with 
an initial 10 variables: time since diagnosis of diabetes, baseline grade of DR, mean 
HbA1c (mean of visits 1 and 2), mean sBP, mean urine ACR, mean haemoglobin, 
triglycerides (baseline measurement), HIV status, age, and scatter laser treatment 
(anytime between visit 1 and visit 2).  Adjusted odds ratios (OR) and 95% CIs were 
calculated for 2 step retinopathy progression.   
 
7.4 Results 
 
7.4.1 Participants  
A total of 313 subjects were assessed between December 2012 and May 2013 
(Figure 7.1).  The death of 15 subjects was confirmed (total 92% follow-up of the 
original 357 subject cohort).  8 subjects were traced but declined assessment.  1 
subject had moved away from Southern Malawi and was unable to return for 
assessment.  1 subject was unable to attend due to disability.  19 subjects could not 
be traced.   
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Figure 7.1 Flow diagram for subjects in the MDRS: enrolment and follow-up at 12 
months 
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7.4.2 Subjects confirmed deceased 
15 subjects were confirmed deceased by the MDRS study team by May 2013.  
Baseline characteristics and grades of retinopathy of these subjects are shown in 
Table 7.1 and 7.2.  Three death certificates were available.  Causes of death 
recorded were ‘upper gastrointestinal bleeding’, ‘meningitis’ and ‘diabetes and 
ascites’.  Three health books were reviewed.  Causes of death recorded were 
‘malaria/hypoglycaemia’, ‘diabetic ketoacidosis’ and ‘hypoglycaemia/anaemia’.  For 
9 subjects the cause of death was assigned based on verbal reports alone: ‘diabetic 
ketoacidosis’ 1 subject, ‘hypoglycaemia’ 1 subject, ‘renal failure secondary to 
diabetes’ 1 subject, ‘Anaemia’ 1 subject and ‘unknown cause’  5 subjects. 
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Table 7.1 Baseline characteristics of 15 subjects from the MDRS cohort study 
confirmed dead by the MDRS team by May 2013. BMI = body mass index. ACR = 
albumin creatinine ratio. 
Characteristic Level 
Female sex 7 (47%) 
Age (median, IQR) 56.2 yrs (51.4 – 63.7) 
Type 1 diabetes  2 
BMI (mean, SD) 23.3 kg/m2 (4.6) 
Overweight (BMI>25 kg/m2)  5 (33%) 
Time since diagnosis of diabetes (median, IQR) 8.7 yrs (4.9 – 13.9) 
Hypertensive (see text) 8 (53%) 
sBP (median, IQR) 130 mmHg (117-152)  
dBP (median, IQR) 79 mmHg (71.5 - 89) 
Mean arterial pressure (median, IQR) 96 mmHg (89-110) 
HbA1c (NSGP) (mean, SD) 8.1% (2.6) 
Fasting blood sugar (mean, SD) 15.1 mg/dL (11.8) 
HIV reactive 5 (33%) 
Anaemia (WHO definition) 9 (60%) 6M; 3F 
Total cholesterol >5.0mmol/L 2 (13%) 
Total cholesterol (mmol/L; mean, SD) 3.4 (1.3) 
HDL cholesterol (mmol/L; mean, SD) 0.90 (0.39) 
LDL cholesterol (mmol/L; mean, SD) 1.75 (0.94) 
Triglycerides (mmol/L; mean, SD) 1.34 (0.71) 
Urine ACR raised (n; %) (M>2.5/F>3.5mg/mmol) 12 (80%) 
Serum creatinine (mean, SD) 152 µmol/L (160) 
Raised serum creatinine (M>110; F>90 μmol/l) 6 (40%) 
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Table 7.2 Baseline prevalence of grades of retinopathy for 15 subjects from the 
MDRS cohort study confirmed dead by the MDRS team by May 2013. STDR = sight 
threatening retinopathy. 
Grade n 
No retinopathy (level 10) 5 (33%) 
Any retinopathy (level 20-71+) 10 (66%) 
Level 20 retinopathy 2 (13%) 
Level 30 retinopathy 3 (20%) 
Level 40 retinopathy 1 (7%) 
Level 50 retinopathy 0 
Proliferative or worse (≥ level 60) 4 (27%) 
Ungradeable 0 
Sight threatening maculopathy 5 (33%) 
STDR 8 (53%) 
No data 0 
 
 
7.4.3 Analysis of bias 
In order to determine the degree to which loss to follow-up may bias results of this 
cohort study, baseline data from subjects seen at 12 months and those lost to 
follow-up were compared.  Baseline demographic, clinical and biochemical 
parameters of the 357 subjects in the MDRS cohort categorised by follow-up are 
shown in Table 7.3.  There was no significant difference between subjects seen at 
12 months and those not seen at 12 months regarding mean duration of diabetes, 
HbA1c, sBP, dBP, mean arterial pressure (MAP), BMI, triglycerides, and mean total, 
HDL and LDL cholesterol.  There was no significant difference between the 
proportions of subjects in each group who were hypertensive, overweight, HIV 
positive, of female sex, had type 1 diabetes or who had raised cholesterol or raised 
urine ACR. 
 
Those subjects not seen at 12 months demonstrated higher mean age, higher 
fasting blood sugar, lower haemoglobin and higher serum creatinine then subjects 
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seen at 12 months.  A greater proportion of subjects not seen at 12 months were 
anaemic and had raised creatinine.  Baseline prevalence of grades of retinopathy for 
357 subjects in the MDRS cohort categorised by follow-up are shown in Table 7.4.  
There was no significant difference between subjects seen at 12 months and not 
seen at 12 months regarding prevalence of any DR, sight threatening retinopathy 
(STDR) and proliferative diabetic retinopathy (PDR).  Table 7.5 shows baseline 
prevalence of corrected Early Treatment of Diabetic Retinopathy Study (ETDRS) 
visual acuities according to better eye for 357 subjects in the MDRS cohort 
categorised by follow-up.  Subjects who were not seen at 12 months had worse 
visual acuities than those seen at 12 months (p= 0.003, Χ2 test for trend). 
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Table 7.3 Baseline demographic, clinical and biochemical parameters of 357 
subjects in the MDRS cohort categorised by follow-up:  traced and assessed at 12 
months (n=313) or not seen at 12 months (n=44). MAP = mean arterial pressure; 
FBS = fasting blood sugar. 
Characteristic at baseline Subjects seen at 
12 months 
Subjects not 
seen at 12 mths 
p value  
n 313 44 NA 
Female sex 188 (60.1%) 28 (63.6%) p=0.74 Fisher’s exact 
Age (yrs; median, IQR) 53.5 (42.5-60.3) 57.4 (53.2-65.7) p=0.005* Unp’ed t-test 
Type 1 diabetes  32 (10.2%) 3 (6.8%) p=0.60 Fisher’s exact 
BMI (kg/m2; mean, SD) 26.5 (5.7) 25.0 (5.6) p=0.10 Unp’ed t-test 
BMI >25 kg/m2 175 (55.9%) 23 (52.3%) p=0.75 Fisher’s exact 
Duration (median, IQR) 4.1 (2.0 – 7.7) 4.9 (1.7 – 9.3) p=0.40 Wilcoxon r. sum 
Hypertensive (see text) 207 (66.1%) 27 (61.4%) p=0.61 Fisher’s exact 
sBP (mmHg; median, IQR) 135 (120 - 156) 134 (119 - 161) p=0.89 Unpaired t-test 
dBP (mmHg; median, IQR)  82 (74-91)  79 (74 - 89) p=0.64 Unpaired t-test 
MAP (mmHg; median, IQR) 100 (90 - 112) 97 (89 – 115) p=0.97 Unpaired t-test 
HbA1c (NGSP %; mean, SD) 7.8 (2.4) 7.9 (3.2) p=0.81 Unpaired t-test 
FBS (mg/dL; mean, SD) 10.1 (5.9) 12.4 (9.0) p=0.025* Unp’ed t-test 
Hb (g/dl) (mean; SD) 14.1 (1.8) 12.6 (2.0) p=0.0001* Unp’d t-test 
Anaemia (see text) 40 (12.8%) 14 (31.8%) p=0.003* Fisher’s exact 
HIV positive 41 (13.1%) 7 (15.9%) p=0.64 Fisher’s exact 
Total chol. >5.0mmol/L 94 (30%) 11 (25%) p=0.60 Fisher’s exact 
Total chol (mmol/L;mean,SD) 4.35 (1.25) 3.97 (1.42) p=0.064 Unpaired t-test 
LDL chol. (mmol/L;mean,SD) 2.47 (0.93) 2.19 (1.06) p=0.067  Unp’ed t-test 
HDL chol (mmol/L;mean,SD) 0.99 (0.33) 0.98 (0.41) p=0.86  Unpaired t-test 
Triglycerides(mmol/L;mean,SD) 1.57 (1.22) 1.24 (0.76) p=0.082 Unpaired t-test 
Raised uACR ‡  101 (32.3%) 21 (47.7%) p=0.061 Fisher’s exact 
Serum creat (µmol/L;mean,SD) 62.0 (23.0) 90.7 (102.9) p=0.0001*Un-p’d t-test  
Raised creatinine  14 (4.5%) 6 (13.6%) p=0.025* Fisher’s exact 
‡Rasied urine ACR: Male>2.5mg/mmol; Female>3.5mg/mmol. † Raised serum creatinine: 
Male>110 μmol/l; Femaile >90μmol/l 
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Table 7.4 Baseline prevalence of grades of retinopathy of 357 subjects in the MDRS 
cohort categorised by follow-up:  traced and assessed at 12 months (n=313) or not 
seen at 12 months (n=44). ST= sight threatening. 
Grade  
(n; %; 95% CI) 
Subjects seen at 12 
months 
   Subjects not seen at 
12 months 
p value  
(Fisher’s exact) 
n 313 44  
No DR (level 10) 155 (49.5; 44.0-55.0) 22 (50.0; 35.2-64.8) p = 0.99 
Any DR (level 20-71+) 157 (50.2; 44.7-55.7) 22 (50; 35.2-64.8) p = 0.99 
Level 20 retinopathy 85 (27.2; 22.3-32.1) 9 (20.5; 8.6-32.4)  
Level 30 retinopathy 21 (6.7; 3.9-9.5) 4 (9.1; 0.6-17.6)  
Level 40 retinopathy 22 (7.0; 4.2-9.8) 4 (9.1; 0.6-17.6)  
Level 50 retinopathy 8 (2.6; 0.8-4.4) 0  
Proliferative (≥60) 21 (6.7; 3.9-9.5) 5 (11.3; 2.0-20.7) p = 0.35 
Ungradeable 1 (0.3; 0-0.9) 0  
ST maculopathy 84 (26.8; 21.9-31.7) 9 (20.5; 8.6-32.4)  
STDR 91 (29.1; 24.1-34.1) 14 (31.8; 18.0-45.6) p = 0.73 
No data 0 0  
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Table 7.5 Baseline prevalence of corrected visual acuities according to better eye 
(ETDRS letters) for 357 subjects in the MDRS cohort categorised by follow-up:  
traced and assessed at 12 months (n=313) or not seen at 12 months (n=44). 
Approximate Snellen acuities in parentheses. 
Visual acuity   313 subjects seen at 12 
months 
44 subjects not seen at 12 
months 
 n % (95% CI) n % (95% CI) 
≥ 90  (6/5) 86 27.5 (22.6-32.5) 2 4.5 (0-10.6) 
80 - 89 (6/7.5) 148 47.3 (41.8-52.8) 23 52.2 (37.4-67.0) 
70 -79 (6/12) 60 19.2 (14.8-23.6) 11 25.0 (12.2-37.8) 
60 - 69 (6/18) 8 2.6 (0.8-4.4) 5 11.4 (2.0-20.8) 
50 - 59 (6/30) 7 2.2 (0.6-3.8) 1 2.3 (0-6.7) 
40 - 49 (6/75) 2 0.6 (0-1.5) 1 2.3 (0-6.7) 
Hand Movements 1 0.3 (0-0.9) 0  
Light Perception 1 0.3 (0-0.9) 0  
No light perception 0  0  
No data 0  1 2.3 (0-6.7) 
 
 
7.4.4 Demographics and clinical and biochemical measurements of 
subjects seen at 12 months 
For 313 subjects seen at month 12 (visit 2), median time to follow-up was 0.90 years 
(range 0.80 – 1.25).  At baseline 41 subjects (13.1%) were HIV positive. At 12 
months an additional 2 subjects were HIV reactive (1 subject WHO stage 1 and 1 
subject who had already commenced anti-retroviral therapy (ART)). 6 subjects 
(1.9%) declined testing.  No trend toward worsening renal function was identified:  
Table 7.6 shows urine ACR measurements at visit 1 and 2.   
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Table 7.6 Urine albumin creatinine ratio (ACR) measurements for 313 subjects in 
the MDRS seen at visit 1 and visit 2 (12 months) 
Characteristic 
 
Visit 1 (baseline) Visit 2 (12 months) 
Urine ACR  
(mg/mmol; mean; SD) 
13.6 (65.4) 9.5 (30.2) 
Urine ACR raised (n; %)  
(M>2.5;F>3.5 mg/mmol) 
101 (32.3%) 
(43 men; 58 women) 
92 (29.4%) 
(36 men; 56 women) 
Urine ACR > 30 mg/mmol  
(n; %) 
21 (6.7%) 
(5 men; 16 women) 
18 (5.8%) 
(4 men; 14 women) 
 
 
7.4.5 Prevalence of grades of retinopathy 
Prevalence of grades of retinopathy for 313 subjects seen at visit 1 and visit 2 are 
shown in Table 7.7.   
 
Table 7.7 Prevalence with 95% CI of retinopathy grades according to worse eye in 
313 subjects in the MDRS seen at visit 1 and 2. 
Grade  
(n; %; 95% CI) 
Visit 1  
(baseline) 
Visit 2 
(12 months) 
No retinopathy (level 10) 155 (49.5; 44.0-55.0) 155 (49.5; 44.0-55.0) 
Any retinopathy (level 20-71+) 157 (50.2; 44.7-55.7) 156 (49.8; 44.3-55.3) 
Level 20 retinopathy 85 (27.2; 22.3-32.1) 73 (23.3; 18.6-28.0) 
Level 30 retinopathy 21 (6.7; 3.9-9.5) 36 (11.5; 8.0-15.0) 
Level 40 retinopathy 22 (7.0; 4.2-9.8) 20 (6.4; 3.7-9.1) 
Level 50 retinopathy 8 (2.6; 0.8-4.4) 4 (1.3; 0.1-2.6) 
Proliferative or worse (≥60) 21 (6.7; 3.9-9.5) 23 (7.3; 4.4-10.2) 
Ungradeable 1 (0.3; 0-0.9) 2 (0.6; 0-1.5) 
Sight threatening maculopathy 84 (26.8; 21.9-31.7) 83 (26.5; 21.6-31.4) 
STDR 91 (29.1; 24.1-34.1) 92 (29.4; 24.4-34.5) 
No data 0 0 
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7.4.6 Treatment 
Of 313 subjects seen at 12 months two were classified as ungradeable (neither 
received laser treatment).  Therefore data for 2 visits was available for 311 subjects.  
Of these subjects, within the first year of the study 34 were listed for both scatter 
laser photocoagulation and macular laser treatment (either unilaterally or 
bilaterally); 31 started the course of treatment and 25 completed the course.  9 
were listed for scatter laser alone; all completed the course.  12 were listed for 
macular laser treatment alone; all completed the course of treatment.  Table 7.8 
shows laser treatment within the first year of the MDRS (i.e. before visit 2) for 
subjects classified by baseline level of retinopathy.   
 
Table 7.8 Laser treatment within the first year of the MDRS study for 311 subjects 
seen at baseline and visit 2 (12 months).  Subjects classified by baseline level of 
retinopathy.   
Baseline level 
of retinopathy 
n Laser photocoagulation 
(listed / started / completed course) 
Scatter and macula Scatter alone Macula alone 
Level 10 154 0 0 0 
Level 20 85 0 0 6/6/6 
Level 30 21 2/1/1 2/2/2 4/4/4 
Level 40 22 10/8/7 1/1/1 2/2/2 
Level 50 8 6/6/4 2/2/2 0 
Level 60 13 10/10/8 2/2/2 0 
Level 70+ 8 6/6/5 2/2/2 0 
Total 311 34/31/25 9/9/9 12/12/12 
 
 
7.4.7 Progression of grades of retinopathy 
Incidences of development of grades of retinopathy for 311 subjects with level 10 
(no retinopathy), level 20, 30, 40, 50, 60 and level 70+ retinopathy at baseline are 
shown in Tables 7.9 to 7.15, respectively.  Incidence of STDR (p<0.001), ST 
maculopathy (p<0.001) and PDR (p<0.001) increased with severity of baseline 
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retinopathy (Χ2 test for trend).  Two (or more) step progression was observed in 29 
subjects (9.3%; 95% CI 6.1-12.5); three (or more) step progression in 11 subjects 
(5.3%; 2.8-7.8).  Of 220 subjects without STDR at baseline (visit 1) 10 (4.5%; 1.8-7.2) 
had developed the condition at visit 2.  Of 225 subjects without ST maculopathy at 
baseline (and whose maculopathy was gradeable) 11 (4.9%; 2.1-7.7) developed the 
condition by visit 2.   
 
Of 269 subjects not listed for scatter laser at baseline 11 (4.1%; 1.7-6.5) developed 
retinopathy requiring scatter laser by visit 2.  Of 268 subjects not listed for macular 
laser at baseline 13 (4.9%; 2.3-7.5) developed maculopathy requiring macular laser 
by visit 2. 4 subjects developed retinopathy requiring both scatter and macular 
laser.  Figure 7.2 shows incidence of progression to level 60+ (PDR) and of 2 step 
and 3-step progression for subjects with level 10, 20, 30, 40 and 50 retinopathy at 
baseline. 
 
Table 7.9 Incidence of development of all grades of DR, any DR, sight threatening 
(ST) maculopathy, STDR, 2-step progression and 3-step progression for 154 persons 
with level 10 (no retinopathy) at baseline. 
Grade progression Number entering 
time interval 
n Incidence %  
(95% CI) 
10 - 10 154 136 88.3 (83.2-93.4) 
10 - 20 154 12 7.8 (3.6-12.0) 
10 - 30 154 6 3.9 (0.8-7.0) 
10 – 40+ 154 0 0 
10 – 20+ (any DR) 154 18 11.7 (6.6-16.8) 
10 - ST maculopathy 154 0 0 
10 – STDR 152 0 0 
10 – 2 step (or greater) 
progression 
154 8 5.2 (1.7-8.7) 
10 - 3 step (or greater) 
progression 
154 2 1.3 (0-3.1) 
n =number of subjects reaching endpoint 
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Table 7.10 Incidence of development of all grades of DR, sight threatening (ST) 
maculopathy, STDR, 2-step progression and 3-step progression for 85 persons with 
level 20 retinopathy at baseline.  
Grade progression Number entering 
time interval 
n Incidence %  
(95% CI) 
20 - 10 85 19 22.4 (13.5-31.3) 
20 - 20 85 52 61.2 (50.8-71.6) 
20 - 30 85 12 14.1 (6.7-21.5) 
20 - 40 85 2 2.4 (0-5.6) 
20 – 50+ 85 0 0 
20 - ST maculopathy 63 7 10.8 (3.1-18.4) 
20 – STDR 63 9 14.3 (5.7-22.9) 
20 – 2 step (or greater) 
progression 
85 6 7.1 (1.6-12.5) 
20 - 3 step (or greater) 
progression 
85 2 2.4 (0-5.6) 
n =number of subjects reaching endpoint 
 
Table 7.11 Incidence of development of all grades of DR, sight threatening (ST) 
maculopathy, STDR, 2-step progression and 3-step progression for 21 persons with 
level 30 retinopathy at baseline. 
Grade progression Number entering 
time interval 
n Incidence % 
30 - 20 21 4 19.0 (2.3-35.8) 
30 - 30 21 11 52.4 (31.0-73.7) 
30 - 40 21 6 28.6 (9.2-47.9) 
30 – 50+ 21 0 0 
30 - ST maculopathy 4 0 0 
30 – STDR 4 0 0 
30 - 2 step (or greater) 
progression 
21 5 23.8 (5.6-42.0) 
30 - 3 step (or greater) 
progression 
21 1 4.8 (0-13.9) 
n =number of subjects reaching endpoint 
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Table 7.12 Incidence of development of level 20 or 30 retinopathy, level 40, level 
50, proliferative DR, ST maculopathy, 2-step progression and 3-step progression for 
22 persons with level 40 retinopathy at baseline. 
Grade progression Number entering 
time interval 
n Incidence % 
40 – 20/30 22 8 36.4 
40 - 40 22 9 40.9 
40 - 50 22 1 4.5 
40 - 60+ (proliferative DR) 22 4 18.2 
40 - ST maculopathy 3 3 100 
40 - 2 step (or greater) 
progression 
22 4 18.2 
40 - 3 step (or greater) 
progression 
22 4 18.2 
n =number of subjects reaching endpoint 
 
Table 7.13 Incidence of development of retinopathy less than level 50, level 50, 
proliferative DR, ST maculopathy, 2-step progression and 3-step progression for 8 
persons with level 50 retinopathy at baseline. 
Grade progression Number entering 
time interval 
n Incidence % 
50 – <50 8 4 50 
50 - 50 8 1 12.5 
50 - 60+ (proliferative DR) 8 3 37.5 
50 - ST maculopathy 1 0 0 
50 - 2 step (or greater) 
progression 
8 2 25 
50 - 3 step (or greater) 
progression 
8 1 12.5 
n =number of subjects reaching endpoint 
Table 7.14 Incidence of development of retinopathy less than level 60, level 60, ST 
maculopathy, 2-step progression and 3-step progression for 13 persons with level 
60 retinopathy at baseline. 
Grade progression Number entering 
time interval 
n Incidence % 
60 – <60 13 5 38.5 
60 - 60 13 6 46.1 
60 - >60 13 2 15.4 
60+ - ST maculopathy 1 1 100 
60 - 2 step (or greater) 
progression 
13 1 7.7 
60 - 3 step (or greater) 
progression 
13 1 7.7 
n =number of subjects reaching endpoint 
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Table 7.15 Incidence of development of level 60 retinopathy, 2-step progression 
and 3-step progression for 8 persons with level 70+ retinopathy at baseline.   
Grade progression Number entering 
time interval 
n Incidence % 
70+ – 60 8 1 12.5 
70+ - 70+ 8 7 87.5 
70+ - 2 step (or greater) 
progression 
8 3 37.5 
70+ - 3 step (or greater) 
progression 
8 0 0 
n =number of subjects reaching endpoint 
 
Figure 7.2 Incidence of progression to proliferative diabetic retinopathy (PDR; level 
60+) and of 2 step and 3-step progression for subjects with level 10 (n=154), level 20 
(n=85), level 30 (n=21), level 40 (n=22) and level 50 (n=8) retinopathy at baseline.  
Error bars indicate 95% CI. Error bars not shown for level 40 and 50 due to the small 
number of subjects in these groups. 
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7.4.8 Associations of progression of retinopathy 
Mean HbA1c was a risk factor for 2 step progression on the LDES scale in 
multivariate analysis (Table 7.16).  Descriptive analysis indicated that urine ACR did 
not demonstrate a linear association with probability of 2 step progression; a 
natural log transformation was more suitable for the model.   
 
Table 7.16 Risk factors for association of progression of diabetic retinopathy by 2 or 
more steps on the LDES scale at 12 months in the MDRS (n=311). 
† Scatter laser treatment received any time between visit 1 and visit 2 
 
  
 OR 95% CI p value 
Univariate logistic regression 
Duration of diabetes (years) 1.07 1.01 - 1.13 0.014* 
Mean HbA1c (NGSP %) 1.23 1.06 - 1.42 0.006* 
Type 1 diabetes  0.65 0.15 - 2.86 0.57 
Baseline grade of DR 1.39 1.14 - 1.70 0.001* 
Scatter laser treatment† 3.08 1.26 - 7.55 0.014* 
Mean sBP (mmHg) 1.02 1.00 - 1.03 0.011* 
log[Mean urine ACR] (mg/mmol) 1.43 1.16 - 1.76 0.001* 
Mean haemoglobin (g/dl) 0.93 0.74 - 1.16 0.51 
HIV positive 0.44 0.10 - 1.94 0.28 
Baseline LDL cholesterol (mmol/L) 0.99 0.65 - 1.49 0.95 
Baseline HDL cholesterol (mmol/L) 1.81 0.61 - 5.42 0.29 
Baseline triglycerides (mmol/L) 1.22 0.96 - 1.55 0.099 
Sex (male) 0.68 0.30 - 1.55 0.36 
Age (years) 1.02 0.99 - 1.05 0.13 
Multivariate logistic regression 
Mean HbA1c (NGSP %) 1.28 1.07 – 1.52 0.006* 
Mean sBP (mmHg) 1.01 0.99 – 1.03 0.14 
Baseline grade of DR 1.43  0.94 – 2.19 0.097 
Baseline triglycerides (mmol/L) 1.27 0.98 – 1.66 0.076 
Scatter laser treatment† 0.67 0.11 – 4.11 0.66 
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7.4.9 Vision  
Visual acuity measurements for 313 subjects seen at baseline and 12 months are 
shown in Table 7.17.  Using WHO definitions [310] the number of subjects at 
baseline and 12 months with ‘normal vision’ (equal to or better than 60 letters) was 
302 (96.5%, 94.4-98.5) and 299 (95.5%, 93.2-97.8), respectively.  The number with 
‘moderate visual impairment’ (50 to 59 letters) was 7 and 7 (2.2%, 0.6-3.9), 
respectively.  The number of ‘severely visually impaired or blind’ (<50 letters) 
subjects was 4 (1.2%, 0-2.5) and 6 (1.9%, 0.4-3.4) respectively.  At visit 2 the most 
common primary causes of visual impairment for subjects with corrected visual 
acuity worse than 80 letters (equivalent to 6/12 Snellen or worse) (n=89) were DR 
(29.2%) cataract (23.6%), and both DR and cataract (19.1%) (Table 7.18).  Therefore 
in 48.3% of cases DR was the sole or equal contributing cause of visual loss. 
 
Data on visual acuity from both visit 1 and 2 were available for 312 subjects.  
Between visits 1 and 2, 77 subjects (24.7%) lost 5 or more ETDRS letters of which 16 
subjects (5.1%) lost 15 or more letters.  3 subjects (1.0%) progressed to moderate 
visual impairment (50-59 letters) and 5 (1.6%) became ‘severely visually impaired or 
blind’ (<50 letters).  The most common primary causes of visual loss for the 77 
subjects who lost five or more letters were DR (29%), cataract (18%), and both DR 
and cataract (8%) (Table 7.19).  In 37% of cases DR was the sole or equal 
contributing cause of visual loss.  In univariate analysis loss of 15 or more ETDRS 
letters was not significantly associated with presence of STDR at visit 2 (OR1.48, 
0.52-4.19, p=0.47), age (OR 1.02, 0.98-1.066, p=0.23) or duration of diabetes (OR 
1.04, 0.96-1.11, p=0.35).   
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Table 7.17 Prevalence with 95% CI of corrected ETDRS visual acuities according to 
better eye in 313 subjects in the MDRS seen at baseline and 12 months. 
Approximate Snellen acuities in parentheses. 
Visual acuity  
(ETDRS letters) 
Visit 1  
(baseline) 
Visit 2  
(12 months) 
 n % (95% CI) n % (95% CI) 
≥ 90  (6/5) 86 27.5 (22.5-32.4) 65 20.8 (16.3-25.3) 
80 - 89 (6/7.5) 148 47.3 (41.8-52.8) 158 50.5 (44.9-56.0) 
70 -79 (6/12) 60 19.2 (14.8-23.5) 55 17.6 (13.4-21.8) 
60 - 69 (6/18) 8 2.6 (0.8-4.3) 21 6.7 (3.9-9.5) 
50 - 59 (6/30) 7 2.2 (0.6-3.9) 7 2.2 (0.6-3.9) 
40 - 49 (6/75) 2 0.6 (0-1.5) 1 0.3 (0-0.9) 
Hand Movements 1 0.3 (0-0.9) 4 1.2 (0-2.5) 
Light Perception 1 0.3 (0-0.9) 0  
No light perception 0  1 0.3 (0-0.9) 
No data 0  1 0.3 (0-0.9) 
 
Table 7.18 Primary causes of visual impairment (VI) in the opinion of the examining 
clinician at visit 2 for MDRS subjects with corrected visual acuity worse than 80 
letters.  Subjects classified according to level of visual impairment (n=89).  
Approximate snellen equivalents: 70-79 letters = 6/12; 60-69 = 6/18; 50-59 = 6/24 
‘Moderate visual impairment’; <50 letters = 6/36 or worse ‘Severely visually 
impaired or blind’. AMD = age related macular degeneration. ERM = epiretinal 
membrane. PCO = posterior capsule opacification. 
Primary cause 
of VI 
Level of visual impairment (ETDRS letters) Total 
70-79 60-69  50-59  <50 
n 55 21 7 6 89 
DR  15 (27%)  7 (33%) 2 2 26 (29.2%) 
DR and cataract 10 (18%) 5 (24%) 1 1 17 (19.1%) 
Cataract 16 (29%) 4 (19%) 0 1 21 (23.6%) 
AMD 1 (2%) 1 (5%) 0 0 2 (2.2%) 
Glaucoma 1 (2%) 0 1 0 2 (2.2%) 
Other 12 (22%)* 4 (19%)‡ 3† 2ƚ 21 (23.6%) 
*2 PCO; 5 no cause identified; 1 dry eye; 1 cataract and dry eye; 1 ERM; 2 central foveal scarring 
‡ 3 no cause identified; 1 PCO and complicated cat surgery 
†1 posterior uveitis (possibly syphilitic); 1 ERM; 1 myopic degeneration and cataract 
Ƚ 1 inherited retinopathy; 1 subject sphenoid meningioma 
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Table 7.19 Primary causes of visual loss between MDRS visits 1 and 2 in the opinion 
of the examining clinician for subjects with loss of 5 or more letters.  Subjects 
classified according to number of letters lost and level of visual impairment (n=77). 
‘Moderate visual impairment’: 50-59 letters (equivalent to 6/24 Snellen).  ‘Severely 
visually impaired or blind’: <50 letters (equivalent to 6/36 or worse). 
Primary cause 
of visual loss 
Number of ETDRS letters lost Level of visual impairment  
5-14 ≥ 15  Total  Progression to 
Mod. VI* 
Progression to 
Severe VI† 
n 61 16 77 3 5 
DR  17 5 22 (29%) 1 2 
DR and cataract 5 1 6 (8%)  1 
Cataract 10 4 14 (18%)  1 
AMD 1 0 1 (1%)   
Glaucoma 2 1 3 (4%) 1  
Other 26≠ 5‡ 31 (40%) 1† 1* 
≠ 1 PCO +complicated cat surgery; 1 dry eye; 1 PCO; 1 central foveal scarring; 22 no cause identified 
‡ 1 sphenoid meningioma; 1 ERM; 3 no cause identified 
† ERM 
* sphenoid meningioma 
 
 
7.5 Discussion 
 
7.5.1 Principal findings 
This chapter details progression of grades of retinopathy and visual impairment 
over 12 months in a treated cohort of people with diabetes from Southern Malawi.  
The MDRS is a 24 month cohort study; the 12 month data presented in this chapter 
is a planned interim analysis.  In 313 subjects (88% of the original 357 subject 
cohort) prevalence of any retinopathy did not change.  However, prevalence of 
STDR and PDR increased from 29.1% (24.1-34.1) to 29.4% (24.4-34.5) and from 6.7% 
(3.9-9.5) to 7.3% (4.4-10.2), respectively.  Incidence at 12 months of any DR in those 
without evidence of retinopathy at baseline was 11.7% (6.6-16.8).  The incidence at 
12 months of STDR for those with level 10 and level 20 retinopathy at baseline was 
0 and 14.3% (5.7-22.9), respectively.  The incidence of PDR for those with level 10, 
level 20, level 30, level 40 and level 50 retinopathy at baseline was 0, 0, 0, 18% and 
38%, respectively.  Higher glycosylated haemoglobin (HbA1c) was a risk factor for 
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progression of retinopathy in multivariate analysis.  Over the follow-up period 77 
subjects (24.7%) lost 5 or more ETDRS letters of which 16 subjects (5.1%) lost 15 or 
more letters.  In 48% of cases DR was the sole or equal contributing cause of visual 
loss.   
 
7.5.2 Strengths and weaknesses of this work 
The MDRS represents the first prospective cohort study of DR from Sub-Saharan 
Africa.  Strengths and weakness of the study are discussed in relation to both 12 
and 24 month data in Chapter 8, Section 8.5.3.  The MDRS was powered for the 
primary endpoint: progression of retinopathy by 2 steps on the LDES scale at 24 
months.  This 12 month analysis is therefore underpowered with respect to this 
endpoint. 
 
7.5.3 Analysis of bias 
The MDRS achieved a high follow-up rate at 12 months: 88% of the original cohort 
assessed. 15 subjects (4.2%) were confirmed dead and it is likely that some of the 
19 (5.3%) untraced subjects also died.  Subjects who were not seen at 12 months 
were older than those subjects who were seen.  Higher mean fasting blood sugar, 
higher serum creatinine and a higher proportion of subjects with raised serum 
creatinine in the ‘not seen’ group may suggest a higher baseline prevalence of 
microvascular complications of diabetes.  Lower mean haemoglobin and higher 
prevalence of anaemia may reflect poor general health and/or nutrition. 
 
7.5.4 Comparison with previous cohort studies of DR  
Few cohort studies are available for comparison from the African continent.  
Chapter 4, Section 4.4.4 details the only published studies and these are 
summarised in Table 4.4.  These studies report incidence and progression of DR at 5 
years and more.  They are therefore discussed in relation to MDRS 5 year data in 
Chapter 9, Section 9.5.4. High quality, prospective cohort studies of DR are available 
from Europe and North America.  Comparison between these studies and MDRS 
data at 12 and 24 months is made in Chapter 8, Section 8.5.6.  The MDRS has 
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demonstrated an association between glycaemic control and DR progression at 12 
months.  This association has been shown previously in large, high-quality studies in 
European and North American populations [12,13,97].  Associations of DR 
progression in the MDRS at 12 and 24 months are discussed in Chapter 8, Section 
8.5.6.  Similarly comparisons to studies reporting visual loss in persons with 
diabetes is made in Chapter 8, Section 8.5.8.  
 
 
7.6 Chapter summary  
This chapter provides an estimate of incidence and progression of grades of 
retinopathy over 12 months in a treated cohort of persons with diabetes in 
Southern Malawi.  Rates of DR progression were high.  Higher glycosylated 
haemoglobin was a risk factor for progression of retinopathy.  The MDRS was 
powered for the primary endpoint: progression of retinopathy by 2 steps on the 
LDES scale at 24 months.  Chapter 8 describes results from the MDRS at 24 months. 
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Chapter 8. 24 month Follow-up of the Malawi Diabetic 
Retinopathy Study Cohort 
 
 
8.1 Aims of the chapter 
This chapter details the demographic characteristics, clinical and biochemical 
parameters, progression of retinopathy grades and visual acuity data for the Malawi 
Diabetic Retinopathy Study (MDRS) cohort at 24 month follow-up. 
 
8.2 Introduction 
The MDRS is a prospective, observational, cohort study of persons attending 2 
hospital diabetes clinics over 24 months. The study aims to describe the prevalence, 
incidence and progression of diabetic retinopathy (DR) in Southern Malawi and to 
investigate the determinants of DR severity and progression in this population. The 
MDRS uses a systematically sampled cohort, standardized clinical photography, 
independent grading by graders in an accredited reading centre and collects data on 
covariates specific to the population.    In this chapter I report data from this cohort, 
24 months after the baseline assessment. 
 
8.3 Methods  
8.3.1 Setting, subjects, clinical assessment and subject tracing 
Study setting, sampling of subjects, clinical assessment and assessment of 
retinopathy are described in Chapter 5, Methods.  Subject tracing and confirmation 
of subject death are described in Chapter 7, Section 7.3.2 and 7.3.3, respectively.  
Subjects were systematically sampled from 2 hospital based, primary care diabetes 
clinics.  At 24 months visual acuity, glycaemic control (HbA1c and fasting blood 
sugar (FBS)), blood pressure, HIV status, urine albumin-creatinine ratio and 
haemoglobin were assessed.  Retinopathy was graded at an accredited reading 
centre using modified Wisconsin grading of 4-field mydriatic photographs. 
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8.3.2 Statistical analysis 
An a priori analysis plan was followed.  As described in Chapter 5 Methods, grades 
of DR were calculated by patient according to the worse or only gradeable eye.  
Visual acuity data were investigated by patient according to the better eye.  The 
MDRS was powered for the primary endpoint at 2 years: progression of retinopathy 
by 2 or more steps on the Liverpool Diabetic Eye Study (LDES) scale.  Cumulative 
and annual incidence rates of grades of DR and sight threatening diabetic 
retinopathy (STDR) were calculated for one year intervals using the life table 
method (described in Chapter 5, Section 5.9.10). 
 
I constructed a logistic regression model (backwards stepwise with probability of 
removal of 0.2) to determine the odds ratio (OR) and 95% CIs for 2 step progression 
on the LDES scale in association with an initial 12 variables: time since diagnosis of 
diabetes, type of diabetes, baseline grade of DR,  mean HbA1c (mean of visits 1, 2 & 
3), mean sBP, mean urine albumin creatinine ratio (ACR), mean haemoglobin, high 
density lipoprotein (HDL) cholesterol (baseline measurement), triglycerides 
(baseline), HIV status, age, and scatter laser treatment any time between visit 1 and 
visit 3.  Mean HbA1c and mean BP were used in the analysis as opposed to baseline 
measurements.  A sensitivity analysis using baseline measurements was performed.  
Data were considered significant when p<0.05.  All tests were two-sided.  All 
calculations were performed using STATA version 12 (StataCorp, Texas, USA). 
 
8.4 Results 
8.4.1 Participants  
A total of 295 subjects were assessed between December 2013 and May 2014 
(82.6% of the original 357 subject cohort) (Figure 8.1).  The death of 15 subjects was 
confirmed during the first 12 months of the study (Chapter 7).  A further 13 deaths 
were recorded by 24 months (total 28; 7.8% of original cohort).  Therefore total 
follow-up in the MDRS was 323: 90.5% of the original cohort.  16 subjects were 
traced but declined assessment.  4 subjects had moved away and were unable to 
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return for assessment (2 to Lilongwe, 1 to South Africa and 1 to the UK).  14 
subjects could not be traced.   
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Figure 8.1 Flow diagram for subjects in the MDRS: enrolment and follow-up at 12 
and 24 months 
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8.4.2 Subjects confirmed deceased 
Baseline characteristics and grades of retinopathy of 28 subjects confirmed 
deceased by May 2014 are shown in Table 8.1 and 8.2.  Three death certificates 
were available.  Causes of death recorded were ‘upper gastrointestinal bleeding’, 
‘meningitis’ and ‘diabetes and ascites’.  Four health books were reviewed.  Causes 
of death recorded were ‘malaria/hypoglycaemia’, ‘diabetic ketoacidosis’, 
‘hypoglycaemia/anaemia’ and ‘heart disease/anaemia’.  For 21 subjects the cause 
of death was assigned based on verbal reports alone: ‘diabetic ketoacidosis’ 3 
subjects, ‘renal failure secondary to diabetes’ 2, ‘brain tumour’ 1 (sphenoid 
meningioma on previous MRI), ‘hypoglycaemia’ 1, ‘anaemia’ 1, and ‘unknown 
cause’  13 subjects. 
 
Cumulative incidence of death in the whole MDRS cohort at 12 and 24 months was 
4.3% (2.2-6.4 95% CI) and 8.0% (5.1-10.9), respectively (n=357; life table method).  
Cumulative incidence of death amongst subjects with STDR at baseline at 12 and 24 
months was 7.6% (2.6-12.6) and 13.2% (6.8-19.6), respectively (n=106).  Cumulative 
incidence of death amongst subjects with proliferative diabetic retinopathy (PDR) at 
baseline at 12 and 24 months was 15.4% (1.5-29.3) and 30.8% (13.1-48.6), 
respectively (n=26).  Cumulative incidence of death amongst subjects listed for any 
laser treatment during the MDRS at 12 and 24 months was 5.8% (0.9-10.7) and 
12.8% (5.7-19.9), respectively (n=85).  Cumulative incidence of death amongst HIV 
positive subjects at 12 and 24 months was 10% (1.7-18.3) and 18.1% (7.4-28.8), 
respectively (n=50).  Cumulative incidence of death amongst subjects with 
moderate visual impairment or worse at baseline (<60 ETDRS letters) at 12 and 24 
months was 15% (0-35) and 39% (12-66), respectively (n=13).  In univariate analysis 
death during the MDRS was associated with STDR (OR 2.51; 95% CI 1.15-5.48; 
p=0.021), PDR (OR 6.47; 2.51-16.7; p=0.0001), HIV (OR 3.72; 1.54-9.00; p=0.003) 
and moderate visual impairment (OR 8.21; 2.48-27.1; p=0.001). 
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Table 8.1 Baseline characteristics of 28 subjects from the MDRS cohort confirmed 
dead by the MDRS team by May 2014. BMI = body mass index. ACR = albumin 
creatinine ratio. 
Characteristic Level 
Female sex 13 (46%) 
Age (median, IQR) 56.4 yrs (49.8–64.5) 
Type 1 diabetes  4 (14%) 
BMI (mean, SD) 23.9 kg/m2 (4.3) 
Overweight (BMI>25 kg/m2)  12 (43%) 
Time since diagnosis of diabetes (median, IQR) 5.8 yrs (2.6 – 12.6) 
Hypertensive (see text) 15 (54%) 
sBP (median, IQR) 128 mmHg (114-158)  
dBP (median, IQR) 79 mmHg (72 - 88) 
Mean arterial pressure (median, IQR) 96 mmHg (90-109) 
HbA1c (NSGP) (mean, SD) 8.7% (3.5) 
Fasting blood sugar (mean, SD) 13.7 mg/dL (11.4) 
HIV reactive 9 (32%) 
Anaemia (WHO definition) 14 (50%) 8M; 6F 
Total cholesterol >5.0mmol/L 7 (25%) 
Total cholesterol (mmol/L; mean, SD) 3.7 (1.3) 
HDL cholesterol (mmol/L; mean, SD) 0.93 (0.39) 
LDL cholesterol (mmol/L; mean, SD) 1.98 (0.95) 
Triglycerides (mmol/L; mean, SD) 1.45 (0.73) 
Urine ACR raised (n; %) (M>2.5/F>3.5 mg/mmol) 19 (68%) 
Serum creatinine (mean, SD) 120 µmol/L (125) 
Raised serum creatinine (M>110; F>90 μmol/l) 8 (20%) 
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Table 8.2 Baseline prevalence of grades of retinopathy for 28 subjects from the 
MDRS cohort confirmed dead by the MDRS team by May 2014. STDR = sight 
threatening retinopathy. 
Grade n 
No retinopathy (level 10) 12 (43%) 
Any retinopathy (level 20-71+) 16 (57%) 
Level 20 retinopathy 2 (7%) 
Level 30 retinopathy 3 (11%) 
Level 40 retinopathy 1 (4%) 
Level 50 retinopathy 2 (7%) 
Proliferative or worse (≥ level 60) 8 (29%) 
Ungradeable 0 
Sight threatening maculopathy 10 (36%) 
STDR 14 (50%) 
No data 0 
 
 
8.4.3 Analysis of bias 
In order to determine the degree to which loss to follow-up may have biased results 
of this cohort study, baseline data from subjects seen at 24 months and those lost 
to follow-up were compared.  Baseline demographic, clinical and biochemical 
parameters of the 357 subjects in the MDRS cohort categorised by follow-up are 
shown in Table 8.3.  There was no significant difference between subjects seen at 
24 months and those not seen at 24 months regarding mean duration of diabetes, 
HbA1c, sBP, dBP, mean arterial pressure (MAP), BMI, triglycerides and HDL 
cholesterol.  There was no significant difference between the proportions of 
subjects in each group who were hypertensive, overweight, HIV positive, of female 
sex, had type 1 diabetes or who had raised cholesterol.  Subjects who were not seen 
at 24 months were older and, at baseline, demonstrated higher mean fasting blood 
sugar and serum creatinine and lower mean haemoglobin, mean total cholesterol 
and mean low density lipoprotein (LDL) cholesterol.  Amongst subjects not seen at 
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24 months, at baseline a greater proportion were anaemic, had raised creatinine 
and had raised urine ACR. 
 
Baseline prevalence of grades of retinopathy for 357 subjects in the MDRS cohort 
categorised by follow-up are shown in Table 8.4.  There was no significant 
difference between subjects seen at 24 months and not seen at 24 months 
regarding prevalence of any DR or STDR.  However, there was a greater baseline 
prevalence of PDR amongst those not seen at 24 months.  There was no significant 
trend towards increasing grade of DR in those subjects not seen at 24 months 
compared to subjects seen at 24 months (p= 0.30, Χ2 test for trend).  Table 8.5 
shows baseline prevalence of corrected Early Treatment of Diabetic Retinopathy 
Study (ETDRS) visual acuities according to better eye for 357 subjects in the MDRS 
cohort categorised by follow-up.  Those subjects not seen at 24 months 
demonstrated worse baseline visual acuities (p= 0.0004, Χ2 test for trend). 
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Table 8.3 Baseline demographic, clinical and biochemical parameters of 357 
subjects in the MDRS cohort categorised by follow-up:  traced and assessed at 24 
months (n=295) or not seen at 24 months (n=62). MAP = mean arterial pressure; 
FBS = fasting blood sugar. 
Characteristic Subjects seen 
at 24 months 
Subjects not 
seen at 24mths 
p value  
n 295 62 NA 
Female sex 180 (61.0%) 36 (58.1%) p=0.671 Fisher’s exact 
Age (yrs; median, IQR) 53.5 (43.4-60.2) 56.2 (48.7-66.0) p=0.040* Unp’ed t-test 
Type 1 diabetes  29 (9.8%) 6 (9.7%) p=0.999 Fisher’s exact 
BMI (kg/m2; mean, SD) 26.7 (5.5) 25.2 (5.4) p=0.051 Unpaired t-test 
Overweight (BMI>25 kg/m2)  168 (56.9%) 31 (50%) p =  0.328 Fisher’s exact 
Duration (median, IQR) 4.1 (1.9 – 8.1) 4.5 (2.1 – 8.1) p=0.583 Wilcoxon r.s. 
Hypertensive (see text) 194 (65.8%) 38 (61.3%) p=0.558 Fisher’s exact 
sBP (mmHg; median, IQR) 135 (121 - 156) 134 (118 - 159) p=0.937 Unpaired t-test 
dBP (mmHg; median, IQR)  82 (74-91)  80 (74 - 89) p=0.744 Unpaired t-test 
MAP (mmHg; median, IQR) 100 (90 - 111) 97 (90 – 116) p=0.930 Unpaired t-test 
HbA1c (NGSP %)(mean, SD) 7.8 (2.4) 8.0 (3.1) p=0.573 Unpaired t-test 
FBS (mg/dL; mean, SD) 10.0 (5.3) 12.5 (9.9) p=0.005* Unp’ed t-test 
Hb (g/dl) (mean; SD) 14.1 (1.8) 13.0 (2.2) p=0.0001* Unp’ed t-test 
Anaemia (see text) 36 (12.2%) 17 (27.4%) p=0.005* Fisher’s exact 
HIV positive 36 (12.2%) 12 (19.4%) p=0.151 Fisher’s exact 
Total chol. >5.0mmol/L 88 (30%) 17 (27.4%) p=0.761 Fisher’s exact 
Total chol(mmol/L;mean,SD) 4.37 (1.25) 3.98 (1.34) p=0.028* Unp’ed t-test 
LDL chol. (mmol/L;mean,SD) 2.49 (0.93) 2.18 (0.99) p=0.019*  Unp’ed t-test 
HDL chol(mmol/L;mean,SD) 0.99 (0.34) 0.96 (0.35) p=0.530  Unpaired t-test 
Triglycerides(mmol/L;mean,SD) 1.57 (1.26) 1.30 (0.65) p=0.102 Unpaired t-test 
Raised uACR 
(M>2.5;F>3.5mg/mmol) 
91 (30.8%) 31 (50%) p=0.005* Fisher’s exact 
Serum creat (µmol/L;mean,SD) 61.1 (21.4) 86.9 (89.8) p=0.0001* Un-p’d t-test  
Raised creat 
(M>110;F>90μmol/l) 
12 (4.1%) 8 (12.9%) p=0.012* Fisher’s exact 
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Table 8.4 Baseline prevalence of grades of retinopathy of 357 subjects in the MDRS 
cohort categorised by follow-up:  traced and assessed at 24 months (n=295) or not 
seen at 24 months (n=44). ST = sight threatening. STDR = sight threatening diabetic 
retinopathy. 
Grade (n; %; 95% CI) Subjects seen at 24 
months 
   Subjects not seen 
at 24 months 
p value  
(Fisher’s exact) 
n 295 62  
No DR (level 10) 140 (47.5; 41.8-53.2)  37 (59.7; 47.5-71.9) p = 0.09  
Any DR (level 20-71+) 154 (52.2; 46.5-57.9) 25 (40.3; 28.1-52.5) p = 0.09  
Level 20 retinopathy 86 (29.2; 24.0-34.4) 8 (12.9; 4.6-21.2)  
Level 30 retinopathy 22 (7.5; 4.5-10.5) 3 (4.8; 0-10.1)  
Level 40 retinopathy 24 (8.1; 5.0-11.2) 2 (3.2; 0-7.6)  
Level 50 retinopathy 6 (2.0; 0.4-3.6) 2 (3.2; 0-7.6)  
Proliferative(≥level 60) 16 (5.4; 2.8-8.0) 10 (16.1; 7.0-25.3) p = 0.007* 
Ungradable 1 (0.3; 0-0.9) 0  
ST maculopathy 81 (27.5; 22.4-32.6) 12 (19.4; 9.6-29.2)  
STDR 88 (29.8; 24.6-35.0)  17 (27.0; 16.0-38.1) p = 0.761  
No data 0 0  
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Table 8.5 Baseline prevalence of corrected visual acuities according to better eye 
(ETDRS letters) for 357 subjects in the MDRS cohort categorised by follow-up:  
traced and assessed at 24 months (n=295) or not seen at 24 months (n=62). 
Approximate Snellen acuities in parentheses. 
Visual acuity   295 subjects seen at 24 
months 
62 subjects not seen at 24 
months 
 n % (95% CI) n % (95% CI) 
≥ 90  (6/5) 82 27.8 (22.7-32.9) 6 9.7 (2.3-17.1) 
80 - 89 (6/7.5) 142 48.1 (42.4-53.8) 29 46.8 (34.4-59.2) 
70 -79 (6/12)   54 18.3 (13.9-22.7) 17 27.4 (16.3-38.6)  
60 - 69 (6/18) 9 3.1 (1.1-5.1) 4 6.5 (0.4-12.6) 
50 - 59 (6/30) 4 1.4 (0.1-2.7) 4 6.5 (0.4-12.6) 
40 - 49 (6/75) 2 0.7 (0-1.7) 1 1.6 (0-4.7) 
Hand Movements 1 0.3 (0-0.9) 0  
Light Perception 1 0.3 (0-0.9) 0  
No light perception 0  0  
No data 0  1 1.6 (0-4.7) 
 
 
8.4.4 Demographics and clinical and biochemical measurements of 
subjects seen at 24 months 
For 295 subjects seen at visit 3 median time to follow-up was 1.9 years (range 1.7-
2.3).  Amongst these 295 subjects at baseline 36 (12.2%) were HIV positive.  By 12 
months 2 more subjects were reactive.  No further subjects were reactive by visit 3 
(24 months).  The status of 13 subjects (3.6%) was not known as they declined 
testing throughout the study.  No trend toward worsening renal function was 
identified:  Table 8.6 shows urine ACR measurements at visit 1 and 3.   
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Table 8.6 Urine albumin creatinine ratio (ACR) measurements for 295 subjects in 
the MDRS seen at visit 1 (baseline) and visit 3 (24 months).  
Characteristic 
 
Visit 1 (baseline) Visit 3 (24 months) 
Urine ACR  
(mg/mmol; mean; SD) 
10.4 (42.5) 8.5 (39.7) 
Urine ACR raised (n; %)  
(M>2.5;F>3.5 mg/mmol) 
92 (31.2%) 
(39 men; 53 women) 
77 (26.1%) 
(32 men; 45 women) 
Urine ACR > 30 mg/mmol  
(n; %) 
18 (6.1%) 
(5 men; 13 women) 
12 (4.1%) 
(1 man; 11 women) 
 
8.4.5 Prevalence of grades of retinopathy at 24 months 
Prevalence of grades of retinopathy for 295 subjects seen at visit 3 are shown in 
Table 8.7.   
 
Table 8.7 Prevalence with 95% CI of retinopathy grades according to worse eye in 
295 subjects in the MDRS seen at visit 3. ST = sight threatening. 
Grade 
(n; %; 95% CI) 
Visit 1 
(baseline) 
Visit 2 
(12 months) 
Visit 3 
(24 months) 
No retinopathy 
(level 10) 
140 (47.5; 41.8-53.2) 141 (47.8; 42.1-53.5) 108 (36.6; 31.1-42.1) 
Any DR (20-71+) 154 (52.2; 46.5-57.9) 143 (48.5; 42.8-54.2) 185 (62.7; 57.2-68.2) 
Level 20 retinopathy 86 (29.2; 24.0-34.4) 67 (22.7; 17.9-27.5) 100 (33.9; 28.5-39.3) 
Level 30 retinopathy 22 (7.5; 4.5-10.5) 34 (11.5; 7.9-15.1) 31 (10.5; 7.0-14.0) 
Level 40 retinopathy 24 (8.1; 5.0-11.2) 20 (6.8; 3.9-9.7) 27 (9.2; 5.9-12.5) 
Level 50 retinopathy 6 (2.0; 0.4-3.6) 4 (1.4; 0-2.7) 5 (1.7; 0.2-3.2) 
Proliferative (≥ 60+) 16 (5.4; 2.8-8.0) 18 (6.1; 3.4-8.8) 22 (7.5; 4.5-10.5) 
Ungradeable 1 (0.3; 0-0.9) 2 (0.7; 0-1.7) 2 (0.7; 0-1.7) 
ST maculopathy 81 (27.5; 22.4-32.6) 78 (25.8; 20.8-30.8) 90 (30.5; 25.3-35.8) 
STDR 88 (29.8; 24.6-35.0) 85 (28.8; 23.6-34.0) 99 (33.6; 28.2-39.0) 
No data 0 9 (3.1; 1.1-5.1) 0 
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8.4.6 Laser treatment 
Table 8.8 details the number of subjects who were listed for, started and completed 
a course of laser treatment during the course of the MDRS (December 2011 until 
May 2014).  Some subjects required multiple treatments of scatter laser, macular 
laser or both.   
 
Table 8.8 Number of subjects listed for, started and completed a course of laser 
treatment during the course of the MDRS (December 2011 until May 2014) 
classified by grade of DR at the start of the study. 
 
Baseline level 
of retinopathy 
n Laser photocoagulation 
(listed/started/completed course) 
Scatter and macular Scatter alone Macular alone 
Level 10 177 0 0 1/0/0 
Level 20 94 0/0/0 1/1/0 12/11/11 
Level 30 25 4/4/3 4/4/4 7/7/7 
Level 40 26 17/16/12 3/3/3 2/2/2 
Level 50 8 6/6/5 2/2/2 0 
Level 60 16 13/13/13 3/2/2 0 
Level 70+ 10 8/8/7 2/2/2 0 
90 1 0 0 0 
Total 357 48/47/40 15/14/13 22/20/20 
 
8.4.7 Progression of grades of retinopathy 
Of the original 357 subject cohort 322 were seen for at least one further study visit 
and are included in the progression analysis below.  Baseline demographics and 
clinical and biochemical measurements for these subjects are shown in Table 8.9.  
Subjects with higher levels of baseline retinopathy were older and had longer 
duration of diabetes, higher sBP, higher HbA1c and lower haemoglobin.   A greater 
proportion of subjects with high DR grades had raised cholesterol, raised urine ACR, 
were of female sex and were HIV negative. 
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Table 8.9 Baseline demographics and clinical and biochemical measurements of 322 
subjects in the MDRS who were seen for at least two study visits. Duration = time 
since diagnosis of diabetes. 
 Baseline grade of retinopathy  
Level 10 Level 
20 
Level 
30 
Level 
40 
Level 
50 
Level 
60+ 
p value 
n† 157 89 22 24 8 21  
Female sex 82  
(52%) 
59  
(66%) 
13 
(59%) 
18 
(75%) 
7  
(88%) 
15  
(71%) 
0.006*  
Χ2 for 
trend 
Age 
(yrs; med,IQR) 
53.7  
(40.3-
59.6) 
52.2  
(41.0-
59.8) 
55.3  
(45.2-
61.1) 
55.5  
(48.1-
60.3) 
55.0  
(49.4-
64.2) 
55.3  
(50.2-
65.5) 
0.38 
Kruskal-
Wallis 
Duration 
(yrs; med,IQR) 
3.0  
(1.4- 
5.1) 
4.8  
(1.9- 
9.3) 
7.6  
(4.3-
11.1) 
7.9  
(4.2-
12.1) 
4.3  
(2.0- 
7.8) 
7.4  
(4.3-
16.3) 
0.0001* 
Kruskal-
Wallis 
sBP 
(mmHg;med,IQR) 
130  
(117- 
150) 
132  
(118-
148) 
140  
(126-
170) 
141  
(130-
172) 
158  
(137-
173) 
166  
(135-
180) 
0.0002* 
Kruskal-
Wallis 
HbA1c 
(NGSP,%;mean;SD) 
7.5  
(2.6) 
8.0  
(2.5) 
8.7 
(2.3) 
8.9 
(1.9) 
7.4  
(1.8) 
7.8  
(1.9) 
0.006* 
Kruskal-
Wallis  
Haemoglobin 
(g/dl; mean; SD) 
14.4  
(1.8) 
14.0 
(1.6) 
14.2 
(1.9) 
13.6 
(1.4) 
13.3 
(2.3) 
12.6 
(2.0) 
0.020* 
Kruskal-
Wallis 
HIV positive 29 
(18.5%) 
8  
(9%) 
0 0 3  
(38%) 
1  
(5%) 
0.032*  
Χ2 for 
trend 
Total cholesterol 
>5.0mmol/L 
38  
(24%) 
27  
(30%) 
5  
(23%) 
10 
(42%) 
4  
(50%) 
12  
(57%) 
0.0007* 
Χ2 for 
trend 
Raised urine 
ACR‡  
42  
(27%) 
(M24;F18) 
24  
(27%) 
(M6;F18) 
10 
(45%) 
(M7;F3) 
10 
(42%) 
(M3;F9) 
3  
(38%) 
(M1;F2) 
15  
(71%) 
(M4;F11) 
0.0001* 
Χ2 for 
trend 
† 1 subject ungradeable at baseline.  ‡Raised urine ACR: Male>2.5 mg/mmol; F>3.5 mg/mmol 
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Table 8.10 shows cumulative yearly incidence for each year of follow-up for 
development of any DR, level 30, level 40 DR, sight threatening maculopathy and 
STDR and progression by 2 and 3 steps on the LDES scale for subjects with no 
retinopathy (level 10) at baseline.  Cumulative yearly incidence of progression to 
higher grades of DR, development of sight threatening maculopathy and STDR and 2 
and 3 step progression for persons with level 20, level 30, and level 40 at baseline 
are shown in Tables 8.11 through 8.13, respectively.  Incidence of STDR (p=0.0001), 
ST maculopathy (p=0.0001) and PDR (p=0.0001) increased with severity of baseline 
retinopathy (Χ2 test for trend).   
 
Of 16 subjects with level 60 DR at baseline, at 12 months the following grades of DR 
were recorded: 2 subjects level 20; 1 level 40; 2 level 50; 6 level 60; 2 level 70; 2 
subjects died and 1 was lost to follow-up.  At 24 months the following grades of DR 
were recorded: 1 subject level 20; 1 level 30; 3 level 40; 1 level 50; 4 level 60; a 
further 1 subject was lost to follow-up and 2 more had died.  Of 10 subjects with 
level 70 or 71 DR at baseline, at 12 months the following grades of DR were 
recorded: 1 subject level 60; 2 level 70; 5 level 71; 2 subjects had died. At 24 months 
the following grades of DR were recorded:  1 subject level 40; 3 level 71; 2 level 72; 
2 more subjects had died. 
 
Two (or more) step progression (from baseline) was observed either at visit 2 or 
visit 3 in 69 subjects (21.4%; 95% CI 16.9-25.9); three (or more) step progression in 
30 subjects (9.3%; 6.1-12.5).  Of 225 subjects without STDR at baseline 23 (10.2%; 
6.3-14.2) developed the condition during the study.  Of 233 subjects without ST 
maculopathy at baseline (and whose maculopathy was gradeable) 25 (10.7%; 6.8-
14.7) developed the condition during the study.  Of 279 subjects not listed for 
scatter laser at baseline and seen for at least 1 further study visit, 15 (5.4%; 2.8-8.1) 
developed retinopathy requiring scatter laser by visit 3.  Of 278 subjects not listed 
for macular laser at baseline and seen for at least 1 further study visit, 22 (7.9; 4.7-
11.1) developed maculopathy requiring macular laser by visit 3. Figure 8.2 shows 
cumulative incidence at 2 years of STDR and PDR and of 2 step and 3-step 
progression for subjects with level 10, 20, 30, 40 and 50 retinopathy at baseline. 
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Table 8.10 Life tables showing cumulative yearly incidence of development of any 
retinopathy, sight-threatening maculopathy, and sight-threatening diabetic 
retinopathy and of progression by 2 (or more) and 3 (or more) steps on the LDES 
scale in the worse eye of subjects with diabetes and no retinopathy at baseline. 
 
 Any retinopathy Level 30 Level 40 
T N n C. Inc. 95% CI N n C. Inc. 95% CI N n C. Inc. 95% CI 
1 177 18 10.8 6.1-15.5 177 6 3.6 0.8-6.4 177 0 0  
2 138 40 38.0 30.2-45.8 150 3 5.6 1.9-9.3 156 1 0.7 0-2.0 
 
 ST maculopathy ‡ STDR ‡  
T N n C. Inc. 95% CI N n C. Inc. 95% CI     
1 177 0 0  174 0 0      
2 156 5 3.4 0.5-6.3 154 4 2.7 0.1-5.3     
 
 2+ Step progression 3+ Step progression  
T N n C. Inc. 95% CI N n C. Inc. 95% CI     
1 177 8 4.8 1.6-8.1 177 2 1.2 0-2.9     
2 148 13 13.7 8.2-19.3 154 1 1.9 0-4.1     
 
T = time from recruitment (years); N = number entering time interval; n = new cases diagnosed 
during year; C. inc. = cumulative incidence (%); CI = confidence interval; ST = sight threatening; STDR 
= sight threatening diabetic retinopathy. ‡ - those with sight threatening maculopathy/STDR at 
baseline omitted from analysis 
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Table 8.11 Life tables showing cumulative yearly incidence of progression to higher 
grades of retinopathy and development of sight threatening maculopathy and STDR 
and of progression by 2 (or more) and 3 (or more) steps on the LDES scale for 
persons with level 20 retinopathy at baseline. 
 Level 30 Level 40 ST maculopathy ‡ 
T N n C. Inc. 95%CI N n C Inc 95% CI N n C Inc 95% CI 
1 94 12 13.1 6.2-20.0 94 2 2.2 0-5.2 70 7 10.3 3.1-17.5 
2 77 13 27.9 18.6-37.2 87 5 7.9 2.3-13.6 59 9 24.3 13.8-34.8 
 
 STDR ‡ 2 Step progression 3 Step progression 
T N n C Inc 95% CI N n C Inc 95% CI N n C Inc 95% CI 
1 70 9 13.2 5.2-21.3 94 6 6.5 1.5-11.6 94 2 2.2 0-5.2 
2 57 9 27.3 16.4-38.2 83 12 20.3 11.9-28.7 87 7 10.2 3.9-16.5 
 
T = time from recruitment (years); N = number entering time interval; n = new cases diagnosed 
during year; C. inc. = cumulative incidence (%); CI = confidence interval; ST = sight threatening; STDR 
= sight threatening diabetic retinopathy. ‡ - those with sight threatening maculopathy/STDR at 
baseline omitted from analysis 
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Table 8.12 Life tables showing cumulative yearly incidence of progression to higher 
grades of retinopathy and development of sight threatening maculopathy and STDR 
and of progression by 2 (or more) and 3 (or more) steps on the LDES scale for 
persons with level 30 retinopathy at baseline. 
 Level 40 Level 50 Level 60 + 
T N n C. Inc. 95% CI N n C Inc 95% CI N n C. Inc 95% CI 
1 25 6 25.5 7.9-43.1 25 0 0  25 0 0  
2 16 4 44.2 23.5-65.0 22 1 4.5 0-13.2 22 2 9.1 0-21.1 
 
 ST maculopathy ‡ STDR ‡  
T N n C. Inc. 95% CI N n C Inc 95% CI     
1 6 0 0  6 0 0      
2 4 1 25.0 0-67.4 4 1 25.0 0-67.4     
 
 2 Step progression 3 Step progression  
T N n C Inc 95% CI N n C Inc 95% CI     
1 25 5 21.3 4.8-37.9 25 1 4.3 0-12.5     
2 17 3 35.2 15.2-55.2 21 6 31.6 12.2-51.0     
 
T = time from recruitment (years); N = number entering time interval; n = new cases diagnosed 
during year; C. inc. = cumulative incidence (%); CI = confidence interval; ST = sight threatening; STDR 
= sight threatening diabetic retinopathy. ‡ - those with sight threatening maculopathy/STDR at 
baseline omitted from analysis 
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Table 8.13 Life tables showing cumulative yearly incidence of progression to higher 
grades of retinopathy and development of sight threatening maculopathy and of 
progression by 2 (or more) and 3 (or more) steps on the LDES scale for persons with 
level 40 retinopathy at baseline. 
 Level 50 Level 60 + ST maculopathy ‡ 
T N n C. Inc. 95% CI N n C Inc 95% CI N n C Inc 95% CI 
1 26 1 4.0 0-11.7 26 4 16 2-30 5 3 60  
2 23 2 13.1 0-27.2 20 5 37 18-56 2 1 80  
 
 2 Step progression 3 Step progression  
T N n C. Inc. 95% CI N n C Inc 95% CI     
1 26 4 16.0 1.6-30.4 26 4 16.0 1.6-30.4     
2 20 8 49.6 29.6-69.6 20 2 24.4 7.2-41.6     
 
T = time from recruitment (years); N = number entering time interval; n = new cases diagnosed 
during year; C. inc. = cumulative incidence (%); CI = confidence interval; ST = sight threatening; STDR 
= sight threatening diabetic retinopathy. ‡ - those with sight threatening maculopathy at baseline 
omitted from analysis 
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Figure 8.2 Cumulative incidence at 2 years of sight threatening diabetic retinopathy 
(STDR) and proliferative diabetic retinopathy (PDR; level 60+) and of 2 (or more) 
step and 3 (or more) step progression on the LDES scale for subjects in the MDRS 
with level 10 (n=177), level 20 (n=94), level 30 (n=25), level 40 (n=26) and level 50 
(n=8) retinopathy at baseline.  Error bars indicate 95% CI. Classes STDR, PDR, 2 step 
progression and 3 step progression are not exclusive i.e. a single subject can develop 
STDR and progress by 2 steps on the LDES scale. 
 
 
 
 
8.4.8 Associations of progression of retinopathy 
For 293 subjects seen at visit 3 higher mean HbA1c and higher baseline grade of 
retinopathy were risk factors for 2 step progression on the LDES scale in 
multivariate analysis (Table 8.14).  HIV infection was negatively associated with 
progression of DR.  Descriptive analysis showed that urine ACR did not demonstrate 
a linear association with probability of 2 step progression; a logarithmic 
transformation (base 10) was more suitable for the model. 
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Table 8.14 Risk factors for association of progression of diabetic retinopathy by 2 or 
more steps on the LDES scale at 24 months in the MDRS (n=293) (univariate and 
multivariate logistic regression) 
† Scatter laser treatment received any time between visit 1 and visit 3 
 
  
 OR 95% CI p value 
Univariate logistic regression 
Duration of diabetes (years) 1.05 1.00 - 1.09 0.042* 
Type 1 diabetes 2.09 0.89 - 4.89 0.090 
Baseline grade of DR 1.48 1.23 - 1.76 0.001* 
Scatter laser treatment† 3.75 1.90 - 7.40 0.001* 
Mean HbA1c (NGSP %) 1.28 1.13 - 1.44 0.001* 
Mean sBP (mmHg) 1.00 0.99  -  1.02 0.684 
log[Mean urine ACR] (mg/mmol) 1.28 1.07 - 1.52 0.005* 
Mean haemoglobin (g/dl) 0.92 0.76 - 1.12 0.432 
HIV positive 0.20 0.05 - 0.85 0.029* 
Baseline LDL cholesterol (mmol/L) 0.99 0.72 - 1.34 0.925 
Baseline HDL cholesterol (mmol/L) 2.24 0.98 - 5.14 0.057 
Baseline triglycerides (mmol/L) 0.78 0.57 - 1.06 0.113 
Sex (male) 1.04 0.58 - 1.87 0.896 
Age (years) 0.99 0.97 - 1.01 0.497 
Multivariate logistic regression 
Mean HbA1c (NGSP %) 1.27 1.12 - 1.45 0.001* 
Baseline grade of DR 1.39 1.02 - 1.91 0.040* 
HIV positive 0.16 0.03 - 0.78 0.023* 
Type 1 diabetes 2.27 0.87 - 5.89 0.094 
Scatter laser treatment† 1.45 0.43 - 4.88 0.546 
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8.4.9 HIV positive subjects  
In the MDRS 50 subjects (14.0%) were HIV positive (48 at baseline and 2 new 
diagnoses during the study).  Of these 50 subjects 43 (86%) were seen at visit 2 and 
38 (76%) were seen at visit 3.  5 subjects died by 12 months and a further 4 died by 
24 months (94% follow-up at 24 months).  Characteristics of MDRS subjects 
classified by HIV status are shown in Table 8.15.  HIV positive subjects were younger 
and demonstrated lower BMI, shorter duration of diabetes, lower sBP and dBP, 
lower LDL and HDL, higher triglycerides and higher serum creatinine  than HIV 
negative subjects.  A higher proportion of HIV positive subjects had raised uACR. 
 
34 subjects (68%) were prescribed antiretroviral therapy (ART) at baseline.  One 
further subject commenced ART during the study. Of 41 HIV positive subjects who 
underwent annual CD4 testing 32 (78%), 25 (61%) and 14 (34%) subjects had a CD4 
count below 500, 350 and 200 cells/mm3 at any visit, respectively. The mean CD4 
count was 389 cells/mm3 (SD 242).  At 24 months 2 step (or greater) progression 
was observed in 2/38 HIV positive subjects (5.3%) compared to 55/251 (21.9%) HIV 
negative subjects (p<0.015 Fisher’s exact). 
 
Both subjects who progressed were female.  The first subject was diagnosed at 
baseline visit (WHO clinical stage 2).  By visit 2 she had commenced ART.  CD4 
counts were: 1106 visit 1; declined blood tests visit 2; 1188 visit 3.  Haemoglobin 
was above 12g/dl at each study visit. Retinopathy grading at baseline and visit 3 
were Level 20 DR, Level 0 maculopathy and Level 30 DR, Level 4 maculopathy, 
respectively.  The second subject was taking ART at enrolment.  CD4 counts were: 
197 visit 1; 258 visit 2; 202 visit 3. The subject was not anaemic at visits 1 and 2 but 
haemoglobin dropped to 11.8g/dl at visit 3.  Retinopathy grading at baseline and 
visit 3 were Level 50 DR, Level 4 maculopathy and Level 60 DR, Level 4 maculopathy, 
respectively.  The low numbers of subjects demonstrating progression of 
retinopathy precludes further analysis of the effects of ART and immune function 
(as measured by CD4 count) on progression.  
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Table 8.15 Demographic clinical and biochemical characteristics of 344 MDRS 
subjects with known HIV status.  Subjects classified by HIV status. 
Characteristic HIV positive HIV negative p value  
n 50 294 NA 
Female sex 24 (48%) 184 (63%) p=0.061 Fisher’s exact 
Age (yrs; median, IQR) 48.2 (41.2-56.0) 53.3 (44.0-61.4) p=0.015* Unp’ed t-test 
Type 1 diabetes  5 (10%) 29 (9.9%) p=0.99 Fisher’s exact 
BMI (kg/m2; mean, SD) ‡ 24.7 (5.0) 26.7 (5.6) p=0.018* Unp’ed t-test 
BMI >25kg/m2 ‡ 22 (44%) 173 (59%) p=0.064 Fisher’s exact 
Duration (median, IQR) ‡ 2.8 (0.8-5.3) 4.4 (2.2-8.3) p=0.002* Wilcoxon r.s. 
Mean sBP(mmHg;med,IQR) 121 (112-140) 137 (122-151) p=0.003* Unp’ed t-test 
Mean dBP(mmHg;med,IQR) 77 (70-83)  83 (74-88)  p=0.019* Unp’ed t-test 
Mean HbA1c (NGSP%;mean,SD) 8.0 (2.9) 7.8 (2.4) p=0.60 Unpaired t-test 
Mean Hb (g/dl; mean; SD) 13.5 (2.0) 13.7 (1.6) p=0.43 Unpaired t-test 
Anaemia (see text)‡ 11 (22%) 40 (13.6%)  p=0.13 Fisher’s exact 
Total chol. >5.0mmol/L‡ 13 (26%) 91 (31%) p=0.62 Fisher’s exact 
Total chol‡ (mmol/L;mean,SD) 4.02 (1.43) 4.35 (1.22) p=0.086 Unpaired t-test 
LDL chol.‡ (mmol/L; mean, SD)  2.06 (0.91) 2.50 (0.94) p=0.002* Unp’ed t-test 
HDL chol.‡ (mmol/L;mean,SD)  0.90 (0.33) 1.00 (0.33) p=0.048*  Unp’ed t-test 
Triglycerides‡(mmol/L;mean,SD) 2.18 (2.15) 1.43 (0.91) p=0.0001* Unp’d t-test 
Raised uACR‡ 
(M>2.5;F>3.5mg/mmol) 
25 (50%) 93 (31.6%)  p=0.015* Fisher’s exact 
Serum creatinine‡ 
(µmol/L;mean,SD) 
82.8 (91.7) 63.1 (28.4) p=0.003* Un-p’ed t-test  
Raised creatinine 
(M>110;F>90μmol/l) 
7 (14%) 19 (6.5%) p=0.079 Fisher’s exact 
‡ Measurement at baseline 
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8.4.10 Vision  
Visual acuity measurements for 295 subjects seen at baseline and 24 months are 
shown in Table 8.16. According to WHO definitions [19] the number of subjects at 
baseline and 24 months with ‘normal vision’ (equal to or better than 60 letters) was 
287 (97.3%, 95.5-99.2) and 289 (98.0%, 96.4-99.6), respectively.  The number with 
‘moderate visual impairment’ (50 to 59 letters) was 4 (1.4, 0.1-2.7) and 5 (1.7%, 0.2-
3.2), respectively.  The number of ‘severely visually impaired or blind’ (<50 letters) 
subjects was 4 (1.4, 0.1-2.7) and 1 (0.3%, 0-0.9), respectively.  At visit 3 the most 
common primary causes of visual impairment for subjects with corrected visual 
acuity worse than 80 letters (equivalent to 6/12 Snellen or worse) (n=118) were DR 
(38.1%),  cataract (22.9%), and both DR and cataract (12.7%)(Table 8.17).  Therefore 
in 50.8% of cases DR was the sole or equal contributing cause of visual loss. 
 
Table 8.16 Prevalence with 95% CI of corrected ETDRS visual acuities according to 
better eye in 295 subjects in the MDRS seen at baseline and 24 months. 
Approximate Snellen acuities in parentheses. 
 
Visual acuity  
(ETDRS letters) 
Visit 1  
(baseline) 
Visit 3  
(24 months) 
 n % (95% CI) n % (95% CI) 
≥ 90  (6/5) 82 27.8 (22.7-32.9) 34 11.5 (7.9-15.1) 
80 - 89 (6/7.5) 142 48.1 (42.4-53.8) 143 48.5 (42.8-54.2) 
70 -79 (6/12) 54 18.3 (13.9-22.7) 78 26.4 (21.4-31.4) 
60 - 69 (6/18) 9 3.1 (1.1-5.1) 34 11.5 (7.9-15.1) 
50 - 59 (6/30) 4 1.4 (0.1-2.7) 5 1.7 (0.2-3.2) 
40 - 49 (6/75) 2 0.7 (0-1.7) 0  
Hand Movements 1 0.3 (0-0.9) 0  
Light Perception 1 0.3 (0-0.9) 0  
No light perception 0  1 0.3 (0-0.9) 
No data 0  0  
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Table 8.17 Primary causes of visual impairment (VI) in the opinion of the examining 
clinician at visit 3 for MDRS subjects with corrected visual acuity worse than 80 
letters.  Subjects classified according to level of visual impairment (n=118).  
Approximate Snellen equivalents: 70-79 letters = 6/12; 60-69 = 6/18; 50-59 = 6/24 
‘Moderate visual impairment’; <50 letters = 6/36 or worse ‘Severely visually 
impaired or blind’. AMD = age related macular degeneration; CRVO = central retinal 
vein occlusion; ERM = epiretinal membrane; PCO = posterior capsule opacification. 
 
Primary 
cause of VI 
Level of visual impairment (ETDRS letters) Total 
70-79 60-69  50-59 <50 
n 78 34 5 1 118 
DR  29 14 2 0 45 (38.1%) 
DR and 
cataract 
11 3 1 0 15 (12.7%) 
Cataract 18 9 0 0 27 (22.9%) 
AMD 3 0 0 0 3 (2.5%) 
Glaucoma 0 1 0 0 1 (0.8%) 
Other 17* 7‡ 2† 1Ƚ 27 (22.9%) 
 
* 13 no cause identified; 1 Optic neuropathy; 1 cataract and CRVO; 1 dry eye; 1 ERM  
‡ 4 no cause identified; 1 ERM; 1 PCO and complicated cat surgery; 1 central foveal scarring 
†1 posterior uveitis (possibly syphilitic); 1 myopic degeneration and cataract 
Ƚ 1 inherited retinopathy 
 
Of 295 subjects seen at baseline and 24 months 127 (43.0%) lost 5 or more ETDRS 
letters over the course of the study of which 17 subjects (5.8%) lost 15 or more 
letters.  The most common primary causes of visual loss for the 127 subjects who 
lost five or more letters were DR (38.6%) cataract (16.5%), and both DR and cataract 
(3.9%)(Table 8.18).  Therefore in 42.5% of cases DR was the sole or equal 
contributing cause of visual loss.  In univariate analysis loss of 15 or more ETDRS 
letters was not significantly associated with presence of STDR at visit 3 (OR1.56, 
0.56-4.33, p=0.390), age (OR 0.97, 0.94-1.01, p=0.110), baseline grade of DR (OR 
1.28, 0.97-1.69, p=0.084) or duration of diabetes (OR 1.01, 0.94-1.09, p=0.725). 
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At baseline 8 subjects (2.2%; 95% CI 0.7 - 3.8) had ‘moderate visual impairment’ (50 
to 59 letters; equivalent to 6/24 Snellen), and 5 subjects (1.4%; 95% CI 0.2-2.6) were 
‘severely visually impaired or blind’ (<50 letters; equivalent to 6/36 or worse).  By 
12 months an additional 3 subjects progressed to moderate visual impairment 
(having had normal vision at baseline) and 5 became ‘severely visually impaired or 
blind’ (3 had normal vision and 2 had moderate visual impairment at baseline).  
Between visit 2 and visit 3 no further subjects developed moderate or severe visual 
impairment.  The cumulative incidence at 24 months of developing ‘moderate VI’ or 
‘severe VI or blindness’ for subjects without these conditions at baseline and with at 
least 1 follow-up visit was 0.9% (0-2.0) and 1.5% (0.2-2.8), respectively (Life table 
method; n=322). 
 
Table 8.18 Primary causes of visual loss in the opinion of the examining clinician for 
127 subjects with loss of 5 or more letters between MDRS visits 1 and 3.  Subjects 
classified according to number of letters lost.  
 
Primary cause of 
visual loss 
Number of letters lost 
5-14 letters ≥ 15 letters  Total  
n 110 17 127 
DR  42 7 49 (38.6%) 
DR and cataract 5 0  5 (3.9%) 
Cataract 20 1 21 (16.5%) 
AMD 2 0 2 (1.6%) 
Glaucoma 2 0 2 (1.6%) 
Other 39≠ 9‡ 37.8 (%) 
 
≠ 1 PCO +complicated cat surgery; 1 PCO; 1 cataract and CRVO; 1 dry eye; 1 ERM; 34 no cause 
identified 
‡ 1 inherited retinopathy; 1 dry eye; 1 ERM; 1 central foveal scarring; 5 no cause identified 
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8.5 Discussion  
 
8.5.1 Headlines 
This study provides critical baseline information on progression of retinopathy and 
visual impairment in patents attending mixed urban and rural diabetes clinics in 
Southern Malawi.  Over 24 months progression to STDR from ‘no retinopathy’ and 
‘background DR’ was approximately 4 times and 3 times that reported in recent 
European studies, respectively.  Higher glycosylated haemoglobin and higher 
baseline grade of DR were risk factors for progression of retinopathy.  The negative 
association of HIV infection with DR progression is a novel finding.  Our results 
highlight the urgent need for provision of services for retinopathy detection and 
management to avoid a large burden of vision loss. 
 
8.5.2 Principal findings 
This chapter details progression of grades of retinopathy and visual impairment 
over 24 months in a treated cohort of people with diabetes from Southern Malawi.  
In 295 subjects (83% of the original 357 subject cohort) prevalence of any 
retinopathy, STDR and PDR increased from 52.2% (95% CI 46.5-57.9) to 62.7% (57.2-
68.2), 29.8% (24.6-35.0) to 33.6% (28.2-39.0) and from 5.4 (2.8-8.0) to 7.5 (4.5-
10.5), respectively.  Cumulative incidence at 24 months of any DR in those without 
evidence of retinopathy at baseline was 38.0% (30.2-45.8).  The cumulative 
incidence at 24 months of STDR for those with level 10, level 20 and level 30 
retinopathy at baseline was 2.7% (0.1-5.3), 27.3% (16.4-38.2) and 25.0% (0-67.4), 
respectively.  The cumulative incidence at 24 months of PDR for those with level 10, 
level 20, level 30 and level 40 retinopathy at baseline was 0, 0, 9% and 37%, 
respectively.  Higher glycosylated haemoglobin (HbA1c), higher baseline grade of DR 
and HIV negative status were risk factors for progression of retinopathy in 
multivariate analysis.  Over the follow-up period 127 subjects (43.0%) lost 5 or more 
ETDRS letters of which 17 subjects (5.8%) lost 15 or more letters.  In 42.5% of cases 
DR was the sole or equal contributing cause of visual loss.  The cumulative incidence 
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at 24 months of developing ‘moderate VI’ or ‘severe VI or blindness’ was 0.9% (0-
2.0) and 1.5% (0.2-2.8), respectively. 
 
8.5.3 Strengths and weaknesses of this work 
The MDRS represents the first prospective cohort study of DR from Sub-Saharan 
Africa.  Strengths of the work include a robust procedure for systematic random 
sampling of subjects, external validation of retinopathy grading at an accredited 
reading centre and a comprehensive assessment of systemic parameters including 
HbA1c, urine ACR and haemoglobin level.  Subject follow-up in this region is 
extremely challenging.  The 90.5% follow-up rate is a considerable achievement.  
The population studied is differentiated from the majority of published studies by 
location, ethnic makeup and by a high prevalence of infective disease (malaria and 
HIV) and anaemia.  Unlike the majority of previous cross sectional studies from 
Africa the MDRS provides data on the number of persons requiring laser treatment 
(new prevalent cases). 
 
The MDRS was a clinic-based study.  Conclusions drawn from this work should be 
generalised with caution.  A large population-based study was beyond the scope 
(and budget) of this PhD fellowship.  Many barriers to clinic attendance exist 
including transportation costs, competing economic tasks (planting and harvesting 
staple crops), caring for family members and ignorance regarding health, disease 
and availability of services. Patients who do not attend clinics may be less likely to 
be diagnosed with diabetes or to comply with therapy.  Conversely those with 
established complications may be more likely to attend clinics and participate in 
research studies.  As explored in Chapter 6, Section 6.4.4, the MDRS included few 
subjects with diet controlled diabetes.  While some patients travel long distances to 
attend clinics, rural subjects are likely to be underrepresented in our study and form 
a selected sub-group of the rural diabetes population. One study from Ethiopia 
suggested a higher prevalence of DR in urban subjects [329] but there are multiple 
potential confounders to this finding.   
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Duration of diabetes is a risk factor for DR progression in all major cohort studies 
[9,83,84,96].  Annual incidence of progression increases with duration of follow-up.  
For example, in the LDES, for subjects with no retinopathy at baseline, incidence of 
STDR was 0.3% (0.1-0.5) in the first year rising to 1.8% (1.2-2.5) in the fifth year [9].  
In comparison with other cohort studies of diabetic retinopathy, 24 month follow-
up is relatively short.  Longer follow-up was not possible within this PhD fellowship.  
However, the assumptions made in the study sample size calculations have been 
borne out in practice.  I estimated a rate of 2 step progression of 20% over 2 years; 
21.4% was recorded.  I aimed for a sample size of 300 subjects; 322 were seen for a 
least 1 further study visit; 295 were seen at 2 years. Therefore despite limitations, I 
believe the size, quality and novel nature of this study and the degree of confidence 
around the findings render them informative from both an epidemiological and a 
policy point of view. 
 
 
8.5.4 Analysis of bias 
The high follow-up achieved in the MDRS notwithstanding it is important to assess 
to what extent the subjects seen at visit 3 are representative of the whole cohort.  
28 subjects (7.8%) were confirmed dead and it is likely that some of the 14 (3.9%) 
untraced subjects also died.  Differences between the ‘seen’ and ‘not seen’ groups 
may be predictors of mortality in this population.  Regarding baseline demographic 
and clinical parameters, subjects not seen at visit 3 were older than those who were 
traced and assessed.  Higher mean fasting blood sugar, higher serum creatinine and 
a higher proportion of subjects with raised serum creatinine, raised urine ACR and 
PDR in the group who were not seen at visit 3 suggests a higher baseline prevalence 
of microvascular complications of diabetes.  Lower mean haemoglobin, mean total 
cholesterol and mean LDL cholesterol and higher prevalence of anaemia in the ‘not 
seen’ group may reflect poor general health and/or suboptimal nutrition. The ‘not 
seen’ group demonstrated worse visual acuities.  Poor vision may be a risk factor for 
mortality either as a marker of microvascular damage in diabetes or as a marker of 
age.   Alternatively poor vision may directly affect an individual’s ability to survive in 
Southern Malawi.  
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8.5.5 Comparison with African studies 
Few cohort studies are available for comparison from the African continent.  
Chapter 4, Section 4.4.4 details the only published studies which are summarised in 
Table 4.4.  These studies report incidence and progression of DR at 5 years and 
more.  They are therefore discussed in relation to MDRS 5 year data in Chapter 9, 
Section 9.5.4. 
 
8.5.6 Comparison with studies in Europe and North America 
High quality prospective cohort studies of DR are available from Europe and North 
America.  Table 8.19 summarises selected studies reporting incidence and 
progression of DR at 1 and 2 years.  The first major, high quality, cohort study of DR, 
the Wisconsin Epidemiological study of Diabetic Retinopathy (WESDR), was 
performed in the 1980s.  Subjects in this study were not assessed annually.  The first 
incidence and progression data were reported at 4 years [83,84].  The WESDR is 
therefore discussed in relation to MDRS 5 year data in Chapter 9, Section 9.5.5. 
 
Younis et al reported data from 4770 persons with type 2 diabetes [9] and 501 with 
type 1 diabetes [96] registered with general practices in one English city who had 
two or more screening events as part of the prospective Liverpool Diabetic Eye 
Study (LDES).  Cumulative incidence of any DR at 2 years in those with no 
retinopathy (Level 10) at baseline was 14.2% (9.9-18.5) in type 1 diabetes and 10.9% 
(9.8-11.8) in type 2 diabetes compared to 38.0% (30.2-45.8) in the MDRS.  The 2 
year cumulative incidence of STDR for those with level 10 and level 20 retinopathy 
at baseline was 0.8 (0-1.8) , 8.4 (3.6-13.1) in type 1 diabetes and  0.8 (0.5-1.1) and 
11.2 (8.9-13.5) in type 2 diabetes, respectively.  The corresponding figures in the 
MDRS were higher: 2.7 (0.1-5.3) and 27.3 (16.4-38.2), respectively.  Unlike the 
MDRS, longer duration of diabetes was associated with progression to STDR in 
multivariate analysis.   
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Data on 20,686 persons with type 2 diabetes seen between 1990 and 2006 as part 
of the English National Screening Program in the county of Norfolk was collected 
retrospectively and reported by Jones et al [327].  Among subjects without 
retinopathy at baseline, cumulative incidence at 2 years of background retinopathy 
(equivalent to LDES level 20) was 12.2% (11.6-12.8), pre-proliferative retinopathy 
(equivalent to level 40) 0.8% (0.7-1.0) and sight threatening maculopathy 0.11% 
(0.06-0.19).  Among those with background retinopathy at baseline, after 2 years 
6.4% (5.4-7.6) developed pre-proliferative retinopathy and 1.27% (0.85-1.89) 
developed sight threatening maculopathy.  Again corresponding figures in the 
MDRS are higher. 
 
Thomas et al [326] reported retrospective data from persons with type 2 diabetes 
attending annual screening in Wales with no retinopathy at first screening event.  
Cumulative incidence of any DR and referable DR (equivalent to LDES level 40, or 
exudate or thickening within 1 disc diameter (DD) of the centre of the fovea, or 
circinate or group of exudates within the macula, or any microaneurysm or 
haemorrhage within 1DD of the centre of the fovea only if associated with a best VA 
of ≤ 6/12. i.e. roughly equivalent to STDR as defined in the present study) at 2 years 
was 21.7% (21.2-22.0) and 0.5% (0.4-0.5), respectively.  The above studies are not 
population-based; a proportion of subjects with diabetes remain undiagnosed in the 
community.  The majority of persons attending DR screening programmes attend a 
primary care diabetes service.  Studies of DR screening programmes therefore 
represent a good comparison for the MDRS which sampled subjects attending 
clinics predominantly for primary diabetes care. 
 
Few cohort studies are available from the Asian continent.  Lin et al [330] 
retrospectively collected data on 63,582 subjects with type 2 diabetes from a 
database of a universal compulsory National Health Insurance program in Taiwan.  
Subjects attending 3 or more hospital outpatient appointments associated with 
diabetes were included.  Prevalence of ‘STDR’ (defined as listing for scatter laser 
treatment, macular laser treatment or pars plana vitrectomy for PDR) was 2.75% for 
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women and 2.87% for men.  Annual incidence ranged between 0.6-1.1% for women 
and 1.5-2.2% for men. 
 
In summary, compared to recent European studies 2 year incidence of any 
retinopathy in the MDRS was higher: 38.0% (30.2-45.8) vs estimates between 3.6% 
[333] and 21.7% [336].  In the MDRS, 2 year progression to STDR from no DR (level 
10) was approximately 3 times that reported in recent European studies of 
screening programmes: 2.7% (0.1-5.3) vs estimates between 0.5% [336] and 0.8% 
[9,96,331].  Progression to STDR at 2 years from background DR (level 20) was 
approximately 2.5 times higher: 27.3 % (16.4-38.2) vs estimates between 6.4 [331] 
and 11.2 [9].  Differences between figures from the MDRS and recent European 
work are likely to reflect multiple disparities between populations including 
ethnicity, access to health services and presence of comorbidities including poorly 
controlled hypertension and infective disease.  
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Table 8.19 Summary table of selected studies reporting incidence and progression of DR at 1 and 2 years. 
{} Subgroup or baseline LDES retinopathy grade: L10 = level 10, L20 = level 20 etc. †95% confidence interval in parentheses.  * Incidence of Level 40 retinopathy only (sight 
threatening maculopathy data not included).  MDRS = Malawi diabetic retinopathy study; LDES = Liverpool diabetic eye study; DR Diabetic retinopathy; STDR = Sight 
threatening diabetic retinopathy; PDR = Proliferative diabetic retinopathy. 
Study Sweden [332] Norfolk [331] LDES [96] LDES [9] UK [333] Wales [336] MDRS 
Dates 1986-1996 1990-2006 1991-1999 1991-99 2000-2008 2005-2009 2012-2014 
Type of study Hospital 
clinic-based 
cohort 
Retrospective 
analysis of 
screening prog. 
Prospective study of DR 
screening programme 
Retrospective analysis of 
primary care attendees 
from diagnosis of diabetes 
Retrospective 
analysis of DR 
screening prog. 
Primary care 
based cohort 
Type of diabetes Type 1  Type 2  Type 1  Type 2  Type 1  Type 2  Type 2  Type 1 & 2 
n 452 20,686 501 20,570 1,757 63,226 49,763 357 
Cumulative 
Incidence of any 
DR (%) † 
1 yr 6 1.6 7.8 
(4.7–10.9) 
5·3 
(4·6–6·0) 
2.0 
(1.4-2.8) 
3.8 
(3.7-4.0) 
12.5 
(12.1-12.8) 
10.8 
(6.1-15.5) 
2 yrs 15 13.1 14.2 
(9.9–18.5) 
10·9 
(9·8–11·8) 
3.6 
(2.8-4.6) 
6.4 
(6.2-6.6) 
21.7 
(21.2-22.0) 
38.0 
(30.2-45.8) 
Cumulative 
Incidence of 
STDR (%) 
1 yr 9 0.1 {L10}* 
1.1 {L20}* 
0.3 {L10} 
3.6 {L20} 
13.5 {L30} 
0·3 {L10} 
5.0 {L20} 
15.0 {L30} 
  0.2 {L10} 0 {L10} 
13.2{L20} 
0 {L30} 
2 yrs 15 0.8 {L10}* 
6.4 {L20}* 
0.8  {L10} 
8.4 {L20} 
33.3 {L30} 
0·8 {L10} 
11.2 {L20} 
27.8 {L30} 
  0.5 {L10} 2.7 {L10} 
27.3 {L20} 
25.0 {L30} 
Cumulative 
Incidence of 
PDR (%) 
1 yr  0.01 {L10} 
0.27 {L20} 
    0 {L10} 0 {L10} 
 0 {L20} 
0 {L30} 
16 {L40} 
2 yrs  0.13 {L10} 
1.58 {L20} 
    0.02 {L10} 0 {L10} 
0 {L20} 
9.1 {L30}  
37{L40} 
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8.5.7 Associations of DR progression  
The MDRS has demonstrated an association between glycaemic control and DR 
progression.  This association has been shown previously in large, high-quality 
studies in European and North American populations [12,13,97].  An association 
between baseline grade of DR and progression was shown in the MDRS which has 
also been shown previously [9,83,84,96].  The WESDR also showed an association 
between baseline grade of DR and visual loss [85] but this is likely to be less relevant 
in the 2010s since the introduction of anti-VEGF therapy.  Consistent associations 
between DR progression and blood pressure [14,157,315,316] as well blood lipid 
levels [15] have been shown in European and North American studies.  The MDRS 
showed no evidence for these associations in a Southern Malawian population.  
However, my analysis does not rule out effects of these variables.  In the MDRS 
mean urine ACR was associated with progression of DR in univariate but not 
multivariate analysis.  Interestingly, in contrast to retinopathy, there was no 
evidence of an overall decline in renal function over 24 months (Section 8.4.4 
above).  Subjects with worsening renal function may have been lost to follow-up or 
died.  The contrasting patterns seen with retinopathy and nephropathy may reflect 
that advanced nephropathy is more immediately fatal than retinopathy. 
 
This study has demonstrated a negative association between DR progression and 
HIV infection, a novel finding.  An important potential confounder of this 
relationship is early diagnosis of diabetes in HIV positive subjects.  Patients 
attending medical facilities for ART treatment may be more likely to be tested for 
diabetes than the general population.  While the logistic regression analysis 
presented above controls for known duration of diabetes the duration of diabetes 
before diagnosis is not known.  Both HIV infection and anti-retroviral therapies are 
associated with a vasculopathy which manifests as increased cardiovascular and 
cerebrovascular risk [326,327].  Low grade proteinuria is highly prevalent in HIV 
positive patients taking ART and is more common in persons with concomitant 
diabetes [334].  A previous cross-sectional study of diabetes complications in 
Blantyre [1] showed a higher prevalence of proteinuria in subjects with diabetes 
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and HIV compared to those with diabetes alone.  My data does not support an 
increased risk of all diabetic microvascular complications in HIV.  
 
8.5.8 Vision   
To my knowledge no studies from Africa have reported longitudinal visual acuity 
(VA) data in subjects with diabetes.  Specifically the Mauritius DR cohort study [215] 
reported VA at baseline but not in the follow-up assessment.  Incidence of visual 
impairment (VI) was reported for persons with type 1 diabetes in the WESDR [85].  
During the first 4 years of follow-up the annual incidence of VI (defined as best-
corrected VA in the better eye of 6/12 or worse) and severe visual impairment (6/60 
or worse) was 0.4% and 1.2%, respectively.  Hall et al [335] studied blind 
registrations attributed to DR in Scotland.  These authors estimated that the annual 
incidence of blindness (defined as visual acuity in the better eye below 3/60) in the 
population with diabetes was 0.04%.  In the MDRS the cumulative incidence at 24 
months of developing ‘moderate VI’ (50 to 59 letters; equivalent to 6/24 Snellen) or 
‘severe VI or blindness’ (<50 letters; equivalent to 6/36 or worse) was 0.9% (0-2.0) 
and 1.5% (0.2-2.8), respectively.  While the MDRS was an observational cohort 
study, subjects could take up a variety of medical interventions which could 
improve VA most notably laser photocoagulation for DR and cataract surgery.  It is 
likely that a greater degree of visual loss would have been recorded without these 
interventions. 
 
8.6 Chapter summary  
This chapter provides an estimate of incidence and progression of grades of 
retinopathy over 24 months in a treated cohort of persons with diabetes in 
Southern Malawi.  In this cohort 2 year progression to STDR from ‘no DR’ and 
‘background DR’ was approximately 4 times and 3 times that reported in recent 
European studies, respectively.  Higher glycosylated haemoglobin and higher 
baseline grade of DR were risk factors for progression of retinopathy.  The negative 
association of HIV infection with DR progression is a novel finding.  When indicated, 
MDRS subjects had access to laser treatment for DR, a factor likely to have 
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mitigated DR progression and visual loss in this cohort.  Progression of retinopathy 
and visual loss in an untreated cohort of subjects with diabetes is considered in 
Chapter 9. 
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Chapter 9. Progression of diabetic retinopathy at 5 years 
 
 
9.1 Background to the study of retiniopathy progression at 5 years 
A cross sectional study of complications of diabetes was conducted at the Queen 
Elizabeth Central Hospital (QECH) diabetes clinic in 2007 [1].  Of 620 subjects 
included in the study 281 were examined for retinopathy by an ophthalmologist.  
The results of this sub-study have been published [2] and are referred to in Chapter 
4, Section 4.4.5 and Chapter 5, Section 5.10.1.  At this time laser treatment was not 
available in the public sector in Blantyre.  A laser was donated to Lions First Sight 
Eye Unit in 2010 by the World Diabetes Foundation, however, few persons were 
treated in 2010 or 2011.  Our group were aware that recall of the 2007 subjects 
would be an extremely valuable opportunity to assess progression of retinopathy 
and visual loss over 5 years in a population not exposed to laser treatment.   
 
9.2 Chapter aims  
In this part of the Malawi Diabetic Retinopathy Study (MDRS) I aimed to trace as 
many of the 2007 subjects as possible, document grades of diabetic retinopathy 
(DR) and thereby assess progression of retinopathy over 5 years, report associations 
of progression with systemic parameters and document visual loss and causes of 
visual loss in an untreated cohort. 
 
9.3 Methods  
9.3.1 Study setting  
The diabetes clinic at QECH is described in Chapter 5 ‘Methods’.  In the period 2007 
to 2012 the clinic has undergone a number of changes.  The number of registered 
patients has increased from approximately 800 to 2000.  A vibrant nurse-led patient 
education programme supported by the World Diabetes Foundation commenced in 
2008.  Its aims are improving compliance with diet and medications and educating 
patients on the complications of diabetes.  An electronic records system (Diabetes 
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and Hypertension System, Baobab Health Trust, Malawi) was installed in early 2010.  
This runs in parallel to the ‘Health passport’ system described in Chapter 5.   
 
In 2007 medications regularly available free of charge were glibenclamide and 
insulin (lente and soluble). Metformin was available from private pharmacies but 
rarely from the hospital pharmacy.  By 2011 metformin was more frequently 
available free of charge.  However, supplies of all drugs remain intermittent.  Tests 
available at the clinic were the same in 2007 as 2012.  Glycaemic control is 
measured by fasting blood sugar on the day of clinic and BP, height and weight are 
measured by nursing staff.  Measurement of lipids, glycosylated haemoglobin and 
urine test sticks for microalbuminuria are not available routinely.  
 
9.3.2 Subjects 
Consecutive patients attending for routine out-patient review between March and 
June 2007 were invited to participate in the original cross sectional study of 
complications of diabetes.  Of 620 subjects included in the study 281 were 
examined for retinopathy by an ophthalmologist.  Sampling was ad hoc: subjects 
had slit lamp examination if the ophthalmologist was present at the particular clinic 
at which they were recruited.   
 
9.3.3 Tracing of subjects from the 2007 cohort 
The 2007 study was not planned as a cohort study.  Subject names and date of birth 
were recorded and a sticker placed in their ‘health passport’.  No contact details 
were recorded.  The population of Blantyre is extremely fluid.  Migration levels 
between rural and urban environments and between towns are known to be high.  
It is common for people who become disabled (e.g. as a result of a stroke) to 
relocate to be cared for by family members.  There exists no mechanism for tracing 
subjects who fail to attend a clinic appointment.  Although no formal study has 
assessed mortality rate in the QECH diabetes clinic population it is believed to be 
high.  Many persons die at home and there is no formal system for registering 
deaths.  Subject tracing was therefore expected to be extremely difficult. 
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Tracing of subjects was systematic.  All subjects recruited to MDRS main cohort 
were asked about participation in the 2007 study and their health passports 
checked for the study sticker.  The QECH diabetes clinic electronic patient record 
system was searched by subject name by the MDRS study team.  Identified persons 
were then contacted by phone.  The MDRS study team attended the diabetes clinic 
weekly between May and November 2012 to approach patients in the clinic waiting 
room.  Finally the President and Vice President of the patient’s organisation the 
Malawi Diabetes Association reviewed the list of subjects from 2007 in order to 
personally identify subject whereabouts.  Written informed consent was obtained 
from all subjects prior to enrolment. 
 
 9.3.4 Confirmation of subject death 
Confirmation of subject death was performed in a systematic manner and is 
described in Chapter 5, Section 5.10.5.  The relatives of subjects reported to be 
deceased were visited at home by the study research nurse between May and 
November 2012.  The nurse was trained to record, on a standard form, brief written 
narratives from families or other reliable informants.  If available the death 
certificate and the health passport were reviewed and cause of death and/or brief 
details of last illness recorded.  A subject was recorded as dead if confirmed by a 
relative or ‘Traditional authority’ (village leader in rural districts), or if a death 
certificate or marked grave was seen by the study nurse.   I assigned a probable 
cause of death after reading the form.  
 
9.3.5 Clinical assessment 
In the 2007 study a self-reported questionnaire was completed with the assistance 
of a research assistant and with reference to the subject’s ‘health passport’.  Data 
was collected on demographic details, diet, past medical history and medications.  
Diabetes with young age at onset and early use of insulin was deemed to be type 1 
with all others as type 2. Subjects with type 2 diabetes were sub-classified based on 
treatment: insulin-requiring with or without oral hypoglycaemic agents, oral 
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hypoglycaemic agents alone or dietary measures alone.  For the purposes of the 
analysis below the 2007 classification of type 1 and type 2 diabetes was retained i.e. 
subjects were not reclassified in 2012.  
 
A physical examination by a trained clinician included BP, body mass index (BMI) 
and neurovascular assessment (abridged four point monofilament examination with 
a 10 g monofilament [312].  Visual acuity (VA) (corrected with pin-hole) was 
measured using a Snellen chart. Fasting blood sugar (FBS), glycosylated 
haemoglobin (HbA1c) and HIV status were tested.  A subgroup of subjects were also 
tested for microalbuminuria and serum creatinine.  In 2012 all subjects were 
assessed in the same manner as subjects of the main MDRS cohort.  Clinical 
assessment is described in Chapter 5 ‘Methods’.  Subjects were classified as 
hypertensive according to the WHO Steps survey definition [17]: subject either 
taking antihypertensive medication, or systolic blood pressure (sBP) ≥140mmHg, or 
diastolic blood pressure (dBP) ≥ 90mmHg.  Thresholds for anaemia were set 
according to WHO guidelines: 13.0g/dL for men; 12.0g/dL for women [307]. 
 
9.3.6 Assessment of retinopathy 
In 2007 slit lamp biomicroscopy retinopathy grading with 90 and 60 D lenses was 
performed by one experienced ophthalmologist (Mr. Simon Glover) [2].  Pupils were 
dilated with 1% tropicamide +/- 10% phenylephrine.  In 2012 all subjects were 
assessed in the same manner as subjects of the main MDRS cohort.  Assessment of 
retinopathy is described in Chapter 5 ‘Methods’.  In both 2007 and 2012 
retinopathy and maculopathy were classified by feature specific grading using 
definitions established in the Liverpool Diabetic Eye Study (LDES)[94] (Chapter 5, 
Table 5.1).  The 2012 grading procedure was more robust: dual grading with 
arbitration of digital fundus photography of four 45° standard fields [94] performed 
by accredited graders at a recognised reading centre (considered a reference 
standard for DR grading).  In contrast 2007 grading was clinical (performed at the 
slit lamp) with no external validation procedure. 
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9.3.7 Statistical analysis 
The 2007 study was not planned as a cohort study.  Therefore no relevant power 
calculation was performed.  As in the main cohort study grades of DR were 
calculated by patient according to the worse or only gradable eye.  Visual acuity 
data were investigated by patient according to the better eye. 95% confidence 
intervals (CIs) were calculated for proportions.  Demographic and clinical 
differences were assessed at baseline with the unpaired t-test, Wilcoxon rank sum 
test, Fisher’s exact test or Χ2 test for trend.  All tests were two-sided and data were 
considered significant when p<0.05.  All Calculations were performed using STATA 
version 12 (StataCorp, Texas, USA). 
 
I constructed a logistic regression model (backwards stepwise with probability of 
removal of 0.2) to determine the odds ratio (OR) and 95% CIs for the primary end 
point (5 years): progression of DR by 2 steps on the Liverpool Diabetic Eye Study 
(LDES) scale.  Where possible the baseline or mean measurement (mean of 
measurements at 2007 and 2012 visits) was used for each variable in the analysis.  
For those variables only measured at the 2012 visit this value was used.  An initial 
11 variables were studied: mean HbA1c, duration of diabetes, baseline grade of DR, 
type of diabetes, mean sBP, haemoglobin level (2012), urine albumin creatinine 
ratio (ACR)(2012), triglycerides (2012), HIV status, age and sex.  I constructed a 
second logistic regression model to determine the OR and 95% Cis for the 
secondary endpoint (5 years): progression to STDR using the same initial 
explanatory variables. 
 
9.4 Results 
9.4.1 Participants 
A total of 135 subjects were assessed (48.0% of the original 281 subject cohort) 
(Figure 9.1).  Of this group, 41 subjects were recruited to the MDRS cohort study 
(Chapter 6) between December 2011 and May 2012.  Additionally 94 subjects were 
traced and seen between July 2012 and January 2013.    15 were traced and 
confirmed as dead.  7 subjects were traced but declined assessment.  3 subjects had 
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moved away from Southern Malawi and were unable to return for assessment.  121 
subjects could not be traced. 
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Figure 9.1. Flow diagram for tracing of subjects from the 2007 QECH survey of 
diabetes complications. 
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9.4.2 Subjects confirmed deceased in 2012 
15 subjects from the original 2007 study were confirmed deceased by the MDRS 
study team in 2012. Baseline characteristics of these subjects are shown in Table 
9.1.  Baseline grades of retinopathy for these subjects are shown in Table 9.2.  No 
death certificates were available; for 5 subjects the health book was reviewed while 
for 10 subjects the cause of death was assigned based on verbal reports alone.  
Cause of death was recorded as: ketoacidosis 1 subject; sepsis 1; renal failure 
secondary to diabetes 1; hypoglycaemia 2; and unknown cause 10 subjects. 
 
Table 9.1 Baseline characteristics (2007) of 15 subjects with diabetes confirmed 
dead by the MDRS team in 2012 
Characteristic Level 
Female sex 9 (60%) 
Age (median, IQR) 60 yrs (56.5 – 61.5) 
Type 1 diabetes 0 
BMI (mean, SD) 25.4 kg/m2 (4.4) 
Overweight (BMI>25 kg/m2) 9 (60%) 
Duration of diabetes (median, IQR) 8.7 yrs (6.3 – 13.7) 
Hypertensive (see text) 11 (73%) 
sBP (median, IQR) 160 mmHg (120-171) 
dBP (median, IQR) 90 mmHg (65-100) 
Mean arterial pressure (median, IQR) 113 mmHg (83.3-123.6) 
HbA1c (NSGP) (mean, SD) 9.9% (2.3) 
Fasting blood sugar (mean, SD) 199.9 mg/dL (96.9) 
HIV reactive 1 (6.6%) 
Urine dipstick None 2; Trace 3; 1+ 3; 2+ 3; 3+ 2; 4+ 0 
Serum creatinine (mean, SD) 98.6 µmol/L (57.5) 
Raised serum creatinine 
(M>110;F>90 μmol/l) 
3 (20%) 
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Table 9.2 Baseline prevalence of grades of retinopathy (2007) for 15 subjects with 
diabetes confirmed dead by the MDRS team in 2012. 
Grade n (%) (95% CI) 
No retinopathy (level 10) 6 (40%) (15.2 – 64.8) 
Any retinopathy (level 20-71+) 9 (60%) (35.2 – 84.8) 
Level 20 retinopathy 3 (20%) (0 – 40.2) 
Level 30 retinopathy 3 (20%) (0 – 40.2) 
Level 40 retinopathy 2 (13%) (0 – 30.0) 
Level 50 retinopathy 0 
Proliferative or worse (≥ level 60) 1 (7%) (0 – 19.9) 
Ungradeable 0 
Sight threatening maculopathy 10 (67%) (43.2-90.8) 
STDR 10 (67%) (43.2-90.8) 
No data 0 
 
 
9.4.3 Analysis of bias 
Baseline demographic, clinical and biochemical characteristics of 281 subjects 
included in the 2007 study categorised by follow-up are shown in Table 9.3.  These 
comparisons are exploratory and p-values are not corrected for multiple 
comparisons.  There was no significant difference between subjects seen in 2012 
and those not seen in 2012 regarding mean BMI, dBP, HbA1c, FBS, serum creatinine 
or duration of diabetes or concerning grades of proteinuria on urine dipstick.  There 
was no significant difference between the proportions of subjects in each group 
who were overweight, hypertensive, HIV positive, of female sex or who had type 1 
diabetes.  There was evidence of a difference between the two groups regarding 
mean age, sBP and mean arterial pressure (MAP) and concerning the proportion of 
subjects with raised creatinine.   
 
Baseline prevalence of grades of retinopathy of 281 subjects included in the 2007 
study categorised by follow-up are shown in Table 9.4.  There was no significant 
difference between subjects seen in 2012 and those not seen in 2012 regarding 
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prevalence of any DR and proliferative DR (PDR).  There was evidence of a 
difference between the two groups with regard to STDR.  Table 9.5 shows baseline 
prevalence of corrected Snellen visual acuities according to better eye for 281 
subjects included in the 2007 study categorised by follow-up.  There was a 
significant difference between the two groups (p= 0.0001, Χ2 test for trend). 
 
Table 9.3 Baseline (2007) demographic, clinical and biochemical parameters of 281 
subjects included in the 2007 study categorised by follow-up:  traced and assessed 
in 2012 (n=135) or not seen in 2012 (n=146). MAP = mean arterial pressure.  
Characteristic Subjects not seen 
in 2012 
Subjects seen in 
2012 
p value 
n 146 135 NA 
Female sex 97 (66.4%) 93 (67.4%) p = 0.703 Fisher’s exact 
Age (yrs; med, IQR) 57.5 (48-65) 52.0 (45-58) p=0.0014* Unp’ed t-test 
Type 1 diabetes 14 (9.6%) 18 (13.3%) p = 0.352 Fisher’s exact 
BMI (kg/m2; mean, SD) 28.6 (5.8) 29.4 (5.9) p=0.2529 Unpaired t-test 
BMI >25 kg/m2 100 (68.5%) 102 (75.6%) p = 0.2319 Fisher’s exact 
Duration (yrs; med, IQR) 5.7 (1.8 - 9.8) 3.93 (2.2 – 7.8) p = 0.234 Wilcoxon r.s. 
Hypertensive (see text) 107 (73.3%) 94 (69.6%) p = 0.511 Fisher’s exact 
sBP (mmHg; med, IQR) 140 (120-160) 130 (120-150) p = 0.015* Unp’red t-test 
dBP (mmHg; med, IQR) 88 (70-92) 80 (70-90) p = 0.117 Unpaired t-test 
MAP (mmHg; med, IQR) 103.3 (90.0-113.3) 96.7 (89.3 – 108.2) p = 0.037* Unp’red t-test 
HbA1c (NGSP%;mean,SD) 9.3 (2.2) 9.4 (2.6) p = 0.727 Unpaired t-test 
FBS (mg/dL; mean, SD) 194.9 (94.3) 183.8 (88.0) p = 0.310 Unpaired t-test 
HIV positive 15 (10.2%) 15 (11.1%) p=0.849 Fisher’s exact 
Urine dipstick None 29; trace 42; 1+ 
25; 2+ 11; 3+ 6; 4+ 3 
None 43;trace 44;1+ 
29; 2+ 6; 3+ 5; 4+ 1 
p = 0.06 Χ2 test for trend 
Serum creatinine ‡  88.3 (31.7) 83.2 (21.7) p = 0.120 Un-p’red t-test 
Raised creatinine†  29 (19.9%) 15 (11.1%) p = 0.049* Fisher’s exact 
†Raised serum creatinine: men >110μmol/l; women >90μmol/l.  ‡ µmol/L; mean, SD 
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Table 9.4 Baseline (2007) prevalence of grades of retinopathy of 281 subjects 
included in the 2007 study categorised by follow-up:  traced and assessed in 2012 
(n=135) or not seen in 2012 (n=146). ST = sight threatening  
Grade 
(n; %; 95% CI) 
Subjects not seen in 
2012 
Subjects seen in 
2012 
p value  
(Fisher’s exact) 
n 146 135  
No DR (level 10) 94 (64.4; 56.6-72.2) 93 (68.9; 61.1-76.7) p = 0.450 
Any DR (level 20-71+) 48 (32.9; 25.3-40.5) 40 (29.6; 21.9-37.3) p = 0.607 
Level 20  14 (9.6; 4.8-14.4) 23 (17.0; 10.7 – 23.4)  
Level 30  15 (10.3; 5.4-15.2) 9 (6.7; 2.5 – 10.9)  
Level 40  7 (4.8; 1.3-8.3) 5 (3.7; 0.5-6.9)  
Level 50  1 (0.7; 0-2.0) 0  
Proliferative (≥level 60) 11 (7.5; 3.2-11.8) 3 (2.2; 0 – 4.7) p = 0.054 
Ungradable 4 (2.7; 0.1-5.3) 2 (1.5; 0 – 3.5)  
ST maculopathy 28 (19.2; 12.8-25.6) 12 (8.9; 4.1 – 13.7)  
STDR 35 (24.0; 17.1-30.9) 17 (12.6; 7.0-18.2) p = 0.021* 
No data 0 0  
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Table 9.5.  Baseline (2007) prevalence with 95% CI of corrected Snellen visual 
acuities according to better eye for 281 subjects included in the 2007 study 
categorised by follow-up:  traced and assessed in 2012 (n=135) or not seen in 2012 
(n=146).  
Visual acuity 146 subjects not seen in 
2012 
135 subjects seen in 
2012 
 n % (95% CI) n % (95% CI) 
6/5 8 5.5 (1.8-9.2) 8 5.9 (1.9-9.9) 
6/6 17 11.6 (6.4-16.9) 37 27.4 (19.9-34.9) 
6/9 41 28.1 (20.8-35.4) 50 37.0 (28.9-45.2) 
6/12 26 17.8 (11.6-24.0) 17 12.6 (7.0-18.2) 
6/18 20 13.7 (8.1-19.3) 15 11.1 (5.8-16.4) 
6/24 7 4.8 (1.3-8.3) 3 2.2 (0-4.7) 
6/36 6 4.1 (0.9-7.3) 0  
6/60 5 3.4 (0.5-6.4) 3 2.2 (0-4.7) 
Hand Movements 4 2.7 (0.1-5.4) 0  
Light Perception 4 2.7 (0.1-5.4) 0  
No light perception 2 1.4 (0-3.3) 0  
No data 6 4.1 (0.9-7.3) 2 1.5 (0-3.5) 
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9.4.4 Demographics and clinical and biochemical measurements of 
subjects seen in 2012 
Demographic, clinical and biochemical characteristics for 135 subjects seen in the 
2007 study and subsequently traced and assessed by the MDRS team in 2012 are 
shown in Table 9.6. 93 subjects (67.4%) were female. Median time to follow up was 
5.3 years (range 4.7 - 5.8 years).  18 subjects (13.3%) had type 1 diabetes. Of 117 
subjects with type 2 diabetes, at baseline (2007) 22 (18.8%) were prescribed insulin 
(with or without oral hypoglycaemics), 88 (75.2%) were managed with oral 
hypoglycaemics and 7 (6.0%) were managed with diet alone. At the follow-up visit 
(2012) 40 (34.2%) were prescribed insulin, 70 (59.8%) were managed with oral 
hypoglycaemics and 7 (6.0%) were managed with diet alone.  In 2012 97 (71.9%) 
subjects were HIV non-reactive.  17 (12.6 %) were reactive: 13 taking ART; 3 known 
HIV+ but not taking ART; and 1 new diagnosis (WHO stage 3).  21 subjects (15.6%) 
declined testing. 2 subjects seroconverted during the follow-up period. 8 men (19.0 
%) and 18 women (19.4 %) were anaemic as defined above.  Of the whole cohort 89 
subjects were taking antihypertensive medications.  Additionally 9 had either sBP 
≥140mmHg or dBP ≥ 90mmHg. 
 
At baseline (2007) the following complications of diabetes were recorded in health 
passports or reported by subjects: stroke 2 subjects (1.5%), ischaemic heart disease 
0. On examination 7 subjects had foot ulcers but none had amputations; 27 (%) had 
objective sensory neuropathy on abridged four point monofilament examination.  
At the follow-up visit (2012) the following complications of diabetes were recorded 
in health passports or reported by subjects: stroke 8 (5.9 %); amputations 3 (2.2 %); 
erectile dysfunction 21 (50.0 % of men); and ischaemic heart disease 3 (2.2 %).  27 
(20.0 %) subjects reported an episode of malaria in the past 12 months; 6 (4.4%) 
and 3 (2.2%) reported ever having TB or syphilis, respectively.  2 subjects (1.5%) 
were current smokers.   
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Table 9.6 Demographic, clinical and biochemical measurements for 135 subjects 
seen in the 2007 study and subsequently traced and assessed by the MDRS team in 
2012. MAP = mean arterial pressure; FBS = Fasting blood sugar. 
Characteristic 2007 visit 2012 visit 
Age (years; median, IQR) 52.0 (45-58) 57.2 (48.3-64.1) 
BMI (kg/m2; mean, SD) 29.4 (5.9) 27.4 (5.6) 
Overweight (BMI>25 kg/m2) 102 (75.6%) 80 (59.3%) 
Duration of diabetes (yrs; med, IQR) 3.93 (2.2 – 7.8) 9.8 (8.2 – 13.6) 
Hypertensive (see text) 94 (69.6%) 98 (72.6%) 
sBP (mmHg; median, IQR) 130 (120-150) 142.5 (123-160) 
dBP (mmHg; median, IQR) 80 (70-90) 81 (73-91) 
MAP (mmHg; median, IQR) 96.7 (89.3 – 108.2) 103 (91-113.6) 
HbA1c (NGSP %) (mean, SD) 9.4 (2.6) 8.3 (2.3) 
FBS (mg/dL; mean, SD) 183.8 (88.0) 180.9 (90.1) 
HIV reactive 15 (11.1%) 17 (12.6%) 
Anaemia (WHO definition) NA 26 (19.3%) 8M; 18F 
Total cholesterol >5.0mmol/L NA 40 (29.6%) 
Total chol. (mmol/L; mean, SD) NA 4.43 (1.12) 
HDL cholesterol (mmol/L; mean, SD) NA 1.12 (0.42) 
LDL cholesterol (mmol/L; mean, SD) NA 2.73 (0.90) 
Triglycerides (mmol/L; mean, SD) NA 1.41 (0.79) 
Urine ACR (mg/mmol; mean; SD) NA 22.48 (66.19) 
Raised Urine ACR (n; %)‡ NA 53 (39.3%) 
Urine dipstick None 43; trace 44; 1+ 
29; 2+ 6; 3+ 5; 4+ 1 
NA 
Serum creatinine (µmol/L;mean,SD) 83.2 (21.7) 85.1 (142.2) 
Raised creatinine†  15 (11.1%) 16 (11.9%) 
†Raised serum creatinine: men >110μmol/l; women >90μmol/l 
‡ Raised urine ACR: men >2.5 mg/mmol; women >3.5mg/mmol 
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9.4.5 Prevalence of grades of retinopathy 
Prevalence of grades of retinopathy for 135 subjects seen in the 2007 study and 
subsequently traced and assessed by the MDRS team in 2012 are shown in Table 
9.7.  2 subjects had received a course of laser treatment between the 2007 study 
and 2012:  1 subject received bilateral scatter laser and bilateral macular grid laser; 
1 subject had received unilateral scatter laser.  
 
Table 9.7 Prevalence with 95% CI of retinopathy grades according to worse eye in 
135 persons with diabetes seen in the 2007 study and subsequently traced and 
assessed by the MDRS team in 2012. ST = sight threatening. 
 
Grade (n; %; 95% CI) 2007 2012 
No DR (level 10) 93 (68.9; 61.1-76.7) 49 (36.3; 28.2 – 44.4) 
Any DR (level 20-71+) 40 (29.6; 21.9-37.3) 85 (63.0; 54.8 – 71.1) 
Level 20  23 (17.0; 10.7 – 23.4) 41 (30.4; 22.6 – 38.1) 
Level 30  9 (6.7; 2.5 – 10.9) 18 (13.3; 7.6 – 19.1) 
Level 40  5 (3.7; 0.5-6.9) 16 (11.9; 6.4 – 17.3) 
Level 50  0 2 (1.5; 0 – 3.5) 
Proliferative (≥level 60+) 3 (2.2; 0 – 4.7) 8 (5.9; 1.9 – 9.9) 
Ungradable 2 (1.5; 0 – 3.5) 0 
ST maculopathy 12 (8.9; 4.1 – 13.7) 51 (37.8; 29.6 – 46.0) 
STDR 17 (12.6; 7.0-18.2) 52 (38.5; 30.3 – 46.7) 
No data 0 1 (0.7; 0 – 2.2) 
 
 
9.4.6 Progression of grades of retinopathy 
Of 135 subjects seen in 2012 two were classified as ‘ungradeable’ at baseline and 1 
subject declined retinal examination in 2012.  Therefore data for 2 visits was 
available for 132 subjects.  Five year incidences of development of grades of 
retinopathy for subjects with level 10 (no retinopathy), level 20, level 30 and level 
40 retinopathy at baseline are shown in Tables 9.8, 9.9, 9.10 and 9.11, respectively.  
Incidence of STDR (p=0.0001), ST maculopathy (p=0.0001) and PDR (p=0.0001) 
231 
 
increased with severity of baseline retinopathy (Χ2 test for trend).  Of 115 subjects 
without STDR at baseline (2007) 34 (29.6%; 21.3-37.9) had developed the condition 
at visit 2.  Of 120 subjects without ST maculopathy at baseline 37 (30.8%) developed 
the condition by visit 2.  Two (or more) step progression was observed in 48 
subjects (36.4%; 95% CI 28.2-44.6); three (or more) step progression in 30 subjects 
(22.7%; 15.6-29.9).  Figure 9.2 shows 5 year incidence of progression to sight 
threatening STDR, PDR and of 2 step and 3-step progression for subjects with level 
10, level 20 and level 30 retinopathy at baseline. 
 
Table 9.8 Five year incidence of development of all grades of DR, any DR, sight 
threatening maculopathy, STDR, 2-step progression and 3-step progression for 93 
persons with level 10 (no retinopathy) at baseline. n =number of subjects reaching 
endpoint. 
Grade progression Number entering 
time interval 
n Incidence %  
(95% CI) 
10 - 10 93 48 51.6 (41.5-61.8) 
10 - 20 93 30 32.3 (22.8-41.8) 
10 - 30 93 9 9.7 (3.7-15.7) 
10 - 40 93 6 6.5 (1.5-11.5) 
10 – 50 93 0 0 
10 – 60+ 93 0 0 
10 - 20+ (any DR) 93 45 48.4 (38.2-58.5) 
10 - ST Maculopathy 93 18 19.4 (11.3-27.4) 
10-STDR 93 18 19.4 (11.3-27.4) 
10-2+ step progression 93 30 32.3 (22.8-41.8) 
10-3+ step progression 93 15 16.1 (8.7-23.6) 
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Table 9.9 Five year incidence of development of all grades of DR, sight threatening 
maculopathy, STDR, 2-step progression and 3-step progression for 23 persons with 
level 20 retinopathy at baseline. n =number of subjects reaching endpoint. 
Grade progression Number entering 
time interval 
n Incidence %  
(95% CI) 
20 - 10 22 1 4.5 (0-13.3) 
20 - 20 22 9 40.9 (20.4-61.5) 
20 - 30 22 5 22.7 (5.2-40.2) 
20 - 40 22 4 18.2 (2.1-34.3) 
20 - 50 22 2 9.1 (0-21.1) 
20 - 60+ 22 1 4.5 (0-13.3) 
20 - ST maculopathy 16 13 81.3 (62.1-100) 
20 – STDR 16 13 81.3 (62.1-100) 
20-2+ step progression 22 8 36.4 (16.3-56.5) 
20-3+ step progression 22 7 31.8 (12.4-51.3) 
 
Table 9.10 Five year incidence of development of all grades of DR, sight threatening 
maculopathy, STDR, 2-step progression and 3-step progression for 9 persons with 
level 30 retinopathy at baseline. n =number of subjects reaching endpoint. 
Grade progression Number entering 
time interval 
n Incidence % 
30 - 30 9 3 33 
30 - 40 9 4 44 
30 - 50 9 0 0 
30 - 60+ 9 2 22 
30 - ST maculopathy 6 4 67 
30 – STDR 6 5 83 
30-2+ step progression 9 5 56 
30-3+ step progression 9 3 33 
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Table 9.11 Five year incidence of development of proliferative DR (PDR), sight 
threatening maculopathy, 2-step progression and 3-step progression for 5 persons 
with level 40 retinopathy at baseline. n =number of subjects reaching endpoint. 
Grade progression Number entering 
time interval 
n Incidence % 
40 - 60+ (PDR) 5 2 40 
40 - ST maculopathy 5 4 80 
40-2+ step progression 5 2 40 
40-3+ step progression 5 2 40 
 
Figure 9.2 Five year incidence of progression to sight threatening DR (STDR), 
proliferative DR (PDR) and of 2 step and 3-step progression for persons with 
diabetes and level 10 (n=93), level 20 (n=23) and level 30 DR (n=9) at baseline.  Error 
bars indicate 95% CI.  
 
 
 
9.4.7 Associations of progression of retinopathy 
Higher mean glycosylated haemoglobin (HbA1c), longer duration of diabetes and 
lower haemoglobin were risk factors for progression of DR by 2 steps on the LDES 
scale in multivariate analysis (Table 9.12).  In those subjects without STDR at 
baseline (n=115) baseline grade of DR was a risk factor for progression to STDR in 
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multivariate analysis (Table 9.13).  Descriptive analysis showed that urine ACR did 
not demonstrate a linear association with probability of STDR; a log transformation 
(base 10) was more suitable for the model.   
 
Table 9.12 Risk factors for association of 5 year progression of diabetic retinopathy 
by 2 steps on the LDES scale in 132 subjects with diabetes. 
 OR 95% CI p value 
Univariate logistic regression 
Mean HbA1c (NGSP %) 1.37 1.13 - 1.66 0.001* 
Duration (years) 1.05 0.99 – 1.12 0.096 
Baseline grade of DR 1.51 1.05 – 2.17 0.026* 
Type 1 diabetes 1.90 0.70 – 5.17 0.210 
Mean sBP (mmHg) 1.00 0.92 – 1.34 0.872 
Haemoglobin (g/dL) 0.86 0.72 – 1.02 0.086 
Log[urine ACR] (mg/mmol) 1.28 0.83 – 1.95 0.261 
LDL cholesterol (mmol/L) 0.91 0.61 -1.37 0.658 
HDL cholesterol (mmol/L) 0.72 0.29 – 1.75 0.466 
Triglycerides (mmol/L) 0.64 0.38 – 1.08 0.093 
HIV positive 0.94 0.32 – 2.75 0.903 
Age (years) 0.97 0.94 – 1.01 0.101 
Sex (male) 0.70 0.32 - 1.54 0.378 
Multivariate logistic regression 
Mean HbA1c (NGSP %) 1.47 1.13-1.90 0.004* 
Duration (years) 1.08 1.00-1.17 0.040* 
Haemoglobin (g/dL) 0.80 0.63-0.99 0.049* 
Triglycerides (mmol/L) 0.55 0.29-1.04 0.065 
Age (years) 0.96 0.92-1.01 0.081 
Type 1 diabetes 0.35 0.08-1.48 0.153 
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Table 9.13 Risk factors for association of 5 year progression to sight threatening 
diabetic retinopathy (STDR) in 115 subjects with diabetes.  
 OR 95% CI p value 
Univariate logistic regression 
Mean HbA1c (NGSP %) 1.22 1.01-1.49 0.044* 
Baseline grade of DR 6.69 2.64-16.98 0.001* 
Type 1 diabetes 3.21 1.06-9.72 0.039* 
Duration of diabetes (years) 1.10 1.02-1.19 0.010* 
Mean sBP (mmHg) 1.00 0.98-1.03 0.658 
Haemoglobin (g/dL) 0.98 0.80-1.20 0.868 
Log[urine ACR] (mg/mmol) 1.60 0.94-2.72 0.080 
LDL cholesterol (mmol/L) 0.89 0.57-1.40 0.613 
HDL cholesterol (mmol/L) 1.00 0.40-2.52 0.997 
Triglycerides (mmol/L) 0.54 0.28-1.06 0.075 
HIV positive 0.98 0.28-3.44 0.979 
Age (years) 0.97 0.94-1.01 0.116 
Sex (male) 1.07 0.45-2.53 0.875 
Multivariate logistic regression 
Baseline grade of DR 6.62 2.32-18.87 0.001* 
Triglycerides (mmol/L) 0.53 0.23-1.21 0.129 
Mean HbA1c (NGSP %) 1.16 0.91-1.47 0.241 
 
 
9.4.8 Vision 
For the purpose of this analysis visual acuity scores from 2007 (corrected Snellen 
acuities in the better eye) were converted to ETDRS letter scores using a standard 
conversion table [337].  Comparison was then made with 2012 ETDRS letters 
measurement in the better eye. (The eye with better vision in 2007 may not have 
been the same as the eye with better vision in 2012).  Visual acuity measurements 
for 135 subjects seen in the 2007 study and subsequently traced and assessed by 
the MDRS team in 2012 are shown in Table 9.14.  In 2012 according to WHO 
definitions [310] 129 subjects (95.6 %; 95% CI 92.1 - 99.0) had ‘normal vision’ (equal 
to or better than 60 letters), 3 subjects (2.2 %; 0-4.7) had ‘moderate visual 
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impairment’ (50 to 59 letters), and 3 subjects (2.2 %; 0-4.7) were ‘severely visually 
impaired or blind’ (<50 letters).  In 2012 the most common primary causes of visual 
impairment for subjects with corrected visual acuity worse than 80 letters 
(equivalent to 6/12 Snellen or worse) (n=53) were DR (43%) cataract (22%), and 
both DR and cataract (21%) (Table 9.15).  Therefore in 64% of cases DR was the sole 
or equal contributing cause of visual loss.  
 
Over the follow-up period 25 subjects (18.8%) lost 5 or more ETDRS letters of which 
7 subjects (5.3%) lost 15 or more letters.  Of these 25 subjects 2 (1.5%) progressed 
to moderate visual impairment (50-59 letters) and 3 (2.3%) became ‘severely 
visually impaired or blind’ (<50 letters).  The most common primary causes of visual 
loss for the 25 subjects who lost five or more letters were DR (36%) cataract (28%), 
and both DR and cataract (20%) (Table 9.16).  Therefore in 56% of cases DR was the 
sole or equal contributing cause of visual loss.  In univariate analysis loss of 5 or 
more ETDRS letters was associated with presence of STDR at follow up visit (OR 
3.29, 95% CI 1.32-8.18, p=0.010) but not age (OR 1.03, 0.99-1.072, p=0.179) or 
duration of diabetes (OR 1.03, 0.96-1.10, p=0.389).   
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Table 9.14 Prevalence with 95% CI of corrected ETDRS visual acuities according to 
better eye in 135 persons with diabetes seen in the 2007 study and subsequently 
traced and assessed by the MDRS team in 2012. Approximate Snellen acuities in 
parentheses. 
Visual acuity 
(ETDRS letters) 
2007 2012 
 n % (95% CI) n % (95% CI) 
≥ 90  (6/5) 8 5.9 (2.0-9.9) 13 9.6 (4.7-14.6) 
80 - 89 (6/7.5) 37 27.4 (19.9-34.9) 69 51.1 (42.7-59.5) 
70 -79 (6/12) 67 49.6 (41.2-58.1) 31 23.0 (15.9-30.1) 
60 - 69 (6/18) 15 11.1 (5.8-16.4) 16 11.9 (6.4-17.3) 
50 - 59 (6/30) 3 2.2 (0-4.7) 3 2.2 (0-4.7) 
40 - 49 (6/75) 0  1 0.7 (0-2.2) 
Hand Movements 3 2.2 (0-4.7) 2 1.5 (0-3.5) 
Light Perception 0  0  
No light perception 0  0  
No data 2 1.5 (0-3.5) 0  
 
  
238 
 
Table 9.15 Primary causes of visual impairment (VI) in the opinion of the examining 
clinician at 2012 visit for subjects with diabetes and corrected visual acuity worse 
than 80 letters.  Subjects classified according to level of visual impairment (n=53).  
Approximate snellen equivalents: 70-79 letters = 6/12; 60-69 = 6/18; 50-59 = 6/24 
‘Moderate visual impairment’; <50 letters = 6/36 or worse ‘Severely visually 
impaired or blind’. 
Primary cause 
of VI 
Level of visual impairment (ETDRS letters) Total 
70-79 60-69 50-59 <50 
n 31 16 3 3 53 
DR 14 (45%) 8 (50%)  1 23 (43%) 
DR and cataract 3 (10%) 4 (25%) 3 1 11 (21%) 
Cataract 10 (32%) 3 (19%)   13 (24%) 
AMD 3 (10%) 0   3 (6%) 
Glaucoma 0 1 (6%)  1 2 (4%) 
Other 1 (3%)* 0   1 (2%) 
* 1 subject PCO  
 
Table 9.16 Primary causes of visual loss between 2007 and 2012 visits in the opinion 
of the examining clinician for subjects with diabetes and loss of 5 or more letters.  
Subjects classified according to number of letters lost and level of visual impairment 
(n=25). 
Primary cause of 
visual loss 
Number of ETDRS letters lost Level of visual impairment 
5-14 ≥15 Total Progression to  
Moderate VI* 
Progression 
to Severe VI† 
n 18 7 25 2 3 
DR 6 3 9 (36%)  1 
DR and cataract 4 1 5 (20%) 2 1 
Cataract 6 1 7 (28%)   
AMD 2  2 (8%)   
Glaucoma  2 2 (8%)  1 
* ‘Moderate visual impairment’ =  50-59 letters (equivalent to 6/24 Snellen) 
† ‘Severely visually impaired or blind’ = <50 letters (equivalent to 6/36 or worse) 
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9.4.9 MDRS 6 and 7 year progression data 
Of the 2007 cohort, 41 subjects were recruited (by systematic random sampling 
from the QECH diabetes clinic) into the main MDRS 24 month cohort study (2012; 
Chapters 6, 7 and 8).  Of these 41 subjects 38 were seen at MDRS visit 2 (2013) and 
36 were seen at MDRS visit 3 (2014) providing 6 and 7 year longitudinal data. 2 
subjects died by visit 2 and a further 1 by visit 3.  Baseline demographic, clinical and 
biochemical measurements for 281 subjects included in the 2007 study categorised 
by inclusion in the main MDRS cohort are shown in Table 9.17.  Prevalence of 
retinopathy grades in the 41 subjects seen in 2007 and subsequently recruited to 
the MDRS main cohort are shown in Table 9.18. 
 
Cumulative incidence at 5, 6 and 7 years of development of grades of retinopathy 
for subjects with level 10 (no retinopathy) and level 20 DR at baseline are shown in 
Tables 9.19 and 9.20, respectively.  Of 3 subjects with level 30 DR at baseline (2007), 
by 7 years 2 had developed PDR and 1 developed level 50 DR; all developed ST 
maculopathy.  The 1 subject with level 40 DR at baseline had level 70 DR at 5 years 
and died before year 6.  The 1 subject with Level 60 at baseline at baseline had 
Level 60 DR at 5 years, received bilateral scatter and macular laser and had level 20 
DR, level 4 maculopathy at 6 years.  Further macular laser was performed after visit 
2.  The subject subsequently moved to Lilongwe and did not attend at 7 years.  Of 
34 subjects without STDR at baseline (2007) and seen at 7 years 12 (35.3%; 19.2-
51.4) had developed the condition at 7 years (of these 11 had ST maculopathy).  
During the course of the study 8 subjects were listed for scatter and macular laser 
(8 started a course of treatment; 7 completed the course), 5 for scatter alone (5 
started a course of treatment; 4 completed the course) and 2 for macular laser 
alone (both completed the course).   
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Table 9.17 Analysis of bias:  baseline demographic, clinical and biochemical 
measurements for 281 subjects with diabetes included in the 2007 cohort study.  
Subjects categorised by inclusion in the main MDRS cohort (2012-2014). 
 
Characteristic Subjects not 
included in MDRS 
main cohort 
Subjects included 
in MDRS main 
cohort 
P value 
n 240 41  
Female sex 164 (68.3%) 26 (63.4%) 0.589 ≠  
Age (yrs, median, IQR) 55 (46-63) 52 (42-57) 0.107 ł   
Type 1 diabetes 28 (11.7%) 4 (9.8%) 0.999 ≠ 
BMI (kg/m2; mean, SD) 28.5 (6.1) 28.9 (6.2) 0.699 ł  
Duration (at baseline) (yrs, 
med, IQR) 
5.0 (2.2-8.9) 4.0 (1.1-10.8) 0.549 ˩ 
sBP (mmHg; med, IQR) 140 (120-155) 130 (128-140) 0.324 ł 
dBP (mmHg; med, IQR) 80 (70-90) 80 (70-90) 0.640 ł 
HbA1c (NSGP%;mean,SD) 9.3 (2.3) 9.9 (3.0) 0.1424 ł 
HIV positive 27 (11.3%) 3 (7.3%) 0.590 ≠ 
Urine dipstick None 59; trace 72; 1+ 
45; 2+ 16; 3+ 7; 4+ 4 
None 13; trace 14; 
1+ 9; 2+ 1; 3+ 4; 4+ 0 
0.894 χ 
Serum creatinine‡  0.97 (0.30) 0.92 (0.32) 0.368 ł  
Raised serum creatinine†  40 (16.7%) 3 (7.3%) 0.160 ≠  
†Raised serum creatinine: men >110μmol/l; women >90μmol/l 
‡Serum creatinine (mg/dl, mean, SD) 
 ≠ Fisher’s exact test; ł Unpaired t-test; ˩ Wilcoxon rank sum; χ Χ2 test for trend 
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Table 9.18 Prevalence with 95% CI of retinopathy grades according to worse eye in 
41 persons with diabetes seen at 4 assessments: 2007 (original study of diabetes 
complications), 2012 (MDRS visit 1), 2013 (MDRS visit 2) and 2014 (MDRS visit 3). 
STM =sight threatening maculopathy. 
Grade 
(n; %;  
95% CI) 
Study Visit 
2007  2012 2013 2014 
n 41 41 38 36 
10 27  
(65.9, 51.4-80.4) 
13  
(31.7, 17.5-45.9) 
15 
(39.5, 24.0-55.0) 
10 
(27.8, 13.2-42.4) 
20 7  
(17.1, 5.6-28.6) 
13 
(31.7, 17.5-45.9) 
7 
(18.4, 6.1-30.7) 
13 
(36.1, 20.4-51.8) 
30 3  
(7.3, 0-15.3) 
6  
(14.6, 3.8-25.4) 
7 
(18.4, 6.1-30.7) 
4 
(11.1, 0.8-21.4) 
40 1  
(2.4, 0-7.1) 
4  
(9.8, 0.7-18.9) 
4 
(10.5, 0.8-20.3) 
4 
(11.1, 0.8-21.4) 
50 0 1  
(2.4, 0-7.1) 
1 
(2.6, 0-7.7) 
1 
(2.8, 0-8.2) 
60+ 1  
(2.4, 0-7.1) 
4  
(9.8, 0.7-18.9) 
4 
(10.5, 0.8-20.3) 
4 
(11.1, 0.8-21.4) 
Any DR 12  
(29.3, 15.4-43.2) 
28 
(68.3, 54.1-82.5) 
23 
(60.5, 45.0-76.0) 
26 
(72.2, 57.6-86.8) 
STM 3  
(7.3, 0-15.3) 
16 
(39.0, 24.1-53.9) 
18 
(47.4, 31.5-63.3) 
12 
(33.3, 17.9-48.7) 
STDR 4  
(9.8, 0.7-18.9) 
17 
(41.5, 26.4-56.6) 
18 
(47.4, 31.5-63.3) 
14 
(38.9, 23.0-54.8) 
Ungrade-
able 
2 
(4.9, 0-11.5) 
0 0 0 
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Table 9.19 Cumulative incidence at 5, 6 and 7 years of development of any 
retinopathy, level 30 DR, level 40 DR, level 60+ DR, sight threatening maculopathy 
and STDR for 27 persons with diabetes and level 10 (no retinopathy) at baseline. 
 Any retinopathy Level 30 
T N n C. Inc. 95% CI N n C. Inc. 95% CI 
5 27 14 51.9 0-13.6 27 1 3.70 0-10.8 
6 13 1 55.5 0-14.2 26 3 15.0 1.4-28.6 
7 12 3 67.2 0-16.3 22 0 15.0 1.1-28.9 
 
 Level 40 Level 60+ 
T N n C. Inc. 95% CI N n C. Inc. 95% CI 
5 27 2 7.4 0-17.3 27 0 0  
6 25 1 11.2 0-23.2 27 2 7.6 0-17.7 
7 23 0 11.2 0-23.4 24 0 7.6 0-17.9 
 
 ST maculopathy STDR 
T N n C.Inc. 95% CI N n C. Inc. 95% CI 
5 27 5 18.5 3.9-33.2 27 5 18.5 3.9-33.2 
6 22 2 26.1 9.4-42.8 22 2 26.1 9.4-42.8 
7 19 1 30.1 12.3-47.9 19 1 30.1 12.3-47.9 
 
T = time from recruitment (years); N = number entering time interval; n = new cases diagnosed 
during year; C. inc. = cumulative incidence (%); CI = confidence interval; ST = sight threatening; STDR 
= sight threatening diabetic retinopathy 
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Table 9.20 Cumulative incidence at 5, 6 and 7 years of development of level 60+ DR, 
sight threatening maculopathy and STDR for 7 subjects with diabetes and level 20 
DR at baseline. 
 Level 60+ ST maculopathy‡ STDR‡ 
T N n C. Inc. N n C. Inc. N n C. Inc. 
5 7 1 14.3 6 4 66.7 6 4 66.7 
6 6 1 28.6 2 1 83.3 2 1 83.3 
7 5 1 42.9 1 1 100 1 1 100 
 
T = time from recruitment (years); N = number entering time interval; n = new cases diagnosed 
during year; C. inc. = cumulative incidence (%); CI = confidence interval; ST = sight threatening; STDR 
= sight threatening diabetic retinopathy. ‡ - those with sight threatening maculopathy/STDR at 
baseline omitted from analysis 
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9.5 Discussion 
 
9.5.1 Principal findings 
This chapter details progression of grades of retinopathy and visual impairment 
over 5 years in a cohort of people with diabetes from Southern Malawi who were 
not treated with laser.  In 135 subjects (48.0% of the original 281 subject cohort) 
prevalence of any retinopathy, STDR and PDR increased from 29.6% (95% CI 21.9-
37.3) to 63.0% (54.8 – 71.1), 12.6% (7.0-18.2) to 38.5% (30.3-46.7) and from 2.2% (0 
– 4.7) to 5.9% (1.9 – 9.9), respectively.  Five year incidence of any DR in those 
without evidence of retinopathy at baseline was 48.4% (38.2-58.5).  The five year 
incidence of STDR for those with level 10 and level 20 retinopathy at baseline was 
19.4% (11.3-27.4) and 81.3% (62.1-100), respectively.  The five year incidence of 
PDR for those with level 10, level 20, level 30 and level 40 retinopathy at baseline 
was 0%, 4.5%, 22% and 40%, respectively.  Higher glycosylated haemoglobin 
(HbA1c), longer duration of diabetes and lower haemoglobin level were risk factors 
for progression of retinopathy in multivariate analysis.  Over the follow-up period 
25 subjects (18.8%) lost 5 or more ETDRS letters of which 7 subjects (5.3%) lost 15 
or more ETDRS letters.  2 subjects (1.5%) progressed to moderate visual impairment 
(50-59 letters) and 3 (2.3%) became ‘severely visually impaired or blind’ (<50 
letters).  In 56% of cases DR was the sole or equal contributing cause of visual loss. 
 
9.5.2 Strengths and weaknesses of this work 
This work, along with the main MDRS cohort, represents the first cohort study of DR 
from Sub-Saharan Africa.  Strengths of the work include a systematic approach to 
subject tracing, a robust procedure for grading retinopathy and the large number of 
systemic parameters which were measured.  Subject follow-up in this region is 
extremely challenging.  The 48% follow-up rate (plus a further 5% confirmed dead) 
is a considerable achievement.  However, this is a limitation of the work; 
conclusions draw from our work should be generalised with caution. 
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In this study the procedures for assessing retinopathy and vision differed between 
the baseline and final assessments.  Detection of retinopathy and maculopathy by 
photographic grading is quoted as being 89–93% sensitive and 86–94% specific 
judged against the standard of a consultant specialist in medical retinal disease 
[94,95].  However, dual grading of retinal photographs at a recognised reading 
centre is now considered the reference standard for grading.  The more robust 
assessment procedure used in 2012 could have detected a greater amount of 
disease.  It is unlikely that this factor would substantially affect the results of this 
study.  There is evidence of differences between measures of visual acuity using 
ETDRS and Snellen charts.  ETDRS measurements yield better VA and differences 
are more marked in persons with low vision [338-340].  The effect of these 
differences in this study would be to reduce the degree of visual loss recorded.     
 
9.5.3 Analysis of bias 
It is important to assess to what extend the subjects who were traced and assessed 
in 2012 are representative of the whole cohort.  While 15 subjects (5.3%) were 
confirmed dead the actual number of deaths is likely to be far higher.  Differences 
between the ‘seen’ and ‘not seen’ groups may be predictors of mortality.  Regarding 
baseline demographic and clinical parameters, subjects not seen in 2012 were older 
and had higher blood pressure than those who were traced and assessed.  A higher 
prevalence of raised serum creatinine and STDR in the group who were not seen in 
2012 suggests a higher baseline prevalence of microvascular complications of 
diabetes.  Vision was worse in the ‘not seen’ group.  This may reflect a greater 
prevalence of STDR and cataract (for which age is a risk factor).  Poor vision may be 
a risk factor for mortality either as a marker of microvascular damage in diabetes or 
as a marker of age.   Alternatively poor vision may directly affect an individual’s 
ability to survive in Southern Malawi.  
 
9.5.4 Comparison with African studies 
Few cohort studies from the African continent are available for comparison.  
Chapter 4, Section 4.4.4 details the only published studies which are summarised in 
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Table 4.4.  In Mauritius 1998 researchers followed up a population based study 
performed in 1992 [212] with a survey of diabetes complications [215].  Of subjects 
with diabetes in the initial survey 40.5% were re-examined.  The 6 year incidence of 
DR and PDR in subjects with diabetes but no DR in the first survey was 23.8% (95% 
CI 18.3-29.3) and 0.4% (0-1.2), respectively.  The 5 year incidence of any DR in our 
study (48.4% (38.2-58.5)) was higher.  
 
In Mauritius the 6 year incidence of PDR in subjects with mild non-proliferative 
diabetic retinopathy (NPDR) (equivalent to level 20 in LDES grading) was 5.2% (0-
10.9).  For subjects with moderate NPDR (equivalent to LDES level 30 or level 40) 
the incidence of PDR was 29.4% (7.7-51.1).  These figures are similar to the five year 
incidences of PDR in our study (level 20 4.5%; level 30 22%; level 40 40%).  Duration 
of diabetes and fasting blood glucose were independently associated with incidence 
of retinopathy.  Differences between the two studies are likely to reflect multiple 
disparities between Mauritius and Southern Malawi including ethnicity, access to 
health services and prevalence of comorbidities. 
 
Although there are few prospective cohort studies from Africa, studies reflecting 
cumulative incidence of DR are available. In South Africa, Distiller at al [237] 
reported on 1520 type 1 and 8026 type 2 persons who had maintained membership 
for ≥ 5 years of a community-based, privately funded diabetes management 
program.  In type 1 subjects prevalence of any retinopathy at baseline and at 5 
years was 22.3% and 28%, respectively and in type 2 subjects 20.5% and 26.6%, 
respectively.  These are much smaller increases in prevalence of any DR than shown 
in the present study: from 29.6% (95% CI 21.9-37.3) to 63.0% (54.8 – 71.1) in 5 
years.  In large part this is likely to reflect better access to health services in the 
South African cohort. 
 
9.5.5 Comparison with studies in Europe and North America 
High quality prospective cohort studies of DR are available from Europe and North 
America.  Table 9.21 summarises selected studies reporting incidence and 
progression of diabetic retinopathy. The Wisconsin Epidemiological study of 
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Diabetic Retinopathy (WESDR) was a population based epidemiological study 
performed in the 1980s.  For subjects with diabetes diagnosed at 30 years of age or 
older who had no retinopathy at baseline 4 year incidence of any retinopathy for 
insulin users and non- users of insulin was 47% and 34%, respectively [83]. Overall 
incidence of PDR in insulin users and non-users of insulin was 7% and 2%, 
respectively.  For those with diabetes diagnosed at less than 30 years and no 
retinopathy at baseline 4 year incidence of retinopathy was 59% [84]. Overall 4 year 
incidence of PDR was 11%. 
 
Younis et al [9] reported data from 4770 persons with type 2 diabetes registered 
with general practices in one English city who had two or more screening events as 
part of the Liverpool Diabetic Eye Study (LDES).  Five year cumulative incidence of 
any DR in those without evidence of retinopathy at baseline was 30·5% (28·2–32·8) 
compared to 48.4% (38.2-58.5) in the present study.  The five year cumulative 
incidence of STDR for those with level 10, level 20 and level 30 retinopathy at 
baseline was 3·9% (2·8–5·0), 28·9 (24·4–33·4) and 63·2 (53·4–73·0), respectively.  
The corresponding figures in our study were much higher: 19.4% (11.3-27.4), 81.3% 
(62.1-100) and 83%, respectively.  As in the present study longer duration of 
diabetes was associated with progression to STDR.  The LDES included a smaller 
number of people with type 1 diabetes.  Younis et al [96] reported data from 501 
subjects.  The five year cumulative incidence of any DR in those without evidence of 
retinopathy at baseline was 36.8% (29.6–44.1).  The five year cumulative incidence 
of STDR for those with level 10, level 20 and level 30 retinopathy at baseline was 
3.9% (1.4–5.4), 26.8% (13.6–40.0) and 66.6% (36.9–95.7), respectively. 
 
More recently Jones et al [331] reported data on 20,686 persons with type 2 
diabetes seen in the county of Norfolk as part of the English national screening 
program.  Among subjects without retinopathy at baseline, cumulative incidence at 
5 years of background retinopathy (equivalent to LDES level 20) was 35.9% (34.8-
37.0), pre-proliferative retinopathy (equivalent to level 40) was 4.0% (3.5-4.4), sight 
threatening maculopathy 0.59% (0.4-0.8), and PDR 0.68% (0.51-0.90).  Among those 
with background retinopathy at baseline, after 5 years 23.0% (20.7-25.6) developed 
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preproliferative retinopathy, 5.2% (4.05-6.67) developed sight threatening 
maculopathy, and 6.1% (4.85-7.66) developed PDR.  Therefore for subjects with 
background retinopathy (equivalent to LDES level 20) at baseline the rate of 
progression to STDR was lower than the present study, however, the incidence of 
PDR was slightly higher.  
 
In Wales, Thomas et al [336] reported incidence of any DR and referable DR 
(equivalent to LDES level 40, or exudate or thickening within 1 disc diameter (DD) of 
the centre of the fovea, or circinate or group of exudates within the macula, or any 
microaneurysm or haemorrhage within 1DD of the centre of the fovea only if 
associated with a best VA of ≤ 6/12. i.e. roughly equivalent to STDR as defined in the 
present study) in persons with type 2 diabetes attending an annual screening 
service and whose first screening episode indicated no evidence of retinopathy.  
After four years the cumulative incidence of any DR and referable DR was 36.0% 
and 1.2%, respectively. 
 
While not designed as observational cohort studies, a number of large randomised 
trials have reported incidence and progression rates of DR.  The United Kingdom 
Prospective Diabetes Study (UKPDS) [13] reported data from 1919 persons with 
type 2 diabetes.  Of 1216 with no retinopathy at baseline 41% developed at least 1 
microaneurysm by 6 years and 22% developed microaneurysms in both eyes or 
worse.  Of 703 subjects with any DR at baseline 29% progressed by 2 or more steps 
on the ETDRS scale.  Development of retinopathy (incidence) was associated with 
baseline glycaemia, glycaemic exposure over 6 years, high blood pressure and with 
not smoking.  In those who already had retinopathy, progression was associated 
with older age, male sex, higher HbA1c and with not smoking.   
 
In summary, compared to recent European studies 5 year incidence of any 
retinopathy in our study was higher: 48.4% (38.2-58.5) vs estimates between 30.5% 
[9] and 40.6% [13,331].  In our study 5 year progression to STDR from no DR (level 
10) was approximately 5 times that reported in recent European studies: 19.4% 
(11.3-27.4) vs estimates between 3.9% [9,96] and 4.0% [331].  Five year progression 
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to STDR from background DR (level 20) was approximately 3 times higher: 81.3% 
(62.1-100) vs estimates between 26.8 [96] and 28.9 [9].  Five year progression to 
PDR from no DR (level 10) and background DR (level 20) was similar in our study to 
recent studies from England [331] and Mauritius [215].  Differences between figures 
from our study and recent European work are likely to reflect multiple disparities 
between populations including ethnicity, access to health services and presence of 
comorbidities including poorly controlled hypertension and infective disease.  
Comparisons between studies must be made with caution in view of different study 
designs and different follow-up rates.  Of particular note mortality rates are likely to 
differ greatly between populations and are an important cause of data censoring. 
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Table 9.21 Summary table of selected studies reporting incidence and progression of diabetic retinopathy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
{} Subgroup or baseline LDES retinopathy grade: L10 = level 10, L20 = level 20 etc. †95% confidence interval in parentheses.  * Incidence of Level 40 retinopathy only (sight 
threatening maculopathy data not included). WESDR = Wisconsin epidemiological study of diabetic retinopathy; MDRS = Malawi diabetic retinopathy study; LDES = 
Liverpool diabetic eye study; UKPDS = United kingdom prospective diabetes study; RCT = Randomised controlled trial; DR Diabetic retinopathy; STDR = Sight threatening 
diabetic retinopathy; PDR = Proliferative diabetic retinopathy.  
Study WESDR 
[23] 
WESDR 
[22] 
Wales [20] UKPDS 
[19] 
LDES [18] LDES [17] Norfolk [21] MDRS Mauritius [15] 
Dates  1979-
1986 
1979-1986 2005-2009 1977-
1991 
1991-1999 1991-
1999 
1990-2006 2007-2012 1992-1998 
Type of 
study 
Primary care based 
cohort 
Retrospective 
analysis of DR 
screening prog. 
RCT Prospective study of DR 
screening programme  
Retrospective 
analysis of DR 
screening  
Primary care 
based cohort 
Population-
based cohort 
Subjects Diagnos
is 
<30yrs 
Diagnosis 
≥30yrs 
Type 2 diabetes Type 2 
diabetes 
Type 1 
diabetes 
Type 2 
diabetes 
Type 2 
diabetes 
All subjects with 
diabetes 
All subjects 
with diabetes 
Follow-
up(yrs) 
4 4 4 5 5 5 5 5 6 
Incidence of 
any DR (%) † 
59 34 {no 
insulin} 
47 {insulin} 
36.0  
(35.3-36.6) 
40.6  
(37.9-
43.4) 
36.8 
(29.6–44.1) 
30·5 
(28·2–
32·8) 
40.6 48.4 
(38.2-58.5) 
23.8 
(18.3-29.3) 
Incidence of 
STDR (%) 
  1.2 {L10}  3.9 {L10} 
26.8 {L20} 
66.6 {L30} 
3.9 {L10} 
28.9 {L20} 
63.2 {L30} 
4.0 {L10}* 
23.0 {L20}* 
19.4 {L10} 
81.3 {L20} 
83.0 {L30} 
 
Incidence of 
PDR (%) 
11 2 {no 
insulin} 
7 {insulin} 
 
    0.68 {L10} 
6.1 {L20} 
0 {L10} 
4.5 {L20} 
22 {L30} 
40 {L40} 
0.4 {10} 
5.2 {20} 
29.4 {30/40} 
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9.5.6 Vision  
Interestingly in our study the overall levels of ‘moderate visual impairment’ (50 to 
59 letters) and ‘severe visual impairment or blindness’ (<50 letters) did not change 
between 2007 and 2012.  The proportion of subjects with VA <70 letters (equivalent 
to 6/12 Snellen) rose from 15.5% to 16.3%.  18.8% of subjects lost 5 or more ETDRS 
letters, 5.3% lost 15 or more letters, 2 subjects (1.5%) progressed to moderate 
visual impairment (50-59 letters) and 3 (2.3%) became ‘severely visually impaired or 
blind’ (<50 letters).  Clearly some subjects recorded better VA in 2012 than in 2007.  
Explanations for this include medical interventions including cataract surgery.  An 
important confounder is the difference in methods of measurement of visual acuity 
in 2007 and 2012 discussed above (Section 9.5.2).  A potential bias is that subjects 
who became visually impaired may have been less likely to attend the follow-up 
visit in 2012.  Visual impairment may increase the chance of mortality in a society 
where loss of vision entails loss of economic productivity.  Together these factors 
may explain why a greater degree a visual impairment was not seen in this cohort 
study.  
 
Few studies reporting visual acuity in subjects with diabetes in Africa are available 
for comparison with our study.  Published studies are summarised in Chapter 4, 
Section 4.4.6 of this thesis.  The Diabetes in Egypt project [246] reported VA in 427 
subjects with diabetes.  Of these 31 (7.3 %) were blind (defined as BCVA in the 
better eye less than 6/60).  Prevalence of visual impairment (VA 6/60 or worse in 
the better eye) in the MDRS main cohort at baseline (Chapter 6) and the present 
study was 1.4% and 2.2%, respectively.  The population-based Mauritius diabetes 
complication study [212] reported best correct visual acuity (BCVA) worse than 6/12 
in 7.1% of subjects with diabetes at baseline.  The corresponding figures in the 
MDRS main cohort at baseline (Chapter 6), the present study in 2007 and the 
present study in 2012 are 7.3%, 15.5% and 16.3%, respectively.  Unfortunately no 
visual acuity data was reported from the follow-up assessment in the Mauritius 
study [215].  Indeed, to our knowledge, no cohort studies of DR from Africa have 
reported VA data except at baseline.   
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Prevalence of visual impairment in subjects with diabetes has been reported in a 
number of studies from Europe and North America.  In the WESDR a VA of 6/60 or 
worse in the better eye was reported at baseline in 3.6% of type 1 subjects and 
1.6% of type 2 subjects [10,11].  In Iceland Kristinsson et al. [290] reported VA of 
6/60 or worse in the better eye in 1.0% of type 1 subjects and 1.6% of type 2 
subjects.  Corresponding figures in the MDRS are 1.4% in the main cohort at 
baseline (Chapter 6) and 2.2% in the present study. Incidence of visual impairment 
(VI) was reported for persons with type 1 diabetes in the WESDR [85]. During the 
first 4 years of follow-up the annual incidence of VI (defined as best-corrected VA in 
the better eye of 6/12 or worse) and severe visual impairment (6/60 or worse) was 
0.4% and 1.2%, respectively.  Increased risk of VI was associated with more severe 
baseline retinopathy, presence of cataract, higher HbA1c, presence of hypertension 
and current smoking, but not proteinuria.   
 
In the UKPDS [341] the percentage of subjects with VA worse than 0.3 LogMAR 
(minimum angle of resolution)(equivalent to 6/12 Snellen) at baseline in the ‘tight 
blood pressure control’ group and the ‘less tight BP control’ group was 1.7% and 
1.8%, respectively.  After 6 years the figures were 6.4% and 5.9%, respectively.  In 
our study the proportion of subjects with VA <70 letters (equivalent to 6/12 Snellen) 
was 15.5% in 2007 and 16.3% in 2012.  Hall et al [335] studied blind registrations 
attributed to DR in Scotland.  These authors estimated that the annual incidence of 
blindness (defined as visual acuity in the better eye below 3/60) in the population 
with diabetes was 0.04%. 
 
Our results can also be compared to population-based (i.e. not confined to persons 
with diabetes) cohort studies reporting incidence of visual impairment.  The Beaver 
Dam eye study [342] reported an overall incidence of VI (VA worse than 6/12 in the 
better eye) between examinations (5-year interval) of 1.4% (varying from 0.1% in 
persons 50–54 years of age to 14.6% in those 85 years of age and older).  The 5 year 
incidence of severe VI (VA<6/60) was 0.4% (varying from 0.0% in persons 50–54 
years of age to 6.9% in those ≥ 85 years of age). 
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9.6 Chapter summary  
This chapter provides an estimate of incidence and progression of grades of 
retinopathy over 5 years in a cohort of persons with diabetes in Southern Malawi.  
In this cohort 5 year progression to STDR from ‘no DR’ and ‘background DR’ was 
approximately 5 times and 3 times that reported in recent European studies, 
respectively.  Higher glycosylated haemoglobin and lower haemoglobin level were 
risk factors for progression of retinopathy.  I have reported prevalence and 
incidence of visual impairment in this cohort.  The vast majority of subjects did not 
have access to laser treatment during the 5 year follow-up period.  Data on 
progression of DR and incidence of visual impairment in an untreated cohort 
provides a baseline against which future studies can judge efficacy and cost 
effectiveness of laser treatment in this population. 
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Chapter 10. Case-Control Study of Endothelial Function in 
Malawian Subjects with Diabetes 
 
 
10.1 Aims of the chapter 
This chapter details the results of a case-control study of endothelial function 
performed in a sub-group of the Malawi Diabetic Retinopathy Study (MDRS) cohort 
and a group of Malawian subjects without diabetes.  
 
10.2 Introduction  
Endothelial dysfunction is implicated in the pathophysiology of diabetic retinopathy 
(DR).  Both diabetes and its complications are associated with altered serum levels 
of biomarkers of endothelial dysfunction and decreased in vivo responsiveness of 
the peripheral vascular endothelium.  This subject is reviewed in Chapter 1, Sections 
1.5.4 and 1.5.5.  In Malawi a number of factors, including high levels of infective 
disease, may modify the local and systemic response to hyperglycaemia and result 
in dysfunction of the vascular endothelium.  In this nested case-control study I 
aimed to characterise endothelial function in Malawian subjects with diabetes and 
investigate relationships with severity of retinopathy.  In this chapter I report the 
results of these investigations.  Firstly in comparison to baseline cross-sectional DR 
data and secondly in relation to progression of DR at 24 months.   
 
10.3 Methods  
 
10.3.1 Subjects and assessment  
Study setting, sampling of subjects, clinical assessment, assessment of retinopathy, 
measurement of serum markers of endothelial dysfunction and pulse amplitude 
tonometry are fully described in Chapter 5, Methods.  In brief, a subset of subjects 
from the main cohort study (described in Chapter 5, Section 5.9) were investigated 
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plus subjects without diabetes.  I studied endothelial function in 4 groups each 
consisting of a minimum of 40 subjects: 
 
1. subjects without diabetes  
2. subjects with diabetes but without DR at baseline 
3. subjects with diabetes and DR but without sight threatening diabetic 
retinopathy (STDR) 
4. subjects with diabetes and STDR  
 
All subjects recruited to the main cohort study were offered the chance to 
participate in the case control study until each of the above groups reached their 
recruitment target.  Inclusion and exclusion criteria were the same as the main 
cohort study.  Inclusion criterion: diagnosis of diabetes according to American 
Diabetes Association (ADA) criteria [123] (Chapter 5, Box 5.1).  Exclusion criteria: 
age <18 years; first visit to the diabetes clinic, residence >60km from the hospital in 
question; diagnosis of gestational diabetes according to ADA criteria [123].  
Systematic random sampling was used to recruit control subjects (without diabetes) 
from spouses of patients attending the QECH diabetes clinic (see Chapter 5, Section 
5.11.3).  Inclusion criterion was being a spouse of a patient attending the QECH 
diabetes clinic.  Exclusion criteria were:  age <18 years and diagnosis of diabetes or 
gestational diabetes according to ADA criteria.  Therefore control subjects with 
fasting blood glucose ≥ 7.0mmol/l or HbA1c ≥ 6.5% were excluded from the study.   
 
 
10.3.2 Statistical analysis 
General statistical methods are described in Chapter 5, Section 5.9.10.  Details of 
specific analyses used in the endothelial sub-study are given in Chapter 5, Section 
5.11.6.  Briefly, endothelial function was compared across 4 groups (described 
above) applying multiple linear regression.  I defined 3 binary variables, namely 
presence of diabetes (yes/no), presence of diabetic retinopathy (yes/no) and 
presence of STDR (yes/no). These factors are nested, for example, absence of 
diabetes implies absence of DR and STDR, and absence of DR implies absence of 
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STDR.  The multiple regression model was constructed taking into account this 
nested design and the factors included in the model were diabetes and the 
interaction terms diabetes*DR and diabetes*DR*STDR. Several outcome variables 
were analysed separately using multiple regression models, these include five 
serum markers: C-reactive protein (CRP), Intercellular adhesion molecule 1 (ICAM-
1), E-selectin, vascular cell adhesion molecule 1 (VCAM-1) and Vascular endothelial 
growth factor (VEGF), in addition to the Reactive Hyperaemia Peripheral Arterial 
Tonometry (rhPAT) index, Framingham reactive hyperaemia index (FRHI) and 
augmentation index (AI). Additionally, I constructed a logistic regression model 
(backwards stepwise with probability of removal of 0.2) to investigate the 
association between presence of diabetes and the following variables: age, sex, 
CRP, VEGF, ICAM-1, VCAM-1, E-selectin, and rhPAT index. Odds ratio (OR) and the 
corresponding 95% CIs were provided. 
 
Baseline endothelial function was compared between subjects with diabetes whose 
retinopathy progressed by 2 steps on the LDES scale and subjects whose 
retinopathy did not progress at 24 months.  Baseline endothelial function was also 
compared between subjects who had died and those who survived at 24 months.  
Multiple logistic regression analysis was used to analyse the effect on progression of 
retinopathy (and, in a separate analysis, on death) of an initial 8 variables: age, sex, 
CRP, VEGF, ICAM-1, VCAM-1, E-selectin, and rhPAT index. Variables including HbA1c 
and sBP could be considered to be on the causative pathway between the 
‘exposure’ (markers of endothelial dysfunction) and the ‘outcomes’ (progression of 
retinopathy or death).  These variables therefore did not meet the definition of 
confounders and were not included in the models.   
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10.4 Results: analysis of baseline data 
10.4.1 Participants  
163 subjects from the MDRS main cohort study were approached to participate in 
the endothelial sub-study.  24 declined; 139 were included.  57 spouses of patients 
attending the QECH diabetes clinic were approached to participate as controls.  15 
declined and 2 were excluded due to raised FBS and/or HbA1c; 40 were included.  
Table 10.1 shows the baseline demographic, clinical and biochemical characteristics 
of included subjects.  
 
Table 10.1 Baseline demographic, clinical and biochemical characteristics of 179 
subjects included in the MDRS sub-study of endothelial function.  Subjects 
categorised by diabetes status and grade of retinopathy: 1=no diabetes (control 
subjects), 2=diabetes no retinopathy, 3=diabetic retinopathy (DR), 4=sight 
threatening diabetic retinopathy (STDR). 
Group 1. Control 2. No DR 3. DR 4. STDR p ≠ 
n 40 53 43 43  
Age (yrs;med,IQR) 53.4 (44-63) 53.4 (44-60) 53.2 (44-62) 54.1 (47-60) 0.98 
Female sex 20 (50%) 29 (55%) 28 (65%) 33 (76%) 0.006* 
Duration (yrs) Ғ NA 2.4 (1.4-5.3) 5.0 (1.3-9.1) 8.1 (4.3-17.0) 0.001* 
sBP (mmHg) Ғ 144 (127-170) 139 (123-158) 139 (117-157) 145 (127-174) 0.15 
dBP (mmHg) Ғ 83.0 (73.5-95) 82 (75.5-91) 80 (73-96) 86 (78-92) 0.55 
BMI >25 kg/m
2
 19 (47.5) 33 (62.3) 28 (65.1) 25 (58.1) 0.34 
HbA1c (IFCC) ‡ 29.1 (4.9) 55.0 (25.5) 62.2 (28.7) 70.7 (23.5) 0.001* 
HbA1c (NGSP%) ‡ 4.8 (0.5) 7.2 (2.3) 7.8 (2.6) 8.6 (2.2) 0.002* 
Hb (g/dl;mean;SD) 15.1 (2.1) 14.3 (2.0) 13.8 (2.1) 13.6 (1.6) 0.004* 
Anaemia 6 (15%) 7 (13%) 7 (16%) 7 (16%) 0.76 
HIV positive 2 (5%) 10 (19%) 6 (14%) 4 (9%) 0.82 
Total chol 
>5mmol/L 
8 (20%) 16 (30%) 15 (35%) 19 (44%) 0.017* 
HDL (mmol/L) ‡ 0.86 (0.37) 0.94 (0.31) 1.02 (0.38) 1.14 (0.38) 0.004* 
LDL (mmol/L) ‡ 2.16 (1.17) 2.31 (0.78) 2.47 (0.98) 2.80 (0.77) 0.005* 
Triglycerides ‡ 1.06 (0.82) 1.85 (1.81) 1.44 (0.98) 1.68 (0.97) 0.005* 
↑ Urine ACR† 7 (18%) 13 (25%) 14 (33%) 23 (53%) 0.003* 
≠ χ
2
 test for trend, ANOVA, or Kruskal Wallis tests as appropriate.   * Denotes statistical significance 
‡ mean, SD;  Ғ median, IQR;  † Raised urine ACR: male >2.5 mg/mmol; female >3.5)mg/mmol 
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10.4.2 Exploratory analysis  
Levels of CRP, VEGF, VCAM, E-selectin and ICAM-1 (measured at recruitment to the 
MDRS) were weakly correlated with each other although the values were 
significantly different than zero (Table 10.2).  The correlation coefficient between 
CRP and VEGF was 0.362 (p=0.001), between CRP and sVCAM-1 was 0.348 (p=0.001) 
and between CRP and E-selectin was 0.326 (p=0.001).  RhPAT was strongly 
correlated with FRHI (correlation coefficient 0.713, p=0.0001) but not AI.  All other 
factors were less strongly correlated (Table 10.2).  E-selectin level correlated with 
HbA1c (correlation coefficient 0.713, p=0.001).  AI correlated strongly with age 
(correlation coefficient 0.802, p=0.001). 
 
Table 10.2 Correlation coefficients for serum markers of endothelial dysfunction 
and measures of clinical endothelial function in 179 subjects. 
  CRP VEGF VCAM E-
selectin 
ICAM rhPAT AI 
Serum 
markers 
CRP 
(mg/L) 
• • • • • • • 
VEGF 
(pg/mL) 
0.362 • • • • • • 
VCAM 
(ng/mL) 
0.348 0.203 • • • • • 
E-
selectin 
(ng/mL) 
0.326 0.065 0.058 • • • • 
ICAM 
(ng/mL) 
0.299 0.094 0.160 0.262 • • • 
Measures 
of 
endothelial 
function 
rhPAT -
0.034 
0.069 -0.025 0.005 0.010 • • 
AI 0.089 0.023 0.118 -0.048 0.062 0.189 • 
FRHI -
0.006 
-
0.032 
-0.014 -0.019 0.046 0.713 0.106 
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10.4.3 Comparison between the 4 study groups  
Levels of serum VEGF in subjects from each of the four study groups are shown in 
Figure 10.1.  The fitted multiple linear regression model showed a significant 
difference in mean serum VEGF between subjects with and without diabetes but 
not between subjects with and without diabetic retinopathy or between subjects 
with and without STDR (Table 10.3).  Higher serum level of E-selectin was detected 
in those with diabetes, although the result did not reach the statistical significant 
threshold (p=0.066).  
 
The presence of DR and STDR was not significantly associated with serum levels of 
E-selectin (p=0.43 for DR; p=0.33 for STDR).  The presence of diabetes, DR and STDR 
was not significantly associated with serum levels of VCAM-1 (p=0.95 for diabetes; 
p=0.61 for DR; p=0.79 for STDR), ICAM-1 (p=0.053; p=0.44; p=0.48), or CRP (p=0.16; 
p=0.79; p=0.14), or with PAT (p=0.14; p=0.90; p=470), AI (p=0.061; p=0.85; p=0.40) 
or FRHI (p=0.33; p=0.84; p=0.40).  When considering subjects with HIV (n=22) and 
without HIV (n=148), those with HIV demonstrated higher serum level of E-selectin 
(unpaired t-test, p=0.015).  Levels of CRP, VEGF, VCAM-1, ICAM-1, rhPAT, FRHI and 
AI were not significantly different between subjects with HIV and without HIV 
(unpaired t-test). 
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Figure 10.1 Baseline serum levels of vascular endothelial growth factor (VEGF) in 
subjects without diabetes (‘Control’, n=40), with diabetes but no diabetic 
retinopathy (‘No DR’, n=53), with diabetic retinopathy (‘DR’, n=43), and with sight 
threatening diabetic retinopathy (‘STDR’, n=43). Bars indicate mean and 95% CIs for 
the population means. 
 
 
Table 10.3 Coefficients, 95% CIs and p-values of the multiple linear regression 
model to assess the association of serum VEGF level with presence of diabetes, 
diabetic retinopathy and sight threatening diabetic retinopathy (STDR) in 179 
subjects. 
 
10.4.4 Logistic regression analysis   
The multivariate regression model that was fitted in the previous section indicated 
that elevated serum VEGF is positively associated with having diabetes in this 
population (Table 10.3). Presence of diabetes and E-selectin were positively 
correlated although the result was just outside the significance boundary. In this 
Presence of Parameter 
estimate 
95% CI for 
parameter 
p value 
Diabetes (Y/N) 209.3 77.2 - 341.4 0.002* 
Diabetic retinopathy (Y/N) -77.0 -205.7 – 51.6 0.24 
STDR (Y/N) -11.8 -144.6 – 120.9 0.86 
Intercept (Y/N) 288.0 189.5 – 386.6 0.0001 
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section I present an analysis of the data using an alternative approach.  I used 
multiple logistic regression where presence of diabetes is the dependent variable 
and the 8 factors described in Table 10.4 are the predictor variables.  Serum level of 
VEGF and E-selectin was significantly, positively associated with presence of 
diabetes in multiple logistic regression. 
 
Table 10.4 Associations of the presence of diabetes in 179 subjects (univariate and 
multivariate logistic regression) 
 
 
  
 OR 95% CI p value 
Univariate logistic regression 
CRP (mg/L) 1.05 0.98 - 1.12 0.18 
VEGF (pg/mL) 1.002 1.000 - 1.004 0.009* 
VCAM-1 (ng/mL) 0.99 0.99 - 1.00 0.58 
E-selectin (ng/mL) 1.03 1.00 - 1.05 0.019* 
ICAM-1 (ng/mL) 1.002 1.00 - 1.01 0.049* 
rhPAT index 2.01 0.99 - 4.09 0.053 
Sex (male) 0.54 0.27 - 1.11 0.094 
Age (years) 1.003 0.97 - 1.03 0.85 
Multiple logistic regression 
VEGF (pg/mL) 1.002 1.000 - 1.004 0.014* 
E-selectin (ng/mL) 1.030 1.004 - 1.056 0.022* 
rhPAT index 1.962 0.936 -  4.112 0.074 
Sex (male) 0.564 0.252 - 1.264 0.17 
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10.5 Results: analysis of progression data 
10.5.1 Participants 
I studied endothelial function in relation to progression of DR at 24 months.  Three 
groups of subjects (described in Section 10.3.1) were included in this analysis: 
subjects with diabetes but no DR at baseline (Group 2), those with DR but not STDR 
(Group 3) and those with STDR (Group 4).  Progression of DR would not occur in 
those subjects without diabetes (Group 1) who were therefore excluded from this 
analysis.  Characteristics of subjects are shown in Table 10.5.  Two (or more) step 
progression (from baseline) was observed at 24 months in 24 subjects (19.2%; 12.3-
26.1 95% CI).  
 
Table 10.5 Characteristics of subjects included in the MDRS endothelial study 
progression analysis categorised by diabetic retinopathy status at baseline. 
DR=diabetic retinopathy; STDR=sight threatening diabetic retinopathy. 
 Group 2 Group 3 Group 4 Total 
Baseline DR status No DR Dr no STDR STDR  
Subjects 53 43 43 139 
Subjects seen at 24 
months 
48 (91%) 40 (93%) 37 (86%) 125 (90%) 
Confirmed dead at 24 
months 
3 3 4 10 (7%) 
Subjects lost to 
follow-up 
0 2 2 4 (3%) 
2-step DR progression 4 (8.3%) 9 (22.5%) 11 (29.7%) 24 (19.2%) 
 
10.5.2 Comparison between progression groups 
Figure 10.2 shows baseline levels of endothelial biomarkers in subjects who 
demonstrated progression of retinopathy by 2 (or more) steps at 24 months (n=24) 
and those who did not (n=101).  Neither VEGF, ICAM-1, E-selectin, VCAM-1, CRP or 
rhPAT index at baseline were associated with progression of DR by 2 (or more) steps 
on the LDES scale at 24 months based on univariate or multivariate regression 
analyses (Table 10.6). 
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Figure 10.2 Baseline serum levels of (A) vascular endothelial growth factor (VEGF), 
(B) E-selection, (C) intercellular adhesion molecule-1 (ICAM-1) and (D) rhPAT index 
in subjects who demonstrated 2 (or more) step progression of diabetic retinopathy 
on the Liverpool Diabetic Eye Study scale at 24 months (n=24) and those who did 
not (n=101).  Bars indicate mean and 95% CIs for the population means. 
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Table 10.6 Risk factors for association of progression of retinopathy by 2 (or more) 
steps on the LDES scale at 24 months in 135 subjects. 
 
 
10.5.3 Comparison between subjects who died and those who 
survived 
I compared levels of serum markers of endothelial dysfunction and the rhPAT index 
measured at baseline in subjects who died (n=10) and those who were alive at 24 
months (n=125).  Figure 10.4 shows baseline levels of VCAM-1 and E-selectin in 
these 2 groups.  Serum VCAM-1 but not E-selectin was associated with death in 
multivariate regression (Table 10.7).   
 
  
 OR 95% CI p value 
Univariate logistic regression 
CRP (mg/L) 0.99 0.97 - 1.03 0.90 
VEGF (pg/mL) 0.99 0.99 - 1.00 0.11 
VCAM-1 (ng/mL) 1.00 0.99 - 1.00 0.54 
E-selectin (ng/mL) 0.99 0.97 - 1.02 0.78 
ICAM-1 (ng/mL) 0.99 0.99 - 1.00 0.68 
rhPAT index 0.74 0.28 - 1.97 0.54 
Sex (male) 0.32 0.10 - 0.99 0.05 
Age (years) 1.01 0.97 - 1.04 0.80 
 
Multivariate logistic regression 
VEGF (pg/mL) 0.99    0.99 - 1.00 0.15    
Sex (male) 0.33    0.09 - 1.25 0.10     
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Figure 10.4 Baseline serum levels of (A) vascular cell adhesion molecule 1 (VCAM-1) 
and (B) E-selection in subjects who died (n=10) and those alive (n=125) at 24 
months in the Malawi Diabetic Retinopathy Study. Bars indicate mean and 95% CIs 
for the population means. 
 
 
 
Table 10.7 Risk factors for association of death in 135 subjects over 24 months in 
the Malawi Diabetic Retinopathy Study (univariate and multivariate logistic 
regression).  Endothelial biomarker measurements taken at baseline. 
 
 OR 95% CI p value 
Univariate logistic regression 
CRP (mg/L) 1.02 1.00-1.04 0.025* 
VEGF (pg/mL) 1.00 0.99-1.00 0.18 
VCAM-1 (ng/mL) 1.00 1.00-1.01 0.001* 
E-selectin (ng/mL) 1.04 1.00-1.08 0.040* 
ICAM-1 (ng/mL) 1.00 0.99-1.01 0.18 
rhPAT index 0.75 0.20-2.75 0.66 
Sex (male) 1.27 0.34-4.75 0.72 
Age (years) 1.05 0.99-1.11 0.10 
Multivariate logistic regression 
VCAM-1 (ng/mL) 1.01 1.00-1.01 0.011* 
E-selectin (ng/mL) 1.05 0.99-1.11 0.098 
Age (years) 1.06 0.97-1.16 0.18 
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10.6 Discussion 
 
10.6.1 Principal findings 
At baseline, levels of CRP, VEGF, VCAM, E-selectin and ICAM-1 were weakly 
correlated with each other.  These biomarkers were studied because of previous 
work demonstrating associations with microangiopathy in diabetes [46-54].  
Subjects with diabetes demonstrated higher levels of serum VEGF.  Higher serum 
VEGF and E-selectin were associated with having diabetes in multivariate 
regression.  E-selectin level correlated with HbA1c and was higher in subjects with 
HIV.  In analysis of progression data there was no significant difference between 
those subjects who demonstrated 2 (or more) step progression at 24 months and 
those who did not in terms of baseline level of CRP, VEGF, VCAM-1, E-selectin, 
ICAM-1 and rhPAT index.  Subjects who died demonstrated higher baseline levels of 
CRP, VCAM-1 and E-selectin.  Serum VCAM-1 was associated with death in 
multivariate regression. 
 
10.6.2 Comparison with studies of endothelial function in diabetes 
The results of this study demonstrate the first evidence of endothelial dysfunction 
in Malawian subjects with diabetes.  A large body of evidence indicates that the 
pathophysiological mechanisms involved in the development of diabetes and its 
vascular complications include chronic low grade inflammation, endothelial 
dysfunction and pro-coagulant imbalance.  An excellent review of this topic has 
been produced by Goldberg [343].  Serum levels of soluble adhesion molecules 
(namely ICAM-1 and E-selectin) were independent predictors of development of 
diabetes in the Nurses Health cohort study [344]. Elevated s-ICAM1 has been 
previously demonstrated in type 1 [345] and type 2 [346] diabetes.  
Elevated VEGF has been shown previously in subjects with diabetes compared to 
control subjects without diabetes [347-350] including one study from North Africa 
[351].  A potential confounder to this relationship has been suggested by 
Schlingemann et al [352].  These authors suggest that artificial ex-vivo release of 
VEGF from platelets in both serum and plasma samples, which correlates with 
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glycaemic control, may be responsible for the differences reported between 
subjects with and without diabetes.  Exploring this relationship in Malawian subjects 
was beyond the scope of the MDRS. 
 
10.6.3 Comparison with studies of endothelial function and 
microvasculopathy in diabetes  
The MDRS did not show a difference in markers of endothelial dysfunction between 
subjects with varying grades of retinopathy.  Nor did my work show differences in 
these markers between subjects in whom retinopathy progressed and those in 
whom it did not.  In contrast there is a considerable body of evidence to suggest 
that inflammatory processes and endothelial dysfunction are key elements in the 
pathogenesis of microvasculopathy in diabetes [343].  Inflammatory and endothelial 
biomarkers are associated with and predictive of microangiopathy.  Cross-sectional 
studies in both type 1 and type 2 diabetes have shown elevated levels of 
biomarkers including CRP,  von Willebrand factor (vWF) and E-selectin  in subjects 
with nephropathy [353,354].  Baseline E-selectin and fibrinogen levels were 
predictive of development of nephropathy in the Diabetes Control and 
Complications Trial (DCCT) cohort (type 1 diabetes) [355]. 
 
Consistent with studies on nephropathy, biomarkers of endothelial dysfunction are 
associated with presence and incidence of DR [343].  Elevated soluble ICAM-1, 
VCAM-1 and E-selectin have been demonstrated in DR in type 2 diabetes [49].  In 
the Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) soluble 
VCAM, tumour necrosis factor-α (TNF-α) and homocysteine levels were associated 
with prevalence of more severe grades of DR in subjects with nephropathy; these 
markers were not associated with progression of DR at 15 years [356].  In the Dutch 
‘Hoorn’ population-based, cohort study of diabetes composite scores of markers of 
both inflammation (CRP and ICAM-1) and endothelial dysfunction (vWF, VCAM-1 
and uACR) were associated with presence of DR [48].  In a cohort study of 725 
African Americans with type 1 diabetes plasma levels of E-selectin were associated 
with progression of DR, E-selectin and TNF-α levels with progression to PDR and 
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sICAM-1 and TNF-α levels with incidence of macular oedema [357].  These 
observations are consistent with the hypothesis, supported by work in mice, that 
retinopathy is associated with low grade chronic inflammation [358].  It is suggested 
that VEGF induces up-regulation of adhesion molecules, including ICAM-1 and 
VCAM-1, facilitating leucocyte adhesion and stasis in the retinal vasculature and 
ultimately endothelial perturbation and cell death [359].   
 
10.6.4 Comparison with studies of endothelial function and mortality 
in diabetes  
I have demonstrated an association between markers of endothelial function and 
mortality in diabetes.  Subjects who died showed higher baseline levels of VCAM-1, 
E-selectin and CRP.  Serum VCAM-1 was associated with death in multivariate 
regression.   The MDRS is the first study to demonstrate this relationship in African 
subjects. E-selectin level correlated with HbA1c and was higher in subjects with HIV.  
It was not possible to accurately assess cause of death for subjects who died during 
the MDRS.  However, diabetic micro- and macro-vasculopathy are likely to be strong 
contributors.   
 
The Dutch ‘Hoorn’ population-based study showed an association between levels of 
vWF, sVCAM-1, sICAM-1 and CRP and cardiovascular mortality in type 2 diabetes 
[46,47].  In a Danish 9 year prospective study of type 2 diabetes sVCAM-1 and CRP 
were associated with mortality [354].  Taken together, the results of these reports 
and the present study are consistent with a role for endothelial dysfunction in the 
fatal micro and macrovascular complications of diabetes.  Associations with 
individual markers are not consistent.  In part this may be due to large biological 
variation in expression and measurement of these biomarkers.  These studies 
support a role for low-grade chronic inflammation, the expression and up-
regulation of adhesion molecules and leucocyte adhesion and stasis in the vascular 
complications of diabetes. 
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10.6.5 Microvascular reactivity in diabetes  
The MDRS did not show evidence of decreased endothelial function, as assessed by 
peripheral artery tonometry, either in analysis of baseline or progression data.  
Contrary to what would be expected in endothelial dysfunction, subjects with 
diabetes demonstrated higher rhPAT index although the relationship was not 
statistically significant.  rhPAT index was not associated with varying degrees of DR.  
Neither rhPAT index, augmentation index or FRHI were associated with DR 
progression or mortality.  Lower rhPAT index has been demonstrated in children 
[66] and adolescents [360] with type 1 diabetes and in adults with type 2 diabetes 
[361] in the developed world.  Recently Lim et al [362] showed an association 
between increasing severity of DR and increasing mean RHI and mean AI (measured 
with the EndoPAT device) in 95 Chinese subjects.  The authors used multivariate 
analysis adjusting for age, gender, duration of diabetes, smoking, HbA1c and 
hypertension.  Flow mediated dilatation (FMD) is an alternative non-invasive test of 
endothelial function (discussed in Chapter 1, Section 1.5.5).  Lower FMD has been 
demonstrated in subjects with diabetes compared to control subjects without 
diabetes [363] and in subjects with DR when compared to those with diabetes but 
no retinopathy [364,365]. 
 
Explanations for a lack of difference in endothelial function as assessed by PAT in 
this study include poor performance of the test.  The EndoPAT has been shown to 
provide an acceptable level of reproducibility [366] and should not be operator 
dependent. Reassuringly the range of values reported above are within the 
expected range of the test.  In my study no positive control was used.  The EndoPAT 
test has been validated for the diagnosis of coronary artery disease against the 
reference standard of acetyl choline angiography [65].  Facilities for assessing 
coronary artery disease are extremely limited in Malawi and assessment of the 
EndoPAT test in this way was not possible.  The influence of environmental factors, 
either short acting (e.g. dietary components) or long term (e.g. domestic smoke 
exposure), on endothelial function and possible physiological differences between 
the Malawian and previously tested populations with regard to the test cannot be 
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ruled out.  Diabetic neuropathy may lead to vasodilation.  This is unlikely to have 
exerted a significant influence on our findings.   
 
10.6.6 Limitations of this work 
The pathophysiology of DR is multifaceted.  Inflammation and endothelial 
dysfunction are complex entities that cannot be accurately reflected by a small 
number of biomarkers.  It is difficult to measure the endothelium in isolation and 
multiple influences including pharmaceutical agents, as well as diabetes, are likely 
to affect its function.  This may account for the weak internal correlation between 
markers of endothelial dysfunction in the MDRS.  Individual markers will be affected 
by particular health states.  For example CRP level is strongly affected by 
intercurrent infection and other inflammatory conditions [367]: an important 
confounder.  The retinal endothelium is a small component of the microvascular 
endothelium and microvascular events may be masked by activation of the 
macrovascular endothelium.  The retinal vasculature is distinct from other 
components of the vascular system [368]; markers measured in peripheral blood 
may be poorly representative of retinal endothelial function. 
 
Endothelial dysfunction has been demonstrated in many acute conditions including 
sepsis [369] and malaria [370] where profound vascular disturbance occurs.  
Diabetes is a chronic disease in which a baseline of endothelial function is difficult 
to establish.  Endothelial dysfunction is evident prior to clinical manifestations of 
microvascular complications [344].  However, endothelial health may vary over time 
(e.g. with varied glycaemic control [371]) and single measurements of biomarkers 
may therefore present an incomplete picture of vascular health.  Future work on 
endothelial function in Malawian subjects with diabetes could include investigation 
of other endothelial biomarkers including angiopoetins, analysis of the activation 
status of circulating leucocyte sub-classes by Fluorescence-Activated Cell Sorting 
(FACS) and direct endothelial cell histology and/or culture following sub-cutaneous 
fat biopsy. 
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10.7 Chapter summary 
The results presented in this chapter provide the first evidence from sub-Saharan 
Africa of endothelial dysfunction in subjects with diabetes and of an association 
between levels of endothelial biomarkers and mortality in these subjects.  
Endothelial biomarkers are unlikely to be useful for diagnosis of diabetes in a low 
resource setting and my data do not support the use of these biomarkers to identify 
patients at high risk of DR.  However, inflammatory activity and endothelial 
dysfunction are potentially important contributors to the macro- and micro-vascular 
complications of diabetes.  These data add to the literature on endothelial 
dysfunction in diabetes but do not provide a basis for testing the effects of 
treatments aimed at decreasing inflammatory activity and improving endothelial 
function as a means of preventing or limiting morbidity and mortality.  Further work 
to study the role of the endothelium in the vascular complications of diabetes in 
sub-Saharan Africa may be justified.  However, it may be challenging to produce 
informative results. 
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Chapter 11. Discussion 
 
 
11.1 Aims of the chapter  
In this chapter I summarise the findings of this thesis and compare these results to 
previously published work in the same field.  I will detail the strengths and 
weakness of the work I have performed and then go on to discuss the 
epidemiological, pathophysiological and health policy implications of my results.  
Finally I will describe ongoing work that has arisen from these results and provide 
suggestions for future work. 
 
11.2 Summary of findings  
At the outset of this work I hypothesised that, in the Malawian population, diabetic 
retinopathy (DR) is more common and progresses more quickly than that seen in 
developed countries (Chapter 4, Section 4.7.3).  I suggested that factors particular 
to this population might alter the spectrum of disease compared to that observed in 
the West, and that these factors include anaemia, co-infection with HIV and poorly 
controlled blood pressure.  I hypothesised that endothelial dysfunction is an 
important pathophysiological mechanism in DR; endothelial perturbation results in 
exhaustion of the mechanisms for endothelial self-repair leading to the 
development of maculopathy and ischaemic retinopathy.   
 
In order to test these hypotheses I recruited a cohort of subjects with diabetes from 
Southern Malawi.  Subjects were systematically sampled from two hospital-based, 
primary care diabetes clinics. Visual acuity, glycaemic control, systolic blood 
pressure, HIV status, urine albumin–creatinine ratio, and haemoglobin and serum 
lipid levels were assessed. Retinopathy was graded at an accredited reading centre 
using modified Wisconsin grading of four-field mydriatic photographs.  Subjects 
were recalled for assessment at 12 and 24 months.  Subjects who did not attend for 
follow-up visits were systematically traced.  Additionally, a previously studied 
cohort of subjects with diabetes was traced and recalled for assessment 5 years 
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after their recruitment to a cross sectional study of the complications of diabetes at 
Queen Elizabeth Central Hospital (QECH), Blantyre in 2007.  Endothelial function 
was explored in a nested case-control study in the main MDRS cohort.  Serum 
markers of endothelial dysfunction and peripheral artery tonometry (PAT; an in vivo 
measure of peripheral vascular endothelial health) were compared across four 
groups: subjects without diabetes, subjects with diabetes and DR, subjects with DR 
but not sight threatening diabetic retinopathy (STDR) and subjects with STDR. 
 
The Malawi Diabetic Retinopathy Study (MDRS) is the first prospective cohort study 
of DR from Sub-Saharan Africa (SSA).  Features which differentiate this work from 
previous cross sectional studies include the high prevalence of infective disease 
(malaria and HIV) and anaemia in the cohort, robust external validation of 
retinopathy grading at an accredited reading centre, data on the number of patients 
requiring laser treatment (new prevalent cases) and a comprehensive assessment 
of systemic parameters including HbA1c, urine ACR and haemoglobin level. 
 
Prevalence of retinopathy 357 patients were recruited to the MDRS.  At baseline 
13.4% subjects were HIV positive; 15.1% were anaemic. The overall prevalence of 
any retinopathy, STDR and proliferative DR (PDR) was 50.1% (95% CI) 44.9–55.3), 
29.4% (24.7–34.1) and 7.3% (4.6–10.0), respectively.  In multivariate logistic analysis 
the presence of STDR was associated with duration of diabetes (years) (OR 1.11, 
95% CI 1.05-1.17), HbA1c (%)(OR 1.31, 1.13-1.50), sBP (mmHg)(OR 1.03, 1.01-1.04), 
haemoglobin (g/dl)(OR 0.80, 0.68-0.95) and LDL cholesterol (mmol/L)(OR 1.63, 1.18-
2.25). No significant association with HIV status was demonstrated.   
 
Incidence and progression of retinopathy Of 357 subjects recruited to the main 
MDRS cohort, 295 were assessed at 24 months, 28 were confirmed dead, 20 
declined assessment and 14 were not traced (90.5% follow-up).  At follow-up 
(median 2.0yrs), in subjects with no retinopathy at baseline, cumulative incidence of 
any retinopathy was 38.0% (95% CI 30.2-45.8).  24 month rates of progression were: 
2 step (or greater) 58/293 (19.8%); STDR 23/225 (10.2%).  Cumulative incidence at 
24 months of STDR for subjects with Level 10 (no retinopathy), Level 20 
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(background) and Level 30 DR at baseline were  2.7% (95% CI 0.1-5.3), 27.3% (16.4-
38.2) and 25.0% (0-67.4), respectively.  In multivariate logistic analysis 2 step 
progression of DR was associated with HbA1c (OR 1.27, 95%CI 1.12-1.45), baseline 
grade of DR (1.39, 1.02-1.91) and HIV infection (OR 0.16, 0.03-0.78).   
 
Of those subjects recruited in 2007 a total of 135 (48% of the original cohort) were 
assessed.  At median follow-up of 5.3 years in subjects with no retinopathy at 
baseline incidence of any DR was 48.4% (38.2-58.5).  5 year rates of progression 
were: 2 step (or greater) 48/132 (36.4%; 95% CI 28.2-44.6); 3 step (or greater) 
30/132 subjects (22.7%; 15.6-29.9); STDR 34/115 (29.6%; 21.3-37.9).  5 year 
incidence of STDR for subjects with Level 10, and Level 20 DR at baseline were 
19.4% (11.3-27.4) and 81.3% (62.1-100), respectively.  In multivariate logistic 
analysis 2 step progression of DR was associated with higher mean HbA1c (OR 1.47, 
95%CI 1.13-1.90), longer duration of diabetes (1.08, 1.00-1.17) and lower 
haemoglobin (OR 0.80, 0.63-0.99).   
 
Vision and laser treatment At baseline 2.2% and 1.4% of subjects in the MDRS 
cohort had visual acuity (VA) worse than 60 letters (equivalent to 6/18 Snellen) and 
less than 50 letters (6/60 Snellen) in the better eye, respectively.  Of patients with 
VA less than 80 letters (6/12 Snellen) DR was the sole or equal contributing cause in 
49% of cases.  During the course of the study 85 people required laser 
photocoagulation (63 scatter treatment with or without macular laser, 22 macular 
laser alone).  In this treated cohort, rates of progression to visual loss were: ≥15 
letters lost 17 subjects (5.8%), moderate visual impairment (<60 letters) 3 (1.0%), 
severe visual impairment (<50 letters) 5 (1.7%).  
 
Mortality in the MDRS 28 subjects died during the MDRS.  Cumulative incidence of 
death in the whole MDRS cohort at 12 and 24 months was 4.3% (2.2-6.4 95% CI) 
and 8.0% (5.1-10.9), respectively.  Cumulative incidence of death amongst subjects 
with STDR at baseline at 12 and 24 months was 7.6% (2.6-12.6) and 13.2% (6.8-
19.6), respectively.  Cumulative incidence of death amongst HIV positive subjects at 
12 and 24 months was 10% (1.7-18.3) and 18.1% (7.4-28.8), respectively.  In 
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univariate analysis death was associated with STDR (OR 2.51; 95% CI 1.15-5.48; 
p=0.021), PDR (OR 6.47; 2.51-16.7; p=0.0001), HIV (OR 3.72; 1.54-9.00; p=0.003) 
and moderate visual impairment (OR 8.21; 2.48-27.1; p=0.001). 
 
Endothelial function 179 subjects were included in the case control study of 
endothelial function: 139 from the MDRS plus 40 subjects without diabetes.  At 
baseline, higher serum VEGF and E-selectin were associated with having diabetes in 
multivariate regression.  The presence of diabetes, DR and STDR was not 
significantly associated with serum levels of VCAM-1, ICAM-1, or CRP or with PAT 
score.  E-selectin level correlated with HbA1c and was higher in subjects with HIV.  
Analysis of progression data showed no significant difference between those 
subjects who demonstrated 2 (or more) step progression at 24 months and those 
who did not in terms of baseline level of CRP, VEGF, VCAM-1, E-selectin, ICAM-1 and 
PAT score.  Subjects who died demonstrated higher baseline levels of CRP, VCAM-1 
and E-selectin.  Serum VCAM-1 was associated with death in multivariate 
regression. 
 
11.3 Comparison with published data: prevalence and incidence of DR, 
vision and mortality 
Prevalence of retinopathy Baseline data from the MDRS cohort is compared with 
previous data from Africa in Chapter 6, Section 6.5.2, and with studies from outside 
Africa in Section 6.5.3.  Prevalence of any DR, PDR and maculopathy in the MDRS 
was higher than population based studies from Egypt [239], Mauritius [212,215] 
and Kenya [A. Bastawrous personal communication] and comparable with clinic 
based studies in the last decade from South Africa [224,241].  The prevalence of 
STDR in the MDRS was approximately 4 times that reported in recent European 
studies; the prevalence of PDR approximately 10 times higher. 
 
Incidence and progression of retinopathy The MDRS is the first high-quality, 
prospective, cohort study of DR from SSA.  Chapter 8, Section 8.5.6 compares data 
from the MDRS to cohort studies from Europe and North America.  Progression to 
276 
 
STDR at 24 months from no retinopathy and background DR occurred 
approximately 3 and 2.5 times more frequently than reported in recent European 
studies, respectively.  MDRS 5 year progression data is compared with studies from 
Africa and then Europe and North American in Chapter 9, Sections 9.5.4 and 9.5.5, 
respectively.  5 year progression to STDR from level 10 and level 20 DR was 
approximately 5 times and 3 times higher than that reported in recent European 
studies, respectively.  5 year progression to PDR was similar to data from recent 
data from England [331] and a high quality study from Mauritius in the 1990s 
[212,215].   
 
Vision Few cross sectional studies have investigated VA in people with diabetes in 
SSA.  Baseline data from the MDRS cohort is compared with previous data in 
Chapter 6, Section 6.5.5.  Prevalence of visual impairment in MDRS was lower than 
that recorded in the Diabetes in Egypt project [239] (results were reported for right 
eyes only as opposed to VA in the better eye) but similar to data from the Wisconsin 
Epidemiological Study of DR (WESDR) [328] and a recent study from Iceland [290].  
To my knowledge no studies from Africa have reported longitudinal visual acuity 
(VA) data in subjects with diabetes.  Incidence of visual impairment in the MDRS is 
compared to previous data in Chapter 8, Section 8.5.8 and Chapter 9, Section 9.5.6.  
It is important to note that subjects in the MDRS were part of a relatively well 
funded observational study which achieved good levels of follow-up, and had access 
to laser therapy and also treatment for other ocular pathology including cataract.  
Levels of visual loss in the MDRS are likely to be lower than in Malawian patients 
not enrolled in research studies.  24 month cumulative incidence of ‘moderate’ and 
‘severe’ visual loss in the MDRS was higher than similar thresholds of visual 
impairment reported in the WESDR at 4 years.  5 year incidence of ‘severe’ visual 
loss in the MDRS 2007 cohort was higher than that reported in the WESDR at 4 
years and also higher than that reported in the Beaver Dam Eye Study (not confined 
to subjects with diabetes) at 5 years [342]. 
 
Mortality Reporting mortality in subjects with diabetes was not a stated aim of the 
MDRS.  Nonetheless this data is an interesting outcome from my work.  24 month 
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cumulative incidence of death in the whole MDRS cohort was 8.0% (5.1-10.9).  24 
months cumulative incidence of death amongst subjects with STDR at baseline at 
was 13.2% (6.8-19.6); amongst HIV positive subjects it was 18.1% (7.4-28.8).  A 
number of high quality studies have reported mortality in subjects with diabetes in 
Africa.  Mortality rates from the population-based Mauritius cohort study of 
diabetes complications have been published pooled with studies from Fiji and 
Nauru.  After median follow-up of 5.0 years mortality in subjects with known 
diabetes was 122/278 (43.9%) for men and 97/317 (30.6%) for women [372].   
 
In a prospective study from Tanzania McLarty et al [373] reported 5 year mortality 
of 40.5% in those with insulin dependent diabetes mellitus (IDDM), 19.0% in 
subjects with non-insulin dependent diabetes mellitus (NIDDM) and 57.0% in 
subjects with indeterminate type.  50% of deaths in IDDM subjects were attributed 
to ketoacidosis; 24% of NIDDM deaths were due to cardiovascular and renal 
disease; 48% of deaths in indeterminate type diabetes were attributed to infection.  
Mortality rates in European and American studies are considerably less.  The United 
Kingdom Prospective Diabetes Study (UKPDS) [132] reported all cause mortality 
across all study participants at mean 10.0 years follow-up to be 17.9% (16.7-19.0).  
In the more recent ACCORD study [138] at mean 3.5 years follow-up all cause 
mortality was 4.5% (4.1-4.9).  Both these large trials studied subjects with type 2 
diabetes.  Crude mortality rates may be misleading; the study of age-standardised, 
cause-specific mortality in the MDRS would be helpful but is beyond the scope of 
this thesis. 
 
11.4 Possible explanations for high prevalence and progression rates 
Differences between prevalence, incidence and progression figures from the MDRS 
and recent European and North American work are likely to reflect multiple 
disparities between the populations studied.  These include ethnicity (genetic 
factors), poor access to health services, late diagnosis of diabetes, inadequate drug 
supplies (sub-optimal primary prevention of complications) and presence of 
comorbidities including poorly controlled hypertension and infective disease.  
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Comparisons between studies must be made with caution in view of different study 
designs and different follow-up rates.  Of particular note, mortality rates are likely 
to differ greatly between populations and are an important cause of data censoring.  
The effects of individual variables on the severity and progression of DR will be 
explored in the latter part of this chapter.  Specifically, the role of the population 
specific risk factors anaemia and HIV will be discussed.  Firstly I will explore the 
implications of high rates of prevalence and progression of DR for health policy 
makers and for clinical practice. 
 
11.5 Implications for health policy makers 
The costs of diabetes to Africa are significant, and are rising rapidly. Kirigia et al. 
[374] estimated that the total economic cost (direct and indirect) of diabetes in the 
WHO Africa region in 2000 was US$67 billion: equivalent to US$8,836 per person 
with diabetes per year. A significant proportion of this figure is accounted for by the 
opportunity cost of productive time lost due to permanent disability and premature 
mortality.  The burden of diabetes and its complications is borne predominantly by 
the working age population [375]. DR is the commonest cause of blindness in the 
working population in the USA and Europe [376]. A disease which reduces the 
economic activity of this group affects individual, household and national 
economies. 
 
The agenda for diabetes care in SSA is dominated at a national level by poorly 
resourced health services and at a community level by poverty. The International 
Diabetes Federation has estimated that in 2010 national funding for the care of 
diabetes in Africa was just US$111 per person [377]. This figure is equivalent, on 
average, to 7% of national healthcare expenditure but varies widely between 
countries. In Malawi the total annual per capita expenditure on all healthcare was 
only US$77 [16]. Opportunity costs will also be lower with the Gross National 
Income per capita only $330, but it is clear that current expenditure is a fraction of 
the cost of the disease. Limited public funding means individual patients and their 
families are forced to spend significant proportions of their income on diabetes 
treatment. Diabetes care must compete with infective diseases and other 
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healthcare initiatives in terms of political and financial priorities. It does not lend 
itself to the vertical programs favoured by donors. However global political 
attention is now turning to non-communicable diseases (NCDs), as witnessed by the 
United Nations high-level meeting on NCD prevention and control, September 2011 
[378].  Policy makers require evidence-based guidance on resource allocation.  
 
In Chapter 4 of this thesis I highlighted the lack of epidemiological data on the 
complications of diabetes in SSA.  Specifically, high-quality cohort studies and 
population-based cross-sectional studies are urgently required by policy makers 
planning the introduction of diabetes services in the region.   The MDRS is the first 
prospective, cohort study of DR from SSA.  Results from this work: prevalence, 
incidence and progression of DR in a mixed rural and urban population attending 
diabetes clinics in one country in SSA represent critical baseline data for future 
studies.    It is against data such as this that future interventions will be judged.  
 
11.6 Implications for clinical practice: barriers to effective care 
delivery  
Data from the MDRS highlight the urgent need for provision of services for 
retinopathy detection and management to avoid a large burden of vision loss.  
Provision of effective care for diabetes and its complications requires not only 
resource allocation but reorganisation of health systems.  Services in SSA have 
traditionally been organised to manage distinct health events, principally episodes 
of infectious diseases, maternal and perinatal disorders and trauma.  NCDs such as 
diabetes demand effective, integrated multidisciplinary services over a lifetime. This 
is a significant challenge for health providers as it impacts on all elements of health 
systems: workforce, facilities, technology and pharmaceuticals as well as leadership 
and governance.  Reductions in microvascular complications from improved 
glycaemic and blood pressure control, as shown in the Diabetes Complications and 
Control Trial (DCCT) [12] and the UKPDS [14], will be maximised if monitoring and 
medications are consistently available. Similarly, provision of services for detection 
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and management of complications, including DR, must be consistent rather than 
intermittent. 
 
Diabetes can be thought of as an index case for NCD healthcare delivery in Africa 
and developing countries worldwide.  The World Health Organisation (WHO) has 
identified the following problems for healthcare delivery in developing countries: 
lack of organisational structure for chronic disease care; minimal staffing and 
training provided to healthcare workers; minimal communication with the public to 
address preventative strategies; non-existence of organised healthcare information 
systems; and lack of involvement and integration with other community resources 
[379].  In Africa, these barriers translate into the inadequacies in diabetes care 
identified by Whiting et al. [380] listed in Box 11.1. In a recent article in the journal 
BMC Medicine I, together with colleagues from Liverpool and Malawi, identified a 
number of specific barriers to DR care in Africa listed in Box 11.2 [381]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Box 11.1 Inadequacies in diabetes care in Africa as identified by Whiting et 
al. [380] 
1. Poor patient attendance at clinics 
2. Low doctor to patient ratio leading to short consultation times and little or no 
time for patient education 
3. Low staff levels including a lack of trained nurses and other health workers 
4. Lack of staff training specific to diabetes 
5. A lack of systematic evaluation and monitoring of the complications of diabetes 
6. Non-existent or inadequate referral systems 
7. Poor record keeping 
8. Non-existent diabetes multidisciplinary healthcare teams 
9. Lack of infrastructure to support services 
10. Lack of national policies 
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The evolving epidemic of diabetes in Africa necessitates a coordinated response 
that involves integrating services at a number of levels.  In the community, 
interventions for the prevention and control of NCDs are necessary.  Several models 
exist in South Africa, for example the Community Health Intervention Programme, 
the efficacy of which is currently being evaluated [382].  Primary prevention of 
complications by systemic risk factor management is a priority.  This requires the 
expansion of health centres and also hospital-based diabetes clinics.  With a rapid 
increase in patient numbers, a simplification of some services has been proposed. 
This might resemble the streamlining of HIV services that was necessary to achieve 
antiretroviral therapy roll out in many states in SSA [383].  Moving away from 
individualised care in vascular risk management has significant drawbacks [384].  
The DART study on routine versus clinically driven monitoring of ART for HIV 
showed that early on a high volume, low complexity approach is non-inferior to 
individualised care [385].  But later, as the disease becomes more complex, 
individualised care is superior [386].  The same may not be true for diabetes where 
Box 11.2 Specific barriers to diabetic retinopathy care in the African region 
identified by Burgess et al [381]. 
1. Lack of ophthalmologists 
2. Low number of ophthalmologists with training and experience in management of 
DR 
3. Low numbers of opticians and ophthalmic clinical officers (OCOs) to perform 
opportunistic screening; commercial opticians are only accessible to the wealthy 
4. Lack of training for opticians and OCOs in fundoscopy 
5. Inadequate referral systems from primary to secondary care and from medical 
departments to ophthalmic services 
6. Non-existent systematic screening programs 
7. Little access to imaging technology including fluorescein angiography and optical 
coherence tomography 
8. Lack of treatment infrastructure including lasers and laser maintenance 
9. Lack of national policies and low government priority 
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many patients present late and the seeds of complications are sown from the 
outset.   
 
Development of specialist services to detect and manage complications is required 
supported by robust referral mechanisms.  The effectiveness of laser 
photocoagulation in reducing the likelihood of visual impairment and blindness in 
patients with PDR [18] and macular oedema [19] is well established.  Recent 
evidence demonstrates better outcomes in the short to medium term from intra-
vitreal anti-VEGF agents (injected into the vitreous) in diabetic maculopathy that 
has already affected vision [387]. This topic is the subject of a recent Cochrane 
review [388].  At present these agents which require multiple repeat injections, are 
prohibitively expensive for widespread use in resource-poor countries 
(approximately US$800 per injection for the drug alone).  However, off-label use of 
the anti-VEGF agent bevacizumab (approximately US$70 per injection), is used in 
some African centres on a paying patient basis, an approach supported by the BOLT 
study [389].  Vitreoretinal surgery has an important role in managing advanced 
disease. Unfortunately published data from this setting is sparse and more research 
on long-term outcomes and cost effectiveness is required. 
 
Provision of laser services requires substantial initial investment in equipment and 
training of ophthalmologists.  However, equipment upkeep costs are small and 
there are no on-going drug costs. The inadequacy of retinal training and paucity of 
referral networks are significant barriers to service development for DR.  I, together 
with colleagues from Liverpool and Malawi, have produced a number of proposals 
to confront these issues listed below in Box 11.3.  Our clinical and research group 
have demonstrated that provision of a laser treatment service is feasible in 
Blantyre, Malawi albeit with external support.  In Queen Elizabeth Central Hospital, 
set-up costs of equipment and training of ophthalmologists has been funded by an 
outside agency: the World Diabetes Foundation.  As part of the capacity building 
agenda of my PhD fellowship I have been involved in training ophthalmic clinical 
officers (OCOs) in the recognition and referral of DR and ophthalmology registrars in 
performing retinal laser. 
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11.7 Determinants of severity and progression: overview 
In Chapter 6 I reported associations between prevalence of STDR in the main MDRS 
cohort and longer duration of diabetes, higher systolic blood pressure, higher 
HbA1c, higher LDL, and lower haemoglobin. The latter finding is novel and is 
discussed separately in Section 11.8.  Progression of DR at 24 months was 
associated with higher mean HbA1c and higher baseline grade of retinopathy.  
Progression was negatively associated with HIV infection (discussed separately in 
Section 11.9).  In the 2007 cohort (Chapter 9) 2 step progression at 5 years was 
associated with higher mean HbA1c, longer duration of diabetes and lower 
haemoglobin. 
 
Box 11.3 Proposals by Burgess et al [381] to improve retinal training and 
retinal referral networks in sub-Saharan Africa 
1. Increase the number of ophthalmologists trained and working in the region to 
allow increased sub-specialisation 
2. Provision of imaging and treatment infrastructure to allow sub-specialty practice 
3. Creation of regional centres of excellence in Africa for provision of tertiary retinal 
care and training 
4. Development of retinal research networks: providing funding both for personnel 
and equipment, facilitating income generation for eye units, setting standards for 
clinical practice, improving the evidence base for this setting, setting the political 
agenda and attracting excellent clinicians. 
5. Prioritisation of sub-specialty development in post-graduate training programs 
6. Promotion of partnership arrangements with retinal centres in developed 
countries to facilitate knowledge and skill sharing 
7. Provision of retinal fellowships tailored to developing world trainees in retinal 
centres in developed countries 
8. Use of donor and government funds to minimise costs of such fellowships for 
trainees on condition of return to practice in country of origin 
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The association between glycaemic control and DR progression has been 
demonstrated previously in both observational (although not, to my knowledge, in 
a population in SSA) and intervention studies.  Literature on this association is 
reviewed in Chapter 3, Section 3.5.  In the Finnish Diabetic Nephropathy (FinnDiane) 
cohort study [390] of subjects with type 1 diabetes, progression of DR to a level 
requiring laser was associated with variability in glycaemic control (HbA1c variability 
when adjusted for mean HbA1c) [390].  While the limited number of assessments in 
the MDRS (baseline, 12 and 24 months) did not permit such an analysis, previous 
work at the QECH diabetes clinic shows highly variable glycaemic control in 
individual subjects (Ingrid Peterson, personal communication).  This is to be 
expected due to intermittent drug supplies and may contribute to the high rates of 
DR progression observed in the MDRS.  
 
In Chapter 3, Section 3.5.1 I discussed the potential disadvantages of HbA1c when 
compared to measurement of fasting plasma glucose (FPG): difficulties in quality 
control and test standardisation as well as variability with haemoglobin variants, 
anaemia and HIV infection.  In Chapter 5, Section 5.12.1 I described the difficulties 
encountered with HbA1c measurement in the MDRS.  FPG was measured in the 
MDRS.  Substitution of FPG for HbA1c in both prevalence and progression analyses 
had little effect on the results (data not shown).  Data from the MDRS demonstrate 
that measurement of HbA1c is feasible in the Malawian population and may be 
useful in assessment of glycaemic control in this region. 
 
As described in Chapter 3, Section 3.5.4 the role of lipids in DR is incompletely 
understood.  In the MDRS higher LDL cholesterol was associated with presence of 
STDR at baseline.  However, no association was demonstrated between LDL 
cholesterol and DR progression.  While lower levels of LDL cholesterol are linked to 
atherosclerosis [391] several studies have shown an association between raised LDL 
and DR severity [392,393].  Interestingly, some studies have found an effect of LDL 
level on maculopathy but not retinopathy [392].  This calls into question our 
analysis based on STDR: a term encompassing a composite threshold of retinopathy 
and maculopathy.  A large number of lipoprotein subtypes are described.  Both 
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apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (HDL-C) have 
been shown to be more accurate markers of cardiovascular risk than LDL 
cholesterol [394].  Modified forms of LDL such as malondialdehyde (MDA)-modified, 
and advanced glycation end (AGE)-product-modified LDL are thought to be 
important in chronic low grade vascular inflammation [395].  The role of 
malnutrition in complications of diabetes has not been widely studied, principally 
because of the low prevalence of under-nutrition in European and North American 
populations with diabetes.  Particular lipid subgroups may be markers of good 
nutrition.  If nutrient deficiencies contribute to microvascular disease then both low 
and high levels of particular lipids may be harmful adding further complexity to this 
area of interest. 
 
In the MDRS main cohort sBP was associated with STDR at baseline but not 
progression of retinopathy.  This is surprising due to the strong weight of evidence 
for the role of BP in DR progression from Western studies (reviewed in Chapter 3, 
Section 3.5.3).  This area deserves further study in African populations.  As expected 
baseline grade of DR was a strong determinant of DR progression at 24 months.  In 
order to assess the effect of other variables without this strong determinant it 
would have been necessary to group subjects according to baseline grade of DR and 
produce a separate model for each group.   In the case of the MDRS the numbers in 
each group would have been too small to adequately power each model.  
 
11.8 Determinants of severity and progression: haemoglobin 
In Chapter 6 I reported an association between prevalence of STDR in the main 
MDRS cohort and lower haemoglobin: a novel finding.  In Chapter 8 (progression at 
24 months) the proportion of subjects who were anaemic at baseline was greater in 
the subjects not assessed (died or lost to follow-up) than those who were seen.  
Haemoglobin was not significantly associated with 2 step progression at 24 months 
in either univariate or multivariate analysis.  In the 2007 cohort (Chapter 9) 2 step 
progression at 5 years was associated with lower haemoglobin level.  Data from the 
MDRS therefore supports an association of haemoglobin level with both severity 
and progression of DR. 
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Cross sectional (but not cohort) studies have demonstrated an association between 
presence of DR and anaemia in India [323-325] and China [187].  To my knowledge 
this relationship has not been demonstrated in an African population.  The 
relationship between haemoglobin and diabetic nephropathy is complex because 
renal failure, from any cause, can lead to anaemia via decreased erythropoietin 
production.  Renal anaemia is a marker for advanced nephropathy. Urine ACR, a 
sensitive marker for nephropathy, was included in my multivariate analyses.  There 
is little data on associations between neuropathy in diabetes and anaemia although 
some evidence supports a role for autonomic neuropathy in abnormalities of 
erythropoietin regulation in type 2 diabetes [396].  It is tempting to hypothesise 
that the mechanism underlying an association between haemoglobin level and DR is 
impaired oxygen delivery and therefore increased oxygen stress at a microvascular 
level. 
 
A potential confounder of the association between haemoglobin and retinopathy is 
socioeconomic status.  Socioeconomic data were not collected in the MDRS.  
Anaemia may be a marker of nutritional status, renal disease (clinical or subclinical), 
comorbidities (anaemia of chronic disease) or poor general health.  The aetiology of 
anaemia in SSA is multifactorial and includes deficiencies of micronutrients (e.g. 
iron, B12, folate); haemoglobinopathies; infections and chronic diseases (e.g., 
malaria, HIV, tuberculosis) [183].  To my knowledge the causes of anaemia in 
Malawian adults has not been studied.  In a high-quality case control study of 
Malawian children severe anaemia was associated with bacteraemia, malaria, 
hookworm, HIV infection, glucose-6-phosphate dehydrogenase deficiency, vitamin 
A deficiency, and vitamin B12 deficiency [397].  Glucose-6-phosphate 
dehydrogenase deficiency is reported to increase risk of PDR in persons with type 1 
diabetes [398].  The prevalence haemoglobinopathies in Malawian adults is not 
known but is thought to be low (S McKew, personal communication).  Micronutrient 
deficiencies are potential therapeutic targets.  Whether treatment of anaemia 
reduces diabetic microvascular complications is not known.  Iron supplementation 
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has significant potential drawbacks in diabetes: both high iron level and iron 
supplementation have been associated with gestational diabetes [399,400]. 
 
11.9 Determinants of severity and progression: HIV 
At baseline, 13.4% of subjects in the main MDRS cohort were HIV positive.  HIV 
infection was negatively associated with presence of STDR in univariate but not 
multivariate analysis.  At 24 months HIV infection was negatively associated with 2 
step progression in multivariate analysis.  Mortality was higher in subjects with HIV 
than in the cohort as a whole.  In the 2007 cohort (Chapter 9) no association 
between HIV infection and 2 step progression at 5 years was demonstrated.  5 year 
mortality in the 2007 cohort could not be reliably determined. However, the 
proportion of subjects with HIV was not significantly different between subjects 
seen in 2012 and those who were not seen.  Data from the MDRS supports a 
negative association between HIV infection and severity and progression of DR: a 
novel finding. 
 
To my knowledge no previous study has investigated the relationship of HIV with 
DR.  HIV can directly affect the kidney leading to HIV associated nephropathy 
(HIVAN) [173].  Proteinuria is the presenting feature of this condition.  HIV and ART 
are associated with peripheral neuropathy.  Therefore, any association between HIV 
and diabetic microvascular complications except DR will be difficult to investigate.  
Both HIV infection and anti-retroviral therapies (ART) are associated with a 
vasculopathy which manifests as increased cardiovascular and cerebrovascular risk 
[326,327].  It is possible that HIV and ART affect DR pathophysiology via multiple 
effects on cardiometabolic traits.  In African populations HIV (when adjusted for 
ART exposure) is associated with lower mean BMI, lower systolic and diastolic BP, 
higher mean triglyceride levels, lower mean HDL and lower mean LDL [401].  ART is 
associated with raised LDL and HDL but lower triglycerides [401].  HIV is weakly 
associated with raised HbA1c while ART is associated with lower HbA1c [401].  
Chronic low grade inflammation is important in the pathophysiology of DR.  HIV is 
generally seen as a pro-inflammatory state.  However, it is conceivable that the 
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effect of HIV on cytokines and other inflammatory mediators as well as leucocytes 
and associated inflammatory cells may affect progression of DR. 
 
An important potential confounder of the association between HIV and DR is early 
diagnosis of diabetes in HIV positive subjects.  Patients attending medical facilities 
for ART treatment may be more likely to be tested for diabetes than the general 
population.  While the logistic regression analyses presented above controlled for 
known duration of diabetes, the duration of diabetes before diagnosis was not 
known.  A potential source of bias is data censoring due to higher mortality in HIV 
infected subjects. 
 
11.10 Determinants of severity and progression: implications  
The observational data presented in this thesis will facilitate design of appropriate 
intervention studies in the region.  The magnitude of effect size for variables such as 
glycaemic control is important information required for accurate cost-effectiveness 
studies and cannot be assumed from studies in Europe and North America.  Ethical 
concerns about such trials could be allayed by intelligent study design; one example 
is the stepped wedge study design.  Case detection of retinopathy in persons with 
diabetes along the UK model will not be cost effective in SSA.  It is likely that 
targeted screening based on determinants of DR severity and progression will be 
employed.  A risk model based on data from the MDRS and similar studies could aid 
effective allocation of resources.  Epidemiological data from the MDRS has 
implications for our understanding of DR pathophysiological.  Mechanisms of 
disease are explored in the next section in the context of results from the case-
control study of endothelial function. 
 
11.11 Implications of endothelial function studies  
Data from the MDRS case-control study of endothelial function are compared to 
previous studies of endothelial function in diabetes in Chapter 10, Section 10.6.2, to 
studies of endothelial function and microvascular disease in diabetes in Section 
10.6.3, to studies of endothelial function and mortality in diabetes in Section 10.6.4, 
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and to studies of microvascular reactivity in diabetes in Section 10.6.5.  Conclusions 
which can be drawn from the MDRS are restricted by the limitations outlined in 
Section 10.6.6.  Results from my studies add to the literature on endothelial 
dysfunction as an important pathological mechanism in DR including in Malawian 
subjects.  The majority of work on endothelial dysfunction in diabetes has been 
performed in the developed world.  I have provided evidence of endothelial 
dysfunction in diabetes in a different population.  
 
Future work on endothelial function in subjects with diabetes could include 
investigation of other endothelial biomarkers including angiopoetins, endothelial 
microparticles and asymmetric dimethyl L-arginine (ADMA).  Analysis of the 
activation status of circulating leucocyte sub-classes by fluorescence-activated cell 
sorting (FACS) would complement studies of the vascular endothelium.  Direct 
endothelial cell histology and/or culture following sub-cutaneous fat biopsy is more 
invasive but would allow laboratory based study of peripheral endothelium.  There 
is clear evidence for an association between acute episodes of infective disease and 
ischaemic vascular events.  For example, between mycoplasma pneumonia and 
stroke [402] and between influenza and stroke [403].  In malaria, episodes of acute 
infection may lead to chronic endothelial activation and alterations in the 
coagulation pathway [370].  Investigation of a role for acute infection (e.g. malaria) 
and endothelial dysfunction in the context of DR would be extremely interesting 
and relevant to subjects with diabetes in Malawi.   
 
11.12 Limitations of the work presented in this thesis 
Specific limitations of the various component studies of the MDRS are discussed in 
the following chapters and summarised here: Chapter 6, Section 6.5.6; Chapter 8, 
Section 8.5.3; Chapter 9, Section 9.5.2; and Chapter 10, Section 10.6.6. 
 
Missing data The proportion of data in the MDRS which was missing was very small.  
Data on a number of potentially interesting variables were not recorded.  I explored 
the possibility of quantifying the burden of malaria in the MDRS cohort.  Measuring 
parasitaemia during acute infection is readily available and cheap.  However, this 
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measure tells one little about the burden of malaria over months or years.  
Measurement of anti-malarial antibodies is possible but was prohibitively 
expensive.  Socioeconomic data was not collected in the MDRS but is being 
collected for participants in the ‘MDRS 2’ (described in Section 11.14 below). 
 
Limitations of specific tests No test is 100% sensitive and specific.  Grading of 
retinal photographs at an accredited reading centre (dual grading with arbitration) 
is the current reference standard for DR classification in the context of research and 
systematic screening.  A small number of subjects were ungradeable on 
photography but gradeable on slit-lamp biomicroscopy; reliance on clinical 
examination was unavoidable in these circumstances.  In each round of assessment 
less than 1% of subjects were ungradeable on both photography and slit-lamp 
biomicroscopy.  Biochemical tests performed at the Wellcome Trust Clinical 
Research Programme Laboratories are subject to internal and external quality 
control.  Specific issues encountered with measurement of HbA1c are discussed in 
Chapter 5 Section 5.12.1. 
 
Cohort study approach Cohort studies are expensive and of long duration.  A major 
advantage of such studies is that exposure (determinants of severity and 
progression) is measured before disease onset thereby reducing bias in terms of 
disease development.  The cohort approach permits study of multiple outcomes 
such as DR progression and mortality.  The results of cohort studies must be 
interpreted in the context of other research, usually including ecological and case-
control studies.  The reference standard for validity is an intervention study to 
reduce/eliminate exposure to a particular variable.  For some variables such as age 
or HIV infection randomised interventions are not possible. 
 
A potential criticism of our methodology is the definition used for any DR: any 
haemorrhage or microaneurysm in either eye, and our assumption in analysis of a 
linear progression of DR.  Haemorrhages and microaneurysms are not specific for 
DR and may be observed in the absence of diabetes.  Wong et al [404] examined 
7992 adults aged 49-73 without diabetes.  4.8% of subjects had retinal changes 
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indistinguishable from DR.  After 3 years follow-up the number of subjects 
progressing to diabetes did not differ between the groups with or without retinal 
changes.  Cugati et al [110] analysed data from the Blue Mountains Eye Study.  In 
1725 subjects without diabetes or retinopathy (microaneurysms, haemorrhages, 
hard or soft exudates) at baseline the 5-year cumulative incidence of retinopathy 
was 9.7% (95% CI 8.3-11.1). Of subjects with retinal signs but no diabetes at 
baseline, 3.5% went on to develop diabetes. 13.3% of retinal changes present at 
baseline progressed but 72.3% regressed or disappeared over the course of the 
study.  Therefore there is an increasing body of evidence that the relationship 
between blood glucose, pre-diabetes, clinical diabetes, hypertension, age and 
detectable retinal changes is more complex than previously thought.  
 
Case-control approach Endothelial function studies were conducted using a case-
control design.  A longitudinal analysis was also performed.  Case-control studies 
are prone to selection bias of both cases and controls.  While we excluded diabetes 
in our control subjects according to ADA criteria [123] and produced robust 
phenotyping for cases and controls, it is possible that unmeasured confounders 
such as exposure to environmental factors including domestic smoke pollution and 
foodstuffs could have influenced our results.  Selecting a list of candidate markers 
of endothelial dysfunction on the basis of previous research is a logical approach.  
However, in the absence of a widely accepted definition of endothelial dysfunction 
and an incomplete understanding of the relationship between endothelial 
pathology and diabetic microvascular complications, it is difficult to draw 
conclusions from our results when few strong associations are recorded.  
 
 
11.13 Ongoing research arising directly from this work 
Further analysis of the MDRS dataset The MDRS has produced a large dataset on 
which further analysis is possible.  The UKPDS outcomes model [405] is a computer 
simulation model based on patient data from the UKPDS.  It is designed to predict 
estimated life expectancy and quality adjusted life expectancy for each member of a 
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given population.  MDRS data could be used to assess the performance of the 
UKPDS outcomes model in a population with diabetes in SSA. 
 
A number of methods have been used to estimate the delay between onset and 
diagnosis of type 2 diabetes from prevalence studies of DR.   Using a simple linear 
model Ellis et al [193] plotted prevalence of any retinopathy with duration of known 
disease using data from the Prevalence of Diabetic Eye Disease in Scotland study.  In 
this model the ‘x’ axis intercept gives the estimate of mean delay in clinical 
diagnosis of diabetes.  This approach has been criticised for using a simplistic linear 
model and for including stages of retinopathy not specific to diabetes.  Porta et al 
[406] examined data from 2 groups of subjects corresponding to type 1 and type 2 
diabetes.  Time for retinopathy to develop after diagnosis of diabetes was defined 
as the mean time for development of ‘moderate DR’ (study specific definition) in 
subjects with type 1 diabetes.  Using a quadratic model the authors estimated this 
figure to be 3.29 years in their study population.  A linear model was used to 
correlate known duration of diabetes with prevalence of ‘moderate DR’ in subjects 
with type 2 diabetes.  The authors extrapolated this model to estimate time from 
appearance of retinopathy to diagnosis of type 2 diabetes.  A figure of 2.66 years 
was reported.  Addition of these figures gives an estimate of 6.05 years between 
onset and diagnosis of type 2 diabetes [406].  A similar analysis would be possible 
with MDRS data. 
 
‘MDRS 2’ In 2013 a grant from the British Council for the Prevention of Blindness 
was secured by my colleagues and I to investigate the effectiveness and cost-
effectiveness of laser treatment for DR in Malawi.  The effectiveness of laser 
treatment in Africa is assumed from landmark studies in resource-rich countries 
without taking account of confounders such as late presentation, HIV, malaria, 
malnutrition episodes and treatment non-availability.  The ‘MDRS 2’ is a prospective 
cohort study which is continuing follow-up of patients that I treated with laser as 
part of the MDRS study and also recruiting new subjects with DR requiring laser 
treatment.  Subjects will be assessed at 24 and 72 months with regard to visual 
acuity and development or regression of proliferative DR.  Results will be compared 
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for non-inferiority with data from the recent Diabetic Retinopathy Clinical Research 
Network (DRCR.net) [407] and other published data. 
 
11.14 Future studies 
Effectiveness and cost-effectiveness of systematic diabetic retinopathy screening in 
Europe is well established.  Systematic screening is cost-effective for sight years 
preserved compared with no screening. Variation in age of onset of diabetes, 
glycaemic control, sensitivity of the screening test and compliance rates influence 
the cost-effectiveness of screening programs [408].  Digital photography, as used by 
the English National Screening Programme [409], with the addition of telemedicine 
links has the potential to deliver cost-effective, accessible screening to rural and 
remote populations. In Europe a strong evidence base has driven the political 
agenda for service development for diabetes and its complications.  Further high-
quality research on the effectiveness and cost-effectiveness of DR case detection 
and management models tailored to local needs is necessary. This evidence should 
effect change in national policies and transform services and outcomes. 
 
My colleagues in the Department of Eye and Vision Science at the University of 
Liverpool and I will shortly submit a grant proposal to investigate the prevention of 
avoidable visual loss from DR in Malawi by developing a targeted screening 
programme.  Specifically we intend to investigate perceived barriers to DR care in 
Malawi, to evaluate implementation of a model of DR screening appropriate to local 
facilities and resource constraints, and to introduce DR screening into 
representative central and district hospital diabetes clinics.  We propose to add a 
call/recall system to the existing database of patients with diabetes at QECH, 
Blantyre.  We intend to use a newly developed low-cost portable fundus camera 
(VisionQuest) to capture retinal images.  Ophthalmic Clinical Officers (OCOs) and 
opticians will be trained in fundus photography and OCOs will receive training in 
image grading and referral guidelines.   
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Having produced an effective and achievable screening model in QECH it will be 
implemented in representative central and district hospitals in a step-wise fashion.  
Data will be collected on the numbers of patients screened, number of screen 
positives (referable retinopathy), sensitivity and specificity of the screening test 
(true and false positives and negatives) against a reference standard of clinical 
examination by an ophthalmologist, proportion of patients unable to be screened 
by photography, number of patients treated with laser and costings. A cost benefit 
analysis will be performed.  Building on our work on the cost-effectiveness of laser 
treatment in Malawi, data collected during the study will be used to develop a 
Markov model of DR screening in SSA.  Model computation will explore the cost-
effectiveness of the programme and the limits on sustainability of screening and 
care in a low-resource setting. We aim to establish an achievable and cost effective 
DR screening model which is generaliseable to regional ophthalmology units and 
district hospitals with diabetes, NCD or vascular risk clinics across sub-Saharan 
Africa (SSA). 
 
11.15 Summary  
The MDRS is the first prospective cohort study of DR in Sub-Saharan Africa.  This 
programme of research has reported prevalence, incidence and progression of DR 
in patients attending diabetes clinics in Southern Malawi: vital data for health policy 
makers in the region.  Observational data regarding determinants of severity and 
progression of DR presented in this thesis (including novel associations) will 
facilitate design of appropriate intervention studies in the region and provide 
insights into the pathophysiology of DR.  My hope is that, building on the MDRS, 
current and future studies will provide an evidence base for cost-effective DR case 
detection and management which is achievable in a low resource setting and 
generaliseable across sub-Saharan Africa. 
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APPENDICES 
 
Appendix 1. Grading definitions used in the ETDRS 
 
Definitions are taken from the ETDRS report 10 [86]. 
 
Definitions of present, absent, questionable and cannot grade 
Present: Grader is greater than 90% certain that feature is present 
Absent: Grader is less than 50% certain that the feature is present 
Questionable: Recorded for a characteristic when a grader is 50 to 90% certain that 
it is present.  When an abnormality is definitely present but its nature is uncertain 
the grader assigns the grade 'questionable' for the characteristic considered to be 
most likely and 'absent' for the one(s) considered less likely.  For example, when an 
abnormality is believed to be either new vessels or IRMA, but is more likely the 
former, the grader assigns the grade of questionable for new vessels and absent for 
IRMA. Only if the grader favours neither characteristic over the other is a grade of 
questionable assigned to both. 
Cannot grade:  Grader is unable to evaluate or distinguish with more than 50% 
confidence the presence or absence of a feature and more than 75% of the image is 
obscured i.e. poor image quality. 
 
Definitions of clinical features of retinopathy 
Microaneurysm: Defined as a red spot less than 125µm in its longest dimension 
(approximately the width of a vein at the disc margin) with sharp margins. 
Haemorrhage:  Defined as either a red spot less than 125µm with irregular margins 
or a red lesion greater than 125µm (unless it is clear that it is a microaneurysm). 
Cotton wool spot (CWS): Superficial white, pale yellow-white or greyish white 
lesion with ill-defined (feathery) edges. 
Venous abnormalities: Three abnormalities are assessed separately.  
(i) Venous beading (VB): localised increases in venous calibre which 
sometimes resemble a string of beads 
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(ii) Venous narrowing: localised narrowing of venous calibre 
(iii) Venous loops and / or reduplication. A venous loop is an abrupt, curving 
deviation of a vein from its normal path. Reduplication of a vein is the 
dilatation of a pre-existing channel or the proliferation of a new channel 
adjacent to original vein. 
Intra-retinal microvascular abnormalities (IRMA): Tortuous intraretinal vascular 
segments, varying in calibre from barely visible to 31 µm (approximately one fourth 
the width of a major vein at the disc margin). 
New vessels at the disc (NVD): New vessels that are clearly located on the surface 
of the retina (not within the retina) or further forward in the vitreous cavity on the 
disc or within 1DD of its margin. 
New vessels elsewhere (NVE): New vessels that are clearly located on the surface 
of the retina (not within the retina) or further forward in the vitreous cavity except 
for those on the disc or within 1DD of its margin. 
Fibrous proliferations at the disc: Fibrous tissue opaque enough to be definitely 
seen, with or without accompanying new vessels, on the disc or within 1DD of its 
margin. 
Fibrous proliferations at the disc Fibrous tissue opaque enough to be definitely 
seen, with or without accompanying new vessels, except for those on the disc or 
within 1DD of its margin. 
Pre-retinal haemorrhage (PRH): Haemorrhage just anterior to the retina or under 
its internal limiting membrane.  Both boat shaped haemorrhages with a fluid level 
and round, oval or linear patches are included. 
Vitreous haemorrhage:  Haemorrhage further forward in the vitreous cavity than 
PRH. 
Hard exudates: Small white or yellowish-white deposits with sharp margins.  Often 
have a slightly waxy or glistening appearance.  Usually located in the outer layers of 
the retina. 
Retinal thickening (oedema): Thickening of the retina (with or without partial loss 
of transparency). 
Drusen:  Deep yellowish white dots, sometimes circumscribed by a thin line of 
pigment. 
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Appendix 2. Search histories for systematic review 
Search histories for the electronic databases Medline (PubMed), EMBASE, Web of 
Science, African index Medicus and OpenSigle. 
Search history Pubmed:  
#1 Search "Diabetic Retinopathy"[Mesh] 
#2  Search Diabetic maculopathy ti, ab 
#3 Search diabet* AND ((macular edema) OR (macular oedema)) 
#4 Search #1 OR #2 OR #3 
#5 Search ("Africa"[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR 
Benin[tw] OR Botswana[tw] OR "Burkina Faso"[tw] OR Burundi[tw] OR 
Cameroon[tw] OR "Canary Islands"[tw] OR "Cape Verde"[tw] OR "Central African 
Republic"[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR "Democratic 
Republic of Congo"[tw] OR Djibouti[tw] OR Egypt[tw] OR "Equatorial Guinea"[tw] 
OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR 
Guinea[tw] OR "Guinea Bissau"[tw] OR "Ivory Coast"[tw] OR "Cote d’Ivoire"[tw] OR 
Jamahiriya[tw] OR Jamahiryia[tw] OR Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR 
Libya[tw] OR Libia[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR 
Mauritania[tw] OR Mauritius[tw] OR Mayote[tw] OR Morocco[tw] OR 
Mozambique[tw] OR Mocambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] 
OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR "Sao Tome"[tw] OR 
Senegal[tw] OR Seychelles[tw] OR "Sierra Leone"[tw] OR Somalia[tw] OR "South 
Africa"[tw] OR "St Helena"[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR 
Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR "Western Sahara"[tw] OR Zaire[tw]  OR 
Zambia[tw] OR Zimbabwe[tw] OR "Central Africa"[tw] OR "Central African"[tw] OR 
"West  Africa"[tw] OR "West African"[tw] OR "Western Africa"[tw] OR "Western 
African"[tw] OR "East Africa"[tw] OR "East African"[tw] OR "Eastern Africa"[tw] OR 
"Eastern African"[tw] OR "North Africa"[tw] OR "North African"[tw] OR "Northern 
Africa"[tw] OR "Northern African"[tw] OR "South African"[tw] OR "Southern 
Africa"[tw] OR "Southern African"[tw] OR "sub Saharan Africa"[tw] OR "sub Saharan 
African"[tw] OR "subSaharan Africa"[tw] OR "subSaharan African"[tw]) NOT 
("guinea pig"[tw] OR "guinea pigs"[tw] OR "aspergillus niger"[tw]) 
#6 Search #4 And #5 
#7 Limit #6 to Human 
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Search history EMBASE: 
1 diabetic retinopathy.mp. or diabetic retinopathy/ 
2 diabetic macular edema/ or retina maculopathy/ or retina macula edema/ or 
diabetic maculopathy.mp. 
3 (diabet* and (macul* edema or macul* oedema)).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer] 
4 (diabet* and macul*).mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer] 
5 1 or 2 or 3 or 4 
6 (Africa or Africa* or Algeria or Angola or Benin or Botswana or Burkina Faso 
or Burundi or Cameroon or Canary Islands or Cape Verde or Central African Republic 
or Chad or Comoros or Congo or Democratic Republic of Congo or Djibouti or Egypt 
or Equatorial Guinea or Eritrea or Ethiopia or Gabon or Gambia or Ghana or Guinea 
or Guinea Bissau or Ivory Coast or (Cote and Ivoire) or Jamahiriya or Jamahiryia or 
Kenya or Lesotho or Liberia or Libya or Libia or Madagascar or Malawi or  Mali or 
Mauritania or Mauritius or Mayote or Morocco or Mozambique or Mocambique or 
Namibia or Niger or Nigeria or Principe or Reunion or Rwanda or Sao Tome or 
Senegal or Seychelles or Sierra Leone or Somalia or South Africa or St Helena or 
Sudan or Swaziland or Tanzania or Togo or Tunisia or Uganda or Western Sahara or 
Zaire or Zambia or Zimbabwe or Central Africa or Central African or West Africa or 
West African or Western Africa or Western African or East Africa or East African or 
Eastern Africa or Eastern African or North Africa or North African or Northern Africa 
or Northern African or South African or Southern Africa or Southern African or 
South Africa).mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer] 
7 5 and 6 
8 Limit 7 to Humans 
 
Search history Web of Science: 
(Diabetic retinopathy) or (Diabetic maculopathy) or ((diabet* AND ((macular 
edema) OR (macular oedema)) [Topic] 
AND 
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(Africa or Africa* or Algeria or Angola or Benin or Botswana or Burkina Faso or 
Burundi or Cameroon or Canary Islands or Cape Verde or Central African Republic or 
Chad or Comoros or Congo or Democratic Republic of Congo or Djibouti or Egypt or 
Equatorial Guinea or Eritrea or Ethiopia or Gabon or Gambia or Ghana or Guinea or 
Guinea Bissau or Ivory Coast or (Cote and Ivoire) or Jamahiriya or Jamahiryia or 
Kenya or Lesotho or Liberia or Libya or Libia or Madagascar or Malawi or Mali or 
Mauritania or Mauritius or Mayote or Morocco or Mozambique or Mocambique or 
Namibia or Niger or Nigeria or Principe or Reunion or Rwanda or Sao Tome or 
Senegal or Seychelles or Sierra Leone or Somalia or South Africa or St Helena or 
Sudan or Swaziland or Tanzania or Togo or Tunisia or Uganda or Western Sahara or 
Zaire or Zambia or Zimbabwe or Central Africa or Central African or West Africa or 
West African or Western Africa or Western African or East Africa or East African or 
Eastern Africa or Eastern African or North Africa or North African or Northern Africa 
or Northern African or South African or Southern Africa or Southern African or 
South Africa) [topic] 
Search history African index Medicus, OpenSigle: 
(Diabetic retinopathy) or (Diabetic maculopathy) or ((diabet* AND ((macular 
edema) OR (macular oedema))
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